

METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES

RELATED APPLICATIONS

[001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application number 62/983,416, filed February 28, 2020, U.S. provisional application number 63/074,841, filed September 4, 2020, and U.S. provisional application number 63/144,853, filed February 2, 2021, each of which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

[002] This disclosure relates to methods and compositions for activation and/or expansion of lymphocyte populations, e.g., tumor infiltrating lymphocytes (TILs).

BACKGROUND

[003] Tumor-infiltrating lymphocytes are white blood cells, including T cells and B cells, that have left the bloodstream and migrated towards a tumor. The presence of lymphocytes in tumors is often associated with better clinical outcomes, and indeed, TILs have been implicated in killing tumor cells. TILs are routinely used as an adoptive cell transfer therapy to treat certain types of cancer. The adoptive transfer of TILs is a powerful approach to the treatment of bulky, refractory cancers, for example, especially in patients with poor prognoses. In adoptive transfer therapy, TILs are expanded *ex vivo* from surgically resected tumors that have been cut into small fragments or from single cell suspensions isolated from the tumor fragments. The common process for TIL expansion requires that multiple individual cultures are established, grown separately, and assayed for specific tumor recognition. TILs are expanded over the course of a few weeks with a high dose of IL-2. Selected TIL lines that present the best tumor reactivity are then further expanded in a "rapid expansion protocol" (REP), which uses anti-CD3 activation for a typical period of two weeks. The final post-REP TIL population is infused back into the patient. Although widely used, these lengthy TIL expansion protocols are not reliable for expanding all TIL populations.

SUMMARY

[004] Provided herein, in some aspects, are TIL activation and/or expansion methods that not only shorten the period of time for expanding TIL populations by, for example,

implementing a single-step rather than a multi-step culture process, but are also useful for expanding diverse populations of TILs. The methods described herein also offer a clinical manufacturing advantage by providing an alternative to feeder cells, in some embodiments.

[005] Surprisingly, the streamlined methods provided herein, in some embodiments, offer a 30-50% increase in fold TIL (e.g., edited TIL) expansion over current TIL expansion protocols, while also supporting proliferation of effector T cells and enrichment of a central memory T cell phenotype, even in the absence of IL-2. The TILs produced by the methods of the present disclosure also express high levels of CD25, a receptor for IL-2, suggesting that the TILs are highly sensitive to endogenous IL-2 survival signals in patients. Experimental data described herein also show, unexpectedly, that the advantages of the methods of the present disclosure apply to both unmodified and modified (e.g., CRISPR/Cas gene or multi-gene edited) TIL populations.

[006] The streamlined methods provided herein produce highly enriched, diverse populations of TILs and thus potentially more effective adoptive TIL transfer therapies.

[007] Some aspects of the present disclosure provide a method of producing an expanded population of TILs, the method comprising culturing the disaggregated tumor sample in a culture medium comprising (a) feeder cells or an agonist of a T cell costimulatory molecule, (b) a T cell receptor (TCR) agonist, and (c) interleukin (IL)-15, thereby producing an expanded population of TILs.

[008] In some embodiments, the culture medium comprises IL-15 at a concentration of greater than 100 ng/ml. In some embodiments, the culture medium comprises IL-15 at a concentration of less than 1000 ng/ml. In some embodiments, the culture medium comprises IL-15 at a concentration of greater than 100 ng/ml and less than 1000 ng/ml.

[009] In some embodiments, the culture medium does not comprise IL-2. In some embodiments, the culture medium does not comprise IL-21. In some embodiments, the culture medium does not comprise IL-2 or IL-21.

[010] In some embodiments, the culture medium further comprises IL-7, for example, at a concentration of 10 U/ml to 7,000 U/ml.

[011] In some embodiments, the TCR agonist is selected from a CD3 agonist, OKT3, and UCHT1. In some embodiments, the TCR agonist is a CD3 agonist. In some embodiments, the TCR agonist is OKT3. In some embodiments, the TCR agonist is UCHT1.

[012] In some embodiments, the CD3 agonist is an anti-CD3 antibody. For example, the anti-CD3 antibody may be a humanized anti-CD3 antibody. In some embodiments, the CD3 agonist is a soluble monospecific complex comprising two anti-CD3 antibodies linked together.

[013] In some embodiments, the agonist of the T cell costimulatory molecule is selected from: a CD28 agonist, a CD137 agonist, a CD2 agonist, and combinations thereof. In some embodiments, the agonist of the T cell costimulatory molecule is a CD28 agonist. In some embodiments, the agonist of the T cell costimulatory molecule is a CD137 agonist. In some embodiments, the agonist of the T cell costimulatory molecule is a CD2 agonist. In some embodiments, the agonist of the T cell costimulatory molecule is a CD28 agonist and a CD137 agonist. In some embodiments, the agonist of the T cell costimulatory molecule is a CD28 agonist and a CD2 agonist. In some embodiments, the agonist of the T cell costimulatory molecule is a CD137 agonist and a CD2 agonist.

[014] In some embodiments, the CD28 agonist comprises a soluble monospecific complex comprising two anti-CD28 antibodies linked together.

[015] In some embodiments, the CD2 agonist comprises a soluble monospecific complex comprising two anti-CD2 antibodies linked together.

[016] In some embodiments, the TCR agonist is linked to a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein each matrix is 1 to 500 nm in length in its largest dimension. In some embodiments, the T cell costimulatory molecule is linked to a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein each matrix is 1 to 500 nm in length in its largest dimension.

[017] In some embodiments, the disaggregated tumor sample comprises tumor fragments, for example, generated by a dissection method, that are 0.5 to 4 mm³ in size. In some embodiments, the disaggregated tumor sample comprises tumor fragments, for example, generated by a mechanical method, that are 25 to 30 mm³ in size. In some embodiments, the tumor fragments comprise digested tumor fragments.

[018] In some embodiments, cells of the expanded TIL population are genetically modified. In some embodiments, cells of the expanded TIL population are epigenetically modified.

[019] In some embodiments, a method of producing an expanded population of TILs comprises genetically modifying cells of the expanded TIL population using a gene-regulating system, for example, selected from a gene-regulating system comprising RNA interference (RNAi) molecules, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), and RNA-guided nucleases. In some embodiments, the gene-regulating system comprises an RNAi molecule. In some embodiments, the gene-regulating system comprises a TALEN. In some embodiments, the gene-regulating system comprises a ZFN. In some embodiments, the gene-regulating system comprises an RNA-guided nuclease. In some

embodiments, the gene-regulating system comprises a Cas enzyme, for example, a Cas9 enzyme, and a guide RNA.

[020] In some embodiments, cells of the TIL population comprise a modification, for example, an insertion, deletion, indel, or substitution, at one or more gene(s) selected from: *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. In some embodiments, the modification results in reduction or inhibition of expression of the one or more gene(s) and/or function of one or more protein(s) encoded by the one or more gene(s). In some embodiments, the cells of the TIL population comprises a modification, optionally an insertion, deletion, indel, or substitution, at the *SOCS1* gene and the *ZC3H12A* gene.

[021] In some embodiments, at least a portion of the culture medium is changed during the culturing. In some embodiments, at least a portion of the culture medium is supplemented with IL-15 during the culturing.

[022] In some embodiments, the culturing occurs over a period of 9-25 days. In some embodiments, the culturing occurs over a period of 9-21 days. In some embodiments, the culturing occurs over a period of 9-14 days.

[023] In some embodiments, at least 10% of the expanded population of TILs have a central memory T cell phenotype. In some embodiments, at least 15% of the expanded population of TILs have a central memory T cell phenotype.

[024] Other aspects of the present disclosure provide a method of producing an expanded population of TILs, the method comprising: culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to produce a population of TILs; and culturing cells of the population of TILs in a second medium comprising feeder cells or an agonist of a T cell costimulatory molecule, a TCR agonist, and IL-15, thereby producing an expanded population of TILs. In some embodiments, the method further comprises modifying cells of the population of TILs from the first medium using a gene-regulating system to produce a subpopulation of modified TILs, wherein the population of TILs cultured in the second medium includes the subpopulation of modified TILs. In some embodiments, the first medium does not comprise IL-2. In some embodiments, the second medium does not comprise IL-2. In some embodiments, neither the first medium nor the second medium comprises IL-2.

[025] Yet other aspects of the present disclosure provide a method for expanding a population of TILs comprising: culturing the population of TILs in a culture medium comprising (a) IL-15 and (b) a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein the matrices are attached to TCR agonists and agonists of a T cell costimulatory molecule, each matrix is 1 to 500 nm in length in its largest dimension, and optionally the method does not comprise the use of feeder cells during expansion of the population of TILs.

[026] Still other aspects of the present disclosure provide a method for expanding a population of TILs comprising: culturing the population of TILs in a culture medium comprising (a) IL-15, (b) a first soluble monospecific complex comprising an anti-CD3 antibody or fragment thereof, (c) a second soluble monospecific complex comprising an anti-CD28 antibody or fragment thereof, and (d) a third soluble monospecific complex comprising an anti-CD2 antibody or fragment thereof, wherein each of the soluble monospecific complexes comprises two antibodies, or fragments thereof, linked together, and each antibody, or fragments thereof, of each of the soluble monospecific complexes specifically binds to the same antigen on the population of TILs.

[027] Also provided herein, in some aspects, is a composition comprising an expanded population of TILs produced by the method of any one of the preceding paragraphs.

[028] Some aspects provide a composition comprising a disaggregated tumor sample in a culture medium comprising (a) feeder cells, (b) a T cell receptor (TCR) agonist, and (c) interleukin (IL)-15, for example, at a concentration of greater than 100 ng/ml and less than 1000 ng/ml. Other aspects provide a composition comprising a disaggregated tumor sample in a culture medium comprising (a) an agonist of a T cell costimulatory molecule, (b) a T cell receptor (TCR) agonist, and (c) interleukin (IL)-15, for example, at a concentration of greater than 100 ng/ml and less than 1000 ng/ml. Yet other aspects provide a composition comprising TILs in a culture medium comprising (a) feeder cells, (b) a T cell receptor (TCR) agonist, and (c) interleukin (IL)-15, for example, at a concentration of greater than 100 ng/ml and less than 1000 ng/ml. Still other aspects provide a composition comprising TILs in a culture medium comprising (a) an agonist of a T cell costimulatory molecule, (b) a T cell receptor (TCR) agonist, and (c) interleukin (IL)-15, for example, at a concentration of greater than 100 ng/ml and less than 1000 ng/ml. In some embodiments, the composition does not comprise IL-2.

BRIEF DESCRIPTION OF THE DRAWINGS

[029] The foregoing and other features and advantages of the present invention will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings.

[030] **FIGS. 1A-1B** present graphs showing fold expansion (FIG. 1A) and percent viabilities (FIG. 1B) of TILs harvested at day 14 of REP containing 6000U/ml IL-2 (conventional process), 1000ng/ml IL-15 (IL15 Process) or 10ng/ml IL-7 and 300ng/ml IL-15 (IL7/15 Process A), or 10ng/ml IL7 and 1000ng/ml IL15 (IL7/15 Process B).

[031] **FIGS. 2A-2B** present graphs showing the percent of TIL that are CD8+ (FIG. 2A) and the percent of TIL that are CCR7+CD45RO+ (FIG. 2B) in TILs harvested at day 14 of REP containing 6000U/ml IL-2 (conventional process), 1000ng/ml IL-15 (IL15 Process) or 10ng/ml IL-7 and 300ng/ml IL-15 (IL7/15 Process A), or 10ng/ml IL7 and 1000ng/ml IL15 (IL7/15 Process B).

[032] **FIGS. 3A-3D** present graphs showing the percentage of CD8+ TIL that express CD107a upon stimulation (FIG. 3A) as well as the percentage of CD107a+ CD8+ TIL that are additionally IFN γ + IL-2+ (FIG. 3B), TNF α + IL-2+ (FIG. 3C), or IFN γ + TNF α + (FIG. 3D), after a 14 day REP containing IL-2 (conventional process), 10ng/ml IL-7 and 300ng/ml IL-15 (IL7/15 Process A), or 10ng/ml IL7 and 1000ng/ml IL15 (IL7/15 Process B).

[033] **FIGS. 4A-4C** present graphs showing the relative fold expansion of *OR1A1* gene-edited TIL (FIG. 4A), *SOCS1* gene-edited TIL (FIG. 4B), and *SOCS1/PTPN2* dual gene-edited (FIG. 4C) TIL expanded in REPs that contain 1000ng/ml IL-15 (IL15 Process), 10ng/ml IL-7 and 300ng/ml IL-15 (IL7/15 Process A), or 10ng/ml IL-7 and 1000ng/ml IL-15 (IL7/15 Process B) compared to the fold expansion of the respective gene-edited TIL grown in IL-2 (conventional process).

[034] **FIGS. 5A-5C** present graphs showing the fold expansion of peripheral blood derived memory T cells after a 14 day expansion in the presence of irradiated PBMCs (at a 1 T cells to 100 irradiated PBMC ratio) additionally 30ng/ml OKT3 ("PBMC REP (1:100)"), with irradiated K562 cells genetically modified to overexpress CD86 and a membrane bound anti-CD3 scFv ("CD86, anti-CD3 K562"), with irradiated K562 cells genetically modified to overexpress CD86, 41BBL, and a membrane bound anti-CD3 scFv ("41BBL, CD86, anti-CD3 K562"), or with irradiated non-genetically modified K562 cells ("unmodified K563").

[035] **FIG. 6** represents graphs T cell exhaustion scores in TILs that were *OR1A1*-edited and then cultured in IL-15 or IL-2

[036] **FIG. 7** represents graphs of cytotoxicity scores in TILs that were *OR1A1*-edited and then cultured in IL-15 or IL-2.

[037] **FIG. 8** represents graphs of expression of IFN γ in TILs that were *OR1A1*-edited and then cultured in IL-15 or IL-2.

- [038] **FIG. 9** depicts a bar graph showing fold expansion for soluble tetramer and artificial antigen presenting cell (aAPC) at day 10 or 11.
- [039] **FIG. 10** depicts a bar graph showing fold expansion for soluble tetramer and aAPC edits at day 18 or day 23.
- [040] **FIG. 11** depicts a bar graph showing central memory phenotype at day 18 or day 23.
- [041] **FIG. 12** depicts a table of editing frequencies at day 18 or 23.
- [042] **FIG. 13** depicts a bar graph showing TIL tumor fragment extrapolated cell counts at day 14 or 20.
- [043] **FIG. 14** depicts a bar graph showing central memory phenotype at day 14 or 20.
- [044] **FIG. 15** depicts a table of editing frequencies at day 14.
- [045] **FIG. 16** depicts tables of editing frequencies at day 14.
- [046] **FIG. 17** depicts bar graphs showing viability of TILs from different donors prepared from tumor fragments and digests.
- [047] **FIG. 18** depicts bar graphs showing cell numbers for TILs from different donors prepared from tumor fragments and digests.
- [048] **FIG. 19** depicts a process layout for expanding TILs from tumor fragments using a soluble activator.
- [049] **FIG. 20** depicts bar graphs showing total cell number (top) and viability (bottom) of TILs from different fragment donors and cultured in either IL-2 or IL-15 prior to electroporation phase.
- [050] **FIG. 21** depicts bar graphs showing total cell number (top) and viability (bottom) of TILs from donor 4375 cultured in either IL2 or IL15 following electroporation. *Indicates absence of cytokine from sample.
- [051] **FIG. 22** depicts tables of editing frequencies at day 17.
- [052] **FIG. 23** depicts FACS gating strategy at day 17 for FIG. 24 to FIG.26.
- [053] **FIG. 24** depicts dot plots showing CD4/CD8 population (top left); CD45RO/CCR7 population gated on CD45/CD3 (top right); CD45RO/CCR7 population gated on CD45/CD3/CD4 (bottom left) and CD45RO/CCR7 population gated on CD45/CD3/CD8 (bottom right) at day 17.
- [054] **FIG. 25** depicts half off-set histograms showing CD28 (top left), CD27 (Top middle) and KLRG1 expression (top right) gated on CD45/CD3; KLRG1 expression gated on CD45/CD3/CD4 (bottom left) and KLRG1 expression gated on CD45/CD3/CD8 (bottom right) at

day 17. Mean fluorescence intensity is shown in CD28 and CD27 graphs while percent positive population is shown in KLRG1 graphs.

[055] **FIG. 26** depicts half off-set histograms showing ICOS (Inducible T-cell COStimulator) expression gated on CD45/CD3 (left), ICOS expression gated on CD45/CD3/CD4 (middle) and ICOS expression gated on CD45/CD3/CD8 (right) at day 17. Mean fluorescence intensity is shown in all the graphs.

DETAILED DESCRIPTION

[056] Improved methods for activating and expanding TILs using unconventional cytokines are provided. These methods include techniques for activating and expanding TILs using more streamlined approaches, including one-step approaches, approaches using agonists for stimulation, approaches more suitable for clinical manufacturing, and approaches without the requirement of feeder cells, are provided. Compositions of expanded populations of TILs are also provided, in addition to populations of expanded TILs enriched in central memory T cell phenotype.

[057] In one aspect, the present disclosure provides methods of expanding a population of TILs that utilize non-traditional cytokines, such as IL-15 and/or IL-7. The provided methods of expanding a population of TILs comprise the steps of culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to obtain a population of TILs; and culturing the population of TILs in a second medium comprising a T cell receptor (TCR) agonist; feeder cells; and greater than 100 ng/ml IL-15, wherein the second medium does not comprise IL-2, thereby expanding the population of TILs.

[058] In another aspect, the present disclosure provides methods of expanding a population of TILs comprising the steps of culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to obtain a population of TILs; modifying members of the population of TILs using a gene-regulating system to obtain a modified population of TILs; and culturing the modified population of TILs in a second medium comprising a TCR agonist; feeder cells; and IL-15, thereby expanding the population of TILs.

[059] Generally, nomenclature used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein is well-known and commonly used in the art. The methods and techniques provided herein are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. Enzymatic reactions

and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of molecular and cell biology and biochemistry described herein are well-known and commonly used in the art.

[060] Unless otherwise defined herein, scientific and technical terms used herein have the meanings that are commonly understood by those of ordinary skill in the art. In the event of any latent ambiguity, definitions provided herein take precedence over any dictionary or extrinsic definition. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The use of "or" means "and/or" unless stated otherwise. The use of the term "including," as well as other forms, such as "includes" and "included," is not limiting.

[061] As used herein, the terms "about" and "approximately" refer to a value being within 5% of a given value or range.

[062] As used herein, the phrase "tumor infiltrating lymphocytes" or "TILs" refers to a population of lymphocytes that have left the bloodstream of a subject and migrated into a tumor. TILs include, but are not limited to, CD8⁺ cytotoxic T cells, CD4⁺ T cells including Th1 and Th17 CD4⁺ T cells, natural killer T cells, and natural killer (NK) cells. TILs include both primary and secondary TILs. "Primary TILs" are those that are obtained from patient tissue samples as outlined herein (sometimes referred to as "freshly harvested"), and "secondary TILs" are any TIL cell populations that have been expanded or proliferated as discussed herein, including, but not limited to bulk TILs and expanded TILs ("REP TILs" or "post-REP TILs"). In some embodiments, primary TILs include tumor reactive T cells that are obtained from peripheral blood of a patient. TIL cell populations can include genetically modified TILs. "TILs" also refers to a population of lymphocytes that have left the blood stream of a subject, have migrated into a tumor and then have departed to again enter the bloodstream.

[063] As used herein, the phrase "population of cells" or "population of TILs" refers to a number of cells or TILs that share common traits. In general, populations generally range from 1×10^6 to 1×10^{10} in number, with different TIL populations comprising different numbers. For example, initial growth of primary TILs in the presence of IL-2 can result in a population of bulk TILs of roughly 1×10^7 cells. REP expansion is generally done to provide populations of 1.5×10^9 to 1.5×10^{10} cells for infusion. In some embodiments, the population of cells is monoclonal. In other embodiments, the population of cells is polyclonal. In some embodiments, when the population of cells is polyclonal, the cells still share one or more common traits. A monoclonal T-cell population will result in the predominance of a single TCR-gene rearrangement pattern. In contrast, polyclonal

T-cell populations have diverse TCR-gene rearrangement pattern, which can make them more effective in certain situations.

[064] As used herein, the phrase “expanding a population of TILs” is synonymous with “proliferating a population of TILs” and refers to increasing the number of cells in a TIL population.

[065] As used herein, the phrase “expansion process” refers to the process whereby the number of cells in a TIL population is increased. Processes where TILs are merely isolated or enriched without substantial increase in the number of TILs are not expansion processes.

[066] As used herein, the term “agonist” refers to a chemical, a molecule, a macromolecule, a complex of molecules, or a complex of macromolecules that binds to a target, either on the surface of a cell or in soluble form. In certain embodiments, when an agonist binds to a target on the surface of a cell, the agonist activates the target to produce a biological response. Agonists include hormones, neurotransmitters, antibodies, and fragments of antibodies.

[067] As used herein, the term “subject” refers to a human being who has a tumor into which a population of lymphocytes that have left the human being’s bloodstream have migrated and transformed into TILs. In some embodiments, this human being may be a patient in need of immunotherapy involving an expanded population of the patient’s own TILs. In other embodiments, this human being may be a patient in need of immunotherapy involving an expanded population of another patient’s own TILs.

[068] As used herein, the term “CD3” refers to the CD3 (cluster of differentiation 3) T cell co-receptor that helps to activate both the cytotoxic T cell (CD8+ naïve T cells) and also T helper cells (CD4+ naïve T cells). CD3 is a protein complex composed of six distinct polypeptide chains (2 CD3 zeta chains, 2 CD3 epsilon chains, 1 CD3e gamma chain, and 1 CD3 delta chain). These chains associate with the T-cell receptor (TCR) alpha and beta chains (or gamma and delta chains) to generate an activation signal in T lymphocytes. The TCR alpha and beta chains (or gamma and delta chains), and CD3 molecules together constitute the TCR complex. The human *CD3E* gene is identified by National Center for Biotechnology Information (NCBI) Gene ID 916. An exemplary nucleotide sequence for a human *CD3E* gene is the NCBI Reference Sequence: NG_007383.1. An exemplary amino acid sequence of a human CD3E polypeptide is provided as SEQ ID NO: 876.

Table 1: Sequences of human Cluster of Differentiation polypeptides and cytokines

NCBI Reference Sequence No.	SEQ ID NO	SEQUENCE
NG_007383.1	876	MQSGTHWRVLGLCLLSVGVWGQDGNEMGGITQTPYKVSISGTTVILTCPQYP GSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPED ANFYLYLRARVCENCMEMDVMSVATIVIVDITGGLLLLVEYWSKNRKA KPVTRGAGAGGRQGRQNKERPPVNPDPYPIRKQGRDLYSGLNQRR
NG_029618.1	877	MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRAS LHKGLDSAVEVCVVYGNYSQQLQVYSKTGFNCDCGKLGNESVTFYQLNLYVNQ TDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFPGPSKPFVWLVVVG VLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYPYAPPRDF AAYRS
NG_050908.1	878	MSFPCKFVASFLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDID DIKWEKTSDDKKIAQFRKEKETFKEDTYKLFKNGTLKIKHLKTDDQDIYKVS YDTKGKNVLEKIFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGK HLKLSQRVITHKWTTSLSAKFCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICG GGSLLMVFVALLVFYITKRKKQRSRRNDEELETARHRAVATEERGRKPHQIPAST PQNPATSQHPPPPGHRSAQSPHPPPPGHRVQHQPQKRPPAPSGTQVHQKQGP PLPRPRVQPKPPHGAENSLSPSSN
NG_016779.1	879	MYRMQLLSIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMLNGINNYKNP KLTRMLTFKFYMPKKATELKHLCLEELKPLEEVLNLAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
NP_001552.2	880	MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSS AGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQ GQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGP SPADLSPGASSVTPAPAREPGHSPQIISFFLALTSTALLFLLFFLTLRFVSVKGRGR KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
NP_003802.1	881	MEYASDASLDPEAPWPPAPRARACRVLPWALVAGLLLLLLAAACAVFLACP WAVSGARASPGSAASPRREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDG PLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYVFFQLELRRVVAGEG SGSVSLALHLQPLRSAAGAAALALTVDLPASSEARNASAFGFQGRLLHLSAGQR LGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSRSE
CAA71044.1	882	MDFQVQIFSFLLISASVIMSRANWVNVISDLKKIEDLIQSMHIDATLYTESDVHP SCKVTAMKCFLELQVISLESGLDASIHDTVENLILANNSLSSNGNVTESGCKEC EELEEKNIKEFLQSFVHIVQMFINTS
AAH47698	883	MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDQKQYESVLMVSIQQLDSMKEI GSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVS EGTTILLNCTGQVKGKPAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLQE IKTCWNKILMGTKEH
BBA22643	884	MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRLIDIVDQLKNYVN DLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIIKKLRKPPS TNAGRRQKHRLTCPSDCSYEKKPPKEFLERFKSLLQKMIHQHLSRTHGSEDS

[069] In Table 1, the presumed leader sequences for proteins that have them are shown as underlined.

[070] As used herein, the term “CD28” refers to cluster of differentiation 28, which is one of the proteins expressed on T cells that provides co-stimulatory signals required for T cell activation and survival. T cell stimulation through CD28 in addition to the T-cell receptor (TCR) can provide a potent signal for the production of various cytokines, such as interleukins. CD28 is

the receptor for CD80 and CD86 proteins. When activated by Toll-like receptor ligands, CD80 expression is upregulated in antigen-presenting cells (APCs). The human *CD28* gene is identified by NCBI Gene ID 940. An exemplary nucleotide sequence for a human *CD28* gene is the NCBI Reference Sequence: NG_029618.1. An exemplary amino acid sequence of a human CD28 polypeptide is provided as SEQ ID NO: 877.

[071] As used herein, the term “CD2” refers to cluster of differentiation 2, which is a cell adhesion molecule found on the surface of T cells and natural killer (NK) cells. CD2 interacts with other adhesion molecules and acts as a co-stimulatory molecule on T and NK cells. The human *CD2* gene is identified by NCBI Gene ID 914. An exemplary nucleotide sequence for a human *CD2* gene is the NCBI Reference Sequence: NG_050908.1. An exemplary amino acid sequence of a human CD2 polypeptide is provided as SEQ ID NO: 878.

[072] As used herein, the term “4-1BB” refers to CD137, which is a T cell costimulator. An exemplary nucleotide sequence for a human *4-1BB* gene is the NCBI Reference Sequence: NG_052834.1. An exemplary amino acid sequence of a human 4-1BB is the NCBI Reference Sequence: NP_001552.2. An exemplary amino acid sequence of a human 4-1BB polypeptide is provided as SEQ ID NO: 880.

[073] As used herein, the term “4-1BB ligand” refers to a type 2 transmembrane glycoprotein that is expressed on activated T-lymphocytes and binds 4-1BB. An exemplary nucleotide sequence for a human *4-1BB* gene is the NCBI Reference Sequence: NC_000019.10 (6,531,026-6,535,924). An exemplary amino acid sequence of a human 4-1BB is the NCBI Reference Sequence: AAA53134.1. An exemplary amino acid sequence of a human 4-1BB ligand polypeptide is provided as SEQ ID NO: 881.

[074] As used herein, the term “cytokine” refers to a broad category of small proteins (about 5-20 kDa in size) that are important in cell signaling. Cytokines are peptides and cannot cross the lipid bilayer of cells to enter the cytoplasm. Cytokines have been shown to be involved in autocrine signaling, paracrine signaling, and endocrine signaling as immunomodulating agents. Cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors, but generally not hormones or growth factors, although there is some overlap in terminology. Cytokines are produced by a broad range of cells, including immune cells like macrophages, B lymphocytes, T lymphocytes, and mast cells, as well as endothelial cells, fibroblasts, and various stromal cells. Cytokines generally act through binding to cell-surface receptors and are especially important in the immune response, since they are involved in regulating the maturation, growth, and responsiveness of particular cell populations.

[075] As used herein, the phrase “T cell-stimulating cytokine” refers to a cytokine that stimulates and/or activates T cell lymphocytes. In some embodiments, the T-cell stimulating cytokine is IL-2, IL-7, IL-15 or IL-21. In certain embodiments, T cell-stimulating cytokines are produced in a cell from a viral vector.

[076] As used herein, the term “IL-2” (also referred to herein as “IL2”) refers to the cytokine and T cell growth factor known as interleukin-2, and includes all forms of IL-2, including human and mammalian forms, forms with conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof. IL-2 is described, *e.g.*, in Nelson, *J. Immunol.* 2004, 172, 3983-88 and Malek, *Annu. Rev. Immunol.* 2008, 26, 453-79, the disclosures of which are incorporated herein by reference in their entireties. The term IL-2 encompasses human, recombinant forms of IL-2, such as aldesleukin (PROLEUKIN, available commercially from multiple suppliers in 22 million IU per single use vials), as well as the form of recombinant IL-2 commercially supplied by CellGenix, Inc., Portsmouth, N.H., USA (CELLGRO GMP) or ProSpec-Tany TechnoGene Ltd., East Brunswick, N.J., USA (Cat. No. CYT-209-b) and other commercial equivalents from other vendors. Aldesleukin (des-alanyl-1, serine-125 human IL-2) is a nonglycosylated human recombinant form of IL-2 with a molecular weight of approximately 15 kDa. The term IL-2 also encompasses pegylated forms of IL-2, including the pegylated IL-2 prodrug NKTR-214, available from Nektar Therapeutics, South San Francisco, Calif., USA. NKTR-214 and pegylated IL-2 suitable for use in the invention is described in U.S. Patent Application Publication No. US 2014/0328791 A1 and International Patent Application Publication No. WO 2012/065086 A1, the disclosures of which are incorporated herein by reference in their entireties. Alternative forms of conjugated IL-2 suitable for use in the invention are described in U.S. Pat. Nos. 4,766,106, 5,206,344, 5,089,261 and 4,902,502, the disclosures of which are incorporated herein by reference in their entireties. Formulations of IL-2 suitable for use in the invention are described in U.S. Pat. No. 6,706,289, the disclosure of which is incorporated herein by reference in its entirety. The human *IL2* gene is identified by NCBI Gene ID 3558. An exemplary nucleotide sequence for a human *IL2* gene is the NCBI Reference Sequence: NG_016779.1. An exemplary amino acid sequence of a human IL-2 polypeptide is provided as SEQ ID NO: 879.

[077] Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a 15.5 - 16 kDa protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes. The major sources of IL-2 are activated CD4+ T cells and activated CD8+ T cells.

[078] IL-2 has essential roles in key functions of the immune system, tolerance and immunity, primarily via its direct effects on T cells. In the thymus, where T cells mature, it prevents autoimmune diseases by promoting the differentiation of certain immature T cells into regulatory T cells, which suppress other T cells that are otherwise primed to attack normal healthy cells in the body. IL-2 enhances activation-induced cell death (AICD). IL-2 also promotes the differentiation of T cells into effector T cells and into memory T cells when the initial T cell is also stimulated by an antigen, thus helping the body fight off infections. Together with other polarizing cytokines, IL-2 stimulates naive CD4⁺ T cell differentiation into Th1 and Th2 lymphocytes while it impedes differentiation into Th17 and follicular Th lymphocytes. Its expression and secretion are tightly regulated and functions as part of both transient positive and negative feedback loops in mounting and dampening immune responses. Through its role in the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones, it plays a role in enduring cell-mediated immunity.

[079] The methods for expanding populations of TILs as provided in the present disclosure utilize IL-15. IL-15 (also referred to herein as "IL15") refers to the cytokine and T cell growth factor known as interleukin-15, and as utilized in the present invention, includes all forms of IL-15, including human and other mammalian forms, forms with conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof. IL-15 is described, *e.g.*, in Steel JC, Waldmann TA, Morris JC (January 2012) "Interleukin-15 biology and its therapeutic implications in cancer," *Trends in Pharmacological Sciences*, 33 (1): 35–41 and Waldmann TA, Tagaya Y (1999) "The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens," *Annual Review of Immunology*, 17: 19–49, the disclosures of which are incorporated herein by reference in their entireties. The term IL-15 also encompasses recombinant forms of IL-15. As used herein, the term IL-15 also encompasses pegylated forms of IL-15. The human *IL15* gene is identified by NCBI Gene ID 3600. An example nucleotide sequence for a human *IL15* gene is the NCBI Reference Sequence: NG_029605.2. An exemplary amino acid sequence of a human IL-15 polypeptide is provided as SEQ ID NO: 882.

[080] IL-15 can be utilized in the methods provided at a final concentration of greater than 0.5 ng/ml. In some embodiments, the final concentration of IL-15 utilized is more than 1 ng/ml. In some embodiments, the final concentration of IL-15 utilized is more than 2 ng/ml. In some embodiments, the final concentration of IL-15 utilized is more than 10 ng/ml. In some embodiments, the final concentration of IL-15 utilized is more than 50 ng/ml. In some embodiments, the final concentration of IL-15 utilized is more than 75 ng/ml. In some

embodiments, the final concentration of IL-15 utilized is more than 100 ng/ml. In some embodiments, the final concentration of IL-15 utilized is more than 150 ng/ml. In some embodiments, the final concentration of IL-15 utilized is more than 200 ng/ml. In some embodiments, the final concentration of IL-15 utilized is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml. In some embodiments, the final concentration of IL-15 utilized is about 300 ng/ml. In some embodiments, the final concentration of IL-15 utilized is about 1000 ng/ml. In further embodiments, the final concentration of IL-15 utilized is greater than 1000 ng/ml. In some embodiments, the final concentration of the IL-15 in the second medium is greater than 100 ng/ml. In further embodiments, the final concentration of IL-15 in the second medium is greater than 100 ng/ml to about 1000 ng/ml. In a specific embodiment, the final concentration of IL-15 in the second medium is about 300 ng/ml.

[081] IL-15 can be utilized in the methods provided at a final concentration of greater than 1 U/ml. In some embodiments, the final concentration of IL-15 utilized is more than 2 U/ml. In some embodiments, the final concentration of IL-15 utilized is more than 4 U/ml. In some embodiments, the final concentration of IL-15 utilized is more than 20 U/ml. In some embodiments, the final concentration of IL-15 utilized is more than 200 U/ml. In some embodiments, the final concentration of IL-15 utilized is less than 20,000 U/ml, optionally less than 18,000, 16,000, 14,000, 12,000, 10,000, 8000, 6000, 4000, or 2000 ng/ml. In some embodiments, the final concentration of IL-15 utilized is about 600 U/ml. In some embodiments, the final concentration of IL-15 utilized is about 2000 U/ml. In further embodiments, the final concentration of IL-15 utilized is greater than 2000 U/ml. In some embodiments, the final concentration of the IL-15 in the second medium is greater than 200 U/ml. In further embodiments, the final concentration of IL-15 in the second medium is greater than 200 U/ml to about 2000 U/ml. In a specific embodiment, the final concentration of IL-15 in the second medium is about 600 U/ml.

[082] IL-7 is a cytokine secreted by stromal cells in the bone marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by normal lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells (as opposed to myeloid progenitor cells where differentiation is stimulated by IL-3). It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis. An example nucleotide sequence for a human *IL7* gene is the NCBI Reference Sequence:

AH006906.2. An exemplary amino acid sequence of a human IL-7 polypeptide is provided as SEQ ID NO: 883.

[083] As utilized in the methods provided herein, a final concentration of IL-7 can be from about 10 U/ml to about 7,000 U/ml. In some embodiments, the final concentration of IL-7 can be from about 5 ng/ml to about 3,500 ng/ml.

[084] IL-21 is a cytokine that has potent regulatory effects on cells of the immune system, including natural killer (NK) cells and cytotoxic T cells that can destroy virally infected or cancerous cells. This cytokine induces cell division/proliferation in its target cells. IL-21 is expressed in activated human CD4+ T cells but not in most other tissues. In addition, IL-21 expression is up-regulated in Th2 and Th17 subsets of T helper cells, as well as T follicular cells. In fact, it was shown that IL-21 can be used to identify peripheral T follicular helper cells. Furthermore, IL-21 is expressed in NK T cells regulating the function of these cells. An example nucleotide sequence for a human *IL21* gene is the NCBI Reference Sequence: LC133256.1. An exemplary amino acid sequence of a human IL-21 polypeptide is provided as SEQ ID NO: 884.

[085] In some embodiments, the T cell-stimulating cytokine utilized in the methods herein is selected from the group consisting of IL-2, IL-7, IL-15, IL-21, and combinations thereof. In some embodiments, the final concentration of the T cell-stimulating cytokine utilized in the first medium is from about 10 U/ml to about 7,000 U/ml. In some embodiments, the final concentration of T cell-stimulating cytokine utilized in the first medium is from about 5 ng/ml to about 3,500 ng/ml.

[086] In certain embodiments, the first medium utilized in the methods herein does not comprise IL-2, IL-21, or both IL-2 and IL-21. In certain embodiments, the second medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In specific embodiments, the first medium does not comprise IL-2. In specific embodiments, the second medium does not comprise IL-2. In specific embodiments, the first medium does not comprise IL-21. In specific embodiments, the second medium does not comprise IL-21.

[087] In some embodiments, the second medium further comprises IL-7. In some embodiments, the final concentration of the IL-7 cytokine in the second medium is from about 10 U/ml to about 7,000 U/ml. In some embodiments, the final concentration of IL-7 in the second medium can be from about 5 ng/ml to about 3,500 ng/ml.

[088] In some embodiments, the first medium utilized in the described methods is supplemented with the T cell-stimulating cytokine at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In some embodiments, the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days,

4 days, 5 days, and 6 days. In one embodiment, 30% to 99% of the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

[089] In some embodiments, the second medium utilized in the described methods is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In one embodiment, 30% to 99% of the second medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

[090] As used herein, the term "fragment" used in association with agonist or antibody, refers to a fragment of the agonist or antibody that retains the ability to specifically bind to an antigen. Examples of fragments of antibodies include (i) an Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) an F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment, which comprises a single variable domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv)). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. Other forms of single chain antibodies, such as diabodies are also encompassed. In addition, single chain antibodies also include "linear antibodies" comprising a pair of tandem Fv segments (VH-CH1-VH-CH1), which, together with complementary light chain polypeptides, form a pair of antigen binding regions.

[091] The term "antibody" refers to an immunoglobulin (Ig) molecule, which is generally comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or a functional fragment, mutant, variant, or derivative thereof, that retains the epitope binding features of an Ig molecule. Such fragment, mutant, variant, or derivative antibody formats are known in the art. In an embodiment of a full-length antibody, each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain variable region (domain) is also designated as VDH in this disclosure. The CH is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL). The CL is comprised of a single CL domain. The light chain variable region (domain) is also designated as VDL in this disclosure. The VH and VL can be further subdivided into regions of hypervariability, termed complementarity determining

regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Generally, each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. Immunoglobulin molecules can be of any type (*e.g.*, IgG, IgE, IgM, IgD, IgA and IgY), class (*e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or subclass.

[092] As used herein, the phrases “specific binding,” “specifically bind” “selective binding” or “selectively binds” are interchangeable and refer to a protein complex, such as an agonist, antagonist, antibody or soluble monospecific complex, interacting with high specificity with a particular antigen, as compared with other antigens for which the complex has a lower affinity to associate. The specific binding interaction can be mediated through ionic bonds, hydrogen bonds, or other types of chemical or physical associations. In certain embodiments, a protein complex specifically binds a particular antigen when it recognizes its target antigen in a complex mixture of proteins and/or macromolecules. Two or more agonist, antagonist, antibody or soluble monospecific complex “bind to the same epitope” if the agonists, antagonist, antibody, or soluble monospecific complex cross-compete (one prevents the binding or modulating effect of the other). Typically, the agonist, antagonist, antibody or soluble monospecific complex binds with an affinity (K_D) of approximately less than 10^{-5} M, such as approximately less than 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M or 10^{-10} M or even lower.

[093] The term “ K_D ” as used herein refers to the dissociation equilibrium constant of a particular agonist-antigen interaction. Typically, the agonists described herein bind to a target with a dissociation equilibrium constant (K_D) of less than approximately 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M or 10^{-10} M or even lower, for example, as determined using surface plasmon resonance (SPR) technology in a Biacore instrument using the agonist as the ligand and the target as the analyte, and bind to a target protein with an affinity corresponding to a K_D that is at least ten-fold lower, such as at least 100-fold lower, for instance at least 1000-fold lower, such as at least 10,000-fold lower, for instance at least 100,000-fold lower than its affinity for binding to a non-specific antigen (*e.g.*, BSA, casein) other than the predetermined antigen or a closely-related antigen. The amount with which the affinity is lower is dependent on the K_D of the agonist, so that when the K_D of the agonist is very low (that is, the agonist is highly specific), the amount with which the affinity for the antigen is lower than the affinity for a non-specific antigen may be at least 10,000-fold.

[094] The term “ k_{off} ” (sec^{-1}) as used herein refers to the dissociation rate constant of a particular agonist-antigen interaction. Said value is also referred to as the k_d value.

[095] The term “ k_{on} ” ($M^{-1} \times sec^{-1}$) as used herein refers to the association rate constant of a particular agonist-antigen interaction.

[096] The term “ KD ” (M) as used herein refers to the dissociation equilibrium constant of a particular agonist-antigen interaction.

[097] The term “ K_A ” (M^{-1}) as used herein refers to the association equilibrium constant of a particular agonist-antigen interaction and is obtained by dividing the k_{on} by the k_{off} .

[098] As used herein, the phrase “anti-CD3 antibody” refers to an antibody or variant thereof, *e.g.*, a monoclonal antibody, and includes human, humanized, chimeric or murine antibodies which are directed against the CD3 receptor in the T cell antigen receptor of mature T cells. Anti-CD3 antibodies include OKT-3, also known as muromonab. Anti-CD3 antibodies also include the UCHT1 clone, also known as T3 and CD3c. Other anti-CD3 antibodies include, for example, oteixizumab, teplizumab, and visilizumab.

[099] As used herein, the phrase “anti-CD28 antibody” refers to an antibody or variant thereof, *e.g.*, a monoclonal antibody, and includes human, humanized, chimeric or murine antibodies which are directed against the CD28 receptor in the T cell antigen receptor of mature T cells.

[0100] In some embodiments, an anti-4-1BB antibody can be utilized as a 4-1BB ligand. As used herein, the phrase “anti-4-1BB antibody” refers to an antibody or variant thereof, *e.g.*, a monoclonal antibody, and includes human, humanized, chimeric or murine antibodies which are directed against 4-1BB.

[0101] As used herein, the phrase “anti-CD2 antibody” refers to an antibody or variant thereof, *e.g.*, a monoclonal antibody, and includes human, humanized, chimeric or murine antibodies which are directed against the CD2 receptor in the T cell antigen receptor of mature T cells.

[0102] As used herein, the term “OKT-3” (also referred to herein as “OKT3”) refers to the anti-CD3 antibody produced by Miltenyi Biotech, Inc., San Diego, Calif., USA) and or biosimilar or variant thereof (*e.g.*, a humanized, chimeric, or affinity matured variant). A hybridoma capable of producing OKT-3 is available in the American Type Culture Collection and assigned the ATCC accession number CRL 8001. A hybridoma capable of producing OKT-3 is available in the European Collection of Authenticated Cell Cultures (ECACC) and assigned Catalogue No. 86022706.

[0103] As used herein, the term “UCHT1” refers to the anti-CD3 antibody described in Beverley and Callard (1981) Eur. J. Immunol. 11: 329-334, and or biosimilar or variant thereof (*e.g.*, a humanized, chimeric, or affinity matured variant). A hybridoma capable of producing an

exemplary UCHT1 is available from Creative Diagnostics, Shirley, NY, USA, and assigned Catalogue No. CSC-H3068.

[0104] As used herein, the phrase “activation signal” refers to one or more non-endogenous stimuli that cause T cells to become activated. In the endogenous process, T cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, the T cells divide rapidly and secrete cytokines that regulate or assist the immune response. The endogenous T cell activation process involves at least (a) activation of the TCR complex, which involves CD3, and (b) co-stimulation of CD28 or 4-1BB by proteins on the APC surface. It is known in the art that the endogenous activation of T cells can be simulated by stimulation of T cells by CD3, CD28 or 4-1BB agonists (*e.g.*, antibodies). Thus, CD3, CD28 and/or 4-1BB can together provide an activation signal to T cells.

[0105] As used herein, the phrase “activating and inducing the population of TILs to proliferate” refers to the process of subjecting a population of TILs to activation signals, so that the TILs increase in number or proliferate and begin producing cytokines (activated TILs) to boost the immune response.

[0106] As used herein, the phrase “tumor cells” or “cancer cells” refers to cells that divide in an uncontrolled manner, forming solid tumors or flooding the blood with abnormal cells. Healthy cells stop dividing when there is no longer a need for more daughter cells, but tumor cells or cancer cells continue to produce copies. They are also able to spread from one part of the body to another in a process known as metastasis. Tumor cells can be isolated from a number of cancer types including bladder cancer, brain cancer, breast cancer (including triple negative breast cancer), cervical cancer, colon and rectal cancer, stomach cancer, endometrial cancer, renal cancer, lip and oral cancer, head and neck cancer (including, for example, head and neck squamous cell carcinoma (HNSCC)) glioblastoma, glioblastoma multiforme, neuroblastoma, liver cancer, mesothelioma, lung cancer (including non-small cell lung cancer (NSCLC) and small cell lung cancer), skin cancer (including but not limited to squamous cell carcinoma, basal cell carcinoma, nonmelanoma skin cancer and melanoma), ovarian cancer, uveal cancer, uterine cancer, pancreatic cancer, prostate cancer, sarcoma, and thyroid cancer. In some embodiments, cancer cells are also isolated from lymphoma. Tumor cells can be isolated from primary tumors and metastases.

[0107] As used herein, the phrase “tumor sample” refers to tumor cells isolated from a subject. In certain embodiments, a tumor sample is at least a portion of a solid tumor that is isolated in its entirety or in part from a subject or patient having a tumor. A tumor sample can be isolated from a number of cancer types, including bladder cancer, brain cancer, breast cancer (including

triple negative breast cancer), cervical cancer, colon and rectal cancer, stomach cancer, endometrial cancer, renal cancer, lip and oral cancer, head and neck cancer (including, for example, head and neck squamous cell carcinoma (HNSCC)) glioblastoma, glioblastoma multiforme, neuroblastoma, liver cancer, mesothelioma, lung cancer (including non-small cell lung cancer (NSCLC) and small cell lung cancer), skin cancer (including but not limited to squamous cell carcinoma, basal cell carcinoma, nonmelanoma skin cancer and melanoma), ovarian cancer, uveal cancer, uterine cancer, pancreatic cancer, prostate cancer, sarcoma, and thyroid cancer. In some embodiments, cancer cells are also isolated from lymphoma. Tumor samples can be isolated from primary tumors and metastases.

[0108] As used herein, the phrase “disaggregated tumor sample” refers to a tumor sample that has been fragmented into “tumor fragments”. The fragmentation may be physical fragmentation, mechanical fragmentation, ultrasonic fragmentation, enzymatic fragmentation, or any combinations thereof. The fragmentation may initially be done mechanically (*e.g.*, by dissection) and optionally be followed by enzymatic digestion of the tumor fragments into a single cell suspension. After enzymatic digestion, the tumor digests may be dissociated. In some embodiments, the tumor digests are mechanically dissociated. After dissociation, the resulting cell suspension may be subject to additional separation techniques to remove contaminating cells such as red blood cells. In some embodiments, mechanical disaggregation methods may include chopping or slicing the tumor into smaller tumor fragments, while enzymatic disaggregation methods may include treating the tumor fragments with specific enzymes, such as proteases.

[0109] As used herein, the phrase “T cell receptor agonist” or “TCR agonist” refers to an agonist of the T cell receptor complex. In some embodiments, the TCR agonist is an antibody. In one embodiment, the antibody is a humanized antibody. Suitable TCR agonists include, without limitation, CD3 agonists (*e.g.*, anti-CD3 antibodies).

[0110] As used herein, the term “medium” refers to a liquid or gel designed to support the survival, growth, and/or proliferation of cells in an artificial environment. A medium generally comprises a defined set of components. Such components may include an energy source, growth factors, hormones, stimulants, activators, sugars, salts, vitamins, and/or amino acids, and/or a combination of these. In many embodiments, the medium is cell culture medium.

[0111] As used herein, the phrase “components of the medium are maintained” refers to a medium comprising a defined set of components, such as particular stimulants and activators, where the identity of the components remains constant, but the concentration of one or more of the components may be varied. In certain embodiments, the concentration of one or more components

in the media varies over time while the cells are cultured in the media. However, when the media is changed the fresh media has the same components for each change.

[0112] As used herein, the phrase “feeder cell” refers to cells used to provide extracellular secretions that help another cell type proliferate. In certain embodiments, the feeder cells referred to herein are peripheral blood mononuclear cell (PBMC) or an antigen-presenting cell (APC).

[0113] As used herein, the phrase “recombinant agonist” refers to an agonist protein that is encoded by a recombinant gene, which has been cloned in a system that supports expression of the gene and translation of mRNA. The recombinant gene is designed to be under the control of a well characterized promoter and to express the target agonist protein within the chosen host cell to achieve high-level protein expression. Modification of the gene by recombinant DNA technology can lead to expression of a mutant protein or a large quantity of protein.

[0114] As used herein, the phrase “central memory T cell phenotype” refers to a subset of T cells that in the human are CD45RO⁺ and express CCR7 (CCR7^{hi}) and CD62L (CD62^{hi}). The surface phenotype of central memory T cells also includes TCR, CD3, CD127 (IL-7R), and, in some cases, IL-15R. Central memory cells are defined as functionally having the ability to recirculate to lymph nodes and the white pulp of the spleen, and exhibit stem cell characteristics in that they are able to both self-renew and differentiate into effector cells. Central memory T cells primarily secrete IL-2 and express CD40L as effector molecules after TCR triggering. Central memory T cells can be both CD4 and CD8 T cells, and in human beings are proportionally enriched in lymph nodes and tonsils.

[0115] As used herein, the term “nanomatrix” refers to a colloidal suspension of more than one matrix of polymer chains. A nanomatrix is a multiphase material that has dimensions of less than 500 nm or structures having nanoscale repeat distances between the different phases that make up the material. Polymers may include polyethylene, polypropylene, polystyrene, polysaccharide, dextran, and other macromolecules, which are composed of many repeated subunits. A nanomatrix may also have embedded additional functional compounds, such as magnetic, paramagnetic, or superparamagnetic nanocrystals. In addition, functional moieties, such as ligands or agonists can be covalently attached or bound to the polymer chains for specific applications.

[0116] As used herein, the term “matrix” or “mobile matrix” refers to a discrete, isolatable, three-dimensional lattice-type structure where the backbone of the structure can be flexible or mobile and can be composed of materials, such as polymers and ceramics. Being a three-dimensional structure, a matrix can have a smallest dimension and a largest dimension, such as a length. A mobile matrix may be of collagen, purified proteins, purified peptides,

polysaccharides, glycosaminoglycans, or extracellular matrix compositions. A polysaccharide may include for example, cellulose ethers, starch, gum arabic, agarose, dextran, chitosan, hyaluronic acid, pectins, xanthan, guar gum, or alginate. Other polymers may include polyesters, polyethers, polyacrylates, polyacrylamides, polyamines, polyethylene imines, polyquaternium polymers, polyphosphazenes, polyvinylalcohols, polyvinylacetates, polyvinylpyrrolidones, block copolymers, or polyurethanes. The mobile matrix may comprise a polymer of dextran. “Matrices” refers to a collection of more than one matrix.

[0117] As used herein, the phrase “largest dimension” in the context of a matrix refers to the longest length of the matrix.

[0118] As used herein, the term “dextran” refers to a complex branched glucan, a polysaccharide derived from the condensation of glucose. Dextran chains are of varying lengths, from 3 to 2000 kilodaltons. The polymer main chain consists of α -1,6 glycosidic linkages between glucose monomers, with branches from α -1,3 linkages.

[0119] As used herein, the phrase “agonists bound to a nanomatrix” refers to agonists that are covalently attached to the polymer chains that comprise the matrices within the nanomatrix.

[0120] As used herein, the phrase “colloidal suspension” refers to a mixture in which one substance, such as a matrix, is suspended throughout another substance, such as a liquid. A colloidal suspension thus has a dispersed phase, *i.e.*, the suspended substance, and a continuous phase, *i.e.*, the medium of suspension, such as a liquid.

[0121] As used herein, the phrase “contacting the population of TILs with a nanomatrix” refers to bringing TILs and the nanomatrix together such that the TILs can associate with nanomatrix-bound functional moieties, such as ligands or agonists, or nanomatrix-embedded functional compounds, such as nanocrystals, through ionic, hydrogen-bonding, or other types of physical or chemical interactions.

[0122] As used herein, the term “nanocrystal” refers to a material particle having at least one dimension smaller than 100 nm, based on quantum dots and composed of atoms in either a single- or poly-crystalline arrangement. The size of nanocrystals distinguishes them from larger crystals.

[0123] As used herein, the phrase “magnetic, paramagnetic, or superparamagnetic nanocrystals” refers to nanocrystals that can be manipulated using magnetic fields. Such nanocrystals commonly consist of at least one component that is a magnetic material, such as iron, nickel, or cobalt.

[0124] As used herein, the phrase “colloidal polymer chains” refers to polymer chains that when linked to each other through covalent bonds or other physical or chemical interactions can form colloidal suspensions.

[0125] As used herein, the phrase “soluble monospecific complex” refers to a complex that comprises two binding proteins that are linked, either directly or indirectly, to each other and bind to the same antigen. The two binding proteins are soluble and not immobilized on a surface, particle, or bead.

[0126] As used herein, the phrase “tetrameric antibody complex” or “TAC” refers to a protein complex comprising two antibodies that act as the first and second agonists that are linked by one or two linker antibodies that bind the antibodies acting as first and second agonists. The linker antibodies may bind the constant region of the agonist antibodies, and where the constant regions are of different isotypes, a bi-specific antibody with one binding region for each isotype may also be used. Support for these complexes can also be found in U.S. Patent No. 4,868,109, incorporated by reference herein in its entirety. In other embodiments, the antibodies, or antigen binding fragments thereof, that act as first and second ligands may be covalently or non-covalently bound by one or more linker molecules. Non-limiting examples of such linker molecules include avidin or streptavidin, which may be used to join biotinylated antibodies, such as antibodies with biotin moieties in the Fc region. In additional embodiments, tetrameric antibody complexes may be used as a mixture of complexes. This includes use of more than one species of complex in a mixture of complexes, wherein the complexes of the entire mixture can contact more than two different ligands.

[0127] As used herein, the phrase “RNA-guided nuclease” refers to a nucleic acid/protein complex based on naturally occurring Type II CRISPR-Cas systems, that is a programmable endonuclease that can be used to perform targeted genome editing. RNA-guided nucleases consist of two components: a short ~100 nucleotide guide RNA (gRNA) that uses 20 variable nucleotides at its 5' end to base pair with a target genomic DNA sequence and a nuclease, *e.g.*, the Cas9 endonuclease, that cleaves the target DNA. RNA-guided nucleases include any naturally occurring CRISPR-Cas systems and variants thereof including naturally occurring Cas DNA endonuclease and variants thereof. Many of these CRISPR-Cas systems and Cas DNA endonucleases are specifically referred to herein.

[0128] As used herein, the term “Cas9” refers to CRISPR associated protein 9, a protein that plays a vital role in the immunological defense of certain bacteria against DNA viruses, and which is heavily utilized in genetic engineering applications. Cas9 is an RNA-guided DNA endonuclease enzyme associated with the CRISPR (clustered regularly interspaced short

palindromic repeats) adaptive immunity system in *Streptococcus pyogenes*. Cas9 can interrogate sections of DNA by checking for sites complementary to a guide RNA (gRNA). If the DNA substrate is complementary to the gRNA, Cas9 cleaves the DNA. The target specificity of Cas9 stems from the gRNA:DNA complementarity and not modifications to the protein itself (like TALENs and Zinc-fingers). Versions of Cas9 that bind but do not cleave cognate DNA can be used to locate transcriptional activators or repressors to specific DNA sequences in order to control transcriptional activation and repression. Native Cas9 requires a guide RNA composed of two disparate RNAs that associate, the CRISPR RNA (crRNA) and the trans-activating crRNA (tracrRNA). Cas9 targeting has been simplified through the engineering of a chimeric single guide RNA.

[0129] As used herein, the phrase “dead Cas9” or “dCas9” refers to Cas9 endonuclease Dead, which is a mutant form of Cas9 whose endonuclease activity is removed through point mutations in its endonuclease domains. Similar to its unmutated form, dCas9 is used in CRISPR systems along with gRNAs to target specific genes or nucleotides complementary to the gRNA with PAM sequences that allow Cas9 to bind. Cas9 ordinarily has 2 endonuclease domains called the RuvC and HNH domains. The point mutations D10A and H840A change two important residues for endonuclease activity that ultimately results in its deactivation. Although dCas9 lacks endonuclease activity, it is still capable of binding to its guide RNA and the DNA strand that is being targeted because such binding is managed by other domains. This alone is often enough to attenuate if not outright block transcription of the targeted gene if the gRNA positions dCas9 in a way that prevents transcriptional factors and RNA polymerase from accessing the DNA. However, this ability to bind DNA can also be exploited for activation since dCas9 has modifiable regions, typically the N and C terminus of the protein, that can be used to attach transcriptional activators.

[0130] Furthermore, in accordance with the present disclosure there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein “Sambrook *et al.*, 1989”); *DNA Cloning: A Practical Approach*, Volumes I and II (D. N. Glover ed. 1985); *Oligonucleotide Synthesis* (M. J. Gait ed. 1984); *Nucleic Acid Hybridization* [B. D. Hames & S. J. Higgins eds. (1985)]; *Transcription And Translation* [B. D. Hames & S. J. Higgins, eds. (1984)]; *Animal Cell Culture* [R. I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F. M. Ausubel *et al.* (eds.), *Current Protocols in*

Molecular Biology, John Wiley & Sons, Inc. (1994). Each of these references are incorporated by reference herein in its entirety.

[0131] Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using the BLAST 2.0 suite of programs using default parameters (Altschul, *et al.*, (1997) Nucleic Acids Res. 25:3389-402, incorporated by reference herein in its entirety).

[0132] As used herein, "nucleic acid targeting sequence" and "nucleic acid binding sequence" are used interchangeably and refer to sequences that bind and/or target nucleic acids.

[0133] As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences, which are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins, it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (*e.g.*, charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences, which differ by such conservative substitutions, are said to have "sequence similarity" or "similarity." Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, *e.g.*, according to the algorithm of Meyers and Miller, (1988) Computer Applic. Biol. Sci. 4:11-17, *e.g.*, as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif., USA). Each of these references are incorporated by reference herein in its entirety.

[0134] As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total

number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

[0135] The term "substantial identity" or "substantially identical" in the context of polynucleotide sequences means that a polynucleotide comprises a sequence that has between 50-100% sequence identity, preferably at least 50% sequence identity, preferably at least 60% sequence identity, preferably at least 70%, more preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by considering codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of between 55-100%, preferably at least 55%, preferably at least 60%, more preferably at least 70%, 80%, 90% and most preferably at least 95%.

Tumor infiltrating lymphocytes (TILs)

[0136] Tumor infiltrating lymphocytes or TILs are a population of cells originally obtained as white blood cells that have left the bloodstream of a subject and migrated into a tumor. TILs include, but are not limited to, CD8⁺ cytotoxic T cells (lymphocytes), Th1 and Th17 CD4⁺ T cells, and natural killer (NK) cells. TILs include both primary and secondary TILs. "Primary TILs" are those that are obtained from patient tissue samples as outlined herein (sometimes referred to as "freshly harvested"), and "secondary TILs" are any TIL cell populations that have been expanded or proliferated as discussed herein.

[0137] TILs can generally be defined either biochemically, using cell surface markers, or functionally, by their ability to infiltrate tumors and effect treatment. TILs can be generally categorized as expressing one or more of the following biomarkers: CD4, CD8, TCR $\alpha\beta$, TCR $\gamma\delta$, CD27, CD28, CD56, CCR7, CD45RA, CD45RO, CD95, PD-1, and CD25. Additionally, and alternatively, TILs can be functionally defined by their ability to infiltrate solid tumors upon reintroduction into a patient. TILs may further be characterized by potency; for example, TILs may be considered potent if, for instance, interferon gamma (IFN γ) release is greater than about 50 pg/ml, greater than about 100 pg/ml, greater than about 150 pg/ml, or greater than about 200 pg/ml upon TCR stimulation.

[0138] Adoptive cell therapy utilizing TILs cultured *ex vivo* by conventional TIL manufacturing processes involves at least two steps, namely at least one rapid expansion protocol (REP) step subsequent to a pre-REP step. Adoptive cell therapy has resulted in successful therapy

following host immunosuppression in patients with melanoma. Current infusion acceptance parameters rely on readouts of the composition of TILs (*e.g.*, CD28, CD8, or CD4 positivity) and on the numerical folds of expansion and viability of the REP product.

[0139] Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system (“cytokine sinks”). Accordingly, some embodiments of the invention may utilize a lymphodepletion step (sometimes also referred to as “immunosuppressive conditioning”) on the patient prior to the introduction of the TILs of the invention. In some embodiments, a lymphodepletion step is not used. Thus, in some embodiments, the subject has undergone lymphodepletion prior to administration of TILs. In many studies, TILs are supported by administration of IL-2 to the subject to facilitate engraftment of the cells. Thus, in some embodiments, the subject receives IL-2 treatment with or after the administration of TILs. In some embodiments, the subject receives high dose or low-dose IL-2 treatment with or after the administration of TILs. In some embodiments, the subject has undergone lymphodepletion prior to administration of TILs as well as receiving IL-2 treatment with or after the administration of TILs. The IL-2 can be high or low dose.

[0140] However, the present disclosure also introduces advantageous manufacturing methods which, in some embodiments, remove the need for prior lymphodepletion and immunosuppressive conditioning or IL-2 administration. In such embodiments, the subject has not undergone lymphodepletion prior to administration of TILs. In some embodiments, the subject does not receive high-dose IL-2 treatment with or after the administration of TILs. In some embodiments, the subject does not receive any IL-2 treatment with or after the administration of TILs. In some embodiments, the subject has not undergone lymphodepletion prior to administration of TILs and does not receive high-dose IL-2 treatment with or after the administration of TILs. In some embodiments, the subject has not undergone lymphodepletion prior to administration of TILs and does not receive any IL-2 treatment with or after the administration of TILs.

Expansion of TILs

[0141] As generally outlined herein, TILs are generally taken from a patient sample and manipulated to expand their number prior to transplant into a patient. In some embodiments, the TILs may be genetically manipulated as discussed below. In general, TILs are initially obtained from a patient tumor sample (“primary TILs”) and then expanded into a larger population for further manipulation as described herein, optionally cryopreserved and re-stimulated, and optionally evaluated for phenotype and metabolic parameters as an indication of TIL health.

[0142] A patient tumor sample may be obtained using methods known in the art, generally via surgical resection, needle biopsy, or other means for obtaining a sample that contains a mixture of tumor and TIL cells. In general, the tumor sample may be from any solid tumor, including primary tumors, invasive tumors or metastases. The solid tumor may be of any cancer type, including, but not limited to, bladder cancer, brain cancer, breast cancer (including triple negative breast cancer), cervical cancer, colon and rectal cancer, stomach cancer, endometrial cancer, renal cancer, lip and oral cancer, head and neck cancer (including, for example, head and neck squamous cell carcinoma (HNSCC)) glioblastoma, glioblastoma multiforme, neuroblastoma, liver cancer, mesothelioma, lung cancer (including non-small cell lung cancer (NSCLC) and small cell lung cancer), skin cancer (including but not limited to squamous cell carcinoma, basal cell carcinoma, nonmelanoma skin cancer and melanoma), ovarian cancer, uveal cancer, uterine cancer, pancreatic cancer, prostate cancer, sarcoma, and thyroid cancer. In some embodiments, useful TILs are obtained from malignant melanoma tumors, as these have been reported to have particularly high levels of TILs. Primary lung, (including non-small cell lung cancer (NSCLC)), bladder, cervical and melanoma tumors or metastases thereof can be used to obtain TILs.

[0143] A solid tumor is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant. Solid tumor cancer refers to malignant, neoplastic, or cancerous solid tumors. Solid tumor cancers include, but are not limited to, bladder cancer, brain cancer, breast cancer (including triple negative breast cancer), cervical cancer, colon and rectal cancer, stomach cancer, endometrial cancer, renal cancer, lip and oral cancer, head and neck cancer (including, for example, head and neck squamous cell carcinoma (HNSCC)) glioblastoma, glioblastoma multiforme, neuroblastoma, liver cancer, mesothelioma, lung cancer (including non-small cell lung cancer (NSCLC) and small cell lung cancer), skin cancer (including but not limited to squamous cell carcinoma, basal cell carcinoma, nonmelanoma skin cancer and melanoma), ovarian cancer, uveal cancer, uterine cancer, pancreatic cancer, prostate cancer, sarcoma, and thyroid cancer. The tissue structure of solid tumors includes interdependent tissue compartments, including the parenchyma (cancer cells) and the supporting stromal cells in which the cancer cells are dispersed, and which may provide a supporting microenvironment.

[0144] Once obtained, the tumor sample is generally fragmented using sharp dissection into small pieces of from about 1 to about 8 mm³, or from about 0.5 to about 4 mm³ with from about 2-3 mm³ being particularly useful. The TILs are cultured from these fragments using enzymatic tumor digests. Such tumor digests may be produced by incubation in enzymatic media (*e.g.*, Roswell Park Memorial Institute (RPMI) 1640 buffer, 2 mM glutamate, 10 µg/ml gentamicin, 30 units/ml of DNase and 1.0 mg/ml of collagenase), followed by mechanical

dissociation (*e.g.*, using a tissue dissociator). Tumor digests may be produced by placing the tumor in enzymatic media and mechanically dissociating the tumor for approximately 1 minute, followed by incubation for 30 minutes at 37° C in 5% CO₂, followed by repeated cycles of mechanical dissociation and incubation under the foregoing conditions until only small tissue pieces are present. At the end of this process, if the cell suspension contains a large number of red blood cells or dead cells, a density gradient separation using FICOLL branched hydrophilic polysaccharide may be performed to remove these cells. Alternative methods known in the art may be used, such as those described in U.S. Patent Application Publication No. 2012/0244133 A1, the disclosure of which is incorporated herein by reference in its entirety. Any of the foregoing methods may be used in any of the embodiments described herein for methods of expanding TILs or methods treating a cancer.

[0145] In general, the harvested cell suspension is called a “primary cell population” or a “freshly harvested” cell population. In some embodiments, fragmentation includes physical fragmentation, including for example, dissection as well as digestion. In some embodiments, the fragmentation is physical fragmentation. In some embodiments, the fragmentation is dissection. In some embodiments, the fragmentation is by digestion. In some embodiments, TILs can be initially cultured from enzymatic tumor digests and tumor fragments obtained from patients.

[0146] In some embodiments, where the tumor is a solid tumor, the tumor undergoes physical fragmentation after the tumor sample is obtained. In some embodiments, the fragmentation occurs before cryopreservation. In some embodiments, the fragmentation occurs after cryopreservation. In some embodiments, the fragmentation occurs after obtaining the tumor and in the absence of any cryopreservation. In some embodiments, the tumor is fragmented and 10, 20, 30, 40 or more fragments or pieces are placed in each container for the first expansion. In some embodiments, the tumor is fragmented, and 30 or 40 fragments or pieces are placed in each container for the first expansion. In some embodiments, the tumor is fragmented, and 40 fragments or pieces are placed in each container for the first expansion. In some embodiments, the multiple fragments comprise about 4 to about 50 fragments, wherein each fragment has a volume of about 27 mm³. In some embodiments, the multiple fragments comprise about 30 to about 60 fragments with a total volume of about 1300 mm³ to about 1500 mm³. In some embodiments, the multiple fragments comprise about 50 fragments with a total volume of about 1350 mm³. In some embodiments, the multiple fragments comprise about 50 fragments with a total mass of about 1 gram to about 1.5 grams. In some embodiments, the multiple fragments comprise about 4 fragments.

[0147] In some embodiments, the TILs are obtained from tumor fragments. In some embodiments, the tumor fragment is obtained by sharp dissection. In some embodiments, the tumor fragment is between about 1 mm³ and 10 mm³. In some embodiments, the tumor fragment is from about 1 mm³ and 8 mm³. In some embodiments, the tumor fragment is from about 0.5 mm³ and 4 mm³. In some embodiments, the tumor fragment is about 1 mm³. In some embodiments, the tumor fragment is about 2 mm³. In some embodiments, the tumor fragment is about 3 mm³. In some embodiments, the tumor fragment is about 4 mm³. In some embodiments, the tumor fragment is about 5 mm³. In some embodiments, the tumor fragment is about 6 mm³. In some embodiments, the tumor fragment is about 7 mm³. In some embodiments, the tumor fragment is about 8 mm³. In some embodiments, the tumor fragment is about 9 mm³. In some embodiments, the tumor fragment is about 10 mm³.

[0148] In some embodiments, the TILs are obtained from tumor digests. In some embodiments, tumor digests are generated by incubation of mechanically dissociated tumor in enzyme media, for example, but not limited to RPMI 1640, 2 mM GlutaMAX, 10 mg/ml gentamicin, 30 U/ml DNase, and 1.0 mg/ml collagenase, followed by mechanical dissociation (GentleMACS, Miltenyi Biotec, Auburn, Calif.). In some embodiments, the mechanically dissociated tumor would be broken up into approximately 1 mm³ pieces. After placing the tumor in enzyme media, the tumor can be mechanically dissociated for approximately 1 minute. The solution can then be incubated for 30 minutes at 37° C in 5% CO₂ and can then be mechanically disrupted again for approximately 1 minute. After being incubated again for 30 minutes at 37° C in 5% CO₂, the tumor can be mechanically disrupted a third time for approximately 1 minute. In some embodiments, after the third mechanical disruption if large pieces of tissue are present, one or two additional mechanical dissociations can be applied to the sample, with or without 30 additional minutes of incubation at 37° C in 5% CO₂. In some embodiments, at the end of the final incubation if the cell suspension contains a large number of red blood cells or dead cells, a density gradient separation using FICOLL can be performed to remove these cells.

[0149] In some embodiments, cells can be optionally frozen or cryopreserved after sample harvest and stored frozen prior to entry into the expansion phase.

[0150] In some embodiments, the methods herein can rescue TIL samples from a previously failed pre-REP expansion. In certain embodiments, the tumor sample is isolated from a subject who has previously had a sample subject to a TIL expansion technique. In some embodiments, the previous TIL expansion technique comprised a pre-REP expansion. In some embodiments, the pre-REP expansion comprises administration of IL-2 to a disaggregated tumor sample from the subject. In some embodiments, in the pre-REP expansion the only T cell-

stimulating cytokine administered to the tumor sample or the TILs expanded from the tumor sample is IL-2. In some embodiments, the previous TIL expansion technique failed. In some embodiments, a TIL expansion technique fails when it does not expand an adequate number of TILs. In some embodiments, an adequate number of TILs is greater than 1000, 5000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000 or 100,000 TILs. In some embodiments, a TIL expansion technique fails when it does not induce an adequate fold expansion of the TILs. In some embodiments, an adequate fold expansion of TILs is greater than 50-, 100-, 1000-, 2000-, 3000-, 4000-, 5000-, 6000-, 7000-, 8000-, 9000- or 10,000-fold expansion. In some embodiments, a portion of the same tumor sample is used in the previous TIL expansion technique and the TIL expansion methods disclosed, herein. In some embodiments, two distinct samples are isolated from the same subject. In some embodiments, the methods described herein are able to provide greater numbers or fold expansion of TILs than the previous expansion technique. In some embodiments, the methods described herein are able to provide a clinically useful number of TILs, wherein the previous expansion technique was unable to provide that number of TILs.

Overview of two step methods for TIL expansion

[0151] In certain methods of activating and expanding TILs, a multi-step process is employed, in addition to the use of feeder cells. This multi-step process includes at least one rapid expansion protocol (REP) step, preceded by a separate pre-REP step.

First expansion step in Multi-step TIL manufacture: pre-REP

[0152] A multi-step TIL manufacture process begins with a pre-REP or first expansion. Generally, pre-REP is initiated using a tumor sample that has been fragmented and/or enzymatically digested and to which one or more T cell-stimulating cytokines selected from IL-2, IL-7, IL-15, IL-21, and combinations thereof is added for slow cytokine-driven growth of the TILs within the tumor sample. The pre-REP or first expansion step can take anywhere between 2 weeks and a few months. Pre-REP can begin with obtaining young TILs, which are capable of increased replication cycles upon administration to a subject/patient and as such may provide additional therapeutic benefits over older TILs (*i.e.*, TILs that have further undergone more rounds of replication prior to administration to a subject/patient).

[0153] In some embodiments, during pre-REP tumor tissue or cells from tumor tissue are grown in standard lab media (including without limitation RPMI) and treated with reagents such as irradiated feeder cells and anti-CD3 antibodies to achieve a desired effect, such as increase in the number of TILs and/or an enrichment of the population for cells containing

desired cell surface markers or other structural, biochemical or functional features. Pre-REP may utilize lab grade reagents (under the assumption that the lab grade reagents get diluted out during a later REP stage), making it easier to incorporate alternative strategies for improving TIL production. Therefore, in some embodiments, the disclosed TLR agonist and/or peptide or peptidomimetics can be included in the culture medium during the pre-REP stage. The pre-REP culture can in some embodiments, include IL-2.

[0154] In some cases, after dissection or digestion of tumor fragments, the resulting cells are cultured in media containing one or more T cell-stimulating cytokines selected from IL-2, IL-7, IL-15, IL-21, and combinations thereof under conditions that favor the growth of TILs over tumor and other cells. In standard methods in the art, tumor digests are incubated in 2 ml wells in media comprising inactivated human AB serum with 6000 U/ml of IL-2 without IL-7, IL-15 or IL-21. In some embodiments of the present invention, 300-6000 U/ml of IL-2 is added. In some embodiments of the present invention, 100-5000 ng/ml of IL-15 is added. In some embodiments of the present invention, from 10 U/ml to 7,000 U/ml of IL-7 and/or IL-21 is added. In some embodiments of the present invention, 100-5000 ng/ml of IL-15 is added and from 10 U/ml to 7,000 U/ml of IL-7 or IL-21 is added. In some embodiments of the present invention, 100-5000 ng/ml of IL-15 is added, 300-6000 U/ml of IL-2 is added and from 10 U/ml to 7,000 U/ml of IL-7 and/or IL-21 is added. During pre-REP, this primary cell population is cultured for a period of days to months, resulting in a bulk TIL population, generally about 1×10^8 bulk TIL cells.

[0155] In one aspect, the present disclosure provides methods of expanding a population of TILs in a disaggregated tumor sample comprising culturing the disaggregated tumor sample in a culture medium comprising IL-15, thereby expanding the population of TILs. In some embodiments, the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 0.5 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 10 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 utilized is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml.

[0156] In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 2 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 20 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 200 U/ml. In some embodiments, the final concentration of IL-15

utilized is less than 20,000 U/ml, optionally less than 18,000, 16,000, 14,000, 12,000, 10,000, 8000, 6000, 4000, or 2000 U/ml.

[0157] In some cases, during the pre-REP or first expansion step, TIL cultures are initiated by the explant of small ($\sim 2 \text{ mm}^3$) tumor fragments or by plating 1×10^6 viable cells of a single cell suspension of enzymatically digested tumor tissue into 2 ml of complete medium (RPMI1640 based medium supplemented with 10% human serum) containing one or more T cell-stimulating cytokines. The cultures are maintained at cell concentrations from 5×10^5 to 2×10^6 cells per ml until several million TIL cells are available, usually 2-4 weeks. Multiple independent cultures are screened by cytokine secretion assay for recognition of autologous tumor cells (if available) and HLA-A2+ tumor cell lines. Two to six independent TIL cultures exhibiting the highest cytokine secretion are then further expanded in complete medium with 6000 U per ml IL-2 until the cell number is over 5×10^7 cells (this cell number is typically reached 3-6 weeks after tumor excision).

[0158] In some cases, the first expansion during pre-REP is performed in a closed system bioreactor, such as G-REX-10 or a G-REX-100.

[0159] In the case where genetically modified TILs are to be used in therapy, the first TIL population (also referred to as the bulk TIL population) can be subjected to genetic modifications prior to the second expansion in the REP step.

[0160] In conventional processes that incorporate the pre-REP step, the demarcation between the pre-REP and the REP occurs once TIL have undergone expansion in the presence of IL-2 and have either reached an appropriate cell number required to initiate a REP or have undergone a pre-REP for a predetermined period of time. In various embodiments, a pre-REP may be complete when the number of TIL obtained is 1×10^6 , 10×10^6 , 4×10^6 or 40×10^6 cells, depending on the manufacturing protocol used. In another embodiment, a pre-REP may be complete when the duration of culture reached is 3 to 14 days or up to 9 to 14 days from when fragmentation occurs. TIL may then either directly cryopreserved for further use, or transitioned to the REP.

[0161] In some cases, the TILs obtained from the pre-REP or first expansion step are stored until phenotyped for selection. In some cases, the TILs obtained from the first expansion are not stored and proceed directly to the second expansion or REP step. In some cases, the TILs obtained from the pre-REP step are not cryopreserved after the first expansion and prior to the second expansion or REP step.

Second and subsequent expansion steps in multi-step TIL manufacture: REP

[0162] In multi-step TIL manufacture, in some cases, the TIL cell population is expanded in number after harvest and initial bulk processing, *i.e.*, pre-REP. This further expansion is referred to as the second expansion, which can include expansion processes generally referred to in the art as a rapid expansion protocol (REP). The second expansion or REP is generally accomplished using a culture media comprising a number of components, including feeder cells, a cytokine source, and an anti-CD3 antibody, in a gas-permeable container. In some cases, the second expansion or REP can be performed using any TIL flasks or containers known by those of skill in the art and can proceed for 7-14 days or longer. In some embodiments, the second and subsequent steps are feeder cell free.

[0163] In some cases, the second expansion or REP can be performed in a gas permeable container using methods known in the art. For example, TILs can be rapidly expanded using non-specific T-cell receptor stimulation in the presence of one or more T cell-stimulating cytokines selected from IL-2, IL-7, IL-15, IL-21, and combinations thereof. The non-specific T-cell receptor stimulus can include, for example, an anti-CD3 antibody, such as about 30 ng/ml of OKT3, a mouse monoclonal anti-CD3 antibody (commercially available from Ortho-McNeil, Raritan, N.J. or Miltenyi Biotec, Auburn, Calif.) or UCHT-1 (commercially available from BioLegend, San Diego, Calif., USA). TILs can be expanded to induce further stimulation of the TILs *in vitro* by including one or more antigens during the second expansion, including antigenic portions thereof, such as epitope(s), of the cancer, which can be optionally expressed from a vector, such as a human leukocyte antigen A2 (HLA-A2) binding peptide, *e.g.*, 0.3 μ M MART-1:26-35 (27 L) or gpl 00:209-217 (210M), optionally in the presence of a T-cell growth factor, such as 300 U/ml IL-2. Other suitable antigens may include, *e.g.*, NY-ESO-1, TRP-1, TRP-2, tyrosinase cancer antigen, MAGE-A3, SSX-2, and VEGFR2, or antigenic portions thereof. TILs may also be rapidly expanded by re-stimulation with the same antigen(s) of the cancer pulsed onto MHC haplotype matched antigen-presenting cells. Alternatively, the TILs can be further re-stimulated with, *e.g.*, irradiated, autologous lymphocytes or with irradiated HLA-A2+ allogeneic lymphocytes and IL-2. In some embodiments, the re-stimulation occurs as part of the second expansion. In some embodiments, the second expansion occurs in the presence of irradiated, autologous lymphocytes or with irradiated HLA-A2+ allogeneic lymphocytes and IL-2.

[0164] In some cases, the second expansion or REP can be conducted in a supplemented cell culture medium comprising one or more T cell-stimulating cytokines IL-2, IL-7, IL-15, IL-21, and combinations thereof, OKT-3, and antigen-presenting feeder cells. In some cases, the antigen-presenting feeder cells (APCs) are PBMCs (peripheral blood mononuclear cells). In some cases,

the ratio of TILs to PBMCs and/or antigen-presenting cells in the rapid expansion and/or the second expansion is 1 to 25 and 1 to 500. In some cases, REP and/or the second expansion is performed in flasks with the bulk TILs being mixed with a 100- or 200-fold excess of inactivated feeder cells, 30 mg/ml OKT3 anti-CD3 antibody and 3000 U/ml IL-2 in 150 ml media. Media replacement is done (generally $\frac{1}{2}$ or $\frac{2}{3}$ media replacement via respiration with fresh media) until the cells are transferred to an alternative growth chamber. Alternative growth chambers include G-REX flasks and other gas permeable containers.

[0165] In one aspect, the second expansion or REP can be conducted in a supplemented cell culture medium comprising IL-15, thereby expanding the population of TILs. In some embodiments, the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 0.5 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 10 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 utilized is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml.

[0166] In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 2 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 20 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 200 U/ml. In some embodiments, the final concentration of IL-15 utilized is less than 20,000 U/ml, optionally less than 18,000, 16,000, 14,000, 12,000, 10,000, 8000, 6000, 4000, or 2000 U/ml.

[0167] In some cases, the second expansion or REP is performed and further comprises a step wherein TILs are selected for superior tumor reactivity. Any selection method known in the art may be used. For example, the methods described in U.S. Patent Application Publication No. 2016/0010058 A1, the disclosure of which is incorporated herein by reference in its entirety, may be used for selection of TILs for superior tumor reactivity. Optionally, a cell viability assay can be performed after the second expansion (including expansions referred to as the REP expansion), using standard assays known in the art. For example, a trypan blue exclusion assay can be done on a sample of the bulk TILs, which selectively labels dead cells and allows a viability assessment. In some cases, TIL samples can be counted and viability determined using a Cellometer K2 automated cell counter (Nexcelom Bioscience, Lawrence, Mass.).

[0168] In some cases, further expansion steps can be performed in addition to the second expansion.

[0169] In some embodiments, the one or more T cell-stimulating cytokines utilized in the methods described herein is selected from the group consisting of IL-2, IL-7, IL-15, IL-21, and combinations thereof. In some embodiments, the final concentration of the T cell-stimulating cytokine utilized in the first medium is about 10 U/ml to about 7,000 U/ml.

[0170] In certain embodiments, the medium utilized in the pre-REP methods described herein does not comprise IL-2, IL-21, or both IL-2 and IL-21. In certain embodiments, the medium utilized in the REP methods does not comprise IL-2, IL-21, or both IL-2 and IL-21. In specific embodiments, the medium utilized in the pre-REP methods does not comprise IL-2. In specific embodiments, the medium utilized in the REP methods does not comprise IL-2. In specific embodiments, the medium utilized in the pre-REP methods does not comprise IL-21. In specific embodiments, the medium utilized in the REP methods does not comprise IL-21.

[0171] In some embodiments, the medium utilized in the REP methods further comprises IL-7. In some embodiments, the final concentration of the IL-7 cytokine in the medium utilized in the REP methods is about 10 U/ml to about 7,000 U/ml.

[0172] In some embodiments, the medium utilized in the pre-REP methods is supplemented with the T cell-stimulating cytokine at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In some embodiments, the medium utilized in the pre-REP methods is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In one embodiment, 30% to 99% of the medium utilized in the pre-REP methods is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

[0173] In some embodiments, the medium utilized in the REP methods is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In one embodiment, 30% to 99% of the medium utilized in the REP methods is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

Feeder cells

[0174] In many cases, the feeder cells used in the multi-step feeder cell-based TIL expansion method are peripheral blood mononuclear cells (PBMCs) obtained from standard whole blood units from healthy blood donors. The PBMCs are obtained using standard methods such as FICOLL-Paque gradient separation. In general, the allogeneic PBMCs are inactivated, either via

irradiation or heat treatment, and used in the REP procedures. In some cases, PBMCs are considered replication incompetent and accepted for use in TIL expansion procedures if the total number of viable cells after 14 days of culture is less than the initial viable cell number put into culture on day 0.

[0175] In some cases, PBMCs are considered replication incompetent and accepted for use in the TIL expansion procedures described herein if the total number of viable cells, cultured in the presence of OKT3 and IL-2, on day 7 and day 14 has not increased from the initial viable cell number put into culture on day 0 of the REP and/or day 0 of the second expansion (*i.e.*, the start day of the second expansion). In some cases, the PBMCs are cultured in the presence of 30 ng/ml OKT3 antibody and 3000 U/ml IL-2.

[0176] In some cases, the second expansion or REP procedure requires a ratio of about 2.5×10^9 feeder cells to between 12.5×10^6 TILs and 100×10^6 TILs.

[0177] After the second expansion step or REP, cells can be harvested. In some embodiments the TILs are harvested after one, two, three, four or more expansion steps. TILs can be harvested in any appropriate and sterile manner, including for example by centrifugation. Methods for TIL harvesting are well known in the art and any such known methods can be employed with the present process.

[0178] In some embodiments, the feeder cells express the TCR agonist. In some embodiments, the feeder cells express an agonist of a T cell costimulatory molecule. In some embodiments, the TCR agonist and/or agonist of a T cell costimulatory molecule are expressed on the surface of the feeder cells.

[0179] In one embodiment, the agonist of a T cell costimulatory molecule is a CD28 agonist. In one embodiment, the agonist of a T cell costimulatory molecule is a CD137 (*i.e.*, 4-1BB) agonist. In one embodiment, the agonist of a T cell costimulatory molecule is a CD2 agonist.

[0180] In some embodiments, a 4-1BB ligand is expressed on the surface of the feeder cells.

[0181] In some embodiments, the feeder cells are genetically modified to express IL-15, IL-7, or both IL-15 and IL-7.

One-step method for expanding and activating TILs

[0182] In one aspect of the one-step process disclosed herein, the pre-REP step of the multi-step TIL expansion protocol is skipped altogether. Significant numbers of TILs can be obtained in 21 days or less during this single expansion step without the use of a pre-REP step, *i.e.*, in a one-step TIL activation and expansion process. In some embodiments, TILs are expanded

using a one-step REP-like process depending on feeder cells. In some embodiments, TILs are expanded using a one-step REP-like process that is feeder cell free. In some embodiments, TILs are expanded in a one-step process using particles, such as Dynabeads. In some embodiments, TILs are expanded in a one-step process using tetrameric antibody complexes (TACs), such as the Immunocult Human T cell Activator from Stemcell Technologies. In some embodiments, TILs are expanded in a one-step process using nanomatrices, such as T cell Transact from Miltenyi Biotec. In some embodiments, TILs are engineered or genetically modified during the one-step TIL expansion process.

[0183] In some embodiments, the TILs are from previous failures using the pre-REP described above. In certain embodiments, a pre-REP failure is a failure to expand TILs isolated from a human subject to 4×10^7 cells in 23 days using the pre-REP protocol. In other embodiments, a pre-REP failure is a failure to expand TILs isolated from a human subject to more than 100x the original number. In other embodiments, a pre-REP failure is a failure to expand TILs isolated from a human subject to 1×10^6 or 1×10^7 cells using the pre-REP protocol. In certain embodiments, the methods provided herein are able to rescue pre-REP failures, *i.e.*, expand cells from samples that have experienced a pre-REP failure.

[0184] In one aspect of the method disclosed herein, the method of expanding a population of TILs in a disaggregated tumor sample comprises culturing the disaggregated tumor sample in a medium, wherein the TILs are contacted with a T cell receptor (TCR) agonist, a CD28 agonist, and a T cell-stimulating cytokine. In some embodiments, the TILs are contacted with a 4-1BB agonist.

[0185] In some embodiments, the disaggregated tumor sample comprises tumor fragments (for example, those generated by mechanical methods) that are 0.5 to 4 mm³ in size. In some embodiments, the tumor fragments are 0.5 to 1 mm³ in size. In some embodiments, the tumor fragments are 1 to 1.5 mm³ in size. In some embodiments, the tumor fragments are 1.5 to 2 mm³ in size. In some embodiments, the tumor fragments are 2 to 2.5 mm³ in size. In some embodiments, the tumor fragments are 2.5 to 3 mm³ in size. In some embodiments, the tumor fragments are 3 to 3.5 mm³ in size. In some embodiments, the tumor fragments are 3.5 to 4 mm³ in size. In some embodiments, the disaggregated tumor sample comprises digested tumor fragments.

[0186] In some embodiments, the disaggregated tumor sample comprises tumor fragments (for example, those generated by dissection methods) that are 25 to 30 mm³ in size. In some embodiments, the tumor fragments are 25 to 26 mm³ in size. In some embodiments, the tumor fragments are 25 to 27 mm³ in size. In some embodiments, the tumor fragments are 25 to 28 mm³ in size. In some embodiments, the tumor fragments are 25 to 29 mm³ in size. In some

embodiments, the tumor fragments are 25 to 30 mm³ in size. In some embodiments, the tumor fragments are 26 to 28 mm³ in size. In some embodiments, the tumor fragments are 25, 26, 27, 28, 29 or 30 mm³ in size. In some embodiments, the disaggregated tumor sample comprises digested tumor fragments.

[0187] In some embodiments, the medium is supplemented with the T cell-stimulating cytokine at a time interval ranging from 1-2 days, 2-3 days, 3-4 days, 4-5 days, or 5-6 days. In some embodiments, the time interval is 1 day. In some embodiments, the time interval is 2 days. In some embodiments, the time interval is 3 days. In some embodiments, the time interval is 4 days. In some embodiments, the time interval is 5 days. In some embodiments, the time interval is 6 days.

[0188] In some embodiments, the final concentration of the T cell-stimulating cytokine is 10 U/ml to 7,000 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 100 U/ml to 200 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 200 U/ml to 300 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 300 U/ml to 400 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 400 U/ml to 500 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 500 U/ml to 600 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 600 U/ml to 700 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 700 U/ml to 800 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 800 U/ml to 900 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 900 U/ml to 1,000 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 1,000 U/ml to 1,500 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 1,500 U/ml to 2,000 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 2,000 U/ml to 2,500 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 2,500 U/ml to 3,000 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 3,000 U/ml to 3,500 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 3,500 U/ml to 4,000 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 4,000 U/ml to 4,500 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 4,500 U/ml to 5,000 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 5,000 U/ml to 5,500 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 5,500 U/ml to 6,000 U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 6,000 U/ml to 6,500

U/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine is 6,500 U/ml to 7,000 U/ml.

[0189] In some embodiments, the final concentration of the T cell-stimulating cytokine is 100-10,000 ng/ml. In some embodiments, the final concentration of T cell-stimulating cytokine utilized is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml. In some embodiments, the final concentration of T cell-stimulating cytokine utilized is about 300 ng/ml. In some embodiments, the final concentration of T cell-stimulating cytokine utilized is about 1000 ng/ml. In further embodiments, the final concentration of T cell-stimulating cytokine utilized is greater than 1000 ng/ml. In some embodiments, the final concentration of the T cell-stimulating cytokine in the second medium is greater than 100 ng/ml. In further embodiments, the final concentration of T cell-stimulating cytokine in the second medium is greater than 100 ng/ml to about 1000 ng/ml. In a specific embodiment, the final concentration of T cell-stimulating cytokine in the second medium is about 300 ng/ml.

[0190] The T-cell stimulating cytokine can be any cytokine effective in stimulating T-cells. In some embodiments, the T cell-stimulating cytokine is IL-2, IL-7, IL-15 and/or IL-21.

[0191] In another aspect, the present disclosure provides methods of expanding a population of TILs in a disaggregated tumor sample comprising culturing the disaggregated tumor sample in a culture medium comprising feeder cells; a TCR agonist; and IL-15, thereby expanding the population of TILs. In some embodiments, the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 0.5 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 10 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 utilized is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml.

[0192] In some embodiments the components of the medium are maintained. In some embodiments, 30% to 99% of the medium is changed at a time interval ranging from 1-2 days, 2-3 days, 3-4 days, 4-5 days, or 5-6 days. In some embodiments, the time interval is 1 day. In some embodiments, the time interval is 2 days. In some embodiments, the time interval is 3 days. In some embodiments, the time interval is 4 days. In some embodiments, the time interval is 5 days. In some embodiments, the time interval is 6 days.

[0193] Also, according to the one step method, TILs can be activated and expanded using a combination of a T cell receptor (TCR) agonist (e.g., an CD3 agonist) and an agonist of a T cell

costimulatory molecule (e.g., a CD28 agonist) in the absence of feeder cells. For example, the TCR agonist and CD28 agonist can be antibodies linked to or complexed with each other or linked to nanomatrices.

[0194] In one aspect, the present disclosure provides methods of expanding a population of TILs in a disaggregated tumor sample comprising culturing the disaggregated tumor sample in a culture medium comprising a TCR agonist; an agonist of a T cell costimulatory molecule; and IL-15, thereby expanding the population of TILs. In some embodiments, the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 0.5 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 10 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 utilized is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml.

[0195] In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 2 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 20 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 200 U/ml. In some embodiments, the final concentration of IL-15 utilized is less than 20,000 U/ml, optionally less than 18,000, 16,000, 14,000, 12,000, 10,000, 8000, 6000, 4000, or 2000 U/ml.

[0196] In some embodiments, the medium comprises feeder cells. In some embodiments, the feeder cells are peripheral blood mononuclear cells (PBMCs). In some embodiments, the feeder cells are antigen presenting cells (APCs). In some embodiments, the feeder cells express the T cell receptor (TCR) agonist and/or the CD28 agonist. In some embodiments, the feeder cells express the T cell receptor (TCR) agonist and/or a 4-1BB agonist, as described in Bartkowiak and Curran, *Front Oncol*, 5:117 (2015), incorporated herein by reference in its entirety. In some embodiments, the 41BB agonist is 41BB ligand. In some embodiments, the T cell receptor (TCR) agonist and/or CD28 are expressed on the surface of the feeder cells. In some embodiments, the feeder cells are genetically modified to express the T cell-stimulating cytokine. In some embodiments, the T-cell agonist is an CD3 agonist. In some embodiments, the CD3 agonist is OKT3 or UCHL1. In some embodiments, the T cell-stimulating cytokine that the feeder cells are genetically modified to express is IL-2, IL-7, IL-15, IL-21, and combinations thereof. In some embodiments, the feeder

cells are genetically modified to express IL-15, IL-7, or both IL-15 and IL-7. In some embodiments, the medium does not comprise feeder cells.

[0197] In some embodiments, the CD28 agonist is soluble in the medium. In some embodiments, the TCR agonist is a CD3 agonist. In some embodiments, the T-cell agonist is an CD3 agonist. In some embodiments, the CD-3 agonist is OKT3 or UCHT.

[0198] In some embodiments, the TCR agonist comprises a soluble monospecific complex comprising two anti-CD3 antibodies linked together. In some embodiments, the CD28 agonist comprises a soluble monospecific complex comprising two anti-CD28 antibodies linked together.

[0199] In some embodiments, the medium comprises a CD2 agonist. In some embodiments, the CD2 agonist comprises a soluble monospecific complex comprising two anti-CD2 antibodies linked together.

[0200] In some embodiments, the soluble monospecific complexes are at a concentration of 0.2-25 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 0.2-1 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 1-2 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 2-5 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 5-10 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 10-15 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 15-20 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 20-25 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are tetrameric antibody complexes (TACs). In some embodiments, each TAC comprises two antibodies from a first animal species bound by two antibody molecules from a second species that specifically bind to the Fc portion of the antibodies from the first animal species. In some embodiments, the anti-CD3 antibody is an OKT3 antibody or an UCHT1 antibody.

[0201] In another aspect, the present disclosure provides methods for expanding a population of TILs comprising culturing the population of TILs in a culture medium comprising IL-15 and a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein the matrices are attached to TCR agonists and agonists of a T cell costimulatory molecule, wherein each matrix is 1 to 500 nm in length in its largest dimension and wherein the method does not comprise the use of feeder cells during expansion of the population of TILs.

[0202] In some embodiments, the TCR agonist and/or the CD28 agonist are linked to a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein each nanomatrix is 1 to 500 nm in length in its largest dimension. In some embodiments, the nanomatrix

is 1 to 50 nm in length in its largest dimension. In some embodiments, the nanomatrix is 50 to 100 nm in length in its largest dimension. In some embodiments, the nanomatrix is 100 to 150 nm in length in its largest dimension. In some embodiments, the nanomatrix is 150 to 200 nm in length in its largest dimension. In some embodiments, the nanomatrix is 200 to 250 nm in length in its largest dimension. In some embodiments, the nanomatrix is 250 to 300 nm in length in its largest dimension. In some embodiments, the nanomatrix is 300 to 350 nm in length in its largest dimension. In some embodiments, the nanomatrix is 350 to 400 nm in length in its largest dimension. In some embodiments, the nanomatrix is 400 to 450 nm in length in its largest dimension. In some embodiments, the nanomatrix is 450 to 500 nm in length in its largest dimension.

[0203] In some embodiments, the TCR agonists and agonists of a T cell costimulatory molecule utilized in the described methods are attached to the same polymer chains. In some embodiments, the TCR agonists and agonists of a T cell costimulatory molecule are attached to different polymer chains. In some embodiments, the TCR agonists are attached to the matrices at 25 µg per mg of matrix. In some embodiments, the agonist of a T cell costimulatory molecule is attached to the matrices at 25 µg per mg of matrix. Typically, the agonists are covalently attached to the polymer chains that comprise the matrices within the nanomatrix.

[0204] In some embodiments, the TCR agonist and the CD28 agonist are attached to the same polymer chains. In some embodiments, the TCR agonist and the CD28 agonist are attached to different polymer chains. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at 25 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 5 µg to about 10 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 10 µg to about 15 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 15 µg to about 20 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 20 µg to about 25 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 25 µg to about 30 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 30 µg to about 35 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 35 µg to about 40 µg per mg of nanomatrix. In some embodiments, the TCR agonist, or fragment thereof, is attached to the nanomatrix at about 40 µg to about 45 µg per mg of nanomatrix. In some embodiments, the TCR

agonist, or fragment thereof, is attached to the nanomatrix at about 45 μg to about 50 μg per mg of nanomatrix. In some embodiments, the TCR agonist is a CD3 agonist.

[0205] In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at 25 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 5 μg to about 10 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 10 μg to about 15 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 15 μg to about 20 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 20 μg to about 25 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 25 μg to about 30 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 30 μg to about 35 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 35 μg to about 40 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 40 μg to about 45 μg per mg of nanomatrix. In some embodiments, the CD28 agonist, or fragment thereof, is attached to the nanomatrix at about 45 μg to about 50 μg per mg of nanomatrix.

[0206] In some embodiments, the nanomatrix further comprises magnetic, paramagnetic or superparamagnetic nanocrystals embedded among or within the matrices of polymer chains. In some embodiments, the matrix of polymer chains comprises a polymer of dextran. In some embodiments, the polymer chains are colloidal polymer chains.

[0207] In some embodiments, the ratio of volume of nanomatrix to volume of TILs in the disaggregated tumor sample is greater than or equal to 1:5. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:10. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:25. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:50. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:100. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:200. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:300. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:400. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:500. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:600. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:700. In some

embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:800. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:900. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:1,000.

[0208] In some embodiments, the ratio of number of matrices to TILs in the disaggregated tumor sample is greater than or equal to 1:500. In some embodiments, the ratio of number of matrices to TILs is 1:500 to 1:750. In some embodiments, the ratio of number of matrices to TILs is 1:750 to 1:1,000. In some embodiments, the ratio of number of matrices to TILs is 1:1,000 to 1:1,250. In some embodiments, the ratio of number of matrices to TILs is 1:1,250 to 1:1,500. In some embodiments, the ratio of number of matrices to TILs is 1:1,500 to 1:1,750. In some embodiments, the ratio of number of matrices to TILs is 1:1,750 to 1:2,000. In some embodiments, the ratio of number of matrices to TILs is 1:2,000 to 1:2,250. In some embodiments, the ratio of number of matrices to TILs is 1:2,250 to 1:2,500. In some embodiments, the ratio of number of matrices to TILs is 1:2,500 to 1:2,750. In some embodiments, the ratio of number of matrices to TILs is 1:2,750 to 1:3,000. In some embodiments, the ratio of number of matrices to TILs is 1:3,000 to 1:3,500. In some embodiments, the ratio of number of matrices to TILs is 1:3,500 to 1:4,000. In some embodiments, the ratio of number of matrices to TILs is 1:4,000 to 1:5,000.

[0209] In some embodiments, the agonists are recombinant agonists. In some embodiments, the agonists are antibodies. In some embodiments, the antibodies are humanized antibodies. In some embodiments, the CD3 agonist is an OKT3 antibody or an UCHT1 antibody.

[0210] In another aspect of the method disclosed herein, the method for expanding a population of TILs comprises contacting the population of TILs with a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein the matrices are attached to CD3 agonists and CD28 agonists, wherein the nanomatrix provides activation signals to the population of TILs, thereby activating and inducing the population of TILs to proliferate, wherein each matrix is 1 to 500 nm in length in its largest dimension, and wherein the method does not comprise the use of feeder cells during expansion of the population of TILs.

[0211] In some embodiments, the population of TILs contacted with the nanomatrix further comprises tumor cells. In some embodiments, the population of TILs is isolated from a subject and contacted with the nanomatrix without an additional expansion process of the population of TILs prior to contacting the population of TILs with the nanomatrix.

[0212] In some embodiments, the CD3 agonists and the CD28 agonists are attached to the same polymer chains. In some embodiments, the CD3 agonists and the CD28 agonists are

attached to different polymer chains. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at 25 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 5 μg to about 10 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 10 μg to about 15 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 15 μg to about 20 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 20 μg to about 25 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 25 μg to about 30 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 30 μg to about 35 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 35 μg to about 40 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 40 μg to about 45 μg per mg of nanomatrix. In some embodiments, the CD3 agonists, or fragments thereof, are attached to the nanomatrix at about 45 μg to about 50 μg per mg of nanomatrix.

[0213] In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at 25 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 5 μg to about 10 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 10 μg to about 15 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 15 μg to about 20 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 20 μg to about 25 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 25 μg to about 30 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 30 μg to about 35 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 35 μg to about 40 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 40 μg to about 45 μg per mg of nanomatrix. In some embodiments, the CD28 agonists, or fragments thereof, are attached to the nanomatrix at about 45 μg to about 50 μg per mg of nanomatrix.

[0214] In some embodiments, the nanomatrix further comprises magnetic, paramagnetic or superparamagnetic nanocrystals embedded among or within the matrices of polymer chains. In

some embodiments, the matrix of polymer chains comprises a polymer of dextran. In some embodiments, the polymer chains are colloidal polymer chains.

[0215] In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:5. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:10. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:25. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:50. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:100. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:200. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:300. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:400. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:500. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:600. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:700. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:800. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:900. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:1,000.

[0216] In some embodiments, the ratio of number of matrices to TILs is greater than or equal to 1:500. In some embodiments, the ratio of number of matrices to TILs is 1:500 to 1:750. In some embodiments, the ratio of number of matrices to TILs is 1:750 to 1:1,000. In some embodiments, the ratio of number of matrices to TILs is 1:1,000 to 1:1,250. In some embodiments, the ratio of number of matrices to TILs is 1:1,250 to 1:1,500. In some embodiments, the ratio of number of matrices to TILs is 1:1,500 to 1:1,750. In some embodiments, the ratio of number of matrices to TILs is 1:1,750 to 1:2,000. In some embodiments, the ratio of number of matrices to TILs is 1:2,000 to 1:2,250. In some embodiments, the ratio of number of matrices to TILs is 1:2,250 to 1:2,500. In some embodiments, the ratio of number of matrices to TILs is 1:2,500 to 1:2,750. In some embodiments, the ratio of number of matrices to TILs is 1:2,750 to 1:3,000. In some embodiments, the ratio of number of matrices to TILs is 1:3,000 to 1:3,500. In some embodiments, the ratio of number of matrices to TILs is 1:3,500 to 1:4,000. In some embodiments, the ratio of number of matrices to TILs is 1:4,000 to 1:5,000.

[0217] In some embodiments, the agonists are recombinant agonists. In some embodiments, the agonists are antibodies. In some embodiments, the antibodies are humanized antibodies. In some embodiments, the CD3 agonist is an OKT3 antibody or an UCHT1 antibody.

[0218] In another aspect, the present disclosure provides methods for expanding a population of TILs comprising culturing the population of TILs in a culture medium comprising IL-15; and a first soluble monospecific complex comprising an anti-CD3 antibody or fragment thereof, a second soluble monospecific complex comprising an anti-CD28 antibody or fragment thereof, and a third soluble monospecific complex comprising an anti-CD2 antibody or fragment thereof, wherein each soluble monospecific complex comprises two antibodies, or fragments thereof, linked together, and each antibody, or fragments thereof, of each soluble monospecific complex specifically binds to the same antigen on the population of TILs. In some embodiments, the soluble monospecific complexes are at a concentration of 0.2-25 μ L/ml. In some embodiments, the need for feeder cells is obviated. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 0.5 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 10 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 utilized is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml.

[0219] In some embodiments, the final concentration of IL-15 in the culture medium is greater than 1 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 2 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 20 U/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 200 U/ml. In some embodiments, the final concentration of IL-15 utilized is less than 20,000 U/ml, optionally less than 18,000, 16,000, 14,000, 12,000, 10,000, 8000, 6000, 4000, or 2000 U/ml.

[0220] In another aspect of the method disclosed herein, the method for expanding a population of TILs comprises contacting the population of TILs with a composition comprising a first, a second, and a third soluble monospecific complex, wherein each soluble monospecific complex comprises two antibodies or fragments thereof linked together, wherein each antibody or fragments thereof of each soluble monospecific complex specifically binds to the same antigen on the population of TILs, wherein the first soluble monospecific complex comprises an anti-CD3 antibody, wherein the second soluble monospecific complex comprises an anti-CD28 antibody, and wherein the third soluble monospecific complex comprises an anti-CD2 antibody, and the method does not comprise the use of feeder cells during expansion of the population of TILs.

[0221] In some embodiments, the population of TILs contacted with the composition further comprises tumor cells. In some embodiments, the population of TILs is isolated from a

subject and contacted with the composition without an additional expansion process of the population of TILs prior to contacting the population of TILs with the composition.

[0222] In some embodiments, the soluble monospecific complexes are at a concentration of 0.2-25 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 0.2-1 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 1-2 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 2-5 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 5-10 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 10-15 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 15-20 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are at a concentration of 20-25 $\mu\text{l/ml}$. In some embodiments, the soluble monospecific complexes are tetrameric antibody complexes (TACs). In some embodiments, each TAC comprises two antibodies from a first animal species bound by two antibody molecules from a second species that specifically bind to the Fc portion of the antibodies from the first animal species. In some embodiments, the anti-CD3 antibody is an OKT3 antibody or an UCHT1 antibody.

[0223] In some embodiments, the TILs are expanded for up to a total of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 days from the initial tumor fragmentation or disaggregation. In some embodiments, the TILs are expanded for a total of 9-25 days, 9-21 days, or 9-14 days. In some embodiments, the TILs are expanded for up to a total of 9 days. In some embodiments, the TILs are expanded for up to a total of 10 days. In some embodiments, the TILs are expanded for up to a total of 11 days. In some embodiments, the TILs are expanded for up to a total of 12 days. In some embodiments, the TILs are expanded for up to a total of 13 days. In some embodiments, the TILs are expanded for up to a total of 14 days. In some embodiments, the TILs are expanded for up to a total of 15 days. In some embodiments, the TILs are expanded for up to a total of 16 days. In some embodiments, the TILs are expanded for up to a total of 17 days. In some embodiments, the TILs are expanded for up to a total of 18 days. In some embodiments, the TILs are expanded for up to a total of 19 days. In some embodiments, the TILs are expanded for up to a total of 20 days. In some embodiments, the TILs are expanded for up to a total of 21 days. In some embodiments, the TILs are expanded for up to a total of 22 days. In some embodiments, the TILs are expanded for up to a total of 23 days. In some embodiments, the TILs are expanded for up to a total of 24 days. In some embodiments, the TILs are expanded for up to a total of 25 days. In some embodiments, the TILs are expanded for up to a total of 26 days. In some embodiments, the TILs are expanded for up to a total of 27 days. In some embodiments, the TILs are expanded for up to a total of 28 days.

[0224] In some embodiments, the population of TILs is expanded 500 to 500,000-fold. In some embodiments, the population of TILs is expanded 500 to 1,000-fold. In some embodiments, the population of TILs is expanded 500 to 4,000-fold. In some embodiments, the population of TILs is expanded 1,000 to 2,500-fold. In some embodiments, the population of TILs is expanded 2,500 to 5,000-fold. In some embodiments, the population of TILs is expanded 5,000 to 10,000-fold. In some embodiments, the population of TILs is expanded 10,000 to 20,000-fold. In some embodiments, the population of TILs is expanded 20,000 to 30,000-fold. In some embodiments, the population of TILs is expanded 30,000 to 40,000-fold. In some embodiments, the population of TILs is expanded 40,000 to 50,000-fold. In some embodiments, the population of TILs is expanded 50,000 to 100,000-fold. In some embodiments, the population of TILs is expanded 100,000 to 150,000-fold. In some embodiments, the population of TILs is expanded 150,000 to 200,000-fold. In some embodiments, the population of TILs is expanded 200,000 to 250,000-fold. In some embodiments, the population of TILs is expanded 250,000 to 300,000-fold. In some embodiments, the population of TILs is expanded 300,000 to 350,000-fold. In some embodiments, the population of TILs is expanded 350,000 to 400,000-fold. In some embodiments, the population of TILs is expanded 400,000 to 450,000-fold. In some embodiments, the population of TILs is expanded 450,000 to 500,000-fold.

[0225] In some embodiments, the population of TILs is expanded from an initial population of TILs of between 100 and 5×10^7 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 100 and 1,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 1,000 and 2,500 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 2,500 and 5,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 5,000 and 7,500 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 7,500 and 10,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 10,000 and 20,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 20,000 and 30,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 30,000 and 40,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 40,000 and 50,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 50,000 and 60,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 60,000 and 70,000 TILs. In some embodiments, the population of TILs is expanded from an initial

population of TILs of between 70,000 and 80,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 80,000 and 90,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 90,000 and 100,000 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 1×10^6 and 2×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 2×10^6 and 3×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 3×10^6 and 4×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 4×10^6 and 5×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 5×10^6 and 6×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 6×10^6 and 7×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 7×10^6 and 8×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 8×10^6 and 9×10^6 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 9×10^6 and 1×10^7 TILs. In some embodiments, the population of TILs is expanded from an initial population of TILs of between 1×10^7 and 5×10^7 TILs.

[0226] In some embodiments, the population of TILs is expanded at least 1,500-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 5,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 7,500-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 10,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 15,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 20,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 25,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 30,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 40,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 50,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 60,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 70,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 80,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 90,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 100,000-fold at day 14 of the expansion. In some embodiments, the

population of TILs is expanded at least 110,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 120,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 130,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at least 140,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at from 1,000-fold to 5,000-fold at day 14 of the expansion. In some embodiments, these fold expansions on day 14 occurred with TILs from pre-REP failures.

[0227] In some embodiments, the population of TILs is expanded at least 150-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 500-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 750-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 1000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 1500-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 2000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 2500-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 3000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 4000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 5000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 6000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 7000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 8000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 9000-fold at day 10 of the expansion. In some embodiments, the population of TILs is expanded at least 10,000-fold at day 10 of the expansion. In some embodiments, these fold expansions on day 10 occurred with TILs from pre-REP failures.

[0228] In some embodiments, the population of TILs is expanded at most 150,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 5,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 7,500-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 10,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 15,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 20,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 25,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 30,000-fold at day 14 of the

expansion. In some embodiments, the population of TILs is expanded at most 40,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 50,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 60,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 70,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 80,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 90,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 100,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 110,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 120,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 130,000-fold at day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 140,000-fold at day 14 of the expansion. In some embodiments, these fold expansions on day 14 occurred with TILs from pre-REP failures.

[0229] In some embodiments, the population of TILs is expanded at least 10,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 15,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 20,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 25,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 30,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 40,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 50,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 60,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 70,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 80,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 90,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 100,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 110,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 120,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 130,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 140,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 150,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 200,000-fold at day 21 of the

expansion. In some embodiments, the population of TILs is expanded at least 300,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at least 400,000-fold at day 21 of the expansion. In some embodiments, these fold expansions on day 21 occurred with TILs from pre-REP failures.

[0230] In some embodiments, the population of TILs is expanded at most 500,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 20,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 25,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 30,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 40,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 50,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 60,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 70,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 80,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 90,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 100,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 110,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 120,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 130,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 140,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 150,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 200,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 300,000-fold at day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 400,000-fold at day 21 of the expansion. In some embodiments, these fold expansions on day 21 occurred with TILs from pre-REP failures.

[0231] In some embodiments, members of the population of TILs are genetically modified. In some embodiments, the population of TILs is genetically modified using an RNA-guided nuclease. In some embodiments, the population of TILs is genetically modified using Cas9 and at least one guide RNA. In some embodiments, members of the population of TILs are epigenetically modified. Various embodiments of genetically modified TILs are provided below.

[0232] In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 2% of the expanded population have a central memory T cell

phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 3% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 4% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 5% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 6% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 7% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 8% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 9% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 11% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 12% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 13% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 14% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein less than 10% of the expanded population have a central memory T cell phenotype.

[0233] In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of

TILs is expanded to produce an expanded population of TILs, wherein 5 to 10% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 15% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 15 to 20% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 20 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 25 to 30% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 30 to 35% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 35 to 40% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 40 to 45% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 45 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion.

[0234] In some embodiments, the population of TILs is expanded to produce an expanded population of TILs that have an increase in abundance of CD8+ cells. In some embodiments, the population of TILs is enriched 10% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 20% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 30% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 40% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 50% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 60% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 70% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 80% after expansion compared to the starting population of TILs. In some embodiments, the population of TILs is enriched 90% after expansion compared to

the starting population of TILs. In some embodiments, the population of TILs is enriched 100% after expansion compared to the starting population of TILs.

[0235] In another aspect, the invention disclosed herein is directed to a composition comprising an expanded population of TILs produced by any of the methods disclosed herein.

Phenotypic characteristics of expanded TILs

[0236] In some cases, the expanded TILs are analyzed for expression of numerous phenotype markers, including those described herein. In some cases, the marker is selected from: TCR α/β , CD57, CD28, CD4, CD27, CD56, CD8a, CD45RA, CD45RO, CD8a, CCR7, CD4, CD3, CD38, and HLA-DR. In some cases, expression of one or more regulatory markers is measured, namely from the group: CD137, CD8a, Lag3, CD4, CD3, PD-1, TIM-3, CD69, CD8a, TIGIT, CD4, CD3, KLRG1, and CD154.

[0237] In some cases, the memory marker is CCR7 or CD62L. In some cases, re-stimulated TILs can also be evaluated for cytokine release, using cytokine release assays. In some cases, TILs can be evaluated for interferon-gamma (IFN-gamma) secretion in response to stimulation either with OKT3 or co-culture with autologous tumor digest.

[0238] In some cases, TILs are evaluated for various regulatory markers, such as TCR α/β , CD56, CD27, CD28, CD57, CD45RA, CD45RO, CD25, CD127, CD95, IL-2R, CCR7, CD62L, KLRG1, and CD122.

T-cell Stimulating Cytokines

[0239] The T-cell stimulating cytokine can be any cytokine effective in stimulating T-cells. In some embodiments, the T cell-stimulating cytokine is IL-2, IL-7, IL-15 and/or IL-21.

[0240] In some embodiments, the methods disclosed herein comprise contacting the disaggregated tumor sample and/or population of TILs with the cytokine IL-15. In some embodiments, the TILs are contacted with the cytokine IL-15 every other day. In some embodiments, the TILs are contacted with the cytokine IL-15 in time intervals of 2, 3, 4, 5, or 6 days. In some embodiments, the TILs are contacted with the cytokine IL-15 in a time interval of 2 days. In some embodiments, the TILs are contacted with the cytokine IL-15 in a time interval of 3 days. In some embodiments, the TILs are contacted with the cytokine IL-15 in a time interval of 4 days. In some embodiments, the TILs are contacted with the cytokine IL-15 in a time interval of 5 days. In some embodiments, the TILs are contacted with the cytokine IL-15 in a time interval of 6 days.

[0241] Concentrations of T-cell stimulating cytokines are expressed either as ng/ml or U (“units”)/ml, herein. The terms International Units (IU) and units are used interchangeably, herein.

Conversion of units between ng/ml and U /ml can vary based on the cytokine used or even the source of a given cytokine. In some embodiments, 2 U/ml of T-cell stimulating cytokine would be the equivalent of 1 ng/ml of T-cell stimulating cytokine. Thus, 20 U/ml of T-cell stimulating cytokine would be the equivalent of 10 ng/ml of T-cell stimulating cytokine, etc. In some embodiments, about 2 U/ml of T-cell stimulating cytokine would be the equivalent of about 1 ng/ml of T-cell stimulating cytokine. As provided above, in some embodiments, the T cell-stimulating cytokine is IL-2, IL-7, IL-15 and/or IL-21. In some embodiments, the conversion provided herein can vary by up to 20% more or less. For example, in some embodiments, 1 unit/ml is the equivalent of 1.6 mg/ml-2.4mg/ml. In some embodiments, the conversion provided herein can vary by up to 10% more or less. For example, in some embodiments, 1 unit/ml is the equivalent of 1.8 mg/ml-2.2mg/ml.

[0242] In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media in the cell culture media is 0.5 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 10 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 0.5 ng/ml to 10 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 10 ng/ml to 25 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 25 ng/ml to 50 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 50 ng/ml to 75 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 75 ng/ml to 100 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 100 ng/ml to 200 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 200 ng/ml to 300 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 300 ng/ml to 400 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 400 ng/ml to 500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 500 ng/ml to 600 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 600 ng/ml to 700 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 700 ng/ml to 800 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 800 ng/ml to 900 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 900 ng/ml to 1000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 1,000 ng/ml to 1,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 1,500 ng/ml to 2,000 ng/ml. In

some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 2,000 ng/ml to 2,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 2,500 ng/ml to 3,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 3,000 ng/ml to 3,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 3,500 ng/ml to 4,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 4,000 ng/ml to 4,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 4,500 ng/ml to 5,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 5,000 ng/ml to 5,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 5,500 ng/ml to 6,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 6,000 ng/ml to 6,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 6,500 ng/ml to 7,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 7,000 ng/ml to 7,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 7,500 ng/ml to 8,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 8,000 ng/ml to 8,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 8,500 ng/ml to 9,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 9,000 ng/ml to 9,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 9,500 ng/ml to 10,000 ng/ml.

[0243] In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media in the cell culture media is 1 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 2 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 20 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 2 U/ml to 20 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 20 U/ml to 50 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 50 U/ml to 100 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 100 U/ml to 150 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 150 U/ml to 200 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 200 U/ml to 400 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 400 U/ml to 600 U/ml. In some embodiments, the final

concentration of the cytokine IL-15 in the cell culture media is 600 U/ml to 800 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 800 U/ml to 1000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 1000 U/ml to 1200 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 1200 U/ml to 1400 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 1400 U/ml to 1600 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 1600 U/ml to 1800 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 1800 U/ml to 2000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 2000 U/ml to 3000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 3000 U/ml to 4000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 4000 U/ml to 5000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 5000 U/ml to 6000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 6000 U/ml to 7000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 7000 U/ml to 8000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 8000 U/ml to 9000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 9000 U/ml to 10,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 10,000 U/ml to 11,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 11,000 U/ml to 12,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 12,000 U/ml to 13,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 13,000 U/ml to 14,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 14,000 U/ml to 15,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 15,000 U/ml to 16,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 16,000 U/ml to 17,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 17,000 U/ml to 18,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 18,000 U/ml to 19,000 U/ml. In some embodiments, the final concentration of the cytokine IL-15 in the cell culture media is 19,000 U/ml to 20,000 U/ml.

[0244] In some embodiments, the methods disclosed herein comprise contacting the disaggregated tumor sample and/or population of TILs with the cytokine IL-7. In some

embodiments, the TILs are contacted with the cytokine IL-7 every other day. In some embodiments, the TILs are contacted with the cytokine IL-7 in time intervals of 2, 3, 4, 5, or 6 days. In some embodiments, the TILs are contacted with the cytokine IL-7 in a time interval of 2 days. In some embodiments, the TILs are contacted with the cytokine IL-7 in a time interval of 3 days. In some embodiments, the TILs are contacted with the cytokine IL-7 in a time interval of 4 days. In some embodiments, the TILs are contacted with the cytokine IL-7 in a time interval of 5 days. In some embodiments, the TILs are contacted with the cytokine IL-7 in a time interval of 6 days.

[0245] In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media in the cell culture media is 0.5 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 10 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 0.5 ng/ml to 10 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 10 ng/ml to 25 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 25 ng/ml to 50 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 50 ng/ml to 75 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 75 ng/ml to 100 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 100 ng/ml to 200 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 200 ng/ml to 300 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 300 ng/ml to 400 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 400 ng/ml to 500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 500 ng/ml to 600 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 600 ng/ml to 700 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 700 ng/ml to 800 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 800 ng/ml to 900 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 900 ng/ml to 1000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 1,000 ng/ml to 1,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 1,500 ng/ml to 2,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 2,000 ng/ml to 2,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 2,500 ng/ml to 3,000 ng/ml. In some embodiments, the final concentration of the

cytokine IL-7 in the cell culture media is 3,000 ng/ml to 3,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 3,500 ng/ml to 4,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 4,000 ng/ml to 4,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 4,500 ng/ml to 5,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 5,000 ng/ml to 5,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 5,500 ng/ml to 6,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 6,000 ng/ml to 6,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 6,500 ng/ml to 7,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 7,000 ng/ml to 7,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 7,500 ng/ml to 8,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 8,000 ng/ml to 8,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 8,500 ng/ml to 9,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 9,000 ng/ml to 9,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 9,500 ng/ml to 10,000 ng/ml.

[0246] In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media in the cell culture media is 1 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 2 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 20 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 2 U/ml to 20 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 20 U/ml to 50 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 50 U/ml to 100 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 100 U/ml to 150 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 150 U/ml to 200 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 200 U/ml to 400 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 400 U/ml to 600 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 600 U/ml to 800 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 800 U/ml to 1000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 1000

U/ml to 1200 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 1200 U/ml to 1400 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 1400 U/ml to 1600 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 1600 U/ml to 1800 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 1800 U/ml to 2000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 2000 U/ml to 3000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 3000 U/ml to 4000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 4000 U/ml to 5000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 5000 U/ml to 6000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 6000 U/ml to 7000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 7000 U/ml to 8000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 8000 U/ml to 9000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 9000 U/ml to 10,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 10,000 U/ml to 11,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 11,000 U/ml to 12,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 12,000 U/ml to 13,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 13,000 U/ml to 14,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 14,000 U/ml to 15,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 15,000 U/ml to 16,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 16,000 U/ml to 17,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 17,000 U/ml to 18,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 18,000 U/ml to 19,000 U/ml. In some embodiments, the final concentration of the cytokine IL-7 in the cell culture media is 19,000 U/ml to 20,000 U/ml.

[0247] In some embodiments, the methods disclosed herein comprise contacting the disaggregated tumor sample and/or population of TILs with the cytokine IL-21. In some embodiments, the TILs are contacted with the cytokine IL-21 every other day. In some embodiments, the TILs are contacted with the cytokine IL-21 in time intervals of 2, 3, 4, 5, or 6 days. In some embodiments, the TILs are contacted with the cytokine IL-21 in a time interval of 2

days. In some embodiments, the TILs are contacted with the cytokine IL-21 in a time interval of 3 days. In some embodiments, the TILs are contacted with the cytokine IL-21 in a time interval of 4 days. In some embodiments, the TILs are contacted with the cytokine IL-21 in a time interval of 5 days. In some embodiments, the TILs are contacted with the cytokine IL-21 in a time interval of 6 days.

[0248] In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media in the cell culture media is 0.5 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 10 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 0.5 ng/ml to 10 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 10 ng/ml to 25 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 25 ng/ml to 50 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 50 ng/ml to 75 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 75 ng/ml to 100 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 100 ng/ml to 200 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 200 ng/ml to 300 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 300 ng/ml to 400 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 400 ng/ml to 500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 500 ng/ml to 600 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 600 ng/ml to 700 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 700 ng/ml to 800 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 800 ng/ml to 900 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 900 ng/ml to 1000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 1,000 ng/ml to 1,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 1,500 ng/ml to 2,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 2,000 ng/ml to 2,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 2,500 ng/ml to 3,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 3,000 ng/ml to 3,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 3,500 ng/ml to 4,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media

is 4,000 ng/ml to 4,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 4,500 ng/ml to 5,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 5,000 ng/ml to 5,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 5,500 ng/ml to 6,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 6,000 ng/ml to 6,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 6,500 ng/ml to 7,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 7,000 ng/ml to 7,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 7,500 ng/ml to 8,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 8,000 ng/ml to 8,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 8,500 ng/ml to 9,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 9,000 ng/ml to 9,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 9,500 ng/ml to 10,000 ng/ml.

[0249] In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media in the cell culture media is 1 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 2 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 20 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 2 U/ml to 20 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 20 U/ml to 50 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 50 U/ml to 100 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 100 U/ml to 150 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 150 U/ml to 200 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 200 U/ml to 400 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 400 U/ml to 600 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 600 U/ml to 800 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 800 U/ml to 1000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 1000 U/ml to 1200 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 1200 U/ml to 1400 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 1400 U/ml to 1600 U/ml. In

some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 1600 U/ml to 1800 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 1800 U/ml to 2000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 2000 U/ml to 3000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 3000 U/ml to 4000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 4000 U/ml to 5000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 5000 U/ml to 6000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 6000 U/ml to 7000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 7000 U/ml to 8000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 8000 U/ml to 9000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 9000 U/ml to 10,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 10,000 U/ml to 11,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 11,000 U/ml to 12,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 12,000 U/ml to 13,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 13,000 U/ml to 14,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 14,000 U/ml to 15,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 15,000 U/ml to 16,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 16,000 U/ml to 17,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 17,000 U/ml to 18,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 18,000 U/ml to 19,000 U/ml. In some embodiments, the final concentration of the cytokine IL-21 in the cell culture media is 19,000 U/ml to 20,000 U/ml.

[0250] In some embodiments, the methods disclosed herein comprise contacting the disaggregated tumor sample and/or population of TILs with the cytokine IL-2. In some embodiments, the TILs are contacted with the cytokine IL-2 every other day. In some embodiments, the TILs are contacted with the cytokine IL-2 in time intervals of 2, 3, 4, 5, or 6 days. In some embodiments, the TILs are contacted with the cytokine IL-2 in a time interval of 2 days. In some embodiments, the TILs are contacted with the cytokine IL-2 in a time interval of 3 days. In some embodiments, the TILs are contacted with the cytokine IL-2 in a time interval of 4 days. In some embodiments, the TILs are contacted with the cytokine IL-2 in a time interval of 5

days. In some embodiments, the TILs are contacted with the cytokine IL-2 in a time interval of 6 days.

[0251] In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media in the cell culture media is 0.51 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 10 ng/ml to 10,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 0.5 ng/ml to 10 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 10 ng/ml to 25 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 25 ng/ml to 50 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 50 ng/ml to 75 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 75 ng/ml to 100 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 100 ng/ml to 200 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 200 ng/ml to 300 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 300 ng/ml to 400 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 400 ng/ml to 500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 500 ng/ml to 600 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 600 ng/ml to 700 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 700 ng/ml to 800 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 800 ng/ml to 900 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 900 ng/ml to 1000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 1,000 ng/ml to 1,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 1,500 ng/ml to 2,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 2,000 ng/ml to 2,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 2,500 ng/ml to 3,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 3,000 ng/ml to 3,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 3,500 ng/ml to 4,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 4,000 ng/ml to 4,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 4,500 ng/ml to 5,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 5,000 ng/ml to 5,500 ng/ml. In some embodiments,

the final concentration of the cytokine IL-2 in the cell culture media is 5,500 ng/ml to 6,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 6,000 ng/ml to 6,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 6,500 ng/ml to 7,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 7,000 ng/ml to 7,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 7,500 ng/ml to 8,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 8,000 ng/ml to 8,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 8,500 ng/ml to 9,000 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 9,000 ng/ml to 9,500 ng/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 9,500 ng/ml to 10,000 ng/ml.

[0252] In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media in the cell culture media is 1 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 2 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 20 U/ml to 20,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 2 U/ml to 20 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 20 U/ml to 50 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 50 U/ml to 100 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 100 U/ml to 150 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 150 U/ml to 200 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 200 U/ml to 400 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 400 U/ml to 600 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 600 U/ml to 800 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 800 U/ml to 1000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 1000 U/ml to 1200 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 1200 U/ml to 1400 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 1400 U/ml to 1600 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 1600 U/ml to 1800 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 1800 U/ml to 2000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture

media is 2000 U/ml to 3000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 3000 U/ml to 4000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 4000 U/ml to 5000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 5000 U/ml to 6000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 6000 U/ml to 7000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 7000 U/ml to 8000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 8000 U/ml to 9000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 9000 U/ml to 10,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 10,000 U/ml to 11,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 11,000 U/ml to 12,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 12,000 U/ml to 13,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 13,000 U/ml to 14,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 14,000 U/ml to 15,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 15,000 U/ml to 16,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 16,000 U/ml to 17,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 17,000 U/ml to 18,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 18,000 U/ml to 19,000 U/ml. In some embodiments, the final concentration of the cytokine IL-2 in the cell culture media is 19,000 U/ml to 20,000 U/ml.

Genetic modification of TILs

[0253] In some cases, the TILs are genetically engineered to include additional functionalities, including, but not limited to, a high-affinity T cell receptor (TCR), *e.g.*, a TCR targeted at a tumor-associated antigen such as MAGE-1, HER2, or NY-ESO-1, or a chimeric antigen receptor (CAR) which binds to a tumor-associated cell surface molecule (*e.g.*, mesothelin) or lineage-restricted cell surface molecule (*e.g.*, EGFR, CD19 or HER2).

[0254] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of one or more endogenous genes. In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising a gene-regulating system capable of reducing the expression and/or function of one or

more endogenous target genes. In some embodiments, these endogenous genes include *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.) In some embodiments, these genes include *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1*, *NFKBIA*. In some embodiments, these genes include *SOCS1* and at least one, two or more genes selected from *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1*, and *NFKBIA*. In some embodiments, these genes include *SOCS1* and *ZC3H12A*.

[0255] Herein, the term “modified TIL” encompasses TILs comprising one or more genomic modifications, effected through non-natural means, resulting in the reduced expression and/or function of one or more endogenous target genes as well as TILs comprising a non-naturally occurring gene-regulating system capable of reducing the expression and/or function of one or more endogenous target genes. The term, “modified TIL” is used interchangeably with the terms “engineered TIL” or “eTILTM”. Herein, an “un-modified TIL” or “control TIL” refers to a TIL or population of TILs wherein the genomes have not been modified through non-naturally occurring means and that does not comprise a non-naturally occurring gene-regulating system or comprises a control gene-regulating system (*e.g.*, an empty vector control, a non-targeting gRNA, a scrambled siRNA, etc.). TILs that occur naturally that have reduced expression and/or function of one or more endogenous genes are included under the terms un-modified or control TILs.

[0256] In some embodiments, the modified TILs manufactured by the methods described herein comprise one or more modifications (*e.g.*, insertions, deletions, or mutations of one or more nucleic acids) in the genomic DNA sequence of an endogenous target gene resulting in the reduced expression and/or function the endogenous gene. In such embodiments, the modified TILs comprise a “modified endogenous target gene.” In some embodiments, the modifications in the genomic DNA sequence reduce or inhibit mRNA transcription, thereby reducing the expression level of the encoded mRNA transcript and protein. In some embodiments, the modifications in the genomic DNA sequence reduce or inhibit mRNA translation, thereby reducing the expression level of the encoded protein. In some embodiments, the modifications in the genomic DNA sequence encode a modified endogenous protein with reduced or altered function compared to the unmodified (*i.e.*, wild-type) version of the endogenous protein (*e.g.*, a dominant-negative mutant, described *infra*). In some embodiments, the modified TILs comprise at least one, two or more

modified endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the modified TILs comprise the modified endogenous target gene *SOCS1* and at least one, two or more modified endogenous target genes selected from *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1*, and *NFKBIA*. In some embodiments, the modified TILs comprise the modified endogenous target genes *SOCS1* and *ZC3H12A*.

[0234] In some embodiments, the modified TILs manufactured by the methods described herein comprise one or more genomic modifications at a genomic location other than an endogenous target gene that result in the reduced expression and/or function of the endogenous target gene or that result in the expression of a modified version of an endogenous protein. For example, in some embodiments, a polynucleotide sequence encoding a gene regulating system is inserted into one or more locations in the genome, thereby reducing the expression and/or function of an endogenous target gene upon the expression of the gene-regulating system. In some embodiments, a polynucleotide sequence encoding a modified version of an endogenous protein is inserted at one or more locations in the genome, wherein the function of the modified version of the protein is reduced compared to the un-modified or wild-type version of the protein (*e.g.*, a dominant-negative mutant, described *infra*).

[0235] In some embodiments, the modified TILs manufactured by the methods described herein comprise one or more modified endogenous target genes, wherein the one or more modifications result in a reduced expression and/or function of a gene product (*i.e.*, an mRNA transcript or a protein) encoded by the endogenous target gene compared to an unmodified TIL. For example, in some embodiments, modified TILs demonstrate reduced expression of an mRNA transcript and/or reduced expression of a protein. In some embodiments, the expression of the gene product in a modified TIL is reduced by at least 5% compared to the expression of the gene product in an unmodified TIL. In some embodiments, the expression of the gene product in a modified TIL is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more compared to the expression of the gene product in an unmodified TIL. In some embodiments, the modified TILs described herein demonstrate reduced expression and/or function of gene products encoded by a plurality (*e.g.*, one or two or more) of endogenous target genes compared to the expression of the gene products in an unmodified TIL. For example, in some embodiments, a modified TIL demonstrates reduced expression and/or function of gene products from 2, 3, 4, 5, 6, 7, 8, 9, 10, or more endogenous target genes compared to the expression of the gene products in an unmodified TIL.

[0236] In some embodiments, the present disclosure provides a modified TIL manufactured by the methods described herein wherein one or more endogenous target genes, or

a portion thereof, are deleted (*i.e.*, “knocked-out”) such that the modified TIL does not express the mRNA transcript or protein. In some embodiments, a modified TIL comprises deletion of a plurality of endogenous target genes, or portions thereof. In some embodiments, a modified TIL comprises deletion of 2, 3, 4, 5, 6, 7, 8, 9, 10, or more endogenous target genes.

[0237] In some embodiments, the modified TILs manufactured by the methods described herein comprise one or more modified endogenous target genes, wherein the one or more modifications to the target DNA sequence result in expression of a protein with reduced or altered function (*e.g.*, a “modified endogenous protein”) compared to the function of the corresponding protein expressed in an unmodified TIL (*e.g.*, a “unmodified endogenous protein”). In some embodiments, the modified TILs described herein comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modified endogenous target genes encoding 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modified endogenous proteins. In some embodiments, the modified endogenous protein demonstrates reduced or altered binding affinity for another protein expressed by the modified TIL or expressed by another cell; reduced or altered signaling capacity; reduced or altered enzymatic activity; reduced or altered DNA-binding activity; or reduced or altered ability to function as a scaffolding protein.

[0238] In some embodiments, the modified endogenous target gene comprises one or more dominant negative mutations. As used herein, a “dominant-negative mutation” refers to a substitution, deletion, or insertion of one or more nucleotides of a target gene such that the encoded protein acts antagonistically to the protein encoded by the unmodified target gene. The mutation is dominant-negative because the negative phenotype confers genic dominance over the positive phenotype of the corresponding unmodified gene. A gene comprising one or more dominant-negative mutations and the protein encoded thereby are referred to as a “dominant-negative mutants”, *e.g.*, dominant-negative genes and dominant-negative proteins. In some embodiments, the dominant negative mutant protein is encoded by an exogenous transgene inserted at one or more locations in the genome of the TIL.

[0239] Various mechanisms for dominant negativity are known. Typically, the gene product of a dominant negative mutant retains some functions of the unmodified gene product but lacks one or more crucial other functions of the unmodified gene product. This causes the dominant-negative mutant to antagonize the unmodified gene product. For example, as an illustrative embodiment, a dominant-negative mutant of a transcription factor may lack a functional activation domain but retain a functional DNA binding domain. In this example, the dominant-negative transcription factor cannot activate transcription of the DNA as the unmodified transcription factor does, but the dominant-negative transcription factor can indirectly inhibit gene expression by preventing the unmodified transcription factor from binding to the transcription-

factor binding site. As another illustrative embodiment, dominant-negative mutations of proteins that function as dimers are known. Dominant-negative mutants of such dimeric proteins may retain the ability to dimerize with unmodified protein but be unable to function otherwise. The dominant-negative monomers, by dimerizing with unmodified monomers to form heterodimers, prevent formation of functional homodimers of the unmodified monomers. Dominant negative mutations of the SOCS1 gene are known in the art and include the murine F59D mutant (*See e.g.*, Hanada *et al.*, J Biol Chem, 276:44:2 (2001), 40746-40754; and Suzuki *et al.*, J Exp Med, 193:4 (2001), 471-482), and the human F58D mutant, identified by sequence alignments of the human and murine SOCS1 amino acid sequences.

[0240] In some embodiments, the modified TILs manufactured by the methods described herein comprise a gene-regulating system capable of reducing the expression and/or function of one or more endogenous target genes selected from *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. (*See* International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.) In some embodiments, the modified TILs manufactured by the methods described herein comprise a gene-regulating system capable of reducing the expression and/or function of one or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the modified TILs described herein comprise a gene-regulating system capable of reducing the expression and/or function of one or more endogenous target genes selected from *SOCS1* and at least one, two or more modified endogenous target genes selected from *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1*, and *NFKBIA*. In some embodiments, the modified TILs described herein comprise a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *ZC3H12A*. In some embodiments, the modified TILs manufactured by the methods described herein comprise a gene-regulating system capable of reducing the expression and/or function of two or more endogenous target genes selected from *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. In some embodiments, the

modified TILs manufactured by the methods described herein comprise a gene-regulating system capable of reducing the expression and/or function of two or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the modified TILs described herein comprise a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and at least one, two or more modified endogenous target genes selected from *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1*, and *NFKBIA*. In some embodiments, the modified TILs described herein comprise a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *ZC3H12A*. The gene-regulating system can reduce the expression and/or function of the endogenous target genes modifications by a variety of mechanisms including by modifying the genomic DNA sequence of the endogenous target gene (*e.g.*, by insertion, deletion, or mutation of one or more nucleic acids in the genomic DNA sequence); by regulating transcription of the endogenous target gene (*e.g.*, inhibition or repression of mRNA transcription); and/or by regulating translation of the endogenous target gene (*e.g.*, by mRNA degradation).

[0241] In some embodiments, the modified TILs manufactured by the methods described herein comprise a gene-regulating system comprising:

(a) one or more nucleic acid molecules capable of reducing the expression and/or modifying the function of a gene product encoded by one or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(b) one or more polynucleotides encoding one or more nucleic acid molecules that are capable of reducing the expression and/or modifying the function of the gene products encoded by one or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(c) one or more proteins capable of reducing the expression and/or modifying the function of the gene products encoded by one or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(d) one or more polynucleotides encoding one or more proteins that are capable of reducing the expression and/or modifying the function of a gene product encoded by one or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(e) one or more guide RNAs (gRNAs) capable of binding to a target DNA sequence in one or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(f) one or more polynucleotides encoding one or more gRNAs capable of binding to a target DNA sequence in one or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(g) one or more site-directed modifying polypeptides capable of interacting with a gRNA and modifying a target DNA sequence in an endogenous gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(h) one or more polynucleotides encoding a site-directed modifying polypeptide capable of interacting with a gRNA and modifying a target DNA sequence in an endogenous gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(i) one or more guide DNAs (gDNAs) capable of binding to a target DNA sequence in two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(j) one or more polynucleotides encoding one or more gDNAs capable of binding to a target DNA sequence in two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(k) one or more site-directed modifying polypeptides capable of interacting with a gDNA and modifying a target DNA sequence in an endogenous gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(l) one or more polynucleotides encoding a site-directed modifying polypeptide capable of interacting with a gDNA and modifying a target DNA sequence in an endogenous gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(m) one or more gRNAs capable of binding to a target mRNA sequence encoded by one or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(n) one or more polynucleotides encoding one or more gRNAs capable of binding to a target mRNA sequence encoded by two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(o) one or more site-directed modifying polypeptides capable of interacting with a gRNA and modifying a target mRNA sequence encoded by an endogenous gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(p) one or more polynucleotides encoding a site-directed modifying polypeptide capable of interacting with a gRNA and modifying a target mRNA sequence encoded

by an endogenous gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;
or

(q) any combination of the above.

[00242] In some embodiments, the modified TILs manufactured by the methods described herein comprise a gene-regulating system comprising:

(a) two or more nucleic acid molecules capable of reducing the expression and/or modifying the function of a gene product encoded by two or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(b) one or more polynucleotides encoding two or more nucleic acid molecules that are capable of reducing the expression and/or modifying the function of the gene products encoded by two or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(c) two or more proteins capable of reducing the expression and/or modifying the function of the gene products encoded by two or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(d) one or more polynucleotides encoding two or more proteins that are capable of reducing the expression and/or modifying the function of a gene product encoded by two or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(e) two or more guide RNAs (gRNAs) capable of binding to a target DNA sequence in two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(f) one or more polynucleotides encoding two or more gRNAs capable of binding to a target DNA sequence in two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(g) two or more guide DNAs (gDNAs) capable of binding to a target DNA sequence in two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(h) one or more polynucleotides encoding two or more gDNAs capable of binding to a target DNA sequence in two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(i) two or more gRNAs capable of binding to a target mRNA sequence encoded by two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(j) one or more polynucleotides encoding two or more gRNAs capable of binding to a target mRNA sequence encoded by two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*;

(k) any combination of the above.

[00243] In some embodiments, one, two or more polynucleotides encoding the gene-regulating system are inserted into the genome of the TILs. In some embodiments, one, two or more polynucleotides encoding the gene-regulating system are expressed episomally and are not inserted into the genome of the TILs.

[00244] In some embodiments, the modified TILs manufactured by the methods described herein comprise reduced expression and/or function of one, two or more endogenous target genes and further comprise one or more exogenous transgenes inserted at one or more genomic loci (*e.g.*, a genetic “knock-in”). In some embodiments, the one, two or more exogenous transgenes encode detectable tags, safety-switch systems, chimeric switch receptors, and/or engineered antigen-specific receptors.

[00245] In some embodiments, the modified TILs manufactured by the methods described herein further comprise an exogenous transgene encoding a detectable tag. Examples of detectable tags include but are not limited to, FLAG tags, poly-histidine tags (*e.g.*, 6xHis), SNAP tags, Halo tags, cMyc tags, glutathione-S-transferase tags, avidin, enzymes, fluorescent proteins, luminescent proteins, chemiluminescent proteins, bioluminescent proteins, and phosphorescent proteins. In some embodiments the fluorescent protein is selected from the group consisting of blue/UV proteins (such as BFP, TagBFP, mTagBFP2, Azurite, EBFP2, mKalama1, Sirius, Sapphire, and T-Sapphire); cyan proteins (such as CFP, eCFP, Cerulean, SCFP3A, mTurquoise, mTurquoise2, monomeric Midoriishi-Cyan, TagCFP, and mTFP1); green proteins (such as: GFP, eGFP, mGFP (A208K mutation), Emerald, Superfolder GFP, Monomeric Azami Green, TagGFP2, mUKG, mWasabi, Clover, and mNeonGreen); yellow proteins (such as YFP, eYFP, Citrine, Venus, SYFP2, and TagYFP); orange proteins (such as Monomeric Kusabira-Orange, mKOκ, mKO2, mOrange, and mOrange2); red proteins (such as RFP, mRaspberry, mCherry, mStrawberry, mTangerine, tdTomato, TagRFP, TagRFP-T, mApple, mRuby, and mRuby2); far-red proteins (such as mPlum, HcRed-Tandem, mKate2, mNeptune, and NirFP); near-infrared proteins (such as TagRFP657, IFP1.4, and iRFP); long stokes shift proteins (such as mKeima Red, LSS-mKate1,

LSS-mKate2, and mBeRFP); photoactivatable proteins (such as PA-GFP, PAmCherry1, and PAMTagRFP); photoconvertible proteins (such as Kaede (green), Kaede (red), KikGR1 (green), KikGR1 (red), PS-CFP2, PS-CFP2, mEos2 (green), mEos2 (red), mEos3.2 (green), mEos3.2 (red), PSmOrange, and PSmOrange); and photoswitchable proteins (such as Dronpa). In some embodiments, the detectable tag can be selected from AmCyan, AsRed, DsRed2, DsRed Express, E2-Crimson, HcRed, ZsGreen, ZsYellow, mCherry, mStrawberry, mOrange, mBanana, mPlum, mRaspberry, tdTomato, DsRed Monomer, and/or AcGFP, all of which are available from Clontech.

[00246] In some embodiments, the modified TILs manufactured by the methods described herein further comprise an exogenous transgene encoding a safety-switch system. Safety-switch systems (also referred to in the art as suicide gene systems) comprise exogenous transgenes encoding for one or more proteins that enable the elimination of a modified TIL after the TIL has been administered to a subject. Examples of safety-switch systems are known in the art. For example, safety-switch systems include genes encoding for proteins that convert non-toxic pro-drugs into toxic compounds such as the Herpes simplex thymidine kinase (Hsv-*tk*) and ganciclovir (GCV) system (Hsv-*tk*/GCV). Hsv-*tk* converts non-toxic GCV into a cytotoxic compound that leads to cellular apoptosis. As such, administration of GCV to a subject that has been treated with modified TILs comprising a transgene encoding the Hsv-*tk* protein can selectively eliminate the modified TILs while sparing endogenous TILs. (See *e.g.*, Bonini *et al.*, Science, 1997, 276(5319):1719-1724; Ciceri *et al.*, Blood, 2007, 109(11):1828-1836; Bondanza *et al.*, Blood 2006, 107(5):1828-1836, incorporated herein by reference in their entireties).

[00247] Additional safety-switch systems include genes encoding for cell-surface markers, enabling elimination of modified TILs by administration of a monoclonal antibody specific for the cell-surface marker via ADCC. In some embodiments, the cell-surface marker is CD20 and the modified TILs can be eliminated by administration of an anti-CD20 monoclonal antibody such as Rituximab (*see e.g.*, Introna *et al.*, Hum Gene Ther, 2000, 11(4):611-620; Serafini *et al.*, Hum Gene Ther, 2004, 14, 63-76; van Meerten *et al.*, Gene Ther, 2006, 13, 789-797, incorporated herein by reference in their entireties). Similar systems using EGF-R and Cetuximab or Panitumumab are described in International PCT Publication No. WO 2018006880, incorporated herein by reference in its entirety. Additional safety-switch systems include transgenes encoding pro-apoptotic molecules comprising one or more binding sites for a chemical inducer of dimerization (CID), enabling elimination of modified TILs by administration of a CID which induces oligomerization of the pro-apoptotic molecules and activation of the apoptosis pathway. In some embodiments, the pro-apoptotic molecule is Fas (also known as CD95) (Thomis *et al.*, Blood, 2001, 97(5), 1249-1257, incorporated herein by reference in its entirety). In some embodiments, the pro-apoptotic

molecule is caspase-9 (Straathof *et al.*, Blood, 2005, 105(11), 4247-4254, incorporated herein by reference in its entirety).

[00248] In some embodiments, the modified TILs manufactured by the methods described herein further comprise an exogenous transgene encoding a chimeric switch receptor. Chimeric switch receptors are engineered cell-surface receptors comprising an extracellular domain from an endogenous cell-surface receptor and a heterologous intracellular signaling domain, such that ligand recognition by the extracellular domain results in activation of a different signaling cascade than that activated by the wild-type form of the cell-surface receptor. In some embodiments, the chimeric switch receptor comprises the extracellular domain of an inhibitory cell-surface receptor fused to an intracellular domain that leads to the transmission of an activating signal rather than the inhibitory signal normally transduced by the inhibitory cell-surface receptor. In particular embodiments, extracellular domains derived from cell-surface receptors known to inhibit immune effector cell activation can be fused to activating intracellular domains. Engagement of the corresponding ligand will then activate signaling cascades that increase, rather than inhibit, the activation of the immune effector cell. For example, in some embodiments, the modified TILs described herein comprise a transgene encoding a PD1-CD28 switch receptor, wherein the extracellular domain of PD1 is fused to the intracellular signaling domain of CD28 (*See e.g.*, Liu *et al.*, Cancer Res 76:6 (2016), 1578-1590 and Moon *et al.*, Molecular Therapy 22 (2014), S201, incorporated herein by reference in its entirety). In some embodiments, the modified TILs described herein comprise a transgene encoding the extracellular domain of CD200R and the intracellular signaling domain of CD28 (*See Oda et al.*, Blood 130:22 (2017), 2410-2419, incorporated herein by reference in its entirety).

[00249] In some embodiments, the modified TILs manufactured by the methods described herein further comprise an engineered antigen-specific receptor recognizing a protein target expressed by a target cell, such as a tumor cell or an antigen presenting cell (APC), referred to herein as “modified receptor-engineered cells” or “modified RE-cells”. The term “engineered antigen receptor” refers to a non-naturally occurring antigen-specific receptor such as a chimeric antigen receptor (CAR) or a recombinant T cell receptor (TCR). In some embodiments, the engineered antigen receptor is a CAR comprising an extracellular antigen binding domain fused via hinge and transmembrane domains to a cytoplasmic domain comprising a signaling domain. In some embodiments, the CAR extracellular domain binds to an antigen expressed by a target cell in an MHC-independent manner leading to activation and proliferation of the RE cell. In some embodiments, the extracellular domain of a CAR recognizes a tag fused to an antibody or antigen-binding fragment thereof. In such embodiments, the antigen-specificity of the CAR is dependent

on the antigen-specificity of the labeled antibody, such that a single CAR construct can be used to target multiple different antigens by substituting one antibody for another (*See e.g.*, US Patent Nos. 9,233,125 and 9,624,279; US Patent Application Publication Nos. 20150238631 and 20180104354, incorporated herein by reference in their entireties). In some embodiments, the extracellular domain of a CAR may comprise an antigen binding fragment derived from an antibody. Antigen binding domains that are useful in the present disclosure include, for example, scFvs; antibodies; antigen binding regions of antibodies; variable regions of the heavy/light chains; and single chain antibodies.

[00250] In some embodiments, the intracellular signaling domain of a CAR may be derived from the TCR complex zeta chain (such as CD3 ζ signaling domains), Fc γ RIII, Fc ϵ RI, or the T-lymphocyte activation domain. In some embodiments, the intracellular signaling domain of a CAR further comprises a costimulatory domain, for example a 4-1BB, CD28, CD40, MyD88, or CD70 domain. In some embodiments, the intracellular signaling domain of a CAR comprises two costimulatory domains, for example any two of 4-1BB, CD28, CD40, MyD88, or CD70 domains. Exemplary CAR structures and intracellular signaling domains are known in the art (*See e.g.*, WO 2009/091826; US 20130287748; WO 2015/142675; WO 2014/055657; and WO 2015/090229, incorporated herein by reference).

[00251] CARs specific for a variety of tumor antigens are known in the art, for example CD171-specific CARs (Park *et al.*, Mol Ther (2007) 15(4):825-833), EGFRvIII-specific CARs (Morgan *et al.*, Hum Gene Ther (2012) 23(10):1043-1053), EGF-R-specific CARs (Kobold *et al.*, J Natl Cancer Inst (2014) 107(1):364), carbonic anhydrase K-specific CARs (Lamers *et al.*, Biochem Soc Trans (2016) 44(3):951-959), FR- α -specific CARs (Kershaw *et al.*, Clin Cancer Res (2006) 12(20):6106-6015), HER2-specific CARs (Ahmed *et al.*, J Clin Oncol (2015) 33(15):1688-1696; Nakazawa *et al.*, Mol Ther (2011) 19(12):2133-2143; Ahmed *et al.*, Mol Ther (2009) 17(10):1779-1787; Luo *et al.*, Cell Res (2016) 26(7):850-853; Morgan *et al.*, Mol Ther (2010) 18(4):843-851; Grada *et al.*, Mol Ther Nucleic Acids (2013) 9(2):32), CEA-specific CARs (Katz *et al.*, Clin Cancer Res (2015) 21(14):3149-3159), IL13R α 2-specific CARs (Brown *et al.*, Clin Cancer Res (2015) 21(18):4062-4072), GD2-specific CARs (Louis *et al.*, Blood (2011) 118(23):6050-6056; Caruana *et al.*, Nat Med (2015) 21(5):524-529), ErbB2-specific CARs (Wilkie *et al.*, J Clin Immunol (2012) 32(5):1059-1070), VEGF-R-specific CARs (Chinnasamy *et al.*, Cancer Res (2016) 22(2):436-447), FAP-specific CARs (Wang *et al.*, Cancer Immunol Res (2014) 2(2):154-166), MSLN-specific CARs (Moon *et al.*, Clin Cancer Res (2011) 17(14):4719-30), NKG2D-specific CARs (VanSeggelen *et al.*, Mol Ther (2015) 23(10):1600-1610), CD19-specific CARs (Axicabtagene ciloleucel (Yescarta[®]) and Tisagenlecleucel (Kymriah[®])). *See also*,

Li *et al.*, J Hematol and Oncol (2018) 11(22), reviewing clinical trials of tumor-specific CARs. Exemplary CARs suitable for use according to the present disclosure are described below in Table 2.

Table 2: Exemplary CAR constructs

CAR Ref ID	Target	Ag-binding domain	Intracellular Domain	Transmembrane Domain	AA SEQ ID	NA SEQ ID
KSQCAR017	human EGFR	Cetuximab H225 scFv	CD3 zeta	CD8a hinge	906	907
KSQCAR1909	human CD19	FMC63 scFv	CD3 zeta	CD8a hinge	908	909
KSQCAR010	human HER2	Herceptin scFv	CD3 zeta	CD8a hinge	910	911

[00252] In some embodiments, the engineered antigen receptor is a recombinant TCR. Recombinant TCRs comprise TCR α and/or TCR β chains that have been isolated and cloned from T cell populations recognizing a particular target antigen. For example, TCR α and/or TCR β genes (*i.e.*, *TRAC* and *TRBC*) can be cloned from T cell populations isolated from individuals with particular malignancies or T cell populations that have been isolated from humanized mice immunized with specific tumor antigens or tumor cells. Recombinant TCRs recognize antigen through the same mechanisms as their endogenous counterparts (*e.g.*, by recognition of their cognate antigen presented in the context of major histocompatibility complex (MHC) proteins expressed on the surface of a target cell). This antigen engagement stimulates endogenous signal transduction pathways leading to activation and proliferation of the TCR-engineered cells.

[00253] Recombinant TCRs specific for tumor antigens are known in the art, for example WT1-specific TCRs (JTCR016, Juno Therapeutics; WT1-TCRc4, described in US Patent Application Publication No. 20160083449), MART-1 specific TCRs (including the DMF4T clone, described in Morgan *et al.*, Science 314 (2006) 126-129); the DMF5T clone, described in Johnson *et al.*, Blood 114 (2009) 535-546); and the ID3T clone, described in van den Berg *et al.*, Mol. Ther. 23 (2015) 1541-1550), gp100-specific TCRs (Johnson *et al.*, Blood 114 (2009) 535-546), CEA-specific TCRs (Parkhurst *et al.*, Mol Ther. 19 (2011) 620-626), NY-ESO and LAGE-1 specific TCRs (1G4T clone, described in Robbins *et al.*, J Clin Oncol 26 (2011) 917-924; Robbins *et al.*, Clin Cancer Res 21 (2015) 1019-1027; and Rapoport *et al.*, Nature Medicine 21 (2015) 914-921), and MAGE-A3-specific TCRs (Morgan *et al.*, J Immunother 36 (2013) 133-151) and Linette *et al.*, Blood 122 (2013) 227-242). (*See also*, Debets *et al.*, Seminars in Immunology 23 (2016) 10-21).

[00254] To generate the recombinant TCRs, the native TRAC (SEQ ID NO: 885) and TRBC (SEQ ID NOs: 886) protein sequences are fused to the C-terminal ends of TCR- α and TCR- β chain variable regions specific for a protein or peptide of interest. For example, the engineered TCR can recognize the NY-ESO peptide (SLLMWITQC, SEQ ID NO: 887), such as the 1G4 TCR or the 95:LY TCR (Robbins *et al*, Journal of Immunology 2008 180:6116-6131). In such illustrative embodiments, the paired 1G4-TCR α/β chains comprise SEQ ID NOs: 888 and 889, respectively and the paired 95:LY-TCR α/β chains comprise SEQ ID NOs: 890 and 891, respectively. The recombinant TCR can recognize the MART-1 peptide (AAGIGILTV, SEQ ID NO: 892), such as the DMF4 and DMF5 TCRs (Robbins *et al*, Journal of Immunology 2008 180:6116-6131). In such illustrative embodiments, the paired DMF4-TCR α/β chains comprise SEQ ID NOs: 893 and 894, respectively and the paired DMF5-TCR α/β chains comprise SEQ ID NOs: 895 and 896, respectively. The recombinant TCR can recognize the WT-1 peptide (RMFPNAPYL, SEQ ID NO: 897), such as the DLT TCR (Robbins *et al*, Journal of Immunology 2008 180:6116-6131). In such illustrative embodiments, the paired high-affinity DLT-TCR α/β chains comprise SEQ ID NOs: 898 and 899, respectively.

[00255] Codon-optimized DNA sequences encoding the recombinant TCR α and TCR β chain proteins can be generated such that expression of both TCR chains is driven off of a single promoter in a stoichiometric fashion. In such embodiment, the P2A sequence (SEQ ID NO: 900) can be inserted between the DNA sequences encoding the TCR β and the TCR α chain, such that the expression cassettes encoding the recombinant TCR chains comprise the following format: TCR β – P2A – TCR α . As an illustrative embodiment, the protein sequence of the 1G4 NY-ESO-specific TCR expressed from such a cassette would comprise SEQ ID NO: 901, the protein sequence of the 95:LY NY-ESO-specific TCR expressed from such a cassette would comprise SEQ ID NO: 902, the protein sequence of the DMF4 MART1-specific TCR expressed from such a cassette would comprise SEQ ID NO: 903, the protein sequence of the DMF5 MART1-specific TCR expressed from such a cassette would comprise SEQ ID NO: 904, and the protein sequence of the DLT WT1-specific TCR expressed from such a cassette would comprise SEQ ID NO: 905.

[00256] In some embodiments, the engineered antigen receptor is directed against a target antigen selected from a cluster of differentiation molecule, such as CD3, CD4, CD8, CD16, CD24, CD25, CD33, CD34, CD45, CD64, CD71, CD78, CD80 (also known as B7-1), CD86 (also known as B7-2), CD96, , CD116, CD117, CD123, CD133, and CD138, CD371 (also known as CLL1); a tumor-associated surface antigen, such as 5T4, BCMA (also known as CD269 and TNFRSF17, UniProt# Q02223), carcinoembryonic antigen (CEA), carbonic anhydrase 9 (CAIX or MN/CAIX), CD19, CD20, CD22, CD30, CD40, disialogangliosides such as GD2, ELF2M, ductal-epithelial

mucin, ephrin B2, epithelial cell adhesion molecule (EpCAM), ErbB2 (HER2/neu), FCRL5 (UniProt# Q68SN8), FKBP11 (UniProt# Q9NYL4), glioma-associated antigen, glycosphingolipids, gp36, GPRC5D (UniProt# Q9NZD1), mut hsp70-2, intestinal carboxyl esterase, IGF-I receptor, ITGA8 (UniProt# P53708), KAMP3, LAGE-1a, MAGE, mesothelin, neutrophil elastase, NKG2D, Nkp30, NY-ESO-1, PAP, prostase, prostate-carcinoma tumor antigen-1 (PCTA-1), prostate specific antigen (PSA), PSMA, prostein, RAGE-1, ROR1, RU1 (SFMBT1), RU2 (DCDC2), SLAMF7 (UniProt# Q9NQ25), survivin, TAG-72, and telomerase; a major histocompatibility complex (MHC) molecule presenting a tumor-specific peptide epitope; tumor stromal antigens, such as the extra domain A (EDA) and extra domain B (EDB) of fibronectin; the A1 domain of tenascin-C (TnC A1) and fibroblast associated protein (FAP); cytokine receptors, such as epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), TFG β -R or components thereof such as endoglin; a major histocompatibility complex (MHC) molecule; a virus-specific surface antigen such as an HIV-specific antigen (such as HIV gp120); an EBV-specific antigen, a CMV-specific antigen, a HPV-specific antigen, a Lassa virus-specific antigen, an Influenza virus-specific antigen as well as any derivate or variant of these surface antigens.

[00257] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of one, two or more endogenous target genes. In some embodiments, these endogenous genes include *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBRI*, *TGFBRI2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.)

[00258] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *ZC3H12A*, *PTPN2*, *CBLB*, *RC3H1* or *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *ZC3H12A*, *PTPN2*, *CBLB*, *RC3H1* or *NFKBIA* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *SOCS1* and *ZC3H12A*, *PTPN2*, *CBLB*, *RC3H1* or *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1*

and *ZC3H12A*, *PTPN2*, *CBLB*, *RC3H1* or *NFKBIA* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00259] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *PTPN2* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *PTPN2* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *SOCS1* and *PTPN2* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *PTPN2* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00260] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *ZC3H12A* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *ZC3H12A* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *SOCS1* and *ZC3H12A* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *ZC3H12A* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00261] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *ZC3H12A* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *ZC3H12A* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *PTPN2* and *ZC3H12A* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *ZC3H12A* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00262] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *CBLB* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *PTPN2* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2*

and *CBLB* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00263] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *ZC3H12A* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *ZC3H12A* and *CBLB* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *ZC3H12A* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *ZC3H12A* and *CBLB* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00264] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *CBLB* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *SOCS1* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *CBLB* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00265] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *RC3H1* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *PTPN2* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *RC3H1* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00266] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *ZC3H12A* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *ZC3H12A* and *RC3H1* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *ZC3H12A* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of

ZC3H12A and *RC3H1* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00267] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *RC3H1* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *SOCS1* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *RC3H1* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00268] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *CBLB* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *CBLB* and *RC3H1* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *CBLB* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *CBLB* and *RC3H1* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00269] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *NFKB1A* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *NFKB1A* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *PTPN2* and *NFKB1A* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *NFKB1A* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00270] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *ZC3H12A* and *NFKB1A* or a gene-regulating system capable of reducing the expression and/or function of *ZC3H12A* and *NFKB1A* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *ZC3H12A* and *NFKB1A* or a gene-regulating system capable of reducing the expression and/or function of

ZC3H12A and *NFKBIA* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00271] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *NFKBIA* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *SOCS1* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *NFKBIA* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00272] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *CBLB* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *CBLB* and *NFKBIA* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *CBLB* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *CBLB* and *NFKBIA* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00273] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *RC3H1* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *RC3H1* and *NFKBIA* and further comprising a CAR or recombinant TCR expressed on the cell surface. In some embodiments, the modified TILs comprise reduced expression and/or function of *RC3H1* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *RC3H1* and *NFKBIA* and further comprising a recombinant expression vector encoding a CAR or a recombinant TCR.

[00274] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising a gene-regulating system capable of reducing the expression and/or function of one or more endogenous target genes. In some embodiments, these endogenous genes include *ANKRD11*, *BCL2L1*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*,

TANK, TGFBRI, TGFBRI2, TIGIT, TNFAIP3, TNIP1, TRAF6, UMPS, WDR6 and ZC3H12A. (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.)

[00275] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *PTPN2* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *PTPN2*.

[00276] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *ZC3H12A* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *ZC3H12A*.

[00277] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *ZC3H12A* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *ZC3H12A*.

[00278] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *CBLB*.

[00279] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *ZC3H12A* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *ZC3H12A* and *CBLB*.

[00280] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *CBLB* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *CBLB*.

[00281] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *RC3H1*.

[00282] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *ZC3H12A* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *ZC3H12A* and *RC3H1*.

[00283] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *RC3H1*.

[00284] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *CBLB* and *RC3H1* or a gene-regulating system capable of reducing the expression and/or function of *CBLB* and *RC3H1*.

[00285] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *PTPN2* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *PTPN2* and *NFKBIA*.

[00286] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *ZC3H12A* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *ZC3H12A* and *NFKBIA*.

[00287] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *SOCS1* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *SOCS1* and *NFKBIA*.

[00288] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *CBLB* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *CBLB* and *NFKBIA*.

[00289] In some embodiments, the present disclosure provides methods of manufacturing modified TILs comprising reduced expression and/or function of *RC3H1* and *NFKBIA* or a gene-regulating system capable of reducing the expression and/or function of *RC3H1* and *NFKBIA*.

Effector functions

[00290] In some embodiments, the modified TILs manufactured by the methods described herein comprise reduced expression and/or function (or a gene-regulating system capable of reducing the expression and/or function) of one or more endogenous target genes selected from *ANKRD11*, *BCL2L1*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A* (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties) and demonstrate an increase in one or more immune cell effector functions. In some embodiments, the modified TILs manufactured by the methods described herein comprise reduced expression and/or function (or a gene-regulating

system capable of reducing the expression and/or function) of one or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA* and demonstrate an increase in one or more immune cell effector functions. Herein, the term “effector function” refers to functions of an immune cell related to the generation, maintenance, and/or enhancement of an immune response against a target cell or target antigen. In some embodiments, the modified TILs manufactured by the methods described herein demonstrate one or more of the following characteristics compared to an unmodified TIL: increased infiltration or migration in to a tumor, increased proliferation, increased or prolonged cell viability, increased resistance to inhibitory factors in the surrounding microenvironment such that the activation state of the cell is prolonged or increased, increased production of pro-inflammatory immune factors (*e.g.*, pro-inflammatory cytokines, chemokines, and/or enzymes), increased cytotoxicity, increased resistance to exhaustion and/or increased percentage of T_{cm}.

[00291] In some embodiments, the modified TILs manufactured by the methods described herein demonstrate increased infiltration into a tumor compared to an unmodified TIL. In some embodiments, increased tumor infiltration by modified TILs refers to an increase the number of modified TILs infiltrating into a tumor during a given period of time compared to the number of unmodified TILs that infiltrate into a tumor during the same period of time. In some embodiments, the modified TILs demonstrate a 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more fold increase in tumor filtration compared to an unmodified immune cell. Tumor infiltration can be measured by isolating one or more tumors from a subject and assessing the number of modified immune cells in the sample by flow cytometry, immunohistochemistry, and/or immunofluorescence.

[00292] In some embodiments, the modified TILs manufactured by the methods described herein demonstrate an increase in cell proliferation compared to an unmodified TIL. In these embodiments, the result is an increase in the number of modified TILs present compared to unmodified TILs after a given period of time. For example, in some embodiments, modified TILs demonstrate increased rates of proliferation compared to unmodified TILs, wherein the modified TILs divide at a more rapid rate than unmodified TILs. In some embodiments, the modified TILs demonstrate a 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more fold increase in the rate of proliferation compared to an unmodified immune cell. In some embodiments, modified TILs demonstrate prolonged periods of proliferation compared to unmodified TILs, wherein the modified TILs and unmodified TILs divide at similar rates, but wherein the modified TILs maintain the proliferative state for a longer period of time. In some embodiments, the modified TILs maintain a proliferative

state for 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more times longer than an unmodified immune cell.

[00293] In some embodiments, the modified TILs manufactured by the methods described herein demonstrate increased or prolonged cell viability compared to an unmodified TIL. In such embodiments, the result is an increase in the number of modified TILs or present compared to unmodified TILs after a given period of time. For example, in some embodiments, modified TILs described herein remain viable and persist for 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more times longer than an unmodified immune cell.

[00294] In some embodiments, the modified TILs manufactured by the methods described herein demonstrate increased resistance to inhibitory factors compared to an unmodified TIL. Exemplary inhibitory factors include signaling by immune checkpoint molecules (*e.g.*, PD1, PDL1, CTLA4, LAG3, IDO) and/or inhibitory cytokines (*e.g.*, IL-10, TGF β).

[00295] In some embodiments, the modified T cells manufactured by the methods described herein demonstrate increased resistance to T cell exhaustion compared to an unmodified T cell. T cell exhaustion is a state of antigen-specific T cell dysfunction characterized by decreased effector function and leading to subsequent deletion of the antigen-specific T cells. In some embodiments, exhausted T cells lack the ability to proliferate in response to antigen, demonstrate decreased cytokine production, and/or demonstrate decreased cytotoxicity against target cells such as tumor cells. In some embodiments, exhausted T cells are identified by altered expression of cell surface markers and transcription factors, such as decreased cell surface expression of CD122 and CD127; increased expression of inhibitory cell surface markers such as PD1, LAG3, CD244, CD160, TIM3, and/or CTLA4; and/or increased expression of transcription factors such as Blimp1, NFAT, and/or BATF. In some embodiments, exhausted T cells demonstrate altered sensitivity cytokine signaling, such as increased sensitivity to TGF β signaling and/or decreased sensitivity to IL-7 and IL-15 signaling. T cell exhaustion can be determined, for example, by co-culturing the T cells with a population of target cells and measuring T cell proliferation, cytokine production, and/or lysis of the target cells. In some embodiments, the modified TILs described herein are co-cultured with a population of target cells (*e.g.*, autologous tumor cells or cell lines that have been engineered to express a target tumor antigen) and effector cell proliferation, cytokine production, and/or target cell lysis is measured. These results are then compared to the results obtained from co-culture of target cells with a control population of immune cells (such as unmodified TILs or immune effector cells that have a control modification).

[00296] In some embodiments, resistance to T cell exhaustion is demonstrated by increased production of one or more cytokines (*e.g.*, IFN γ , TNF α , or IL-2) from the modified TILs compared to the cytokine production observed from the control population of immune cells. In some embodiments, a 1.1-, 1.2-, 1.3-, 1.4-, 1.5-, 1.6-, 1.7-, 1.8-, 1.9-, 2.0-, 2.5-, 3.0-, 3.5-, 4.0-, 4.5-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-fold increase (or more) in cytokine production from the modified TILs compared to the cytokine production from the control population of immune cells is indicative of an increased resistance to T cell exhaustion. In some embodiments, resistance to T cell exhaustion is demonstrated by increased proliferation of the modified TILs compared to the proliferation observed from the control population of immune cells. In some embodiments, a 1.1-, 1.2-, 1.3-, 1.4-, 1.5-, 1.6-, 1.7-, 1.8-, 1.9-, 2.0-, 2.5-, 3.0-, 3.5-, 4.0-, 4.5-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-fold increase (or more) in proliferation of the modified TILs compared to the proliferation of the control population of immune cells is indicative of an increased resistance to T cell exhaustion. In some embodiments, resistance to T cell exhaustion is demonstrated by increased target cell lysis by the modified TILs compared to the target cell lysis observed by the control population of immune cells. In some embodiments, a 1.1-, 1.2-, 1.3-, 1.4-, 1.5-, 1.6-, 1.7-, 1.8-, 1.9-, 2.0-, 2.5-, 3.0-, 3.5-, 4.0-, 4.5-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-fold increase (or more) in target cell lysis by the modified TILs compared to the target cell lysis by the control population of immune cells is indicative of an increased resistance to T cell exhaustion.

[00297] In some embodiments, exhaustion of the modified TILs compared to control populations of immune cells is measured during the *in vitro* or *ex vivo* manufacturing process. For example, in some embodiments, TILs isolated from tumor fragments are modified according to the methods described herein and then expanded in one or more rounds of expansion to produce a population of modified TILs. In such embodiments, the exhaustion of the modified TILs can be determined immediately after harvest and prior to a first round of expansion, after the first round of expansion but prior to a second round of expansion, and/or after the first and the second round of expansion. In some embodiments, exhaustion of the modified TILs compared to control populations of immune cells is measured at one or more time points after transfer of the modified TILs into a subject. For example, in some embodiments, the modified cells are produced according to the methods described herein and administered to a subject. Samples can then be taken from the subject at various time points after the transfer to determine exhaustion of the modified TILs *in vivo* over time.

[00298] In some embodiments, the modified TILs manufactured by the methods described herein demonstrate increased expression or production of pro-inflammatory immune factors

compared to an unmodified TIL. Examples of pro-inflammatory immune factors include cytolytic factors, such as granzyme B, perforin, and granulysin; and pro-inflammatory cytokines such as interferons (IFN α , IFN β , IFN γ), TNF α , IL-1 β , IL-12, IL-2, IL-17, CXCL8, and/or IL-6.

[00299] In some embodiments, the modified TILs manufactured by the methods described herein demonstrate increased cytotoxicity against a target cell compared to an unmodified TIL. In some embodiments, the modified TILs demonstrate a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more fold increase in cytotoxicity against a target cell compared to an unmodified immune cell.

[00300] Assays for measuring immune effector function are known in the art. For example, tumor infiltration can be measured by isolating tumors from a subject and determining the total number and/or phenotype of the lymphocytes present in the tumor by flow cytometry, immunohistochemistry, and/or immunofluorescence. Cell-surface receptor expression can be determined by flow cytometry, immunohistochemistry, immunofluorescence, Western blot, and/or qPCR. Cytokine and chemokine expression and production can be measured by flow cytometry, immunohistochemistry, immunofluorescence, Western blot, ELISA, and/or qPCR. Responsiveness or sensitivity to extracellular stimuli (*e.g.*, cytokines, inhibitory ligands, or antigen) can be measured by assaying cellular proliferation and/or activation of downstream signaling pathways (*e.g.*, phosphorylation of downstream signaling intermediates) in response to the stimuli. Cytotoxicity can be measured by target-cell lysis assays known in the art, including *in vitro* or *ex vivo* co-culture of the modified TILs with target cells and *in vivo* murine tumor models, such as those described throughout the Examples.

Regulation of endogenous pathways and genes

[00301] In some embodiments, the modified TILs manufactured by the methods described herein demonstrate a reduced expression and/or function of one, two or more endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. Further details on the endogenous target genes are provided below in Table 3. In such embodiments, the reduced expression or function of the one, two or more endogenous target genes enhances one or more effector functions of the immune cell.

[00302] In some embodiments, the modified effector cells manufactured by the methods described herein comprise reduced expression and/or function of the Suppressors of cytokine signaling SOCS 1 (*SOCS1*) gene. The SOCS1 protein comprises C-terminal SOCS box motifs, an SH2-domain, an ESS domain, and an N-terminal KIR domain. The 12 amino-acid residues called

the kinase inhibitory region (KIR) has been found to be critical in the ability of SOCS1 to negatively regulate JAK1, TYK2 and JAK2 tyrosine kinase function.

[00303] In some embodiments, the modified effector cells manufactured by the methods described herein comprise reduced expression and/or function of the *PTPN2* gene. The protein tyrosine phosphatase family (PTP) dephosphorylate phospho-tyrosine residues by their phosphatase catalytic domain. PTPN2 functions as a brake on both TCRs and cytokines, which signal through JAK/STAT signaling complexes, and thus serves as a checkpoint on both Signals 1 and 3. Following T Cell engagement with antigen and activation of the TCR, positive signals are amplified downstream by the kinases Lck and Fyn by phosphorylation of tyrosine residues. PTPN2 serves to dephosphorylate both Lck and Fyn and thus attenuate TCR signaling. In addition, following T cell encounter with cytokines and signaling through common γ chain receptor complex, which transmit positive signals through JAK/STAT signaling, PTPN2 also attenuates by dephosphorylation of STAT1 and STAT3. The sum functional impact of PTPN2 loss on T cell function is a lowering of the activation threshold needed for fulminant T cell activation through the TCR, and a hypersensitivity to growth and differentiation-enhancing cytokines.

[00304] In addition, deletion of PTPN2 in the whole mouse increases cytokine levels, lymphocytic infiltration in nonlymphoid tissues and early signs of rheumatoid arthritis-like symptoms; these mice do not survive past 5 weeks of age. Thus, PTPN2 has been identified as critical for postnatal development in mice. Consistent with this autoimmune phenotype, deletion of *Ptpn2* in the T cell lineage from birth also results in an increase in lymphocytic infiltration in non-lymphoid tissues. Importantly, an inducible knockout of *Ptpn2* in adult mouse T cells did not result in any autoimmune manifestations. Outside of its role in autoimmunity, *Ptpn2* deletion was identified to associate with a small percentage of T cell acute lymphoblastic leukemia in humans (ALL), and to enhance skin tumor development in a two-stage chemically-induced carcinogenicity

[00305] In some embodiments, the modified effector cells manufactured by the methods described herein comprise reduced expression and/or function of the *ZC3H12A* gene. The *ZC3H12A* gene encodes Zc3h12, also referred to as MCPIP1 and Regnase-1, which is an RNase that possesses an RNase domain just upstream of a CCCH-type zinc-finger motif. Through its nuclease activity, Zc3h12a targets and destabilizes the mRNAs of transcripts, such as IL-6, by binding a conserved stem loop structure within the 3' UTR of these genes. In T cells, Zc3h12a controls the transcript levels of a number of pro-inflammatory genes, including c-Rel, Ox40 and IL-2. Regnase-1 activation is transient and is subject to negative feedback mechanisms including proteasome-mediated degradation or mucosa-associated lymphoid tissue 1 (MALT1) mediated cleavage. The deubiquitination activity of Regnase-1 promotes the cleavage of polyubiquitin

chains, thus stabilizing protein targets that would otherwise be targeted for degradation. Regnase-1 deubiquitination of TNF receptor-associated factor (TRAF) members regulates JNK and NF-kappa B signaling pathways and is capable of stabilizing hypoxia-inducible factor-1A in conditions of cell stress. The major function of Regnase-1 is promoting mRNA decay via its ribonuclease activity by specifically targeting a subset of genes in different cell types. In monocytes, Regnase-1 downregulates IL-6 and IL-12B mRNAs, thus mitigating inflammation, whereas in T cells, it restricts T-cell activation by targeting c-Rel, Ox40 and IL-2 transcripts. In cancer cells, Regnase-1 promotes apoptosis by inhibiting anti-apoptotic genes including Bcl2L1, Bcl2A1, RelB and Bcl3.

[00306] In some embodiments, the modified effector cells manufactured by the methods described herein comprise reduced expression and/or function of the *CBLB* gene. This gene encodes CBL-B, also referred to as RNF56, Nbla00127 and Cbl proto-oncogene B. CBL-B is an E3 ubiquitin-protein ligase and a member of the CBL gene family. CBL-B functions as a negative regulator of T-cell activation. CBL-B expression in T cells causes ligand-induced T cell receptor down-modulation, controlling the activation degree of T cells during antigen presentation. Mutation of the CBLB gene has been associated with autoimmune conditions such as type 1 diabetes.

[00307] In some embodiments, the modified effector cells manufactured by the methods described herein comprise reduced expression and/or function of the *RC3H1* gene. This gene encodes Ring finger and CCCH-type domains 1, also referred to as Roquin-1. Roquin-1 recognizes and binds to a constitutive decay element (CDE) in the 3' UTR of mRNAs, leading to mRNA deadenylation and degradation. Alternative splicing results in multiple transcript variants.

[00308] In some embodiments, the modified effector cells manufactured by the methods described herein comprise reduced expression and/or function of the *NFKBIA* gene. This gene encodes IκBα, also referred to as NFκB inhibitor alpha, MAD-3, NFKBI and EDAID2. IκBα is one member of a family of cellular proteins that function to inhibit the NF-κB transcription factor. IκBα inhibits NF-κB by masking the nuclear localization signals (NLS) of NF-κB proteins and keeping them sequestered in an inactive state in the cytoplasm. In addition, IκBα blocks the ability of NF-κB transcription factors to bind to DNA, which is required for NF-κB's proper functioning. The *NFKBIA* gene is mutated in some Hodgkin's lymphoma cells; such mutations inactivate the IκBα protein, thus causing NF-κB to be chronically active in the lymphoma tumor cells and this activity contributes to the malignant state of these tumor cells.

Table 3: Endogenous target genes

Gene Symbol	Gene Name	Human UniProt Ref.	Human NCBI Ref	Murine UniProt Ref.	Murine NCBI Ref
<i>SOCS1</i>	suppressor of cytokine signaling 1	O15524	8651 (SEQ ID NO: 1)	O35716	12703 (SEQ ID NO: 2)
<i>PTPN2</i>	protein tyrosine phosphatase, non-receptor type 2	P17706	5771 (SEQ ID NO: 3)	Q06180	19255 (SEQ ID NO: 4)
<i>ZC3H12A</i>	Endoribonuclease ZC3H12A	Q5D1E8	80149 (SEQ ID NO: 5)	Q5D1E7	230738 (SEQ ID NO: 6)
<i>CBLB</i>	Cbl proto-oncogene B	Q13191	868 (SEQ ID NO:7)	Q3TTA7	208650 (SEQ ID NO:8)
<i>RC3H1</i>	Ring finger and CCCH-type domains 1	Q5TC82	149041 (SEQ ID NO:9)	Q4VGL6	381305 (SEQ ID NO:10)
<i>NFKBIA</i>	NFKB inhibitor alpha	P25963	4792 (SEQ ID NO:11)	Q9Z1E3	18035 (SEQ ID NO:12)

[00309] In some embodiments, the modified TILs comprise reduced expression and/or function of any one or two or more of *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* or *NFKBIA*. In some embodiments, the modified TILs comprise reduced expression and/or function of at least one endogenous target gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *CBLB*. In some embodiments, the modified TILs comprise reduced expression and/or function of at least two endogenous target genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *CBLB*.

[00310] In some embodiments, the modified TILs comprise reduced expression and/or function of at least one endogenous target gene selected from *CBLB*, *PTPN2*, *ZC3H12A*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *SOCS1*. In some embodiments, the modified TILs comprise reduced expression and/or function of at least two endogenous target genes selected from *CBLB*, *PTPN2*, *ZC3H12A*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *SOCS1*.

[00311] In some embodiments, the modified TILs comprise reduced expression and/or function of at least one endogenous target gene selected from *CBLB*, *SOCS1*, *ZC3H12A*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *PTPN2*. In some embodiments, the modified TILs comprise reduced expression and/or function of at least two

endogenous target genes selected from *CBLB*, *SOCS1*, *ZC3H12A*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *PTPN2*.

[00312] In some embodiments, the modified TILs comprise reduced expression and/or function of at least one endogenous target gene selected from *CBLB*, *SOCS1*, *PTPN2*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *ZC3H12A*. In some embodiments, the modified TILs comprise reduced expression and/or function of at least two endogenous target genes selected from *CBLB*, *SOCS1*, *PTPN2*, *RC3H1* and *NFKBIA* and further comprise reduced expression and/or function of *ZC3H12A*.

[00313] In some embodiments, the modified TILs comprise reduced expression and/or function of at least one endogenous target gene selected from *CBLB*, *SOCS1*, *PTPN2*, *ZC3H12A* and *NFKBIA* and further comprise reduced expression and/or function of *RC3H1*. In some embodiments, the modified TILs comprise reduced expression and/or function of at least two endogenous target genes selected from *CBLB*, *SOCS1*, *PTPN2*, *ZC3H12A* and *NFKBIA* and further comprise reduced expression and/or function of *RC3H1*.

[00314] In some embodiments, the modified TILs comprise reduced expression and/or function of at least one endogenous target gene selected from *CBLB*, *SOCS1*, *PTPN2*, *ZC3H12A* and *RC3H1* and further comprise reduced expression and/or function of *NFKBIA*. In some embodiments, the modified TILs comprise reduced expression and/or function of at least two endogenous target genes selected from *CBLB*, *SOCS1*, *PTPN2*, *ZC3H12A* and *RC3H1* and further comprise reduced expression and/or function of *NFKBIA*.

Gene-Regulating Systems

[00315] Herein, the term “gene-regulating system” refers to a protein, nucleic acid, or combination thereof that is capable of modifying an endogenous target DNA sequence when introduced into a cell, thereby regulating the expression or function of the encoded gene product. Numerous gene regulating systems suitable for use in the methods of the present disclosure are known in the art including, but not limited to, shRNAs, siRNAs, zinc-finger nuclease systems, TALEN systems, and CRISPR/Cas systems. Gene regulating systems comprise gene editing systems including zinc-finger nuclease systems, TALEN systems, and CRISPR/Cas systems. In some embodiments, the gene-regulating system is a gene-editing system. Gene editing systems suitable for use in the methods of the present disclosure are known in the art including, but not limited to, zinc-finger nuclease systems, TALEN systems, and CRISPR/Cas systems.

[00316] As used herein, “regulate,” when used in reference to the effect of a gene-regulating system on an endogenous target gene encompasses any change in the sequence of the endogenous target gene, any change in the epigenetic state of the endogenous target gene, and/or any change in the expression or function of the protein encoded by the endogenous target gene.

[00317] In some embodiments, the gene-regulating system may mediate a change in the sequence of the endogenous target gene, for example, by introducing one or more mutations into the endogenous target sequence, such as by insertion or deletion of one or more nucleic acids in the endogenous target sequence. Exemplary mechanisms that can mediate alterations of the endogenous target sequence include, but are not limited to, non-homologous end joining (NHEJ) (*e.g.*, classical or alternative), microhomology-mediated end joining (MMEJ), homology-directed repair (*e.g.*, endogenous donor template mediated), SDSA (synthesis dependent strand annealing), single strand annealing or single strand invasion.

[00318] In some embodiments, the gene-regulating system may mediate a change in the epigenetic state of the endogenous target sequence. For example, in some embodiments, the gene-regulating system may mediate covalent modifications of the endogenous target gene DNA (*e.g.*, cytosine methylation and hydroxymethylation) or of associated histone proteins (*e.g.*, lysine acetylation, lysine and arginine methylation, serine and threonine phosphorylation, and lysine ubiquitination and sumoylation).

[00319] In some embodiments, the gene-regulating system may mediate a change in the expression of the protein encoded by the endogenous target gene. In such embodiments, the gene-regulating system may regulate the expression of the encoded protein by modifications of the endogenous target DNA sequence, or by acting on the mRNA product encoded by the DNA sequence. In some embodiments, the gene-regulating system may result in the expression of a modified endogenous protein. In such embodiments, the modifications to the endogenous DNA sequence mediated by the gene-regulating system result in the expression of an endogenous protein demonstrating a reduced function as compared to the corresponding endogenous protein in an unmodified TIL. In such embodiments, the expression level of the modified endogenous protein may be increased, decreased or may be the same, or substantially similar to, the expression level of the corresponding endogenous protein in an unmodified immune cell.

Nucleic acid-based gene-regulating systems

[00320] In some embodiments, the present disclosure provides nucleic acid gene-regulating systems comprising one, two or more nucleic acids capable of reducing the expression and/or

function of at least one, two, or more endogenous gene selected from *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBRI*, *TGFBRI2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.) In some embodiments, the present disclosure provides nucleic acid gene-regulating systems comprising one, two or more nucleic acids capable of reducing the expression and/or function of at least one endogenous gene selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the present disclosure provides nucleic acid gene-regulating systems comprising nucleic acids capable of reducing the expression and/or function of *SOCS1* and at least one, two or more endogenous target genes selected from *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1*, and *NFKBIA*. In some embodiments, the present disclosure provides modified TILs manufactured by the methods described herein comprising such gene-regulating systems. As used herein, a nucleic acid-based gene-regulating system is a system comprising one or more nucleic acid molecules that is capable of regulating the expression of an endogenous target gene without the requirement for an exogenous protein. In some embodiments, the gene-regulating system comprises an RNA interference molecule or antisense RNA molecule that is complementary to a target nucleic acid sequence.

[00321] An “antisense RNA molecule” refers to an RNA molecule, regardless of length, that is complementary to an mRNA transcript. Antisense RNA molecules refer to single stranded RNA molecules that can be introduced to a cell, tissue, or subject and result in decreased expression of an endogenous target gene product through mechanisms that do not rely on endogenous gene silencing pathways, but rather rely on RNaseH-mediated degradation of the target mRNA transcript. In some embodiments, an antisense nucleic acid comprises a modified backbone, for example, phosphorothioate, phosphorodithioate, or others known in the art, or may comprise non-natural internucleoside linkages. In some embodiments, an antisense nucleic acid can comprise locked nucleic acids (LNA).

[00322] “RNA interference molecule” as used herein refers to an RNA polynucleotide that mediates the decreased the expression of an endogenous target gene product by degradation of a target mRNA through endogenous gene silencing pathways (e.g., Dicer and RNA-induced silencing complex (RISC)). Exemplary RNA interference agents include micro RNAs (also

referred to herein as “miRNAs”), short hairpin RNAs (shRNAs), small interfering RNAs (siRNAs), RNA aptamers, and morpholinos.

[00323] In some embodiments, the gene-regulating system comprises one or more miRNAs. miRNAs are naturally occurring, small non-coding RNA molecules of about 21-25 nucleotides in length. miRNAs are at least partially complementary to one or more target mRNA molecules. miRNAs can downregulate (*e.g.*, decrease) expression of an endogenous target gene product through translational repression, cleavage of the mRNA, and/or deadenylation.

[00324] In some embodiments, the gene-regulating system comprises one or more shRNAs. shRNAs are single stranded RNA molecules of about 50-70 nucleotides in length that form stem-loop structures and result in degradation of complementary mRNA sequences. shRNAs can be cloned in plasmids or in non-replicating recombinant viral vectors to be introduced intracellularly and result in the integration of the shRNA-encoding sequence into the genome. As such, an shRNA can provide stable and consistent repression of endogenous target gene translation and expression.

[00325] In some embodiments, nucleic acid-based gene-regulating system comprises one or more siRNAs. siRNAs refer to double stranded RNA molecules typically about 21-23 nucleotides in length. The siRNA associates with a multi protein complex called the RNA-induced silencing complex (RISC), during which the “passenger” sense strand is enzymatically cleaved. The antisense “guide” strand contained in the activated RISC then guides the RISC to the corresponding mRNA because of sequence homology and the same nuclease cuts the target mRNA, resulting in specific gene silencing. Optimally, an siRNA is 18, 19, 20, 21, 22, 23 or 24 nucleotides in length and has a 2-base overhang at its 3' end. siRNAs can be introduced to an individual cell and/or culture system and result in the degradation of target mRNA sequences. siRNAs and shRNAs are further described in Fire *et al.*, Nature, 391:19, 1998 and US Patent Nos. 7,732,417; 8,202,846; and 8,383,599.

[00326] In some embodiments, the gene-regulating system comprises one or more morpholinos. “Morpholino” as used herein refers to a modified nucleic acid oligomer wherein standard nucleic acid bases are bound to morpholine rings and are linked through phosphorodiamidate linkages. Similar to siRNA and shRNA, morpholinos bind to complementary mRNA sequences. However, morpholinos function through steric inhibition of mRNA translation and alteration of mRNA splicing rather than targeting complementary mRNA sequences for degradation.

[00327] In some embodiments, the gene-regulating system comprises a nucleic acid molecule that binds to a target RNA sequence that is at least 90% identical to an RNA sequence

encoded by a DNA sequence defined by a set of genomic coordinates shown in Tables 4, 5, 9-12, and 17-22. Throughout this application, the referenced genomic coordinates are based on genomic annotations in the GRCh38 (also referred to as hg38) assembly of the human genome from the Genome Reference Consortium, available at the National Center for Biotechnology Information website. Tools and methods for converting genomic coordinates between one assembly and another are known in the art and can be used to convert the genomic coordinates provided herein to the corresponding coordinates in another assembly of the human genome, including conversion to an earlier assembly generated by the same institution or using the same algorithm (*e.g.*, from GRCh38 to GRCh37), and conversion an assembly generated by a different institution or algorithm (*e.g.*, from GRCh38 to NCBI33, generated by the International Human Genome Sequencing Consortium). Available methods and tools known in the art include, but are not limited to, NCBI Genome Remapping Service, available at the National Center for Biotechnology Information website, UCSC LiftOver, available at the UCSC Genome Brower website, and Assembly Converter, available at the Ensembl.org website.

[00328] In some embodiments, the nucleic acid-based gene-regulating system comprises at least one nucleic acid molecule (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein the at least one nucleic acid molecule is a *SOCS1*-targeting nucleic acid molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2). In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2).

[00329] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 (human genome) or Table 5 (mouse genome). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA

sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 23-35 and 56-187. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target human RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 23-35 and 56-187.

[00330] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule is a *SOCS1*-targeting shRNA or siRNA molecule. In some embodiments, the at least one *SOCS1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the at least one *SOCS1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the at least one *SOCS1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-55 or 23-200. In some embodiments, the at least one *SOCS1*-targeting shRNA or siRNA molecule binds to a target human RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 23-35 and 56-187. In some embodiments, the at least one *SOCS1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-55 or 23-200. In some embodiments, the at least one *SOCS1*-targeting shRNA or siRNA molecule binds to a target human RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 23-35 and 56-187.

[00331] In some embodiments, the nucleic acid-based gene-regulating system comprises at least one *SOCS1*-targeting siRNA molecule or shRNA molecule selected from those known in the art. For example, in some embodiments, the *SOCS1*-targeting nucleic acid molecule is a *SOCS1*-targeting siRNA comprising a nucleic acid sequence selected from SEQ ID NOs: 13-22. (See International PCT Publication Nos. WO 2017120996; WO 2018137295; WO 2017120998; and WO 2018137293, incorporated by reference herein in their entireties) (Table 6). In some

embodiments, the *SOCS1*-targeting siRNA molecule or shRNA molecule is encoded by a nucleic acid sequence selected from SEQ ID NOs: 13-200. In some embodiments, the *SOCS1*-targeting siRNA molecule or shRNA molecule is encoded by a human nucleic acid sequence selected from SEQ ID NOs: 23-35 and 56-187. In some embodiments, the *SOCS1*-targeting nucleic acid molecule is a *SOCS1*-targeting shRNA molecule or siRNA molecule that binds to a human target sequence selected from SEQ ID NOs: 23-35 (*See* US Patent No. 8,324,369, incorporated herein by reference in its entirety) (Table 7). In some embodiments, the *SOCS1*-targeting nucleic acid molecule is a *SOCS1*-targeting shRNA molecule or siRNA molecule that binds to a mouse target sequence selected from SEQ ID NOs: 36-55 (*See* US Patent No. 9,944,931, incorporated by reference herein in its entirety) (Table 8).

Table 4: SOCS1 Human Genome Coordinates

Target	Coordinates	Target	Coordinates
<i>SOCS1</i>	chr16:11255187-11255206	<i>SOCS1</i>	chr16:11254923-11254942
<i>SOCS1</i>	chr16:11255238-11255257	<i>SOCS1</i>	chr16:11255431-11255450
<i>SOCS1</i>	chr16:11255058-11255077	<i>SOCS1</i>	chr16:11255463-11255482
<i>SOCS1</i>	chr16:11255158-11255177	<i>SOCS1</i>	chr16:11255343-11255362
<i>SOCS1</i>	chr16:11255239-11255258	<i>SOCS1</i>	chr16:11255088-11255107
<i>SOCS1</i>	chr16:11255237-11255256	<i>SOCS1</i>	chr16:11254834-11254853
<i>SOCS1</i>	chr16:11255019-11255038	<i>SOCS1</i>	chr16:11254922-11254941
<i>SOCS1</i>	chr16:11255066-11255085	<i>SOCS1</i>	chr16:11255098-11255117
<i>SOCS1</i>	chr16:11255238-11255257	<i>SOCS1</i>	chr16:11254993-11255012
<i>SOCS1</i>	chr16:11255168-11255187	<i>SOCS1</i>	chr16:11254840-11254859
<i>SOCS1</i>	chr16:11255079-11255098	<i>SOCS1</i>	chr16:11255400-11255419
<i>SOCS1</i>	chr16:11255287-11255306	<i>SOCS1</i>	chr16:11254920-11254939
<i>SOCS1</i>	chr16:11255249-11255268	<i>SOCS1</i>	chr16:11254966-11254985
<i>SOCS1</i>	chr16:11255186-11255205	<i>SOCS1</i>	chr16:11254860-11254879
<i>SOCS1</i>	chr16:11255236-11255255	<i>SOCS1</i>	chr16:11254980-11254999
<i>SOCS1</i>	chr16:11255116-11255135	<i>SOCS1</i>	chr16:11254857-11254876
<i>SOCS1</i>	chr16:11255070-11255089	<i>SOCS1</i>	chr16:11254874-11254893
<i>SOCS1</i>	chr16:11255117-11255136	<i>SOCS1</i>	chr16:11255028-11255047
<i>SOCS1</i>	chr16:11255283-11255302	<i>SOCS1</i>	chr16:11254956-11254975
<i>SOCS1</i>	chr16:11255442-11255461	<i>SOCS1</i>	chr16:11254908-11254927
<i>SOCS1</i>	chr16:11255209-11255228	<i>SOCS1</i>	chr16:11255337-11255356
<i>SOCS1</i>	chr16:11254932-11254951	<i>SOCS1</i>	chr16:11254836-11254855
<i>SOCS1</i>	chr16:11254966-11254985	<i>SOCS1</i>	chr16:11254842-11254861
<i>SOCS1</i>	chr16:11254950-11254969	<i>SOCS1</i>	chr16:11254865-11254884
<i>SOCS1</i>	chr16:11255049-11255068	<i>SOCS1</i>	chr16:11254830-11254849
<i>SOCS1</i>	chr16:11255155-11255174	<i>SOCS1</i>	chr16:11255401-11255420
<i>SOCS1</i>	chr16:11255460-11255479	<i>SOCS1</i>	chr16:11254864-11254883
<i>SOCS1</i>	chr16:11255037-11255056	<i>SOCS1</i>	chr16:11255311-11255330

Target	Coordinates	Target	Coordinates
<i>SOCS1</i>	chr16:11255154-11255173	<i>SOCS1</i>	chr16:11255343-11255362
<i>SOCS1</i>	chr16:11255115-11255134	<i>SOCS1</i>	chr16:11255342-11255361
<i>SOCS1</i>	chr16:11254985-11255004	<i>SOCS1</i>	chr16:11255272-11255291
<i>SOCS1</i>	chr16:11255013-11255032	<i>SOCS1</i>	chr16:11254866-11254885
<i>SOCS1</i>	chr16:11255016-11255035	<i>SOCS1</i>	chr16:11255310-11255329
<i>SOCS1</i>	chr16:11255139-11255158	<i>SOCS1</i>	chr16:11255336-11255355
<i>SOCS1</i>	chr16:11255248-11255267	<i>SOCS1</i>	chr16:11255416-11255435
<i>SOCS1</i>	chr16:11255217-11255236	<i>SOCS1</i>	chr16:11255402-11255421
<i>SOCS1</i>	chr16:11254994-11255013	<i>SOCS1</i>	chr16:11255467-11255486
<i>SOCS1</i>	chr16:11254965-11254984	<i>SOCS1</i>	chr16:11254873-11254892
<i>SOCS1</i>	chr16:11255219-11255238	<i>SOCS1</i>	chr16:11255265-11255284
<i>SOCS1</i>	chr16:11255173-11255192	<i>SOCS1</i>	chr16:11254820-11254839
<i>SOCS1</i>	chr16:11255210-11255229	<i>SOCS1</i>	chr16:11254848-11254867
<i>SOCS1</i>	chr16:11255062-11255081	<i>SOCS1</i>	chr16:11255317-11255336
<i>SOCS1</i>	chr16:11255259-11255278	<i>SOCS1</i>	chr16:11255351-11255370
<i>SOCS1</i>	chr16:11255230-11255249	<i>SOCS1</i>	chr16:11254811-11254830
<i>SOCS1</i>	chr16:11255084-11255103	<i>SOCS1</i>	chr16:11255353-11255372
<i>SOCS1</i>	chr16:11255175-11255194	<i>SOCS1</i>	chr16:11255350-11255369
<i>SOCS1</i>	chr16:11255419-11255438	<i>SOCS1</i>	chr16:11255309-11255328
<i>SOCS1</i>	chr16:11254903-11254922	<i>SOCS1</i>	chr16:11255390-11255409
<i>SOCS1</i>	chr16:11255089-11255108	<i>SOCS1</i>	chr16:11255478-11255497
<i>SOCS1</i>	chr16:11255379-11255398	<i>SOCS1</i>	chr16:11255330-11255349
<i>SOCS1</i>	chr16:11255206-11255225	<i>SOCS1</i>	chr16:11254875-11254894
<i>SOCS1</i>	chr16:11255090-11255109	<i>SOCS1</i>	chr16:11255124-11255143
<i>SOCS1</i>	chr16:11255208-11255227	<i>SOCS1</i>	chr16:11255352-11255371
<i>SOCS1</i>	chr16:11254956-11254975	<i>SOCS1</i>	chr16:11254872-11254891
<i>SOCS1</i>	chr16:11255118-11255137	<i>SOCS1</i>	chr16:11255331-11255350
<i>SOCS1</i>	chr16:11254906-11254925	<i>SOCS1</i>	chr16:11255315-11255334
<i>SOCS1</i>	chr16:11255167-11255186	<i>SOCS1</i>	chr16:11255482-11255501
<i>SOCS1</i>	chr16:11254835-11254854	<i>SOCS1</i>	chr16:11254995-11255014
<i>SOCS1</i>	chr16:11255292-11255311	<i>SOCS1</i>	chr16:11255316-11255335
<i>SOCS1</i>	chr16:11255416-11255435	<i>SOCS1</i>	chr16:11255308-11255327
<i>SOCS1</i>	chr16:11255136-11255155	<i>SOCS1</i>	chr16:11255321-11255340
<i>SOCS1</i>	chr16:11254964-11254983	<i>SOCS1</i>	chr16:11255322-11255341
<i>SOCS1</i>	chr16:11254896-11254915	<i>SOCS1</i>	chr16:11255330-11255349
<i>SOCS1</i>	chr16:11254940-11254959	<i>SOCS1</i>	chr16:11255368-11255387
<i>SOCS1</i>	chr16:11255349-11255368	<i>SOCS1</i>	chr16:11255377-11255396
<i>SOCS1</i>	chr16:11254992-11255011	<i>SOCS1</i>	chr16:11255380-11255399

Table 5: *Socs1* Murine Genome Coordinates

Target	Coordinates
<i>Socs1</i>	chr16:10784479-10784498
<i>Socs1</i>	chr16:10784409-10784428

Target	Coordinates
<i>Socs1</i>	chr16:10784456-10784475
<i>Socs1</i>	chr16:10784322-10784341
<i>Socs1</i>	chr16:10784548-10784567
<i>Socs1</i>	chr16:10784596-10784615
<i>Socs1</i>	chr16:10784264-10784283
<i>Socs1</i>	chr16:10784628-10784647
<i>Socs1</i>	chr16:10784526-10784545
<i>Socs1</i>	chr16:10784508-10784527
<i>Socs1</i>	chr16:10784565-10784584
<i>Socs1</i>	chr16:10784474-10784493
<i>Socs1</i>	chr16:10784293-10784312

Table 6: Exemplary human *SOCS1* siRNAs

Target	Sequence	SEQ ID
SOCS1_siRNA_1	CGCACUUCCGCACAUUCCGUUCG	13
SOCS1_siRNA_2	GGGGAGGGUCUCUGGCUUUUUUU	14
SOCS1_siRNA_3	CAGCAUUAACUGGGAUGCCGUGU	15
SOCS1_siRNA_4	CCAGGACCUGAACUCGCACCUC	16
SOCS1_siRNA_5	UACAUAUACCCAGUAUCUUUGCA	17
SOCS1_siRNA_6	GCCGACAAUGCAGUCUCCACAGC	18
SOCS1_siRNA_7	CCCCUGGUUGUUGUAGCAGCUUA	19
SOCS1_siRNA_8	CUGCUGUGCAGAAUCCUAUUUUA	20
SOCS1_siRNA_9	UGGGAUGCCGUGUUAUUUUGUUA	21
SOCS1_siRNA_10	UCGCACCUCCUACCUCUUAUGU	22

Table 7: Exemplary human *SOCS1* shRNA and siRNA target sequences

Target	Sequence	SEQ ID
SOCS1_shRNA_1	CACGCACTTCCGCACATTC	23
SOCS1_shRNA_2	TTCCGTTCGCACGCCGATT	24
SOCS1_shRNA_3	GAGCTTCGACTGCCTCTTC	25
SOCS1_siRNA_1	CGCACTTCCGCACATTCCGTTCG	26
SOCS1_siRNA_2	GGGGAGGGTCTCTGGCTTTATTT	27
SOCS1_siRNA_3	CAGCATTAAGTGGGATGCCGTGT	28
SOCS1_siRNA_4	CCAGGACCTGAACTCGCACCTCC	29
SOCS1_siRNA_5	TACATATACCCAGTATCTTTGCA	30
SOCS1_siRNA_6	GCCGACAATGCAGTCTCCACAGC	31
SOCS1_siRNA_7	CCCCTGGTTGTTGTAGCAGCTTA	32
SOCS1_siRNA_8	CTGCTGTGCAGAATCCTATTTTA	33
SOCS1_siRNA_9	TGGGATGCCGTGTTATTTTGTTA	34

SOCS1_siRNA_10	TCGCACCTCCTACCTCTTCATGT	35
----------------	-------------------------	----

Table 8: Exemplary murine *Socs1* shRNA and siRNA target sequences

Target	Sequence	SEQ ID
ND000214	TTTCGAGCTGCTGGAGCACTA	36
ND000219	TCGAGCTGCTGGAGCACTACG	37
TRCN0000231240	TCGCCAACGGAAGTCTTCTT	38
ND000218	ACTTCTGGCTGGAGACCTCAT	39
TRCN0000067420	GCGAGACCTTCGACTGCCTTT	40
TRCN0000067418	CGACACTCACTTCCGCACCTT	41
ND000220	CTACCTGAGTTCCTTCCCCTT	42
TRCN0000231238	TTCCGCTCCCACTCCGATTAC	43
TRCN0000231241	TAACCCGGTACTCCGTGACTA	44
ND000216	TACTCCGTGACTACCTGAGTT	45
ND000211	CTTCCGCTCCCACTCCGATTA	46
TRCN0000067422	GCGCGACAGTCGCCAACGGAA	47
TRCN0000231239	TGGACGCCTGCGGCTTCTATT	48
TRCN0000067419	CGCATCCCTCTTAACCCGGTA	49
ND000212	TACATATTCCCAGTATCTTTG	50
TRCN0000231242	GCGCCTTATTATTCTTATTA	51
TRCN0000067421	CCGTGACTACCTGAGTTCCTT	52
ND000215	GGAGGGTCTCTGGCTTCATTT	53
ND000213	TTCGCGCTCAGCGTGAAGATG	54
ND000217	ATCCCTCTTAACCCGGTACTC	55

[00332] In some embodiments, the nucleic acid-based gene-regulating system comprises at least one nucleic acid molecule (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein the at least one nucleic acid molecule is a *PTPN2*-targeting nucleic acid molecule. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule is an siRNA or an shRNA molecule. In some embodiments, the at least one *PTPN2*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *PTPN2*-targeting siRNA or

an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00333] In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 (human genome) or Table 10 (mouse genome). In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 201-314. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 201-314.

[00334] In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule is a *SOCS1*-targeting shRNA or siRNA molecule. In some embodiments, the at least one *PTPN2*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *PTPN2*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *PTPN2*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *PTPN2*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 201-314. In some embodiments, the at least one *PTPN2*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *PTPN2*-targeting

shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-314.

Table 9: PTPN2 Human Genome Coordinates

Target	Coordinates
<i>PTPN2</i>	Chr18:12859218-12859237
<i>PTPN2</i>	Chr18:12884109-12884128
<i>PTPN2</i>	Chr18:12817227-12817246
<i>PTPN2</i>	Chr18:12817234-12817253
<i>PTPN2</i>	Chr18:12884091-12884110
<i>PTPN2</i>	Chr18:12884121-12884140
<i>PTPN2</i>	Chr18:12831010-12831029
<i>PTPN2</i>	Chr18:12817208-12817227
<i>PTPN2</i>	Chr18:12817158-12817177
<i>PTPN2</i>	Chr18:12831016-12831035
<i>PTPN2</i>	Chr18:12817228-12817247
<i>PTPN2</i>	Chr18:12830964-12830983
<i>PTPN2</i>	Chr18:12801972-12801991
<i>PTPN2</i>	Chr18:12836818-12836837
<i>PTPN2</i>	Chr18:12817215-12817234
<i>PTPN2</i>	Chr18:12802018-12802037
<i>PTPN2</i>	Chr18:12884116-12884135
<i>PTPN2</i>	Chr18:12840739-12840758
<i>PTPN2</i>	Chr18:12802004-12802023
<i>PTPN2</i>	Chr18:12840767-12840786
<i>PTPN2</i>	Chr18:12817197-12817216
<i>PTPN2</i>	Chr18:12884108-12884127
<i>PTPN2</i>	Chr18:12817221-12817240
<i>PTPN2</i>	Chr18:12836820-12836839
<i>PTPN2</i>	Chr18:12884124-12884143
<i>PTPN2</i>	Chr18:12830996-12831015
<i>PTPN2</i>	Chr18:12830942-12830961
<i>PTPN2</i>	Chr18:12884112-12884131
<i>PTPN2</i>	Chr18:12817193-12817212
<i>PTPN2</i>	Chr18:12859205-12859224
<i>PTPN2</i>	Chr18:12817202-12817221
<i>PTPN2</i>	Chr18:12859216-12859235
<i>PTPN2</i>	Chr18:12859215-12859234
<i>PTPN2</i>	Chr18:12817201-12817220
<i>PTPN2</i>	Chr18:12802134-12802153
<i>PTPN2</i>	Chr18:12884075-12884094
<i>PTPN2</i>	Chr18:12884115-12884134
<i>PTPN2</i>	Chr18:12840757-12840776

Target	Coordinates
<i>PTPN2</i>	Chr18:12814205-12814224
<i>PTPN2</i>	Chr18:12840777-12840796
<i>PTPN2</i>	Chr18:12814277-12814296
<i>PTPN2</i>	Chr18:12840746-12840765
<i>PTPN2</i>	Chr18:12801989-12802008
<i>PTPN2</i>	Chr18:12819237-12819256
<i>PTPN2</i>	Chr18:12814348-12814367
<i>PTPN2</i>	Chr18:12794428-12794447
<i>PTPN2</i>	Chr18:12831005-12831024
<i>PTPN2</i>	Chr18:12825890-12825909
<i>PTPN2</i>	Chr18:12840723-12840742
<i>PTPN2</i>	Chr18:12840747-12840766
<i>PTPN2</i>	Chr18:12802068-12802087
<i>PTPN2</i>	Chr18:12840716-12840735
<i>PTPN2</i>	Chr18:12840773-12840792
<i>PTPN2</i>	Chr18:12831012-12831031
<i>PTPN2</i>	Chr18:12814240-12814259
<i>PTPN2</i>	Chr18:12802130-12802149
<i>PTPN2</i>	Chr18:12794454-12794473
<i>PTPN2</i>	Chr18:12817208-12817227
<i>PTPN2</i>	Chr18:12819226-12819245
<i>PTPN2</i>	Chr18:12825889-12825908
<i>PTPN2</i>	Chr18:12840782-12840801
<i>PTPN2</i>	Chr18:12836812-12836831
<i>PTPN2</i>	Chr18:12817298-12817317
<i>PTPN2</i>	Chr18:12817324-12817343
<i>PTPN2</i>	Chr18:12819268-12819287
<i>PTPN2</i>	Chr18:12817303-12817322
<i>PTPN2</i>	Chr18:12825927-12825946
<i>PTPN2</i>	Chr18:12817220-12817239
<i>PTPN2</i>	Chr18:12825901-12825920
<i>PTPN2</i>	Chr18:12814222-12814241
<i>PTPN2</i>	Chr18:12831000-12831019
<i>PTPN2</i>	Chr18:12840738-12840757
<i>PTPN2</i>	Chr18:12802057-12802076
<i>PTPN2</i>	Chr18:12802069-12802088
<i>PTPN2</i>	Chr18:12884123-12884142
<i>PTPN2</i>	Chr18:12814294-12814313
<i>PTPN2</i>	Chr18:12817283-12817302
<i>PTPN2</i>	Chr18:12830945-12830964
<i>PTPN2</i>	Chr18:12817284-12817303
<i>PTPN2</i>	Chr18:12817256-12817275
<i>PTPN2</i>	Chr18:12884062-12884081
<i>PTPN2</i>	Chr18:12814295-12814314
<i>PTPN2</i>	Chr18:12817313-12817332

Target	Coordinates
<i>PTPN2</i>	Chr18:12814255-12814274
<i>PTPN2</i>	Chr18:12814253-12814272
<i>PTPN2</i>	Chr18:12814257-12814276
<i>PTPN2</i>	Chr18:12814256-12814275
<i>PTPN2</i>	Chr18:12840753-12840772
<i>PTPN2</i>	Chr18:12830957-12830976
<i>PTPN2</i>	Chr18:12802093-12802112
<i>PTPN2</i>	Chr18:12817333-12817352
<i>PTPN2</i>	Chr18:12794479-12794498
<i>PTPN2</i>	Chr18:12814223-12814242
<i>PTPN2</i>	Chr18:12802089-12802108
<i>PTPN2</i>	Chr18:12794463-12794482
<i>PTPN2</i>	Chr18:12794436-12794455
<i>PTPN2</i>	Chr18:12794416-12794435
<i>PTPN2</i>	Chr18:12817235-12817254
<i>PTPN2</i>	Chr18:12836793-12836812
<i>PTPN2</i>	Chr18:12801986-12802005
<i>PTPN2</i>	Chr18:12817165-12817184
<i>PTPN2</i>	Chr18:12817179-12817198
<i>PTPN2</i>	Chr18:12794425-12794444
<i>PTPN2</i>	Chr18:12802146-12802165

Table 10: *Ptpn2* Murine Genome Coordinates

Target	Coordinates
<i>Ptpn2</i>	Chr18:67680998-67681017
<i>Ptpn2</i>	Chr18:67677801-67677820
<i>Ptpn2</i>	Chr18:67680904-67680923
<i>Ptpn2</i>	Chr18:67681553-67681572
<i>Ptpn2</i>	Chr18:67688965-67688984
<i>Ptpn2</i>	Chr18:67680958-67680977
<i>Ptpn2</i>	Chr18:67688944-67688963
<i>Ptpn2</i>	Chr18:67677855-67677874
<i>Ptpn2</i>	Chr18:67677734-67677753
<i>Ptpn2</i>	Chr18:67680967-67680986
<i>Ptpn2</i>	Chr18:67688912-67688931
<i>Ptpn2</i>	Chr18:67680881-67680900
<i>Ptpn2</i>	Chr18:67681529-67681548

[00335] In some embodiments, the nucleic acid-based gene-regulating system comprises at least one nucleic acid molecule (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein the at least one nucleic acid molecule is a *ZC3H12A*-targeting nucleic acid molecule. In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target

RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule is an siRNA or an shRNA molecule. In some embodiments, the at least one *ZC3H12A*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *ZC3H12A*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00336] In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 (human genome) or Table 12 (mouse genome). In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-337 or 331-797. In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-337 or 331-797.

[00337] In some embodiments, the at least one *ZC3H12A*-targeting nucleic acid molecule is a *ZC3H12A* -targeting shRNA or siRNA molecule. In some embodiments, the at least one *ZC3H12A*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *ZC3H12A*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the *ZC3H12A*-targeting nucleic acid molecule is a *ZC3H12A*-targeting siRNA comprising a nucleic acid sequence selected from SEQ ID NOs: 328-330 or 329 and 330 (human) (*See Liu et al.*, Scientific Reports (2016), 6, Article # 24073 and Mino *et al.*, Cell (2015) 161(5), 1058-1073, incorporated herein by reference in its

entirety). In some embodiments, the at least one *ZC3H12A*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797. In some embodiments, the at least one *ZC3H12A*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 336-789. In some embodiments, the at least one *ZC3H12A*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797. In some embodiments, the at least one *ZC3H12A*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 336-789. In some embodiments, the *ZC3H12A*-targeting nucleic acid molecule is a *ZC3H12A*-targeting shRNA molecule encoded by a nucleic acid sequence selected from SEQ ID NOs: 331-337 (See Huang *et al.*, J Biol Chem (2015) 290(34), 20782-20792, incorporated by reference herein in its entirety).

Table 11: ZC3H12A Human Genome Coordinates

Target	Coordinates
<i>ZC3H12A</i>	Chr1:37481708-37481727
<i>ZC3H12A</i>	Chr1:37475808-37475827
<i>ZC3H12A</i>	Chr1:37475809-37475828
<i>ZC3H12A</i>	Chr1:37475684-37475703
<i>ZC3H12A</i>	Chr1:37481823-37481842
<i>ZC3H12A</i>	Chr1:37480415-37480434
<i>ZC3H12A</i>	Chr1:37475756-37475775
<i>ZC3H12A</i>	Chr1:37481692-37481711
<i>ZC3H12A</i>	Chr1:37481648-37481667
<i>ZC3H12A</i>	Chr1:37480284-37480303
<i>ZC3H12A</i>	Chr1:37481779-37481798
<i>ZC3H12A</i>	Chr1:37475827-37475846
<i>ZC3H12A</i>	Chr1:37481747-37481766
<i>ZC3H12A</i>	Chr1:37482445-37482464
<i>ZC3H12A</i>	Chr1:37475631-37475650
<i>ZC3H12A</i>	Chr1:37480274-37480293
<i>ZC3H12A</i>	Chr1:37482967-37482986
<i>ZC3H12A</i>	Chr1:37482922-37482941
<i>ZC3H12A</i>	Chr1:37480273-37480292
<i>ZC3H12A</i>	Chr1:37482886-37482905
<i>ZC3H12A</i>	Chr1:37483185-37483204
<i>ZC3H12A</i>	Chr1:37475817-37475836
<i>ZC3H12A</i>	Chr1:37483033-37483052
<i>ZC3H12A</i>	Chr1:37480408-37480427
<i>ZC3H12A</i>	Chr1:37483026-37483045

Target	Coordinates
ZC3H12A	Chr1:37483463-37483482
ZC3H12A	Chr1:37480362-37480381
ZC3H12A	Chr1:37482962-37482981
ZC3H12A	Chr1:37475775-37475794
ZC3H12A	Chr1:37475509-37475528
ZC3H12A	Chr1:37475722-37475741
ZC3H12A	Chr1:37475818-37475837
ZC3H12A	Chr1:37482966-37482985
ZC3H12A	Chr1:37480388-37480407
ZC3H12A	Chr1:37483142-37483161
ZC3H12A	Chr1:37482448-37482467
ZC3H12A	Chr1:37483049-37483068
ZC3H12A	Chr1:37482905-37482924
ZC3H12A	Chr1:37482733-37482752
ZC3H12A	Chr1:37480423-37480442
ZC3H12A	Chr1:37482456-37482475
ZC3H12A	Chr1:37483551-37483570
ZC3H12A	Chr1:37481767-37481786
ZC3H12A	Chr1:37475715-37475734
ZC3H12A	Chr1:37483377-37483396
ZC3H12A	Chr1:37475593-37475612
ZC3H12A	Chr1:37475875-37475894
ZC3H12A	Chr1:37475534-37475553
ZC3H12A	Chr1:37482764-37482783
ZC3H12A	Chr1:37475869-37475888
ZC3H12A	Chr1:37483437-37483456
ZC3H12A	Chr1:37475598-37475617
ZC3H12A	Chr1:37482438-37482457
ZC3H12A	Chr1:37483257-37483276
ZC3H12A	Chr1:37483263-37483282
ZC3H12A	Chr1:37482545-37482564
ZC3H12A	Chr1:37483015-37483034
ZC3H12A	Chr1:37481595-37481614
ZC3H12A	Chr1:37482923-37482942
ZC3H12A	Chr1:37483143-37483162
ZC3H12A	Chr1:37482348-37482367
ZC3H12A	Chr1:37483018-37483037
ZC3H12A	Chr1:37482612-37482631
ZC3H12A	Chr1:37475613-37475632
ZC3H12A	Chr1:37475563-37475582
ZC3H12A	Chr1:37475535-37475554
ZC3H12A	Chr1:37482843-37482862
ZC3H12A	Chr1:37480424-37480443
ZC3H12A	Chr1:37482606-37482625
ZC3H12A	Chr1:37483098-37483117

Target	Coordinates
ZC3H12A	Chr1:37483508-37483527
ZC3H12A	Chr1:37483559-37483578
ZC3H12A	Chr1:37483256-37483275
ZC3H12A	Chr1:37475936-37475955
ZC3H12A	Chr1:37475607-37475626
ZC3H12A	Chr1:37475809-37475828
ZC3H12A	Chr1:37483186-37483205
ZC3H12A	Chr1:37481747-37481766
ZC3H12A	Chr1:37482734-37482753
ZC3H12A	Chr1:37483278-37483297
ZC3H12A	Chr1:37482332-37482351
ZC3H12A	Chr1:37483109-37483128
ZC3H12A	Chr1:37475633-37475652
ZC3H12A	Chr1:37482591-37482610
ZC3H12A	Chr1:37483271-37483290
ZC3H12A	Chr1:37483603-37483622
ZC3H12A	Chr1:37482504-37482523
ZC3H12A	Chr1:37483252-37483271
ZC3H12A	Chr1:37483119-37483138
ZC3H12A	Chr1:37482343-37482362
ZC3H12A	Chr1:37483144-37483163
ZC3H12A	Chr1:37483213-37483232
ZC3H12A	Chr1:37482981-37483000
ZC3H12A	Chr1:37482789-37482808
ZC3H12A	Chr1:37483159-37483178
ZC3H12A	Chr1:37482349-37482368
ZC3H12A	Chr1:37483602-37483621
ZC3H12A	Chr1:37481596-37481615
ZC3H12A	Chr1:37482537-37482556
ZC3H12A	Chr1:37482370-37482389
ZC3H12A	Chr1:37475546-37475565
ZC3H12A	Chr1:37482598-37482617
ZC3H12A	Chr1:37483146-37483165
ZC3H12A	Chr1:37475812-37475831
ZC3H12A	Chr1:37483400-37483419
ZC3H12A	Chr1:37475703-37475722
ZC3H12A	Chr1:37483418-37483437
ZC3H12A	Chr1:37480284-37480303
ZC3H12A	Chr1:37482800-37482819
ZC3H12A	Chr1:37475721-37475740
ZC3H12A	Chr1:37482715-37482734
ZC3H12A	Chr1:37480281-37480300
ZC3H12A	Chr1:37482491-37482510
ZC3H12A	Chr1:37483497-37483516
ZC3H12A	Chr1:37475899-37475918

Target	Coordinates
ZC3H12A	Chr1:37475889-37475908
ZC3H12A	Chr1:37482375-37482394
ZC3H12A	Chr1:37475741-37475760
ZC3H12A	Chr1:37482900-37482919
ZC3H12A	Chr1:37482442-37482461
ZC3H12A	Chr1:37481644-37481663
ZC3H12A	Chr1:37482464-37482483
ZC3H12A	Chr1:37482994-37483013
ZC3H12A	Chr1:37483437-37483456
ZC3H12A	Chr1:37482736-37482755
ZC3H12A	Chr1:37482538-37482557
ZC3H12A	Chr1:37483515-37483534
ZC3H12A	Chr1:37475874-37475893
ZC3H12A	Chr1:37483145-37483164
ZC3H12A	Chr1:37482587-37482606
ZC3H12A	Chr1:37475482-37475501
ZC3H12A	Chr1:37475844-37475863
ZC3H12A	Chr1:37480415-37480434
ZC3H12A	Chr1:37481709-37481728
ZC3H12A	Chr1:37483366-37483385
ZC3H12A	Chr1:37475627-37475646
ZC3H12A	Chr1:37482447-37482466
ZC3H12A	Chr1:37481758-37481777
ZC3H12A	Chr1:37483560-37483579
ZC3H12A	Chr1:37475869-37475888
ZC3H12A	Chr1:37481655-37481674
ZC3H12A	Chr1:37481645-37481664
ZC3H12A	Chr1:37483016-37483035
ZC3H12A	Chr1:37475838-37475857
ZC3H12A	Chr1:37482850-37482869
ZC3H12A	Chr1:37475510-37475529
ZC3H12A	Chr1:37483510-37483529
ZC3H12A	Chr1:37483064-37483083
ZC3H12A	Chr1:37483149-37483168
ZC3H12A	Chr1:37483449-37483468
ZC3H12A	Chr1:37483264-37483283
ZC3H12A	Chr1:37475508-37475527
ZC3H12A	Chr1:37480415-37480434
ZC3H12A	Chr1:37482918-37482937
ZC3H12A	Chr1:37482474-37482493
ZC3H12A	Chr1:37483232-37483251
ZC3H12A	Chr1:37475732-37475751
ZC3H12A	Chr1:37481602-37481621
ZC3H12A	Chr1:37480289-37480308
ZC3H12A	Chr1:37483165-37483184

Target	Coordinates
ZC3H12A	Chr1:37483248-37483267
ZC3H12A	Chr1:37483078-37483097
ZC3H12A	Chr1:37483017-37483036
ZC3H12A	Chr1:37483174-37483193
ZC3H12A	Chr1:37482857-37482876
ZC3H12A	Chr1:37475578-37475597
ZC3H12A	Chr1:37480329-37480348
ZC3H12A	Chr1:37480288-37480307
ZC3H12A	Chr1:37481600-37481619
ZC3H12A	Chr1:37483212-37483231
ZC3H12A	Chr1:37483337-37483356
ZC3H12A	Chr1:37475542-37475561
ZC3H12A	Chr1:37483197-37483216
ZC3H12A	Chr1:37482730-37482749
ZC3H12A	Chr1:37475599-37475618
ZC3H12A	Chr1:37483262-37483281
ZC3H12A	Chr1:37482790-37482809
ZC3H12A	Chr1:37482719-37482738
ZC3H12A	Chr1:37482860-37482879
ZC3H12A	Chr1:37483443-37483462
ZC3H12A	Chr1:37483558-37483577
ZC3H12A	Chr1:37481599-37481618
ZC3H12A	Chr1:37475845-37475864
ZC3H12A	Chr1:37475730-37475749
ZC3H12A	Chr1:37482524-37482543
ZC3H12A	Chr1:37482849-37482868
ZC3H12A	Chr1:37475529-37475548
ZC3H12A	Chr1:37475664-37475683
ZC3H12A	Chr1:37482972-37482991
ZC3H12A	Chr1:37483321-37483340
ZC3H12A	Chr1:37482984-37483003
ZC3H12A	Chr1:37475807-37475826
ZC3H12A	Chr1:37483213-37483232
ZC3H12A	Chr1:37482427-37482446
ZC3H12A	Chr1:37483104-37483123
ZC3H12A	Chr1:37482879-37482898
ZC3H12A	Chr1:37483409-37483428
ZC3H12A	Chr1:37482752-37482771
ZC3H12A	Chr1:37480391-37480410
ZC3H12A	Chr1:37475694-37475713
ZC3H12A	Chr1:37482458-37482477
ZC3H12A	Chr1:37475774-37475793
ZC3H12A	Chr1:37475574-37475593
ZC3H12A	Chr1:37475803-37475822
ZC3H12A	Chr1:37481605-37481624

Target	Coordinates
ZC3H12A	Chr1:37482437-37482456
ZC3H12A	Chr1:37482825-37482844
ZC3H12A	Chr1:37483595-37483614
ZC3H12A	Chr1:37483510-37483529
ZC3H12A	Chr1:37483283-37483302
ZC3H12A	Chr1:37482446-37482465
ZC3H12A	Chr1:37475700-37475719
ZC3H12A	Chr1:37475721-37475740
ZC3H12A	Chr1:37475628-37475647
ZC3H12A	Chr1:37482848-37482867
ZC3H12A	Chr1:37483134-37483153
ZC3H12A	Chr1:37475543-37475562
ZC3H12A	Chr1:37482799-37482818
ZC3H12A	Chr1:37483296-37483315
ZC3H12A	Chr1:37483332-37483351
ZC3H12A	Chr1:37483600-37483619
ZC3H12A	Chr1:37482410-37482429
ZC3H12A	Chr1:37481718-37481737
ZC3H12A	Chr1:37483395-37483414
ZC3H12A	Chr1:37482428-37482447
ZC3H12A	Chr1:37475562-37475581
ZC3H12A	Chr1:37483500-37483519
ZC3H12A	Chr1:37475827-37475846
ZC3H12A	Chr1:37483586-37483605
ZC3H12A	Chr1:37483089-37483108
ZC3H12A	Chr1:37483419-37483438
ZC3H12A	Chr1:37480285-37480304
ZC3H12A	Chr1:37483256-37483275
ZC3H12A	Chr1:37483420-37483439
ZC3H12A	Chr1:37475691-37475710
ZC3H12A	Chr1:37483419-37483438
ZC3H12A	Chr1:37475918-37475937
ZC3H12A	Chr1:37475589-37475608
ZC3H12A	Chr1:37482362-37482381
ZC3H12A	Chr1:37482566-37482585
ZC3H12A	Chr1:37482963-37482982
ZC3H12A	Chr1:37483420-37483439
ZC3H12A	Chr1:37483139-37483158
ZC3H12A	Chr1:37483619-37483638
ZC3H12A	Chr1:37481764-37481783
ZC3H12A	Chr1:37475650-37475669
ZC3H12A	Chr1:37483405-37483424
ZC3H12A	Chr1:37483037-37483056
ZC3H12A	Chr1:37483211-37483230
ZC3H12A	Chr1:37475537-37475556

Target	Coordinates
ZC3H12A	Chr1:37475756-37475775
ZC3H12A	Chr1:37482403-37482422
ZC3H12A	Chr1:37482455-37482474
ZC3H12A	Chr1:37480311-37480330
ZC3H12A	Chr1:37482586-37482605
ZC3H12A	Chr1:37483099-37483118
ZC3H12A	Chr1:37483342-37483361
ZC3H12A	Chr1:37481823-37481842
ZC3H12A	Chr1:37482777-37482796
ZC3H12A	Chr1:37482412-37482431
ZC3H12A	Chr1:37483604-37483623
ZC3H12A	Chr1:37483438-37483457
ZC3H12A	Chr1:37482445-37482464
ZC3H12A	Chr1:37483331-37483350
ZC3H12A	Chr1:37483111-37483130
ZC3H12A	Chr1:37482847-37482866
ZC3H12A	Chr1:37483249-37483268
ZC3H12A	Chr1:37481754-37481773
ZC3H12A	Chr1:37475684-37475703
ZC3H12A	Chr1:37482519-37482538
ZC3H12A	Chr1:37482475-37482494
ZC3H12A	Chr1:37482613-37482632
ZC3H12A	Chr1:37482939-37482958
ZC3H12A	Chr1:37475541-37475560
ZC3H12A	Chr1:37481763-37481782
ZC3H12A	Chr1:37483231-37483250
ZC3H12A	Chr1:37482953-37482972
ZC3H12A	Chr1:37482407-37482426
ZC3H12A	Chr1:37475808-37475827
ZC3H12A	Chr1:37481620-37481639
ZC3H12A	Chr1:37475592-37475611
ZC3H12A	Chr1:37483156-37483175
ZC3H12A	Chr1:37480329-37480348
ZC3H12A	Chr1:37475573-37475592
ZC3H12A	Chr1:37483198-37483217
ZC3H12A	Chr1:37483557-37483576
ZC3H12A	Chr1:37482892-37482911
ZC3H12A	Chr1:37483334-37483353
ZC3H12A	Chr1:37481708-37481727
ZC3H12A	Chr1:37483063-37483082
ZC3H12A	Chr1:37482998-37483017
ZC3H12A	Chr1:37482942-37482961
ZC3H12A	Chr1:37475508-37475527
ZC3H12A	Chr1:37482371-37482390
ZC3H12A	Chr1:37483119-37483138

Target	Coordinates
ZC3H12A	Chr1:37482798-37482817
ZC3H12A	Chr1:37475859-37475878
ZC3H12A	Chr1:37483401-37483420
ZC3H12A	Chr1:37482851-37482870
ZC3H12A	Chr1:37475524-37475543
ZC3H12A	Chr1:37475601-37475620
ZC3H12A	Chr1:37475815-37475834
ZC3H12A	Chr1:37482801-37482820
ZC3H12A	Chr1:37475544-37475563
ZC3H12A	Chr1:37483010-37483029
ZC3H12A	Chr1:37483077-37483096
ZC3H12A	Chr1:37482404-37482423
ZC3H12A	Chr1:37475692-37475711
ZC3H12A	Chr1:37483596-37483615
ZC3H12A	Chr1:37483372-37483391
ZC3H12A	Chr1:37481596-37481615
ZC3H12A	Chr1:37480370-37480389
ZC3H12A	Chr1:37480377-37480396
ZC3H12A	Chr1:37483381-37483400
ZC3H12A	Chr1:37482899-37482918
ZC3H12A	Chr1:37480373-37480392
ZC3H12A	Chr1:37481847-37481866
ZC3H12A	Chr1:37483330-37483349
ZC3H12A	Chr1:37483065-37483084
ZC3H12A	Chr1:37482499-37482518
ZC3H12A	Chr1:37483105-37483124
ZC3H12A	Chr1:37475631-37475650
ZC3H12A	Chr1:37483530-37483549
ZC3H12A	Chr1:37483407-37483426
ZC3H12A	Chr1:37483308-37483327
ZC3H12A	Chr1:37482853-37482872
ZC3H12A	Chr1:37482934-37482953
ZC3H12A	Chr1:37475591-37475610
ZC3H12A	Chr1:37475826-37475845
ZC3H12A	Chr1:37475865-37475884
ZC3H12A	Chr1:37481784-37481803
ZC3H12A	Chr1:37480322-37480341
ZC3H12A	Chr1:37475664-37475683
ZC3H12A	Chr1:37475757-37475776
ZC3H12A	Chr1:37483385-37483404
ZC3H12A	Chr1:37482933-37482952
ZC3H12A	Chr1:37475866-37475885
ZC3H12A	Chr1:37475843-37475862
ZC3H12A	Chr1:37475797-37475816
ZC3H12A	Chr1:37475642-37475661

Target	Coordinates
ZC3H12A	Chr1:37483270-37483289
ZC3H12A	Chr1:37483024-37483043
ZC3H12A	Chr1:37483201-37483220
ZC3H12A	Chr1:37482447-37482466
ZC3H12A	Chr1:37483253-37483272
ZC3H12A	Chr1:37483429-37483448
ZC3H12A	Chr1:37483195-37483214
ZC3H12A	Chr1:37481648-37481667
ZC3H12A	Chr1:37483424-37483443
ZC3H12A	Chr1:37475580-37475599
ZC3H12A	Chr1:37482980-37482999
ZC3H12A	Chr1:37480408-37480427
ZC3H12A	Chr1:37483405-37483424
ZC3H12A	Chr1:37475740-37475759
ZC3H12A	Chr1:37480387-37480406
ZC3H12A	Chr1:37483507-37483526
ZC3H12A	Chr1:37483110-37483129
ZC3H12A	Chr1:37483325-37483344
ZC3H12A	Chr1:37481692-37481711
ZC3H12A	Chr1:37475826-37475845
ZC3H12A	Chr1:37483098-37483117
ZC3H12A	Chr1:37481758-37481777
ZC3H12A	Chr1:37480320-37480339
ZC3H12A	Chr1:37483380-37483399
ZC3H12A	Chr1:37483011-37483030
ZC3H12A	Chr1:37483509-37483528
ZC3H12A	Chr1:37483509-37483528
ZC3H12A	Chr1:37482768-37482787
ZC3H12A	Chr1:37475804-37475823
ZC3H12A	Chr1:37475808-37475827
ZC3H12A	Chr1:37475859-37475878
ZC3H12A	Chr1:37482973-37482992
ZC3H12A	Chr1:37475634-37475653
ZC3H12A	Chr1:37475854-37475873
ZC3H12A	Chr1:37480334-37480353
ZC3H12A	Chr1:37480414-37480433
ZC3H12A	Chr1:37480316-37480335
ZC3H12A	Chr1:37482971-37482990
ZC3H12A	Chr1:37482781-37482800
ZC3H12A	Chr1:37483173-37483192
ZC3H12A	Chr1:37482391-37482410
ZC3H12A	Chr1:37482392-37482411
ZC3H12A	Chr1:37482936-37482955
ZC3H12A	Chr1:37483408-37483427
ZC3H12A	Chr1:37481779-37481798

Target	Coordinates
ZC3H12A	Chr1:37483206-37483225
ZC3H12A	Chr1:37482561-37482580
ZC3H12A	Chr1:37481745-37481764
ZC3H12A	Chr1:37475802-37475821
ZC3H12A	Chr1:37483494-37483513
ZC3H12A	Chr1:37483371-37483390
ZC3H12A	Chr1:37482552-37482571
ZC3H12A	Chr1:37475491-37475510
ZC3H12A	Chr1:37482479-37482498
ZC3H12A	Chr1:37483140-37483159
ZC3H12A	Chr1:37483313-37483332
ZC3H12A	Chr1:37483458-37483477
ZC3H12A	Chr1:37483320-37483339
ZC3H12A	Chr1:37483204-37483223
ZC3H12A	Chr1:37475792-37475811
ZC3H12A	Chr1:37483475-37483494
ZC3H12A	Chr1:37475577-37475596
ZC3H12A	Chr1:37475787-37475806
ZC3H12A	Chr1:37483574-37483593
ZC3H12A	Chr1:37480284-37480303
ZC3H12A	Chr1:37482369-37482388
ZC3H12A	Chr1:37483384-37483403
ZC3H12A	Chr1:37483425-37483444
ZC3H12A	Chr1:37482582-37482601
ZC3H12A	Chr1:37483153-37483172
ZC3H12A	Chr1:37482935-37482954
ZC3H12A	Chr1:37483378-37483397
ZC3H12A	Chr1:37482952-37482971
ZC3H12A	Chr1:37483399-37483418
ZC3H12A	Chr1:37483309-37483328
ZC3H12A	Chr1:37483200-37483219
ZC3H12A	Chr1:37481641-37481660
ZC3H12A	Chr1:37481656-37481675
ZC3H12A	Chr1:37483036-37483055
ZC3H12A	Chr1:37483474-37483493
ZC3H12A	Chr1:37483004-37483023
ZC3H12A	Chr1:37481846-37481865
ZC3H12A	Chr1:37483205-37483224
ZC3H12A	Chr1:37483406-37483425
ZC3H12A	Chr1:37480336-37480355
ZC3H12A	Chr1:37481716-37481735
ZC3H12A	Chr1:37480335-37480354
ZC3H12A	Chr1:37481659-37481678
ZC3H12A	Chr1:37475809-37475828
ZC3H12A	Chr1:37482565-37482584

Target	Coordinates
<i>ZC3H12A</i>	Chr1:37482491-37482510
<i>ZC3H12A</i>	Chr1:37483379-37483398
<i>ZC3H12A</i>	Chr1:37481654-37481673
<i>ZC3H12A</i>	Chr1:37482567-37482586
<i>ZC3H12A</i>	Chr1:37481614-37481633
<i>ZC3H12A</i>	Chr1:37482562-37482581
<i>ZC3H12A</i>	Chr1:37475868-37475887
<i>ZC3H12A</i>	Chr1:37482557-37482576
<i>ZC3H12A</i>	Chr1:37483511-37483530
<i>ZC3H12A</i>	Chr1:37475615-37475634
<i>ZC3H12A</i>	Chr1:37483333-37483352
<i>ZC3H12A</i>	Chr1:37482840-37482859
<i>ZC3H12A</i>	Chr1:37483545-37483564
<i>ZC3H12A</i>	Chr1:37482830-37482849
<i>ZC3H12A</i>	Chr1:37482444-37482463
<i>ZC3H12A</i>	Chr1:37482571-37482590
<i>ZC3H12A</i>	Chr1:37482553-37482572
<i>ZC3H12A</i>	Chr1:37483543-37483562
<i>ZC3H12A</i>	Chr1:37483542-37483561
<i>ZC3H12A</i>	Chr1:37482575-37482594
<i>ZC3H12A</i>	Chr1:37475855-37475874
<i>ZC3H12A</i>	Chr1:37482572-37482591

Table 12: *Zc3h12a* Murine Genome Coordinates

Target	Coordinates
<i>Zc3h12a</i>	Chr1:125122335-125122354
<i>Zc3h12a</i>	Chr1:125121083-125121102
<i>Zc3h12a</i>	Chr1:125120961-125120980
<i>Zc3h12a</i>	Chr1:125122390-125122409
<i>Zc3h12a</i>	Chr1:125120373-125120392
<i>Zc3h12a</i>	Chr1:125122250-125122269
<i>Zc3h12a</i>	Chr1:125122375-125122394
<i>Zc3h12a</i>	Chr1:125120975-125120994

Table 13: Exemplary murine *Zc3h12a* siRNA sequence

Target	Sequence	SEQ ID
<i>Zc3h12a</i> _siRNA_1	CCUGGACAACUCCUUCGUAAGAAA	328

Table 14: Exemplary human *ZC3H12A* siRNA sequences

Target	Sequence	SEQ ID
<i>ZC3H12A</i> _siRNA_2	GUGUCCCCUAUGGAAGGAAA	329
<i>ZC3H12A</i> _siRNA_3	CAACUCCUUCGUAAGAAA	330

Table 15: Murine *Zc3h12a* shRNA and siRNA target sequences

<i>Zc3h12a</i> _shRNA_1	AGCGAGGCCACACAGATATTA	331
<i>Zc3h12a</i> _shRNA_2	GCTATGATGACCGCTTCATTG	332
<i>Zc3h12a</i> _shRNA_3	TGGTCTGAGCCGTACCCATTA	333
<i>Zc3h12a</i> _shRNA_4	CTGTGTACAGAGGCGAGATTT	334
<i>Zc3h12a</i> _siRNA_1	CCTGGACAACCTTCCTTCGTAAGAAA	335

Table 16: Human *ZC3H12A* shRNA and siRNA target sequences

Target	Sequence	SEQ ID
<i>ZC3H12A</i> _siRNA_2	GTGTCCCTATGGAAGGAAA	336
<i>ZC3H12A</i> _siRNA_3	CAACTTCCTTCGTAAGAAA	337

[00338] In some embodiments, the nucleic acid-based gene-regulating system comprises at least one nucleic acid molecule (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein the at least one nucleic acid molecule is a *CBLB*-targeting nucleic acid molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule is an siRNA or an shRNA molecule. In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00339] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17

(human genome) or Table 18 (mouse genome). In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 798-808. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 798-808.

[00340] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule is a *CBLB*-targeting shRNA or siRNA molecule. In some embodiments, the at least one *CBLB*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *CBLB*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *CBLB*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823. In some embodiments, the at least one *CBLB*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 798-808. In some embodiments, the at least one *CBLB*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823. In some embodiments, the at least one *CBLB*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 798-808.

Table 17: *CBLB* Human Genome Coordinates

Target	Coordinates
<i>CBLB</i>	chr3:105853475-105853494
<i>CBLB</i>	chr3:105853600-105853619

Target	Coordinates
<i>CBLB</i>	chr3:105720111-105720130
<i>CBLB</i>	chr3:105867412-105867431
<i>CBLB</i>	chr3:105867529-105867548
<i>CBLB</i>	chr3:105720160-105720179
<i>CBLB</i>	chr3:105853421-105853440
<i>CBLB</i>	chr3:105751453-105751472
<i>CBLB</i>	chr3:105693541-105693560
<i>CBLB</i>	chr3:105867449-105867468
<i>CBLB</i>	chr3:105853514-105853533

Table 18: *Cblb* Mouse Genome Coordinates

Target	Coordinates
<i>Cblb</i>	chr16:52152499-52152518
<i>Cblb</i>	chr16:52139574-52139593
<i>Cblb</i>	chr16:52139603-52139622
<i>Cblb</i>	chr16:52112122-52112141
<i>Cblb</i>	chr16:52112134-52112153
<i>Cblb</i>	chr16:52152535-52152554
<i>Cblb</i>	chr16:52142891-52142910
<i>Cblb</i>	chr16:52135797-52135816
<i>Cblb</i>	chr16:52131105-52131124
<i>Cblb</i>	chr16:52112169-52112188
<i>Cblb</i>	chr16:52204542-52204561
<i>Cblb</i>	chr16:52131058-52131077
<i>Cblb</i>	chr16:52135876-52135895
<i>Cblb</i>	chr16:52135763-52135782
<i>Cblb</i>	chr16:52139509-52139528

[00341] In some embodiments, the nucleic acid-based gene-regulating system comprises at least one nucleic acid molecule (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein the at least one nucleic acid molecule is a *RC3H1*-targeting nucleic acid molecule. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule. In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%,

98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00342] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 (human genome) or Table 20 (mouse genome). In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 824-836. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 824-836.

[00343] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule is a *RC3H1*-targeting shRNA or siRNA molecule. In some embodiments, the at least one *RC3H1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *RC3H1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *RC3H1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *RC3H1*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 824-836. In some embodiments, the at least one *RC3H1*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA

sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *RC3H1*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 824-836.

Table 19: *RC3H1* Human Genome Coordinates

Target	Coordinates
<i>RC3H1</i>	chr1:173946812-173946831
<i>RC3H1</i>	chr1:173992926-173992945
<i>RC3H1</i>	chr1:173980872-173980891
<i>RC3H1</i>	chr1:173982779-173982798
<i>RC3H1</i>	chr1:173980941-173980960
<i>RC3H1</i>	chr1:173992844-173992863
<i>RC3H1</i>	chr1:173992895-173992914
<i>RC3H1</i>	chr1:173992882-173992901
<i>RC3H1</i>	chr1:173961717-173961736
<i>RC3H1</i>	chr1:173984495-173984514
<i>RC3H1</i>	chr1:173980811-173980830
<i>RC3H1</i>	chr1:173964926-173964945
<i>RC3H1</i>	chr1:173982894-173982913

Table 20: *Rc3h1* Mouse Genome Coordinates

Target	Coordinates
<i>Rc3h1</i>	chr1:160930251-160930270
<i>Rc3h1</i>	chr1:160930280-160930299
<i>Rc3h1</i>	chr1:160930154-160930173
<i>Rc3h1</i>	chr1:160942614-160942633
<i>Rc3h1</i>	chr1:160930266-160930285
<i>Rc3h1</i>	chr1:160930185-160930204
<i>Rc3h1</i>	chr1:160938126-160938145
<i>Rc3h1</i>	chr1:160930198-160930217

[00344] In some embodiments, the nucleic acid-based gene-regulating system comprises at least one nucleic acid molecule (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein the at least one nucleic acid molecule is a *NFKBIA*-targeting nucleic acid molecule. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO:

11) or the *Nfkb* gene (SEQ ID NO: 12). In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule is an siRNA or an shRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12). In some embodiments, the at least one *NFKBIA*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12).

[00345] In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 (human genome) or Table 22 (mouse genome). In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 845-856. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 845-856.

[00346] In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule is a *NFKBIA*-targeting shRNA or siRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *NFKBIA*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *NFKBIA*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments,

the at least one *NFKBIA*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a human RNA sequence encoded by one of SEQ ID NOs: 845-856. In some embodiments, the at least one *NFKBIA*-targeting shRNA or siRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *NFKBIA*-targeting shRNA or siRNA molecule binds to a human target RNA sequence that is 100% identical to a human RNA sequence encoded by one of SEQ ID NOs: 845-856.

Table 21: *NFKBIA* Human Genome Coordinates

Target	Coordinates
<i>NFKBIA</i>	chr14:35404635-35404654
<i>NFKBIA</i>	chr14:35402653-35402672
<i>NFKBIA</i>	chr14:35402494-35402513
<i>NFKBIA</i>	chr14:35404445-35404464
<i>NFKBIA</i>	chr14:35403152-35403171
<i>NFKBIA</i>	chr14:35403258-35403277
<i>NFKBIA</i>	chr14:35404463-35404482
<i>NFKBIA</i>	chr14:35403202-35403221
<i>NFKBIA</i>	chr14:35404411-35404430
<i>NFKBIA</i>	chr14:35402666-35402685
<i>NFKBIA</i>	chr14:35403330-35403349
<i>NFKBIA</i>	chr14:35403695-35403714

Table 22: *Nfkb* Mouse Genome Coordinates

Target	Coordinates
<i>Nfkb</i>	chr12:55491236-55491255
<i>Nfkb</i>	chr12:55491172-55491191
<i>Nfkb</i>	chr12:55491206-55491225
<i>Nfkb</i>	chr12:55490633-55490652
<i>Nfkb</i>	chr12:55491112-55491131
<i>Nfkb</i>	chr12:55490800-55490819
<i>Nfkb</i>	chr12:55490821-55490840
<i>Nfkb</i>	chr12:55490526-55490545
<i>Nfkb</i>	chr12:55491657-55491676
<i>Nfkb</i>	chr12:55491177-55491196
<i>Nfkb</i>	chr12:55491675-55491694
<i>Nfkb</i>	chr12:55490773-55490792
<i>Nfkb</i>	chr12:55490809-55490828
<i>Nfkb</i>	chr12:55491735-55491754
<i>Nfkb</i>	chr12:55490571-55490590
<i>Nfkb</i>	chr12:55490588-55490607

<i>Nfkb1a</i>	chr12:55491715-55491734
<i>Nfkb1a</i>	chr12:55492316-55492335
<i>Nfkb1a</i>	chr12:55491207-55491226

[00347] In some embodiments, the at least one *SOCS1*-, *PTPN2*-, *ZC3H12A*-, *CBLB*-, *RC3H1*- or *NFKB1A*-targeting siRNA molecule or shRNA molecule is obtained from commercial suppliers such as Sigma Aldrich®, Dharmacon®, ThermoFisher®, and the like. In some embodiments, the at least one *SOCS1*-, *PTPN2*-, or *ZC3H12A*-targeting siRNA molecule is one shown in Table 23. In some embodiments, the at least one *SOCS1*-, *PTPN2*-, or *ZC3H12A*-targeting shRNA molecule is one shown in Table 24.

Table 23: Exemplary *SOCS1*, *PTPN2*, *ZC3H12A*, *RC3H1* and *NFKB1A* siRNAs

Target Gene	siRNA construct
<i>SOCS1</i>	MISSION® esiRNA targeting mouse <i>Socs1</i> (SigmaAldrich# EMU203261)
	Rosetta Predictions human (SigmaAldrich# NM_003745)
	Rosetta Predictions murine (SigmaAldrich# NM_009896)
<i>PTPN2</i>	MISSION® esiRNA human <i>PTPN2</i> (esiRNA1) (SigmaAldrich# EHU113971)
	human Rosetta Predictions (SigmaAldrich# NM_002828)
	human Rosetta Predictions (SigmaAldrich# NM_080422)
	human Rosetta Predictions (SigmaAldrich# NM_080423)
	murine Rosetta Predictions (SigmaAldrich# NM_001127177)
<i>ZC3H12A</i>	MISSION® esiRNA targeting human <i>ZC3H12A</i> (esiRNA1) (SigmaAldrich# EHU009491)
	MISSION® esiRNA targeting mouse <i>Zc3h12a</i> (esiRNA1) (SigmaAldrich# EMU048551)
	Rosetta Predictions human (SigmaAldrich# NM_025079)
	Rosetta Predictions mouse (SigmaAldrich# NM_153159)
<i>RC3H1</i>	MISSION® esiRNA targeting mouse <i>Cytl4</i> (SigmaAldrich# EHU032691)
<i>NFKB1A</i>	MISSION® esiRNA targeting mouse <i>Ephb4</i> (SigmaAldrich# EMU043721)

Table 24: Exemplary *SOCS1*, *PTPN2*, *ZC3H12A*, *RC3H1* and *NFKB1A* shRNAs

Target Gene	shRNA construct
<i>SOCS1</i>	MISSION® shRNA Plasmid DNA human (SigmaAldrich# SHCLND-NM_003745)
	MISSION® shRNA Plasmid DNA murine (SigmaAldrich# SHCLND-NM_009896)
<i>PTPN2</i>	MISSION® shRNA Plasmid human (SigmaAldrich# SHCLND-NM_002827)
	MISSION® shRNA Plasmid murine (SigmaAldrich# SHCLND-NM_011201)
<i>ZC3H12A</i>	MISSION® shRNA Plasmid DNA human (SigmaAldrich# SHCLND-NM_025079)
	MISSION® shRNA Plasmid DNA mouse (SigmaAldrich# SHCLND-NM_153159)

Target Gene	shRNA construct
<i>RC3H1</i>	MISSION® shRNA Plasmid DNA human (SigmaAldrich# SHCLND-NM_172071)
<i>NFKBIA</i>	MISSION® shRNA Plasmid DNA human (SigmaAldrich# SHCLND-NM_020529)

[00348] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *SOCS1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *PTPN2*-targeting nucleic acid molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00349] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00350] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *PTPN2*-targeting

nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00351] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *SOCS1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *PTPN2*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *PTPN2*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00352] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00353] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00354] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *SOCS1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *ZC3H12A*-targeting nucleic acid molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00355] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence

encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00356] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00357] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *SOCS1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *ZC3H12A*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *ZC3H12A*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00358] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded

by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00359] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00360] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *PTPN2*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *ZC3H12A*-targeting nucleic acid molecule. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00361] In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9

or Table 10 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00362] In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00363] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *PTPN2*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *ZC3H12A*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *PTPN2*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *PTPN2*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00364] In some embodiments, the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA

sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00365] In some embodiments, the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00366] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *CBLB*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *PTPN2*-targeting nucleic acid molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *CBLB* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00367] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00368] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00369] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *CBLB*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *PTPN2*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *PTPN2*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB*

gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00370] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00371] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00372] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *CBLB*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *ZC3H12A*-targeting nucleic acid molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *CBLB*-targeting nucleic acid

molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00373] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00374] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00375] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *CBLB*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *ZC3H12A*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *ZC3H12A*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting siRNA or shRNA

molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00376] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00377] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00378] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *SOCS1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *CBLB*-targeting nucleic acid molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least

95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00379] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18.

[00380] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823.

[00381] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *SOCS1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *CBLB*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *CBLB*-

targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00382] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18.

[00383] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823.

[00384] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino),

wherein at least one nucleic acid molecule is a *RC3H1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *PTPN2*-targeting nucleic acid molecule. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00385] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00386] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00387] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *RC3H1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *PTPN2*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *PTPN2*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00388] In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00389] In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target

RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00390] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *RC3H1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *ZC3H12A*-targeting nucleic acid molecule. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00391] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00392] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99%

identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00393] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *RC3H1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *ZC3H12A*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *ZC3H12A*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00394] In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00395] In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00396] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *SOCS1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *RC3H1*-targeting nucleic acid molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00397] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence

encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00398] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844.

[00399] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *SOCS1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *RC3H1*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *RC3H1*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00400] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA

sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00401] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844.

[00402] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *CBLB*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *RC3H1*-targeting nucleic acid molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00403] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some

embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00404] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844.

[00405] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *CBLB*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *RC3H1*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *RC3H1*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00406] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17

or Table 18 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00407] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844.

[00408] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *NFKBIA*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *PTPN2*-targeting nucleic acid molecule. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00409] In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00410] In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *PTPN2*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00411] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *NFKBIA*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *PTPN2*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *PTPN2*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *NFKBIA*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by

the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00412] In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00413] In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327. In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *PTPN2*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 201-327.

[00414] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *NFKBIA*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *ZC3H12A*-targeting nucleic acid molecule. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID

NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00415] In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00416] In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *ZC3H12A*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00417] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *NFKBIA*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *ZC3H12A*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *ZC3H12A*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is

at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *NFKBIA*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00418] In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00419] In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337. In some embodiments, the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875 and the at least one *ZC3H12A*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 331-797 or 331-337.

[00420] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino),

wherein at least one nucleic acid molecule is a *SOCS1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *NFKBIA*-targeting nucleic acid molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00421] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00422] In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875.

[00423] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *SOCS1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *NFKBIA*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *NFKBIA*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *SOCS1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00424] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00425] In some embodiments, the at least one *SOCS1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some

embodiments, the at least one *SOCSI*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 23-200 or 23-55 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875.

[00426] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *CBLB*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *NFKBIA*-targeting nucleic acid molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12). In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12).

[00427] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00428] In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99%

identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875.

[00429] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *CBLB*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *NFKBIA*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *NFKBIA*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *CBLB*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00430] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00431] In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *CBLB*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 798-823 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875.

[00432] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two nucleic acid molecules (*e.g.*, an siRNA, an shRNA, an RNA aptamer, or a morpholino), wherein at least one nucleic acid molecule is a *RC3H1*-targeting nucleic acid molecule and at least one nucleic acid molecule is a *NFKBIA*-targeting nucleic acid molecule. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00433] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence

encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00434] In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *NFKBIA*-targeting nucleic acid molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875.

[00435] In some embodiments, the nucleic acid-based gene-regulating system comprises at least two siRNA or shRNA molecules, wherein at least one siRNA or shRNA molecule is a *RC3H1*-targeting siRNA or shRNA molecule and at least one siRNA or shRNA molecule is a *NFKBIA*-targeting siRNA or shRNA molecule. In some embodiments, the at least one *RC3H1*-targeting nucleic acid molecule is an siRNA or an shRNA molecule and at least one *NFKBIA*-targeting nucleic acid molecule is an siRNA or shRNA molecule. In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *RC3H1*-targeting siRNA or an shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00436] In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21

or Table 22. In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00437] In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875. In some embodiments, the at least one *RC3H1*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 824-844 and the at least one *NFKBIA*-targeting siRNA or shRNA molecule binds to a target RNA sequence that is 100% identical to an RNA sequence encoded by one of SEQ ID NOs: 845-875.

Protein-based gene-regulating systems

[00438] In some embodiments, the present disclosure provides protein gene-regulating systems comprising one, two or more proteins capable of reducing the expression and/or function of at least one, two or more endogenous genes selected from *ANKRD11*, *BCL2L1*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBRI*, *TGFBRI2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.) In some embodiments, the present disclosure provides protein gene-regulating systems comprising one, two or more proteins capable of reducing the expression and/or function of at least one, two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the present disclosure provides modified TILs manufactured by the methods described herein comprising such gene-regulating systems. In some embodiments, a protein-based gene-regulating system is a system comprising one or more proteins capable of regulating the expression of an endogenous target gene in a sequence specific manner without the requirement for a nucleic acid guide molecule. In some embodiments, the protein-

based gene-regulating system comprises a protein comprising one or more zinc-finger binding domains and an enzymatic domain. In some embodiments, the protein-based gene-regulating system comprises a protein comprising a Transcription activator-like effector nuclease (TALEN) domain and an enzymatic domain. Such embodiments are referred to herein as “TALENs”.

Zinc finger systems

[00439] In some embodiments, the present disclosure provides zinc finger gene-regulating systems comprising one, two or more zinc finger fusion proteins capable of reducing the expression and/or function of at least one, two or more endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the present disclosure provides modified TILs manufactured by the methods described herein comprising such gene-regulating systems. Herein, zinc finger-based systems comprise a fusion protein with two protein domains: a zinc finger DNA binding domain and an enzymatic domain. A “zinc finger DNA binding domain”, “zinc finger protein”, or “ZFP” is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion. The zinc finger domain, by binding to a target DNA sequence, directs the activity of the enzymatic domain to the vicinity of the sequence and, hence, induces modification of the endogenous target gene in the vicinity of the target sequence. A zinc finger domain can be engineered to bind to virtually any desired sequence. Accordingly, after identifying a target genetic locus containing a target DNA sequence at which cleavage or recombination is desired (*e.g.*, a target locus in a target gene referenced in Tables 2 or 3), one or more zinc finger binding domains can be engineered to bind to one or more target DNA sequences in the target genetic locus. Expression of a fusion protein comprising a zinc finger binding domain and an enzymatic domain in a cell, effects modification in the target genetic locus.

[00440] In some embodiments, a zinc finger binding domain comprises one or more zinc fingers. Miller *et al.* (1985) EMBO J. 4:1609-1614; Rhodes (1993) Scientific American February:56-65; U.S. Pat. No. 6,453,242. Typically, a single zinc finger domain is about 30 amino acids in length. An individual zinc finger binds to a three-nucleotide (*i.e.*, triplet) sequence (or a four-nucleotide sequence which can overlap, by one nucleotide, with the four-nucleotide binding site of an adjacent zinc finger). Therefore, the length of a sequence to which a zinc finger binding domain is engineered to bind (*e.g.*, a target sequence) will determine the number of zinc fingers in an engineered zinc finger binding domain. For example, for ZFPs in which the finger motifs do not bind to overlapping subsites, a six-nucleotide target sequence is bound by a two-finger binding

domain; a nine-nucleotide target sequence is bound by a three-finger binding domain, etc. Binding sites for individual zinc fingers (*i.e.*, subsites) in a target site need not be contiguous, but can be separated by one or several nucleotides, depending on the length and nature of the amino acid sequences between the zinc fingers (*i.e.*, the inter-finger linkers) in a multi-finger binding domain. In some embodiments, the DNA-binding domains of individual ZFPs comprise between three and six individual zinc finger repeats and can each recognize between 9 and 18 base pairs.

[00441] Zinc finger binding domains can be engineered to bind to a sequence of choice. See, for example, Beerli *et al.* (2002) *Nature Biotechnol.* 20:135-141; Pabo *et al.* (2001) *Ann. Rev. Biochem.* 70:313-340; Isalan *et al.* (2001) *Nature Biotechnol.* 19:656-660; Segal *et al.* (2001) *Curr. Opin. Biotechnol.* 12:632-637; Choo *et al.* (2000) *Curr. Opin. Struct. Biol.* 10:411-416. An engineered zinc finger binding domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein. Engineering methods include, but are not limited to, rational design and various types of selection.

[00442] Selection of a target DNA sequence for binding by a zinc finger domain can be accomplished, for example, according to the methods disclosed in U.S. Pat. No. 6,453,242. It will be clear to those skilled in the art that simple visual inspection of a nucleotide sequence can also be used for selection of a target DNA sequence. Accordingly, any means for target DNA sequence selection can be used in the methods described herein. A target site generally has a length of at least 9 nucleotides and, accordingly, is bound by a zinc finger binding domain comprising at least three zinc fingers. However, binding of, for example, a 4-finger binding domain to a 12-nucleotide target site, a 5-finger binding domain to a 15-nucleotide target site or a 6-finger binding domain to an 18-nucleotide target site, is also possible. As will be apparent, binding of larger binding domains (*e.g.*, 7-, 8-, 9-finger and more) to longer target sites is also possible.

[00443] In some embodiments, the protein-based gene-regulating system comprises at least one zinc finger fusion protein (ZFP) that comprises a *SOCS1*-targeting zinc finger binding domain. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2). In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2).

[00444] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA

sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200.

[00445] In some embodiments, the protein-based gene-regulating system comprises at least one zinc finger fusion protein (ZFP) that comprises a *PTPN2*-targeting zinc finger binding domain. In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00446] In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327. In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327.

[00447] In some embodiments, the protein-based gene-regulating system comprises at least one zinc finger fusion protein (ZFP) that comprises a *ZC3H12A*-targeting zinc finger binding domain. In some embodiments, the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00448] In some embodiments, the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797. In some embodiments, the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797.

[00449] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *CBLB*-targeting zinc finger binding domain. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00450] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823.

[00451] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *RC3H1*-targeting zinc finger binding domain. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is

100% identical to a target DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00452] In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844.

[00453] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *NFKBIA*-targeting zinc finger binding domain. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00454] In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875.

[00455] In some embodiments, the at least one *SOCS1*-, *PTPN2*-, *ZC3H12A*-, *CBLB*-, *RC3H1*- or *NFKBIA*-targeting ZFP is obtained from commercial suppliers such as Sigma Aldrich,

Dharmacon, ThermoFisher, and the like. For example, in some embodiments, the at least one *SOCS1*, *PTPN2*, or *ZC3H12A* ZFP is one shown in Table 25.

Table 25: Exemplary *SOCS1*, *PTPN2*, and *ZC3H12A* Zinc Finger Systems

Target Gene	Zinc Finger System
<i>SOCS1</i>	CompoZr® Knockout ZFN plasmid Human <i>SOCS1</i> (NM_003745) (SigmaAldrich# CKOZFND20320)
	CompoZr® Knockout ZFN plasmid Mouse <i>Socs1</i> (NM_009896.2) (SigmaAldrich# CKOZFND41801)
<i>PTPN2</i>	CompoZr® Knockout ZFN human plasmid <i>PTPN1</i> (NM_002827) (SigmaAldrich# CKOZFND2121)
	CompoZr® Knockout ZFN murine plasmid <i>Ptpn1</i> (NM_011201.3) (SigmaAldrich# CKOZFND39626)
<i>ZC3H12A</i>	CompoZr® Knockout ZFN Kit, ZFN plasmid Human <i>ZC3H12A</i> (NM_025079) (SigmaAldrich# CKOZFND23094)
	CompoZr® Knockout ZFN Kit, ZFN plasmid mouse <i>Zc3h12a</i> (NM_153159.2) (SigmaAldrich# CKOZFND44851)

[00456] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *SOCS1*-targeting zinc finger binding domain and at least one ZFP comprises a *PTPN2*-targeting zinc finger binding domain. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00457] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting

zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00458] In some embodiments, the at least one SOCS1-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00459] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *SOCS1*-targeting zinc finger binding domain and at least one ZFP comprises a *ZC3H12A*-targeting zinc finger binding domain. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00460] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00461] In some embodiments, the at least one SOCS1-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00462] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *PTPN2*-targeting zinc finger binding domain and at least one ZFP comprises a *ZC3H12A*-targeting zinc finger binding domain. In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00463] In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00464] In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00465] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *CBLB*-targeting zinc finger binding domain and at least one ZFP comprises a *PTPN2*-targeting zinc finger binding domain. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00466] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00467] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00468] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *CBLB*-targeting zinc finger binding domain and at least one ZFP comprises a *ZC3H12A*-targeting zinc finger binding domain. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00469] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00470] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of

SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00471] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *SOCS1*-targeting zinc finger binding domain and at least one ZFP comprises a *CBLB*-targeting zinc finger binding domain. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00472] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18.

[00473] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of

SEQ ID NOs: 798-823 or 798-808. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808.

[00474] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *RC3H1*-targeting zinc finger binding domain and at least one ZFP comprises a *PTPN2*-targeting zinc finger binding domain. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00475] In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00476] In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID

NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00477] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *RC3H1*-targeting zinc finger binding domain and at least one ZFP comprises a *ZC3H12A*-targeting zinc finger binding domain. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00478] In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00479] In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting zinc finger binding domain

binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00480] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *SOCS1*-targeting zinc finger binding domain and at least one ZFP comprises a *RC3H1*-targeting zinc finger binding domain. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00481] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00482] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *CBLB*-targeting zinc finger binding domain and at least one ZFP comprises a *RC3H1*-targeting zinc finger binding domain. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target

DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00483] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00484] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836.

[00485] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *NFKBIA*-targeting zinc finger binding domain and at least one ZFP comprises a *PTPN2*-targeting zinc finger binding domain. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene

(SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00486] In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00487] In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00488] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *NFKBIA*-targeting zinc finger binding domain and at least one ZFP comprises a *ZC3H12A*-targeting zinc finger binding domain. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *NFKBIA* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one

ZC3H12A-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00489] In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00490] In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00491] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *SOCS1*-targeting zinc finger binding domain and at least one ZFP comprises a *NFKBIA*-targeting zinc finger binding domain. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting zinc finger

binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12).

[00492] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00493] In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *SOCS1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00494] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *CBLB*-targeting zinc finger binding domain and at least one ZFP comprises a *NFKBIA*-targeting zinc finger binding domain. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12). In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12).

[00495] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00496] In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *CBLB*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00497] In some embodiments, the protein-based gene-regulating system comprises at least two ZFPs, wherein at least one ZFP comprises a *RC3H1*-targeting zinc finger binding domain and at least one ZFP comprises a *NFKBIA*-targeting zinc finger binding domain. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3hl* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12). In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3hl* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12).

[00498] In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00499] In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *RC3H1*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting zinc finger binding domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00500] The enzymatic domain portion of the zinc finger fusion proteins can be obtained from any endo- or exonuclease. Exemplary endonucleases from which an enzymatic domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalogue, New England Biolabs, Beverly, Mass.; and Belfort *et al.* (1997) *Nucleic Acids Res.* 25:3379-3388. Additional enzymes which cleave DNA are known (*e.g.*, 51 Nuclease; mung bean nuclease; pancreatic DNaseI; micrococcal nuclease; yeast HO endonuclease; see also Linn *et al.* (eds.) *Nucleases*, Cold Spring Harbor Laboratory Press, 1993). One or more of these enzymes (or functional fragments thereof) can be used as a source of cleavage domains.

[00501] Exemplary restriction endonucleases (restriction enzymes) suitable for use as an enzymatic domain of the ZFPs described herein are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding. Certain restriction enzymes (*e.g.*, Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains. For example, the Type IIS

enzyme FokI catalyzes double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. *See*, for example, U.S. Pat. Nos. 5,356,802; 5,436,150 and 5,487,994; as well as Li *et al.* (1992) Proc. Natl. Acad. Sci. USA 89:4275-4279; Li *et al.* (1993) Proc. Natl. Acad. Sci. USA 90:2764-2768; Kim *et al.* (1994a) Proc. Natl. Acad. Sci. USA 91:883-887; Kim *et al.* (1994b) J. Biol. Chem. 269:31,978-31,982. Thus, in one embodiment, fusion proteins comprise the enzymatic domain from at least one Type IIS restriction enzyme and one or more zinc finger binding domains.

[00502] An exemplary Type IIS restriction enzyme, whose cleavage domain is separable from the binding domain, is FokI. This particular enzyme is active as a dimer. Bitinaite *et al.* (1998) Proc. Natl. Acad. Sci. USA 95: 10,570-10,575. Thus, for targeted double-stranded DNA cleavage using zinc finger-FokI fusions, two fusion proteins, each comprising a FokI enzymatic domain, can be used to reconstitute a catalytically active cleavage domain. Alternatively, a single polypeptide molecule containing a zinc finger binding domain and two FokI enzymatic domains can also be used. Exemplary ZFPs comprising FokI enzymatic domains are described in US Patent No. 9,782,437.

TALEN systems

[00503] In some embodiments, the present disclosure provides TALEN gene-regulating systems comprising one, two or more TALEN fusion proteins capable of reducing the expression and/or function of at least two endogenous genes selected from *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the present disclosure provides modified TILs manufactured by the methods described herein comprising such gene-regulating systems. TALEN-based systems comprise a TALEN fusion protein comprising a TAL effector DNA binding domain and an enzymatic domain. They are made by fusing a TAL effector DNA-binding domain to a DNA cleavage domain (a nuclease which cuts DNA strands). The FokI restriction enzyme described above is an exemplary enzymatic domain suitable for use in TALEN-based gene-regulating systems.

[00504] TAL effectors are proteins that are secreted by *Xanthomonas* bacteria via their type III secretion system when they infect plants. The DNA binding domain contains a repeated, highly conserved, 33–34 amino acid sequence with divergent 12th and 13th amino acids. These two positions, referred to as the Repeat Variable Diresidue (RVD), are highly variable and strongly correlated with specific nucleotide recognition. Therefore, the TAL effector domains can be engineered to bind specific target DNA sequences by selecting a combination of repeat segments containing the appropriate RVDs. The nucleic acid specificity for RVD combinations is as follows:

HD targets cytosine, NI targets adenine, NG targets thymine, and NN targets guanine (though, in some embodiments, NN can also bind adenine with lower specificity).

[00505] Methods and compositions for assembling the TAL-effector repeats are known in the art. *See e.g.*, Cermak *et al*, Nucleic Acids Research, 39:12, 2011, e82. Plasmids for constructions of the TAL-effector repeats are commercially available from Addgene.

[00506] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *SOCS1*-targeting TAL effector domain. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2). In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2).

[00507] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187.

[00508] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *PTPN2*-targeting TAL effector domain. In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00509] In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA

sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00510] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *ZC3H12A*-targeting TAL effector domain. In some embodiments, the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00511] In some embodiments, the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00512] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *CBLB*-targeting TAL effector domain. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00513] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808.

[00514] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *RC3H1*-targeting TAL effector domain. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a target DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00515] In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 7 or Table 8. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836.

[00516] In some embodiments, the protein-based gene-regulating system comprises at least one TALEN fusion protein that comprises a *NFKBIA*-targeting TAL effector domain. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100%

identical to a target DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12).

[00517] In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00518] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *SOCS1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *PTPN2*-targeting TAL effector domain. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00519] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting TAL

effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00520] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00521] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *SOCS1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *ZC3H12A*-targeting TAL effector domain. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00522] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00523] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00524] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *PTPN2*-targeting TAL effector domain and at least one Talen fusion protein comprises a *ZC3H12A*-targeting TAL effector domain. In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00525] In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00526] In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314 and the at least one *ZC3H12A*-targeting TAL effector domain binds

to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00527] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *CBLB*-targeting TAL effector domain and at least one Talen fusion protein comprises a *PTPN2*-targeting TAL effector domain. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00528] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00529] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or

798-808 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00530] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *CBLB*-targeting TAL effector domain and at least one Talen fusion protein comprises a *ZC3H12A*-targeting TAL effector domain. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00531] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00532] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00533] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *SOCS1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *CBLB*-targeting TAL effector domain. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00534] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18.

[00535] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808.

[00536] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *RC3H1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *PTPN2*-targeting TAL

effector domain. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00537] In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00538] In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00539] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *RC3H1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *ZC3H12A*-targeting TAL effector domain. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least

one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00540] In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00541] In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00542] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *SOCS1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *RC3H1*-targeting TAL effector domain. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *SOCS1*-targeting TAL

effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00543] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00544] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *CBLB*-targeting TAL effector domain and at least one Talen fusion protein comprises a *RC3H1*-targeting TAL effector domain. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00545] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined

by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00546] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836.

[00547] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *NFKBIA*-targeting TAL effector domain and at least one Talen fusion protein comprises a *PTPN2*-targeting TAL effector domain. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkbia* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00548] In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00549] In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00550] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *NFKBIA*-targeting TAL effector domain and at least one Talen fusion protein comprises a *ZC3H12A*-targeting TAL effector domain. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00551] In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00552] In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting TAL effector domain

binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797 or 338-789. In some embodiments, the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797 or 338-789.

[00553] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *SOCS1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *NFKBIA*-targeting TAL effector domain. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00554] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00555] In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200 or 56-187 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *SOCS1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200 or 200/337

56-187 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00556] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *CBLB*-targeting TAL effector domain and at least one Talen fusion protein comprises a *NFKBIA*-targeting TAL effector domain. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00557] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00558] In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *CBLB*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00559] In some embodiments, the protein-based gene-regulating system comprises at least two Talen fusion proteins, wherein at least one Talen fusion protein comprises a *RC3H1*-targeting TAL effector domain and at least one Talen fusion protein comprises a *NFKBIA*-targeting TAL effector domain. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00560] In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00561] In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *RC3H1*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting TAL effector domain binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

Combination nucleic acid/protein-based gene-regulating systems

[00562] Combination gene-regulating systems comprise a site-directed modifying polypeptide and a nucleic acid guide molecule. Herein, a “site-directed modifying polypeptide” refers to a polypeptide that binds to a nucleic acid guide molecule, is targeted to a target nucleic acid sequence, (for example, an endogenous target DNA or RNA sequence) by the nucleic acid guide molecule to which it is bound, and modifies the target nucleic acid sequence (*e.g.*, cleavage, mutation, or methylation of a target nucleic acid sequence).

[00563] A site-directed modifying polypeptide comprises two portions, a portion that binds the nucleic acid guide and an activity portion. In some embodiments, a site-directed modifying polypeptide comprises an activity portion that exhibits site-directed enzymatic activity (*e.g.*, DNA methylation, DNA or RNA cleavage, histone acetylation, histone methylation, etc.), wherein the site of enzymatic activity is determined by the guide nucleic acid. In some cases, a site-directed modifying polypeptide comprises an activity portion that has enzymatic activity that modifies the endogenous target nucleic acid sequence (*e.g.*, nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity). In other cases, a site-directed modifying polypeptide comprises an activity portion that has enzymatic activity that modifies a polypeptide (*e.g.*, a histone) associated with the endogenous target nucleic acid sequence (*e.g.*, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity or demyristoylation activity). In some embodiments, a site-directed modifying polypeptide comprises an activity portion that modulates transcription of a target DNA sequence (*e.g.*, to increase or decrease transcription). In some embodiments, a site-directed modifying polypeptide comprises an activity portion that modulates expression or translation of a target RNA sequence (*e.g.*, to increase or decrease transcription).

[00564] The nucleic acid guide comprises two portions: a first portion that is complementary to, and capable of binding with, an endogenous target nucleic sequence (referred to herein as a “nucleic acid-binding segment”), and a second portion that is capable of interacting with the site-directed modifying polypeptide (referred to herein as a “protein-binding segment”). In some embodiments, the nucleic acid-binding segment and protein-binding segment of a nucleic

acid guide are comprised within a single polynucleotide molecule. In some embodiments, the nucleic acid-binding segment and protein-binding segment of a nucleic acid guide are each comprised within separate polynucleotide molecules, such that the nucleic acid guide comprises two polynucleotide molecules that associate with each other to form the functional guide.

[00565] The nucleic acid guide mediates the target specificity of the combined protein/nucleic acid gene-regulating systems by specifically hybridizing with a target nucleic acid sequence. In some embodiments, the target nucleic acid sequence is an RNA sequence, such as an RNA sequence comprised within an mRNA transcript of a target gene. In some embodiments, the target nucleic acid sequence is a DNA sequence comprised within the DNA sequence of a target gene. Reference herein to a target gene encompasses the full-length DNA sequence for that particular gene which comprises a plurality of target genetic loci (*i.e.*, portions of a particular target gene sequence (*e.g.*, an exon or an intron)). Within each target genetic loci are shorter stretches of DNA sequences referred to herein as “target DNA sequences” that can be modified by the gene-regulating systems described herein. Further, each target genetic loci comprises a “target modification site,” which refers to the precise location of the modification induced by the gene-regulating system (*e.g.*, the location of an insertion, a deletion, or mutation, the location of a DNA break, or the location of an epigenetic modification). The gene-regulating systems described herein may comprise 2 or more nucleic acid guides (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleic acid guides).

[00566] In some embodiments, the combined protein/nucleic acid gene-regulating systems comprise site-directed modifying polypeptides derived from Argonaute (Ago) proteins (*e.g.*, *T. thermophiles* Ago or TtAgo). In such embodiments, the site-directed modifying polypeptide is a *T. thermophiles* Ago DNA endonuclease, and the nucleic acid guide is a guide DNA (gDNA) (*See*, Swarts *et al.*, Nature 507 (2014), 258-261). In some embodiments, the present disclosure provides a polynucleotide encoding a gDNA. In some embodiments, a gDNA-encoding nucleic acid is comprised in an expression vector, *e.g.*, a recombinant expression vector. In some embodiments, the present disclosure provides a polynucleotide encoding a TtAgo site-directed modifying polypeptide or variant thereof. In some embodiments, the polynucleotide encoding a TtAgo site-directed modifying polypeptide is comprised in an expression vector, *e.g.*, a recombinant expression vector.

[00567] In some embodiments, the gene editing systems described herein are CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR Associated) nuclease systems. In some embodiments, the CRISPR/Cas system is a Class 2 system. Class 2 CRISPR/Cas systems are divided into three types: Type II, Type V, and Type VI systems. In some embodiments,

the CRISPR/Cas system is a Class 2 Type II system, utilizing the Cas9 protein. In such embodiments, the site-directed modifying polypeptide is a Cas9 DNA endonuclease (or variant thereof), and the nucleic acid guide molecule is a guide RNA (gRNA). In some embodiments, the CRISPR/Cas system is a Class 2 Type V system, utilizing the Cas12 proteins (*e.g.*, Cas12a (also known as Cpf1), Cas12b (also known as C2c1), Cas12c (also known as C2c3), Cas12d (also known as CasY), and Cas12e (also known as CasX)). In such embodiments, the site-directed modifying polypeptide is a Cas12 DNA endonuclease (or variant thereof), and the nucleic acid guide molecule is a gRNA. In some embodiments, the CRISPR/Cas system is a Class 2 and Type VI system, utilizing the Cas13 proteins (*e.g.*, Cas13a (also known as C2c2), Cas13b, and Cas13c). (*See*, Pyzocha *et al.*, ACS Chemical Biology, 13(2), 347-356). In such embodiments, the site-directed modifying polypeptide is a Cas13 RNA ribonuclease and the nucleic acid guide molecule is a gRNA.

[00568] A Cas polypeptide refers to a polypeptide that can interact with a gRNA molecule and, in concert with the gRNA molecule, home or localize to a target DNA or target RNA sequence. Cas polypeptides include naturally occurring Cas proteins and engineered, altered, or otherwise modified Cas proteins that differ by one or more amino acid residues from a naturally-occurring Cas sequence.

[00569] A guide RNA (gRNA) comprises two segments, a DNA-binding segment and a protein-binding segment. In some embodiments, the protein-binding segment of a gRNA is comprised in one RNA molecule and the DNA-binding segment is comprised in another separate RNA molecule. Such embodiments are referred to herein as “double-molecule gRNAs” or “two-molecule gRNA” or “dual gRNAs.” In some embodiments, the gRNA is a single RNA molecule and is referred to herein as a “single-guide RNA” or an “sgRNA.” The term “guide RNA” or “gRNA” is inclusive, referring both to two-molecule guide RNAs and sgRNAs.

[00570] The protein-binding segment of a gRNA comprises, in part, two complementary stretches of nucleotides that hybridize to one another to form a double stranded RNA duplex (dsRNA duplex), which facilitates binding to the Cas protein. The nucleic acid-binding segment (or “nucleic acid-binding sequence”) of a gRNA comprises a nucleotide sequence that is complementary to and capable of binding to a specific target nucleic acid sequence. The protein-binding segment of the gRNA interacts with a Cas polypeptide and the interaction of the gRNA molecule and site-directed modifying polypeptide results in Cas binding to the endogenous nucleic acid sequence and produces one or more modifications within or around the target nucleic acid sequence. The precise location of the target modification site is determined by both (i) base-pairing complementarity between the gRNA and the target nucleic acid sequence; and (ii) the location of

a short motif, referred to as the protospacer adjacent motif (PAM), in the target DNA sequence (referred to as a protospacer flanking sequence (PFS) in target RNA sequences). The PAM/PFS sequence is required for Cas binding to the target nucleic acid sequence. A variety of PAM/PFS sequences are known in the art and are suitable for use with a particular Cas endonuclease (*e.g.*, a Cas9 endonuclease). (*See e.g.*, Nat Methods. 2013 Nov; 10(11): 1116–1121 and Sci Rep. 2014; 4: 5405). In some embodiments, the PAM sequence is located within 50 base pairs of the target modification site in a target DNA sequence. In some embodiments, the PAM sequence is located within 10 base pairs of the target modification site in a target DNA sequence. The DNA sequences that can be targeted by this method are limited only by the relative distance of the PAM sequence to the target modification site and the presence of a unique 20 base pair sequence to mediate sequence-specific, gRNA-mediated Cas binding. In some embodiments, the PFS sequence is located at the 3' end of the target RNA sequence. In some embodiments, the target modification site is located at the 5' terminus of the target locus. In some embodiments, the target modification site is located at the 3' end of the target locus. In some embodiments, the target modification site is located within an intron or an exon of the target locus.

[00571] In some embodiments, the present disclosure provides a polynucleotide encoding a gRNA. In some embodiments, a gRNA-encoding nucleic acid is comprised in an expression vector, *e.g.*, a recombinant expression vector. In some embodiments, the present disclosure provides a polynucleotide encoding a site-directed modifying polypeptide. In some embodiments, the polynucleotide encoding a site-directed modifying polypeptide is comprised in an expression vector, *e.g.*, a recombinant expression vector.

Cas proteins

[00572] In some embodiments, the site-directed modifying polypeptide is a Cas protein. Cas molecules of a variety of species can be used in the methods and compositions described herein, including Cas molecules derived from *S. pyogenes*, *S. aureus*, *N. meningitidis*, *S. thermophiles*, *Acidovorax avenae*, *Actinobacillus pleuropneumoniae*, *Actinobacillus succinogenes*, *Actinobacillus suis*, *Actinomyces sp.*, *Cycliphilus denitrificans*, *Aminomonas paucivorans*, *Bacillus cereus*, *Bacillus smithii*, *Bacillus thuringiensis*, *Bacteroides sp.*, *Blastopirellula marina*, *Bradyrhizobium sp.*, *Brevibacillus laterosporus*, *Campylobacter coli*, *Campylobacter jejuni*, *Campylobacter lari*, *Candidatus puniceispirillum*, *Clostridium cellulolyticum*, *Clostridium perfringens*, *Corynebacterium accolens*, *Corynebacterium diphtheria*, *Corynebacterium matruchotii*, *Dinoroseobacter shibae*, *Eubacterium dolichum*, *Gammaproteobacterium*, *Gluconacetobacter diazotrophicus*, *Haemophilus parainfluenzae*, *Haemophilus sputum*, *Helicobacter canadensis*, *Helicobacter cinaedi*, *Helicobacter mustelae*, *Ilyobacter polytropus*,

Kingella kingae, *Lactobacillus crispatus*, *Listeria ivanovii*, *Listeria monocytogenes*, *Listeriaceae bacterium*, *Methylocystis* sp., *Methylosinus trichosporium*, *Mobiluncus mulieris*, *Neisseria bacilliformis*, *Neisseria cinerea*, *Neisseria flavescens*, *Neisseria lactamica*, *Neisseria meningitidis*, *Neisseria* sp., *Neisseria wadsworthii*, *Nitrosomonas* sp., *Parvibaculum lavamentivorans*, *Pasteurella multocida*, *Phascolarctobacterium succinatutens*, *Ralstonia syzygii*, *Rhodopseudomonas palustris*, *Rhodovulum* sp., *Simonsiella muelleri*, *Sphingomonas* sp., *Sporolactobacillus vineae*, *Staphylococcus aureus*, *Staphylococcus lugdunensis*, *Streptococcus* sp., *Subdoligranulum* sp., *Tistrella mobilis*, *Treponema* sp., or *Verminephrobacter eiseniae*.

[00573] In some embodiments, the Cas protein is a naturally-occurring Cas protein. In some embodiments, the Cas endonuclease is selected from the group consisting of C2C1, C2C3, Cpf1 (also referred to as Cas12a), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Cse1, Cse2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, and Csf4.

[00574] In some embodiments, the Cas protein is an endoribonuclease such as a Cas13 protein. In some embodiments, the Cas13 protein is a Cas13a (Abudayyeh *et al.*, Nature 550 (2017), 280-284), Cas13b (Cox *et al.*, Science (2017) 358:6336, 1019-1027), Cas13c (Cox *et al.*, Science (2017) 358:6336, 1019-1027), or Cas13d (Zhang *et al.*, Cell 175 (2018), 212-223) protein.

[00575] In some embodiments, the Cas protein is a wild-type or naturally occurring Cas9 protein or a Cas9 ortholog. Wild-type Cas9 is a multi-domain enzyme that uses an HNH nuclease domain to cleave the target strand of DNA and a RuvC-like domain to cleave the non-target strand. Binding of WT Cas9 to DNA based on gRNA specificity results in double-stranded DNA breaks that can be repaired by non-homologous end joining (NHEJ) or homology-directed repair (HDR). Exemplary naturally occurring Cas9 molecules are described in Chylinski *et al.*, RNA Biology 2013 10:5, 727-737 and additional Cas9 orthologs are described in International PCT Publication No. WO 2015/071474. Such Cas9 molecules include Cas9 molecules of a cluster 1 bacterial family, cluster 2 bacterial family, cluster 3 bacterial family, cluster 4 bacterial family, cluster 5 bacterial family, cluster 6 bacterial family, a cluster 7 bacterial family, a cluster 8 bacterial family, a cluster 9 bacterial family, a cluster 10 bacterial family, a cluster 11 bacterial family, a cluster 12 bacterial family, a cluster 13 bacterial family, a cluster 14 bacterial family, a cluster 15 bacterial family, a cluster 16 bacterial family, a cluster 17 bacterial family, a cluster 18 bacterial family, a cluster 19 bacterial family, a cluster 20 bacterial family, a cluster 21 bacterial family, a cluster 22 bacterial family, a cluster 23 bacterial family, a cluster 24 bacterial family, a cluster 25 bacterial

family, a cluster 26 bacterial family, a cluster 27 bacterial family, a cluster 28 bacterial family, a cluster 29 bacterial family, a cluster 30 bacterial family, a cluster 31 bacterial family, a cluster 32 bacterial family, a cluster 33 bacterial family, a cluster 34 bacterial family, a cluster 35 bacterial family, a cluster 36 bacterial family, a cluster 37 bacterial family, a cluster 38 bacterial family, a cluster 39 bacterial family, a cluster 40 bacterial family, a cluster 41 bacterial family, a cluster 42 bacterial family, a cluster 43 bacterial family, a cluster 44 bacterial family, a cluster 45 bacterial family, a cluster 46 bacterial family, a cluster 47 bacterial family, a cluster 48 bacterial family, a cluster 49 bacterial family, a cluster 50 bacterial family, a cluster 51 bacterial family, a cluster 52 bacterial family, a cluster 53 bacterial family, a cluster 54 bacterial family, a cluster 55 bacterial family, a cluster 56 bacterial family, a cluster 57 bacterial family, a cluster 58 bacterial family, a cluster 59 bacterial family, a cluster 60 bacterial family, a cluster 61 bacterial family, a cluster 62 bacterial family, a cluster 63 bacterial family, a cluster 64 bacterial family, a cluster 65 bacterial family, a cluster 66 bacterial family, a cluster 67 bacterial family, a cluster 68 bacterial family, a cluster 69 bacterial family, a cluster 70 bacterial family, a cluster 71 bacterial family, a cluster 72 bacterial family, a cluster 73 bacterial family, a cluster 74 bacterial family, a cluster 75 bacterial family, a cluster 76 bacterial family, a cluster 77 bacterial family, or a cluster 78 bacterial family.

[00576] In some embodiments, the naturally occurring Cas9 polypeptide is selected from the group consisting of SpCas9, SpCas9-HF1, SpCas9-HF2, SpCas9-HF3, SpCas9-HF4, SaCas9, FnCpf, FnCas9, eSpCas9, and NmeCas9. In some embodiments, the Cas9 protein comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a Cas9 amino acid sequence described in Chylinski *et al.*, RNA Biology 2013 10:5, 727-737; Hou *et al.*, PNAS Early Edition 2013, 1-6).

[00577] In some embodiments, the Cas polypeptide comprises one or more of the following activities:

(a) a nickase activity, *i.e.*, the ability to cleave a single strand, *e.g.*, the non-complementary strand or the complementary strand, of a nucleic acid molecule;

(b) a double stranded nuclease activity, *i.e.*, the ability to cleave both strands of a double stranded nucleic acid and create a double stranded break, which in an embodiment is the presence of two nickase activities;

(c) an endonuclease activity;

(d) an exonuclease activity; and/or

(e) a helicase activity, *i.e.*, the ability to unwind the helical structure of a double stranded nucleic acid.

[00578] In some embodiments, the Cas polypeptide is fused to heterologous proteins that recruit DNA-damage signaling proteins, exonucleases, or phosphatases to further increase the likelihood or the rate of repair of the target sequence by one repair mechanism or another. In some embodiments, a WT Cas polypeptide is co-expressed with a nucleic acid repair template to facilitate the incorporation of an exogenous nucleic acid sequence by homology-directed repair.

[00579] In some embodiments, different Cas proteins (*i.e.*, Cas9 proteins from various species) may be advantageous to use in the various provided methods in order to capitalize on various enzymatic characteristics of the different Cas proteins (*e.g.*, for different PAM sequence preferences; for increased or decreased enzymatic activity; for an increased or decreased level of cellular toxicity; to change the balance between NHEJ, homology-directed repair, single strand breaks, double strand breaks, etc.).

[00580] In some embodiments, the Cas protein is a Cas9 protein derived from *S. pyogenes* and recognizes the PAM sequence motif NGG, NAG, NGA (Mali *et al*, Science 2013; 339(6121): 823-826). In some embodiments, the Cas protein is a Cas9 protein derived from *S. thermophiles* and recognizes the PAM sequence motif NGGNG and/or NNAGAAW (W = A or T) (See, *e.g.*, Horvath *et al*, Science, 2010; 327(5962): 167-170, and Deveau *et al*, J Bacteriol 2008; 190(4): 1390-1400). In some embodiments, the Cas protein is a Cas9 protein derived from *S. mutans* and recognizes the PAM sequence motif NGG and/or NAAR (R = A or G) (See, *e.g.*, Deveau *et al*, J BACTERIOL 2008; 190(4): 1390-1400). In some embodiments, the Cas protein is a Cas9 protein derived from *S. aureus* and recognizes the PAM sequence motif NNGRR (R = A or G). In some embodiments, the Cas protein is a Cas9 protein derived from *S. aureus* and recognizes the PAM sequence motif N GRRT (R = A or G). In some embodiments, the Cas protein is a Cas9 protein derived from *S. aureus* and recognizes the PAM sequence motif N GRRV (R = A or G). In some embodiments, the Cas protein is a Cas9 protein derived from *N. meningitidis* and recognizes the PAM sequence motif N GATT or N GCTT (R = A or G, V = A, G or C) (See, *e.g.*, Hou *et al*, PNAS 2013, 1-6). In the aforementioned embodiments, N can be any nucleotide residue, *e.g.*, any of A, G, C or T. In some embodiments, the Cas protein is a Cas13a protein derived from *Leptotrichia shahii* and recognizes the PFS sequence motif of a single 3' A, U, or C.

[00581] In some embodiments, a polynucleotide encoding a Cas protein is provided. In some embodiments, the polynucleotide encodes a Cas protein that is at least 90% identical to a Cas protein described in International PCT Publication No. WO 2015/071474 or Chylinski *et al.*,

RNA Biology 2013 10:5, 727-737. In some embodiments, the polynucleotide encodes a Cas protein that is at least 95%, 96%, 97%, 98%, or 99% identical to a Cas protein described in International PCT Publication No. WO 2015/071474 or Chylinski *et al.*, RNA Biology 2013 10:5, 727-737. In some embodiments, the polynucleotide encodes a Cas protein that is 100% identical to a Cas protein described in International PCT Publication No. WO 2015/071474 or Chylinski *et al.*, RNA Biology 2013 10:5, 727-737.

Cas Mutants

[00582] In some embodiments, the Cas polypeptides are engineered to alter one or more properties of the Cas polypeptide. For example, in some embodiments, the Cas polypeptide comprises altered enzymatic properties, *e.g.*, altered nuclease activity, (as compared with a naturally occurring or other reference Cas molecule) or altered helicase activity. In some embodiments, an engineered Cas polypeptide can have an alteration that alters its size, *e.g.*, a deletion of amino acid sequence that reduces its size without significant effect on another property of the Cas polypeptide. In some embodiments, an engineered Cas polypeptide comprises an alteration that affects PAM recognition. For example, an engineered Cas polypeptide can be altered to recognize a PAM sequence other than the PAM sequence recognized by the corresponding wild-type Cas protein.

[00583] Cas polypeptides with desired properties can be made in a number of ways, including alteration of a naturally occurring Cas polypeptide or parental Cas polypeptide, to provide a mutant or altered Cas polypeptide having a desired property. For example, one or more mutations can be introduced into the sequence of a parental Cas polypeptide (*e.g.*, a naturally occurring or engineered Cas polypeptide). Such mutations and differences may comprise substitutions (*e.g.*, conservative substitutions or substitutions of non-essential amino acids); insertions; or deletions. In some embodiments, a mutant Cas polypeptide comprises one or more mutations (*e.g.*, at least 1, 2, 3, 4, 5, 10, 15, 20, 30, 40 or 50 mutations) relative to a parental Cas polypeptide.

[00584] In an embodiment, a mutant Cas polypeptide comprises a cleavage property that differs from a naturally occurring Cas polypeptide. In some embodiments, the Cas is a deactivated Cas (dCas) mutant. In such embodiments, the Cas polypeptide does not comprise any intrinsic enzymatic activity and is unable to mediate target nucleic acid cleavage. In such embodiments, the dCas may be fused with a heterologous protein that is capable of modifying the target nucleic acid in a non-cleavage-based manner. For example, in some embodiments, a dCas protein is fused to transcription activator or transcription repressor domains (*e.g.*, the Kruppel associated box (KRAB or SKD); the Mad mSIN3 interaction domain (SID or SID4X); the ERF repressor domain (ERD);

the MAX-interacting protein 1 (MXI1); methyl-CpG binding protein 2 (MECP2); etc.). In some such cases, the dCas fusion protein is targeted by the sgRNA to a specific location (*i.e.*, sequence) in the target nucleic acid and exerts locus-specific regulation such as blocking RNA polymerase binding to a promoter (which selectively inhibits transcription activator function), and/or modifying the local chromatin status (*e.g.*, when a fusion sequence is used that modifies the target DNA or modifies a polypeptide associated with the target DNA). In some cases, the changes are transient (*e.g.*, transcription repression or activation). In some cases, the changes are inheritable (*e.g.*, when epigenetic modifications are made to the target DNA or to proteins associated with the target DNA, *e.g.*, nucleosomal histones).

[00585] In some embodiments, the dCas is a dCas13 mutant (Konermann *et al.*, Cell 173 (2018), 665-676). These dCas13 mutants can then be fused to enzymes that modify RNA, including adenosine deaminases (*e.g.*, ADAR1 and ADAR2). Adenosine deaminases convert adenine to inosine, which the translational machinery treats like guanine, thereby creating a functional A → G change in the RNA sequence. In some embodiments, the dCas is a dCas9 mutant.

[00586] In some embodiments, the mutant Cas9 is a Cas9 nickase mutant. Cas9 nickase mutants comprise only one catalytically active domain (either the HNH domain or the RuvC domain). The Cas9 nickase mutants retain DNA binding based on gRNA specificity but are capable of cutting only one strand of DNA resulting in a single-strand break (*e.g.*, a “nick”). In some embodiments, two complementary Cas9 nickase mutants (*e.g.*, one Cas9 nickase mutant with an inactivated RuvC domain, and one Cas9 nickase mutant with an inactivated HNH domain) are expressed in the same cell with two gRNAs corresponding to two respective target sequences; one target sequence on the sense DNA strand, and one on the antisense DNA strand. This dual-nickase system results in staggered double stranded breaks and can increase target specificity, as it is unlikely that two off-target nicks will be generated close enough to generate a double stranded break. In some embodiments, a Cas9 nickase mutant is co-expressed with a nucleic acid repair template to facilitate the incorporation of an exogenous nucleic acid sequence by homology-directed repair.

[00587] In some embodiments, the Cas polypeptides described herein can be engineered to alter the PAM/PFS specificity of the Cas polypeptide. In some embodiments, a mutant Cas polypeptide has a PAM/PFS specificity that is different from the PAM/PFS specificity of the parental Cas polypeptide. For example, a naturally occurring Cas protein can be modified to alter the PAM/PFS sequence that the mutant Cas polypeptide recognizes to decrease off target sites, improve specificity, or eliminate a PAM/PFS recognition requirement. In some embodiments, a Cas protein can be modified to increase the length of the PAM/PFS recognition sequence. In some

embodiments, the length of the PAM recognition sequence is at least 4, 5, 6, 7, 8, 9, 10 or 15 amino acids in length. Cas polypeptides that recognize different PAM/PFS sequences and/or have reduced off-target activity can be generated using directed evolution. Exemplary methods and systems that can be used for directed evolution of Cas polypeptides are described, *e.g.*, in Esvelt *et al.* Nature 2011, 472(7344): 499-503.

[00588] Exemplary Cas mutants are described in International PCT Publication No. WO 2015/161276 and Konermann *et al.*, Cell 173 (2018), 665-676 which are incorporated herein by reference in their entireties.

Guide RNAs (gRNAs)

[00589] The present disclosure provides guide RNAs (gRNAs) that direct a site-directed modifying polypeptide to a specific target nucleic acid sequence. A gRNA comprises a nucleic acid-targeting segment and protein-binding segment. The nucleic acid-targeting segment of a gRNA comprises a nucleotide sequence that is complementary to a sequence in the target nucleic acid sequence. As such, the nucleic acid-targeting segment of a gRNA interacts with a target nucleic acid in a sequence-specific manner via hybridization (*i.e.*, base pairing), and the nucleotide sequence of the nucleic acid-targeting segment determines the location within the target nucleic acid that the gRNA will bind. The nucleic acid-targeting segment of a gRNA can be modified (*e.g.*, by genetic engineering) to hybridize to any desired sequence within a target nucleic acid sequence.

[00590] The protein-binding segment of a guide RNA interacts with a site-directed modifying polypeptide (*e.g.*, a Cas protein) to form a complex. The guide RNA guides the bound polypeptide to a specific nucleotide sequence within target nucleic acid via the above-described nucleic acid-targeting segment. The protein-binding segment of a guide RNA comprises two stretches of nucleotides that are complementary to one another and which form a double stranded RNA duplex.

[00591] In some embodiments, a gRNA comprises two separate RNA molecules. In such embodiments, each of the two RNA molecules comprises a stretch of nucleotides that are complementary to one another such that the complementary nucleotides of the two RNA molecules hybridize to form the double-stranded RNA duplex of the protein-binding segment. In some embodiments, a gRNA comprises a single RNA molecule (sgRNA).

(i) The specificity of a gRNA for a target locus is mediated by the sequence of the nucleic acid-binding segment, which comprises about 20 nucleotides that are complementary to a target nucleic acid sequence within the target locus. In some embodiments, the corresponding target nucleic acid sequence is approximately 20 nucleotides in length. In some

embodiments, the nucleic acid-binding segments of the gRNA sequences of the present disclosure are at least 90% complementary to a target nucleic acid sequence within a target locus. In some embodiments, the nucleic acid-binding segments of the gRNA sequences of the present disclosure are at least 95%, 96%, 97%, 98%, or 99% complementary to a target nucleic acid sequence within a target locus. In some embodiments, the nucleic acid-binding segments of the gRNA sequences of the present disclosure are 100% complementary to a target nucleic acid sequence within a target locus. In some embodiments, the target nucleic acid sequence is an RNA target sequence. In some embodiments, the target nucleic acid sequence is a DNA target sequence. In some embodiments, the target nucleic acid sequence is a DNA target sequence from an endogenous genes including *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.)_

[00592] In some embodiments, the gene-regulating system comprises at least one gRNA molecule that comprises a *SOCS1*-targeting nucleic acid-binding segment (*i.e.*, a *SOCS1*-targeting gRNA). In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2). In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2).

[00593] In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 3 or Table 4. In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5. In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187. In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecules binds to a target DNA sequence that

is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187. Exemplary *SOCS1* target DNA sequences are shown in Tables 26 and 27.

[00594] In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187. In some embodiments, the nucleic acid-binding segment of the at least one *SOCS1*-targeting gRNA molecules is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187. Exemplary DNA sequences encoding the nucleic acid-binding segment of the *SOCS1*-targeting gRNAs are shown in Tables 26 and 27.

Table 26: Exemplary human SOCS1 target sequences

Target	Sequence	SEQ ID
hSOCS1_gRNA_1	GCGGCTGCGCGCCGAGCCCG	56
hSOCS1_gRNA_2	GGACGCCTGCGGATTCTACT	57
hSOCS1_gRNA_3	GGCTGCCATCCAGGTGAAAG	58
hSOCS1_gRNA_4	GCGGCTGTCGCGCACCAGGA	59
hSOCS1_gRNA_5	TGGACGCCTGCGGATTCTAC	60
hSOCS1_gRNA_6	GACGCCTGCGGATTCTACTG	61
hSOCS1_gRNA_7	AGTGCTCCAGCAGCTCGAAG	62
hSOCS1_gRNA_8	GCCGGCCGCTTTCACCTGGA	63
hSOCS1_gRNA_9	AGTAGAATCCGCAGGCGTCC	64
hSOCS1_gRNA_10	CGCACCAGGAAGGTGCCCAC	65
hSOCS1_gRNA_11	GGCCGGCCTGAAAGTGCACG	66
hSOCS1_gRNA_12	TCCGTTCGCACGCCGATTAC	67
hSOCS1_gRNA_13	AGCGCGCTCCTGGACGCCTG	68
hSOCS1_gRNA_14	CGGCTGCGCGCCGAGCCCGT	69
hSOCS1_gRNA_15	ACGCCTGCGGATTCTACTGG	70
hSOCS1_gRNA_16	CGAGGCCATCTTCACGCTAA	71
hSOCS1_gRNA_17	TCAGGCCGGCCGCTTTCACC	72
hSOCS1_gRNA_18	CTTAGCGTGAAGATGGCCTC	73
hSOCS1_gRNA_19	GCCGGTAATCGGCGTGCGAA	74
hSOCS1_gRNA_20	CTGCATTGTCGGCTGCCACC	75
hSOCS1_gRNA_21	GTGCGCCCCGTGCACGCTCA	76
hSOCS1_gRNA_22	GCTGTGCCGCCAGCGCATCG	77
hSOCS1_gRNA_23	CACGCGGCGCTGGCGCAGCG	78
hSOCS1_gRNA_24	GCTCCTGCAGCGGCCGCACG	79
hSOCS1_gRNA_25	AGCTCTCGCGGCTGCCATCC	80
hSOCS1_gRNA_26	TGGTGCGCGACAGCCGCCAG	81
hSOCS1_gRNA_27	GATGGTAGCACACAACCAGG	82
hSOCS1_gRNA_28	AGAGGCAGTCGAAGCTCTCG	83
hSOCS1_gRNA_29	GCTGGCGGCTGTCGCGCACC	84

Target	Sequence	SEQ ID
hSOCS1_gRNA_30	CCGAGGCCATCTTCACGCTA	85
hSOCS1_gRNA_31	GGGGCCCCCAGCATGCGGCG	86
hSOCS1_gRNA_32	GCTGCTGGAGCACTACGTGG	87
hSOCS1_gRNA_33	CGAGCTGCTGGAGCACTACG	88
hSOCS1_gRNA_34	CGAAAAAGCAGTTCCGCTGG	89
hSOCS1_gRNA_35	GCAGGCGTCCAGGAGCGCGC	90
hSOCS1_gRNA_36	GGGGCCCCTGAGCGTGCACG	91
hSOCS1_gRNA_37	GCGGCGCCGCGCCGCATGCT	92
hSOCS1_gRNA_38	GCACGCGGCGCTGGCGCAGC	93
hSOCS1_gRNA_39	TGGGGGCCCTGAGCGTGCA	94
hSOCS1_gRNA_40	CAGGAAGGTGCCCACGGGCT	95
hSOCS1_gRNA_41	TGCGCCCCGTGCACGCTCAG	96
hSOCS1_gRNA_42	GCCATCCAGGTGAAAGCGGC	97
hSOCS1_gRNA_43	CACGCGCGCCAGCGCGCTCC	98
hSOCS1_gRNA_44	GGGCCCCCAGTAGAATCCGC	99
hSOCS1_gRNA_45	ATCCGCGTGCACCTTCAGGC	100
hSOCS1_gRNA_46	CGAGCCCGTGGGCACCTTCC	101
hSOCS1_gRNA_47	CCACAGCAGCAGAGCCCCGA	102
hSOCS1_gRNA_48	AGCCAGGTTCTCGCGGCCCA	103
hSOCS1_gRNA_49	AAAGTGCACGCGGATGCTCG	104
hSOCS1_gRNA_50	CTCTTCCTCCTCCTCGCCCG	105
hSOCS1_gRNA_51	GCGTGCACGGGGCGCACGAG	106
hSOCS1_gRNA_52	AAGTGCACGCGGATGCTCGT	107
hSOCS1_gRNA_53	CGTGCGCCCCGTGCACGCTC	108
hSOCS1_gRNA_54	GCAGCGGCCCGCACGCGGCGC	109
hSOCS1_gRNA_55	CCTTAGCGTGAAGATGGCCT	110
hSOCS1_gRNA_56	CAGGTTCTCGCGGCCACGG	111
hSOCS1_gRNA_57	GCGCACCAGGAAGGTGCCCA	112
hSOCS1_gRNA_58	GCTGCCGGTCAAATCTGGAA	113
hSOCS1_gRNA_59	CGGCGTGCGAACGGAATGTG	114
hSOCS1_gRNA_60	CAGCAGCAGAGCCCCGACGG	115
hSOCS1_gRNA_61	GGGCGAAAAAGCAGTTCCGC	116
hSOCS1_gRNA_62	CGCACGCGGCGCTGGCGCAG	117
hSOCS1_gRNA_63	GGATGCGAGCCAGGTTCTCG	118
hSOCS1_gRNA_64	TGGCGGCACAGCTCCTGCAG	119
hSOCS1_gRNA_65	GCGCCCGCGGCCGTGCCCCG	120
hSOCS1_gRNA_66	GGCGCCGCGCCGCATGCTGG	121
hSOCS1_gRNA_67	CGGTGGCCACGATGCGCTGG	122
hSOCS1_gRNA_68	TGCTGTGGAGACTGCATTGT	123
hSOCS1_gRNA_69	TAGGATGGTAGCACACAACC	124
hSOCS1_gRNA_70	GCGGCCGTGCCCCGCGGTCC	125
hSOCS1_gRNA_71	GAGCATCCGCGTGCACCTTC	126
hSOCS1_gRNA_72	CGCTGCCGGTCAAATCTGGA	127
hSOCS1_gRNA_73	CAGCGCATCGTGGCCACCGT	128
hSOCS1_gRNA_74	GCGGATGCTCGTGGGTCCCG	129

Target	Sequence	SEQ ID
hSOCS1_gRNA_75	CGGCGCCGCGCCGCATGCTG	130
hSOCS1_gRNA_76	CGGTCAAATCTGGAAGGGGA	131
hSOCS1_gRNA_77	AGGAAGGTTCTGGCCGCCGT	132
hSOCS1_gRNA_78	CCACGGTGGCCACGATGCGC	133
hSOCS1_gRNA_79	CGCTGCGCCAGCGCCGCGTG	134
hSOCS1_gRNA_80	AGGAGCTCAGGTAGTCGCGG	135
hSOCS1_gRNA_81	GCAGCGGGGCCCCCAGCATG	136
hSOCS1_gRNA_82	GGAAGGAGCTCAGGTAGTCG	137
hSOCS1_gRNA_83	TCGCGGAGGACGGGGTTGAG	138
hSOCS1_gRNA_84	CGACTGCCTCTTCGAGCTGC	139
hSOCS1_gRNA_85	GCGCCGCGTGCGGCCGCTGC	140
hSOCS1_gRNA_86	CACCGTGGGCCGCGAGAACC	141
hSOCS1_gRNA_87	GTGCCCCGCGGTCCCGGCC	142
hSOCS1_gRNA_88	CTGCCGGTCAAATCTGGAAG	143
hSOCS1_gRNA_89	CTTCCCCTTCCAGATTTGAC	144
hSOCS1_gRNA_90	CTCAGGTAGTCGCGGAGGAC	145
hSOCS1_gRNA_91	CGGGCGCTGCCGGTCAAATC	146
hSOCS1_gRNA_92	GGAAGGTTCTGGCCGCCGTC	147
hSOCS1_gRNA_93	GCTCAGGTAGTCGCGGAGGA	148
hSOCS1_gRNA_94	GCGGAAGTGCGTGTCGCCGG	149
hSOCS1_gRNA_95	GGACCGCGGGGCACGGCCGC	150
hSOCS1_gRNA_96	GGGACCGCGGGGCACGGCCG	151
hSOCS1_gRNA_97	GCGCGTGATGCGCCGGTAAT	152
hSOCS1_gRNA_98	TCAGGTAGTCGCGGAGGACG	153
hSOCS1_gRNA_99	TGCGGAAGTGCGTGTCGCCG	154
hSOCS1_gRNA_100	GGGGCCGGGACCGCGGGGCA	155
hSOCS1_gRNA_101	CCGTCGGGGCTCTGCTGCTG	156
hSOCS1_gRNA_102	GAAGGTTCTGGCCGCCGTCG	157
hSOCS1_gRNA_103	GTGTGCTACCATCCTACAGA	158
hSOCS1_gRNA_104	GTCGCGGAGGACGGGGTTGA	159
hSOCS1_gRNA_105	CGCTGGCGCGCGTGATGCGC	160
hSOCS1_gRNA_106	GCGTGACGGCGGGCGCTGC	161
hSOCS1_gRNA_107	TCTGGAAGGGGAAGGAGCTC	162
hSOCS1_gRNA_108	GTGCGTGTCGCCGGGGGCCG	163
hSOCS1_gRNA_109	GGGCACGGCCGCGGGCGCGC	164
hSOCS1_gRNA_110	GTTAATGCTGCGTGACGGC	165
hSOCS1_gRNA_111	GCACGGCCGCGGGCGCGCGG	166
hSOCS1_gRNA_112	GGGGCACGGCCGCGGGCGCG	167
hSOCS1_gRNA_113	GTGCGGAAGTGCGTGTCGCC	168
hSOCS1_gRNA_114	GAGGAAGAGGAGGAAGGTTT	169
hSOCS1_gRNA_115	GGCTGGCCCCTTCTGTAGGA	170
hSOCS1_gRNA_116	GGGGCCGGGGCCGGGACCGC	171
hSOCS1_gRNA_117	CGCGGAGGACGGGGTTGAGG	172
hSOCS1_gRNA_118	TTTCGCCCTTAGCGTGAAGA	173
hSOCS1_gRNA_119	GGCACGGCCGCGGGCGCGCG	174

Target	Sequence	SEQ ID
hSOCS1_gRNA_120	AGTCGCGGAGGACGGGGTTG	175
hSOCS1_gRNA_121	GGGCCGGGGCCGGGACCGCG	176
hSOCS1_gRNA_122	AAGTGC GTGTCGCCGGGGGC	177
hSOCS1_gRNA_123	CTCCGGCTGGCCCCCTTCTGT	178
hSOCS1_gRNA_124	GGCGGCGCCGCGCCGCATGC	179
hSOCS1_gRNA_125	AGTGC GTGTCGCCGGGGGCC	180
hSOCS1_gRNA_126	TGTGCGGAAGTGC GTGTCGC	181
hSOCS1_gRNA_127	GTGTCGCCGGGGGGCCGGGGC	182
hSOCS1_gRNA_128	TGTCGCCGGGGGGCCGGGGCC	183
hSOCS1_gRNA_129	GCGGTCCCGGCCCGGCCCC	184
hSOCS1_gRNA_130	CGCGGGGGCCGCGGGCGAGG	185
hSOCS1_gRNA_131	CGCGGGCGAGGAGGAGGAAG	186
hSOCS1_gRNA_132	GGGCGAGGAGGAGGAAGAGG	187

Table 27: Exemplary murine Socs1 target sequences

Target	Sequence	SEQ ID
mSocs1_gRNA_1	GAAGTGCACGCGGATGCTCG	188
mSocs1_gRNA_2	AGTGCTCCAGCAGCTCGAAA	189
mSocs1_gRNA_3	GCCGGCCGCTTCCACTTGA	190
mSocs1_gRNA_4	GCTGTGTCGCCAGCGCATCG	191
mSocs1_gRNA_5	GCGACTGTGCGGCACCAAGA	192
mSocs1_gRNA_6	GCGTGACGGGGCGCACGAG	193
mSocs1_gRNA_7	TCACGGAGTACCGGGTTAAG	194
mSocs1_gRNA_8	GGACGCCTGCGGCTTCTATT	195
mSocs1_gRNA_9	GCGCGAAGAAGCAGTTCCGT	196
mSocs1_gRNA_10	GCTCAGCGTGAAGATGGCTT	197
mSocs1_gRNA_11	CGAGCCCGTGGGCACCTTCT	198
mSocs1_gRNA_12	ATCCGCGTGCACTTCCAGGC	199
mSocs1_gRNA_13	CGCCAGGTTCTCGCGACCCA	200

[00595] In some embodiments, the gene-regulating system comprises at least one gRNA molecule that comprises a *PTPN2*-targeting nucleic acid-binding segment (*i.e.*, a *PTPN2*-targeting gRNA). In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00596] In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%,

or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314. Exemplary *PTPN2*/*Ptpn2* target DNA sequences are shown in Tables 28 and 29.

[00597] In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the nucleic acid-binding segment of the at least one *PTPN2*-targeting gRNA molecules is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314. Exemplary DNA sequences encoding the nucleic acid-binding segment of the *PTPN2*-targeting gRNAs are shown in Tables 28 and 29.

Table 28: Exemplary human *PTPN2* gRNA sequences

Target	Sequence	SEQ ID
hPTPN2_gRNA_1	CCATGCCCAACCACCATCGAG	201
hPTPN2_gRNA_2	TCTACGGAAACGTATTCGAG	202
hPTPN2_gRNA_3	TTAGTATATTGAGAACTTG	203
hPTPN2_gRNA_4	GCACTACAGTGGATCACCGC	204
hPTPN2_gRNA_5	TGTCATGCTGAACCGCATTG	205
hPTPN2_gRNA_6	GGAAACTTGGCCACTCTATG	206
hPTPN2_gRNA_7	GTATTTGAAATTATTAATGC	207
hPTPN2_gRNA_8	CAGTTTAGTTGACATAGAAG	208
hPTPN2_gRNA_9	GGGTCTGAATAAGACCCATT	209
hPTPN2_gRNA_10	CCATGACTATCCTCATAGAG	210
hPTPN2_gRNA_11	CCATGACTATCCTCATAGAG	211
hPTPN2_gRNA_12	CTCTTCGAACTCCCGCTCGA	212
hPTPN2_gRNA_13	GAACCCTGACCATGGGCCTG	213

Target	Sequence	SEQ ID
hPTPN2_gRNA_14	GCTCCTTGAACCCTGACCAT	214
hPTPN2_gRNA_15	AGTTGGATACTCAGCGTCGC	215
hPTPN2_gRNA_16	CCGCTCGATGGTGGTGGGCA	216
hPTPN2_gRNA_17	CAGAAATGGCAGCATGTGTT	217
hPTPN2_gRNA_18	GCACTACAGTGGATCACCGC	218
hPTPN2_gRNA_19	GGTAGACACTTGTCTTGTTT	219
hPTPN2_gRNA_20	TGGCAGCATGTGTTAGGAAG	220
hPTPN2_gRNA_21	AGGCCCATGGTCAGGGTTCA	221
hPTPN2_gRNA_22	G TTCAGCATGACAACTGCTT	222
hPTPN2_gRNA_23	CAATGGAGGAGAACAGTGAG	223
hPTPN2_gRNA_24	CTCTTCTATGTCAACTAAAC	224
hPTPN2_gRNA_25	AGTGGATCACCGCAGGCCCA	225
hPTPN2_gRNA_26	CTGACAGGTGACCGATGTAC	226
hPTPN2_gRNA_27	AACTCCCGCTCGATGGTGGT	227
hPTPN2_gRNA_28	GTCTCCCTGATCCATCCAGT	228
hPTPN2_gRNA_29	TAGAGGAAAGTCCTGTACAT	229
hPTPN2_gRNA_30	ATGTATGGAAAGGATGGTAA	230
hPTPN2_gRNA_31	GCCCAATGCCTGCACTACAG	231
hPTPN2_gRNA_32	CGAGCGGGAGTTCTGAAGAGT	232
hPTPN2_gRNA_33	TCACCGCAGGCCCATGGTCA	233
hPTPN2_gRNA_34	CAGTTTAGTTGACATAGAAG	234
hPTPN2_gRNA_35	CCATGCCACCACCATCGAG	235
hPTPN2_gRNA_36	GCCAAACCATAAGCCAGAAA	236
hPTPN2_gRNA_37	CCGATTCTTTCTCCACAATG	237
hPTPN2_gRNA_38	TTCGAACTCCCGCTCGATGG	238
hPTPN2_gRNA_39	AGTGCAGGCATTGGGCGCTC	239
hPTPN2_gRNA_40	GGAAACTTGGCCACTCTATG	240
hPTPN2_gRNA_41	ATCCACTGTAGTGCAGGCAT	241
hPTPN2_gRNA_42	CACTCTATGAGGATAGTCAT	242
hPTPN2_gRNA_43	CCACTCTATGAGGATAGTCA	243
hPTPN2_gRNA_44	TCCACTGTAGTGCAGGCATT	244
hPTPN2_gRNA_45	AAGTTCTTTCCATCGTTTCT	245
hPTPN2_gRNA_46	TCGCTGGCAGCCGCTGTACT	246
hPTPN2_gRNA_47	GAACTCCCGCTCGATGGTGG	247
hPTPN2_gRNA_48	AGGATGGTAAAGGCACCAAC	248
hPTPN2_gRNA_49	AAAGGGAGATTCTAGTATAC	249
hPTPN2_gRNA_50	AGAATTTAGGATGTATGGAA	250
hPTPN2_gRNA_51	GGGTCTGAATAAGACCCATT	251
hPTPN2_gRNA_52	GGCACCAACTGGATGGATCA	252
hPTPN2_gRNA_53	CTCTAAAATGCAAGATACAA	253
hPTPN2_gRNA_54	GTATTTGAAATTATTAATGC	254
hPTPN2_gRNA_55	CCTTTCTTGCAGATGGAAAA	255
hPTPN2_gRNA_56	CTGCACCTTCTGAGCTGTGG	256
hPTPN2_gRNA_57	ATGCTGCCATTTCTGGCTTA	257
hPTPN2_gRNA_58	TTTCTTTAAACAGCATCTCT	258

Target	Sequence	SEQ ID
hPTPN2_gRNA_59	AGACATGGAATGCAGAATGC	259
hPTPN2_gRNA_60	AGGCACCAACTGGATGGATC	260
hPTPN2_gRNA_61	TAATGACTGAAAAATACAAT	261
hPTPN2_gRNA_62	GAATGCAGAATGCAGGAAAT	262
hPTPN2_gRNA_63	TTAGGATGTATGGAAAGGA	263
hPTPN2_gRNA_64	CTAACACATGCTGCCATTTC	264
hPTPN2_gRNA_65	TCATACATGGCTATAATAGA	265
hPTPN2_gRNA_66	ACGATGGAAAGAACTTTCTA	266
hPTPN2_gRNA_67	ACGTATTCGAGAGGACAGAA	267
hPTPN2_gRNA_68	GCGGTGATCCACTGTAGTGC	268
hPTPN2_gRNA_69	TATTAATGCTGGATGTAAA	269
hPTPN2_gRNA_70	GAGATGCTGTTTAAAGAAAC	270
hPTPN2_gRNA_71	CAGCAAGAATTTAGGATGTA	271
hPTPN2_gRNA_72	TTGACATAGAAGAGGCACAA	272
hPTPN2_gRNA_73	GATTCAGGGACTCCAAAATC	273
hPTPN2_gRNA_74	CTCACTTTCATTATACTACC	274
hPTPN2_gRNA_75	TTAGTATATTGAGAACTTG	275
hPTPN2_gRNA_76	AGGGACTCCAAAATCTGGCC	276
hPTPN2_gRNA_77	AGGTTAAATGTGCACAGTAC	277
hPTPN2_gRNA_78	ATCACCGCAGGCCCATGGTC	278
hPTPN2_gRNA_79	AGCATCTCTTGGTCATCTGT	279
hPTPN2_gRNA_80	GAAGGAGCAAAATGTATAAA	280
hPTPN2_gRNA_81	GCCATTTCTGGCTTATGGTT	281
hPTPN2_gRNA_82	CTGGATGGATCAGGGAGACA	282
hPTPN2_gRNA_83	AAATACAATGGGAACAGAAT	283
hPTPN2_gRNA_84	ATAATGACTGAAAAATACAA	284
hPTPN2_gRNA_85	CATGCCCACCACCATCGAGC	285
hPTPN2_gRNA_86	AACATGAGAAAATACCGAAT	286
hPTPN2_gRNA_87	AGAAATGAAGCTGGTGATTC	287
hPTPN2_gRNA_88	CCGCATTGTGGAGAAAGAAT	288
hPTPN2_gRNA_89	GAAATGAAGCTGGTGATTCA	289
hPTPN2_gRNA_90	TTGTTTAAAGTGAGAGAATC	290
hPTPN2_gRNA_91	CCGCGACTCACCAAGTACAG	291
hPTPN2_gRNA_92	GAACATGAGAAAATACCGAA	292
hPTPN2_gRNA_93	TATACTACCTGGCCAGATTT	293
hPTPN2_gRNA_94	TATGAGAATCTCAGTTGATC	294
hPTPN2_gRNA_95	TCAACTGAGATTCTCATACA	295
hPTPN2_gRNA_96	TGAGAATCTCAGTTGATCTG	296
hPTPN2_gRNA_97	ATGAGAATCTCAGTTGATCT	297
hPTPN2_gRNA_98	TGGTAAAGGCACCAACTGGA	298
hPTPN2_gRNA_99	TGTCATGCTGAACCGCATTG	299
hPTPN2_gRNA_100	TTGGTGAATGATCAAAGGC	300
hPTPN2_gRNA_101	ATGAAAGTGAGATATTGTTC	301
hPTPN2_gRNA_102	TATTTCTCATAGTGCTCTA	302
hPTPN2_gRNA_103	AGAAGGAGCAAAATGTATAA	303

Target	Sequence	SEQ ID
hPTPN2_gRNA_104	TTTGTGGTGAATGATCAA	304
hPTPN2_gRNA_105	TCTACGGAAACGTATTCGAG	305
hPTPN2_gRNA_106	AAAGGCCACCACAGCTCAGA	306
hPTPN2_gRNA_107	AGGTGCAGCAGATGAAACAG	307
hPTPN2_gRNA_108	GGCTCCTTGAACCCTGACCA	308
hPTPN2_gRNA_109	AAGGAGTTACATCTTAACAC	309
hPTPN2_gRNA_110	TAAATGCAAGATACAATGG	310
hPTPN2_gRNA_111	ACAAGTGTCTACCAGAGAGA	311
hPTPN2_gRNA_112	GCGCTCTGGCACCTTCTCTC	312
hPTPN2_gRNA_113	CTGCTGCACCTTCTGAGCTG	313
hPTPN2_gRNA_114	TCTTCCCTACCTAGAAACGA	314

Table 29: Exemplary murine Ptpn2 gRNA sequences

Target	Sequence	SEQ ID
mPTPN2_gRNA_1	AATCTGGCCAGGTGGTATAA	315
mPTPN2_gRNA_2	AATATGAGAAAGTATCGAAT	316
mPTPN2_gRNA_3	ATCACTGCAGGTCCATGGTC	317
mPTPN2_gRNA_4	ATGTGCACAGTACTGGCCAA	318
mPTPN2_gRNA_5	GGCAGCATGTGTTTCGGAAGT	319
mPTPN2_gRNA_6	AAGAAGTTTAGAAATGAAGC	320
mPTPN2_gRNA_7	GCCACACCATGAGCCAGAAA	321
mPTPN2_gRNA_8	CCTTTCTTGCAGATGGAAAA	322
mPTPN2_gRNA_9	GTACTTTGCTCCTTCTATTA	323
mPTPN2_gRNA_10	AGAAATGAAGCTGGTGACTC	324
mPTPN2_gRNA_11	GTTTAGCATGACAACTGCTT	325
mPTPN2_gRNA_12	GCCCGATGCCCGCACTGCAA	326
mPTPN2_gRNA_13	TGACAGAGAAATGGTGTTTA	327

[00598] In some embodiments, the gene-regulating system comprises at least one gRNA molecule that comprises a *ZC3H12A*-targeting nucleic acid-binding segment (*i.e.*, a *ZC3H12A*-targeting gRNA). In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00599] In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%,

97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. Exemplary *ZC3H12A* target DNA sequences are shown in Tables 30 and 31.

[00600] In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the nucleic acid-binding segment of the at least one *ZC3H12A*-targeting gRNA molecules is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. Exemplary DNA sequences encoding the nucleic acid-binding segment of the *ZC3H12A/Zc3h12a*-targeting gRNAs are shown in Tables 30 and 31.

Table 30: Exemplary human *ZC3H12A* gRNA sequences

Target	Sequence	SEQ ID
hZC3H12A_gRNA_1	AAGCTGGCCTACGAGTCTGA	338
hZC3H12A_gRNA_2	GCGGGACTAGAGGGAGCTGA	339
hZC3H12A_gRNA_3	CAGCTCCCTCTAGTCCCGCG	340
hZC3H12A_gRNA_4	CAGGACGCTGTGGATCTCCG	341
hZC3H12A_gRNA_5	AACATACTTGTTCATTGACGA	342
hZC3H12A_gRNA_6	CTCACCTGTGATGGGCACGT	343
hZC3H12A_gRNA_7	AACACGGGACAGCCACCGAG	344
hZC3H12A_gRNA_8	CGACAGATTCATTGTGAAGC	345
hZC3H12A_gRNA_9	ACACCATCACGACGCGTGGG	346
hZC3H12A_gRNA_10	TCCCAGCCATGGGAACAAGG	347
hZC3H12A_gRNA_11	GGAGTGGAAGCGCTTCATCG	348
hZC3H12A_gRNA_12	TTAGGGGTGCCACCACCCCG	349
hZC3H12A_gRNA_13	GACACATACCGTGACCTCCA	350
hZC3H12A_gRNA_14	CCGGCCCAGTGGGTCATCAG	351
hZC3H12A_gRNA_15	CCTGGAAGTGCAGATGAAGG	352
hZC3H12A_gRNA_16	GTCTCTCCCTCCCAGCCAT	353
hZC3H12A_gRNA_17	TCCCCAGGGTCCCGCCAAGA	354
hZC3H12A_gRNA_18	AGTGAGCAGTGCAGCCTGGA	355
hZC3H12A_gRNA_19	TGTCCTCTCCCTCCCAGCCA	356

Target	Sequence	SEQ ID
hZC3H12A_gRNA_20	CTGGACTGGGATGAAGGTGA	357
hZC3H12A_gRNA_21	GGGGTGGGCCCCGGCTCACCA	358
hZC3H12A_gRNA_22	CACCACCCCGCGGGACTAGA	359
hZC3H12A_gRNA_23	CTGCTGCCACTGCCCCCGCT	360
hZC3H12A_gRNA_24	CGGCCCCGACGTGCCCATCAC	361
hZC3H12A_gRNA_25	CACTGCCCCCGCTAGGTGCG	362
hZC3H12A_gRNA_26	ATACACGCTGGCCTGCTCCT	363
hZC3H12A_gRNA_27	CAAACACTGTGATGTCTGTG	364
hZC3H12A_gRNA_28	GCGGGACCCTGGGGATGCCT	365
hZC3H12A_gRNA_29	GCGGGAGCGCCAGACCTCAC	366
hZC3H12A_gRNA_30	AGGACAGGCTTCTCTCCACA	367
hZC3H12A_gRNA_31	GCAGACACCAACACGGTGCT	368
hZC3H12A_gRNA_32	CCACCACCCCGCGGGACTAG	369
hZC3H12A_gRNA_33	ATCCCCAGGGTCCCGCCAAG	370
hZC3H12A_gRNA_34	CCTGGAGGAAGGAGCAGCCT	371
hZC3H12A_gRNA_35	AGAGCCAGATGTCGGAAGTT	372
hZC3H12A_gRNA_36	ATGACCCACTGGGCGGCAC	373
hZC3H12A_gRNA_37	GCAGCTTTGGGCCACAGAC	374
hZC3H12A_gRNA_38	ACTCTCTGTTAGCAGAGAGC	375
hZC3H12A_gRNA_39	CCAGGAAGGAAATGCACCTA	376
hZC3H12A_gRNA_40	AGGCACCACTCACCTGTGAT	377
hZC3H12A_gRNA_41	CTGGGCCCCGTGCCGGCCCCAG	378
hZC3H12A_gRNA_42	CAGCCAGCTGCTGGGGGTCC	379
hZC3H12A_gRNA_43	TCCACTCCTGCCGCTCGCCT	380
hZC3H12A_gRNA_44	CGTCCAGGCAGACACCAACA	381
hZC3H12A_gRNA_45	CCCACCCACATCAGTCCTTC	382
hZC3H12A_gRNA_46	GCCAGCTCTTGACCCGGCCT	383
hZC3H12A_gRNA_47	CTGCCCTCCTTTTCTCTTC	384
hZC3H12A_gRNA_48	CCAGCCCCACCATGAGTCTG	385
hZC3H12A_gRNA_49	GCCGATTCTTCCACCCAGAG	386
hZC3H12A_gRNA_50	CTCCCAGAAGAGGAAAAGGA	387
hZC3H12A_gRNA_51	GTGGGGCAGGGCAGGCAGCC	388
hZC3H12A_gRNA_52	GGGTCAAGAGCTGGCCGCTG	389
hZC3H12A_gRNA_53	ATGCCCCCTGATGACCCACT	390
hZC3H12A_gRNA_54	AGCCTTCTCTGCCTTTGGCC	391
hZC3H12A_gRNA_55	CTCTGCCTTTGGCCGGGCCA	392
hZC3H12A_gRNA_56	GGAACCCAGCCTGCCCTCCC	393
hZC3H12A_gRNA_57	GGCAGGAGCCTCGCACCTAG	394
hZC3H12A_gRNA_58	TCCAGACCAGCACATCCTG	395
hZC3H12A_gRNA_59	GTGAGCAGTGCAGCCTGGAT	396
hZC3H12A_gRNA_60	GAGCCAGATGTCGGAAGTTT	397
hZC3H12A_gRNA_61	GGCCGATGGCAAGCCTTGCT	398
hZC3H12A_gRNA_62	AGGAGCCTCGCACCTAGCGG	399
hZC3H12A_gRNA_63	AGGTCCCCAAGAGGAAAACA	400
hZC3H12A_gRNA_64	CGCTGAGGAGGCCTCGGCC	401

Target	Sequence	SEQ ID
hZC3H12A_gRNA_65	GAGGACAGCCACAGCCGTCA	402
hZC3H12A_gRNA_66	CAGCCCCACCATGAGTCTGT	403
hZC3H12A_gRNA_67	ACCCCCAGAGCCCCAAGCA	404
hZC3H12A_gRNA_68	GAGGCACCACTCACCTGTGA	405
hZC3H12A_gRNA_69	CCAAGAGGAAAACAGGGCAC	406
hZC3H12A_gRNA_70	GTACGTCTCCCAGGATTGCC	407
hZC3H12A_gRNA_71	CACAGCCTCCACCAGGTGCG	408
hZC3H12A_gRNA_72	GATCTCGGCAGCCAGCTGCT	409
hZC3H12A_gRNA_73	CAGCCTTCTCTGCCTTTGGC	410
hZC3H12A_gRNA_74	CAGAAGTGACACTTACCTCA	411
hZC3H12A_gRNA_75	GCTGGCCGCTGAGGAGGCCT	412
hZC3H12A_gRNA_76	CAGCTCCCTCTAGTCCCGCG	413
hZC3H12A_gRNA_77	CGGGGTGGGCCCGGCTCACC	414
hZC3H12A_gRNA_78	GACACATAACCGTGACCTCCA	415
hZC3H12A_gRNA_79	CAGGAAGGAAATGCACCTAT	416
hZC3H12A_gRNA_80	AGTGGCCAGCACCCATGGCC	417
hZC3H12A_gRNA_81	CTCTCCTATTCTTCCCAGCA	418
hZC3H12A_gRNA_82	GCCCCGAGTCCAGGCAATCCT	419
hZC3H12A_gRNA_83	CACCTTCATCTGCAGTTCCA	420
hZC3H12A_gRNA_84	GGCACAGGCAGACAGGTGAG	421
hZC3H12A_gRNA_85	AGCACCCATGGCCCCGGCCAA	422
hZC3H12A_gRNA_86	CCACAGGCAGCTTACTCACT	423
hZC3H12A_gRNA_87	TTCTGTGCTCCAAAGTGAG	424
hZC3H12A_gRNA_88	ACCGCAGCCTTCTCTGCCTT	425
hZC3H12A_gRNA_89	GGGAGCCAATGCCCCGAGTCC	426
hZC3H12A_gRNA_90	TTCCCAGCAAGGCTTGCCAT	427
hZC3H12A_gRNA_91	AGCCAGATGTCGGAACTTTG	428
hZC3H12A_gRNA_92	TACACGGGCTACAGTCCCTA	429
hZC3H12A_gRNA_93	TCTGTGTAGACCCTCTTGG	430
hZC3H12A_gRNA_94	AAGCTGCCCCCAGCGCTCTG	431
hZC3H12A_gRNA_95	CTTTGGGGGGTTCGAGGAGG	432
hZC3H12A_gRNA_96	GGGCCGATGGCAAGCCTTGC	433
hZC3H12A_gRNA_97	CACAGGCAGCTTACTCACTG	434
hZC3H12A_gRNA_98	CCCAGACCAGCACATCCTGC	435
hZC3H12A_gRNA_99	AGGCTGGGTTCATACCATA	436
hZC3H12A_gRNA_100	GGACTTCTAATTGCTGAGAA	437
hZC3H12A_gRNA_101	CTCAAATTCCCACAGACTCA	438
hZC3H12A_gRNA_102	AAAACAGGGCACAGGCAGAC	439
hZC3H12A_gRNA_103	CCAGATGTCGGAACTTTGGG	440
hZC3H12A_gRNA_104	CTCCCTCTAGTCCCGCGGGG	441
hZC3H12A_gRNA_105	AGCCCCCAGTGCAGAGCCCA	442
hZC3H12A_gRNA_106	CCTGGACGCCCAGCTTCTGC	443
hZC3H12A_gRNA_107	CAGGGGCTGGCAGGAGCCCCG	444
hZC3H12A_gRNA_108	CCTTGTTCCCATGGCTGGGA	445
hZC3H12A_gRNA_109	CTCATCTGCCACAGAGCGCT	446

Target	Sequence	SEQ ID
hZC3H12A_gRNA_110	GGCAGACACCAACACGGTGC	447
hZC3H12A_gRNA_111	TCCCTCTTGATTCTCTTCC	448
hZC3H12A_gRNA_112	CCCTCCCAGCCATGGGAACA	449
hZC3H12A_gRNA_113	GCGTAAGAAGCCACTCACTT	450
hZC3H12A_gRNA_114	TGTGTTTCCCCCGCACCTGG	451
hZC3H12A_gRNA_115	CTGAGACCAGTGGTCATCGA	452
hZC3H12A_gRNA_116	GGGCAGCGACCTGAGACCAG	453
hZC3H12A_gRNA_117	AGCAATTAGAAGTCCCTGCA	454
hZC3H12A_gRNA_118	TGGGTGAGCTGGTGAAACAC	455
hZC3H12A_gRNA_119	CTGTTAGCAGAGAGCTGGAC	456
hZC3H12A_gRNA_120	CCCCTGATGACCCACTGGGC	457
hZC3H12A_gRNA_121	GTTACACCATCACGACGCG	458
hZC3H12A_gRNA_122	TGTCCAGGCTGGGCCCCGTGC	459
hZC3H12A_gRNA_123	ACACAGACCTATGCCCCATC	460
hZC3H12A_gRNA_124	GGCTGCCTGCCCTGCCCCAC	461
hZC3H12A_gRNA_125	CCATAGGTGCATTTCCTTCC	462
hZC3H12A_gRNA_126	CAGGCTGGGTTCATACCAT	463
hZC3H12A_gRNA_127	GCCCCATCACAGCCTCCACC	464
hZC3H12A_gRNA_128	TGCCCTCCTTTTCCTCTTCT	465
hZC3H12A_gRNA_129	GCCAGATGTCGGAACCTTGG	466
hZC3H12A_gRNA_130	CAGGCAGACAGGTGAGAGGA	467
hZC3H12A_gRNA_131	CCAGGAGTCTGAGCTATGAG	468
hZC3H12A_gRNA_132	GCTCCAGGTTGGGAGCCTTA	469
hZC3H12A_gRNA_133	CTCACCTGTGATGGGCACGT	470
hZC3H12A_gRNA_134	AGCTGGCCTACGAGTCTGAC	471
hZC3H12A_gRNA_135	GTGGGTGGGGGCAGTGGGTA	472
hZC3H12A_gRNA_136	CATCTGCAGTTCCAGGGCCG	473
hZC3H12A_gRNA_137	GATGACCCACTGGGCCGCA	474
hZC3H12A_gRNA_138	TGACCTCCAAGGCGAGCGGC	475
hZC3H12A_gRNA_139	GGATCTCGGCAGCCAGCTGC	476
hZC3H12A_gRNA_140	TCCTTTTCCTCTTCTGGGAG	477
hZC3H12A_gRNA_141	CACGACGCGTGGGTGGCAAG	478
hZC3H12A_gRNA_142	TTCACACCATCACGACGCGT	479
hZC3H12A_gRNA_143	GCAGGAGCCTCGCACCTAGC	480
hZC3H12A_gRNA_144	CACCCCTAAGGCTCCCAACC	481
hZC3H12A_gRNA_145	TTGTCCTTGCTTGGGGCTCT	482
hZC3H12A_gRNA_146	CAGGACAGGCTTCTCTCCAC	483
hZC3H12A_gRNA_147	CACCTGGTGGAGGCTGTGAT	484
hZC3H12A_gRNA_148	CGTCTGTGGGAGCCAGTCTG	485
hZC3H12A_gRNA_149	CCCCCAAAGTTCCGACATC	486
hZC3H12A_gRNA_150	AGGCAGCCTGGCCAAGGAGC	487
hZC3H12A_gRNA_151	TCTGCCTTTGGCCGGGCCAT	488
hZC3H12A_gRNA_152	GGACAGGCTTCTCTCCACAG	489
hZC3H12A_gRNA_153	ACGTGCCCATCACAGGTGAG	490
hZC3H12A_gRNA_154	AGAGAGTGAGCAGTGCAGCC	491

Target	Sequence	SEQ ID
hZC3H12A_gRNA_155	CGCAGGAAGTTGTCCAGGCT	492
hZC3H12A_gRNA_156	GGCTGGGAGCTCAGATCCAT	493
hZC3H12A_gRNA_157	CAGCTCACCCAGCACCGTGT	494
hZC3H12A_gRNA_158	CCAGCACATCCTGCGGGAAC	495
hZC3H12A_gRNA_159	GACCTCCTTGTTCCCATGGC	496
hZC3H12A_gRNA_160	GGGGTTCGAGGAGGAGGCC	497
hZC3H12A_gRNA_161	CAGAGAAGGCTGCGGTGGCT	498
hZC3H12A_gRNA_162	GGGAGTGAGTCCAGCGTCTG	499
hZC3H12A_gRNA_163	CAGGAGCCTCGCACCTAGCG	500
hZC3H12A_gRNA_164	GGAGGAGGCCCTGGTGAGCC	501
hZC3H12A_gRNA_165	CAAGCAAGGACAAAAATGGC	502
hZC3H12A_gRNA_166	CGTCAGGGCACCCCAAGGCC	503
hZC3H12A_gRNA_167	GCTGGCAGTGAAGTGGTTTC	504
hZC3H12A_gRNA_168	ACCTCCTTGTTCCCATGGCT	505
hZC3H12A_gRNA_169	TCCCGCAGGATGTGCTGGTC	506
hZC3H12A_gRNA_170	AGGGACTGTAGCCCGTGTA	507
hZC3H12A_gRNA_171	CCAGTACTCTCGAGGTGGAA	508
hZC3H12A_gRNA_172	AATTCCACAGACTCATGGT	509
hZC3H12A_gRNA_173	CCCACCCCGAGCCCCTTACA	510
hZC3H12A_gRNA_174	GTGCATTTCCTTCCTGGAAG	511
hZC3H12A_gRNA_175	TCAGCGGCCAGCTCTTGACC	512
hZC3H12A_gRNA_176	GGCCCGGCCAAAGGCAGAGA	513
hZC3H12A_gRNA_177	ACAGAGCGCTGGGGGCAGCT	514
hZC3H12A_gRNA_178	TCTTGATTTCCTCTCCAGGA	515
hZC3H12A_gRNA_179	GCAAGGACAAAAATGGCCGG	516
hZC3H12A_gRNA_180	CAGGGCAGGCAGCCTGGCCA	517
hZC3H12A_gRNA_181	ATCTCGGCAGCCAGCTGCTG	518
hZC3H12A_gRNA_182	CCCGCAGGATGTGCTGGTCT	519
hZC3H12A_gRNA_183	GGCTCCAGGTTGGGAGCCTT	520
hZC3H12A_gRNA_184	CAACACGGTGCTGGGTGAGC	521
hZC3H12A_gRNA_185	GCAGCCGTGTCCCTATGGTA	522
hZC3H12A_gRNA_186	TGTCCTTGCTTGGGGCTCTG	523
hZC3H12A_gRNA_187	TCATGGTGGGGCTGGCTTCC	524
hZC3H12A_gRNA_188	GAAGCTGGGCTATTCATCCA	525
hZC3H12A_gRNA_189	GACCCTCTTGGCGGGACCCT	526
hZC3H12A_gRNA_190	GGAAAGGCAGGGGGCGCGGG	527
hZC3H12A_gRNA_191	AGGTCTGTGTTAGACCCTCT	528
hZC3H12A_gRNA_192	CTCAGCTCCCTCTAGTCCCG	529
hZC3H12A_gRNA_193	TAGGGACTGTAGCCCGTGTA	530
hZC3H12A_gRNA_194	AGGGGGCATAAACCTGCAGA	531
hZC3H12A_gRNA_195	CTCCCAGGATTGCCTGGACT	532
hZC3H12A_gRNA_196	GGGATGAAGGTGAAGGCCGC	533
hZC3H12A_gRNA_197	TGCAGAGCCCAGGGGCTGGC	534
hZC3H12A_gRNA_198	GAATCGGCACTTGATCCCAT	535
hZC3H12A_gRNA_199	CCGAGGCTGCTCCTTCCTCC	536

Target	Sequence	SEQ ID
hZC3H12A_gRNA_200	CCAGCTTCTGCAGGACGCTG	537
hZC3H12A_gRNA_201	GGGCCGGCACGGGCCAGCC	538
hZC3H12A_gRNA_202	TGAGGTCTGGCGCTCCCGCT	539
hZC3H12A_gRNA_203	TTGGGGTGCCCTGACGGCTG	540
hZC3H12A_gRNA_204	ACTAGAGGGAGCTGAGGGCA	541
hZC3H12A_gRNA_205	CCAGTTCCCGCAGGATGTGC	542
hZC3H12A_gRNA_206	TATGCCCCCTGATGACCCAC	543
hZC3H12A_gRNA_207	GTGAGAGGAGAGCATTGGCA	544
hZC3H12A_gRNA_208	AGCTTACTCACTGGGGTGCT	545
hZC3H12A_gRNA_209	ATCACAGCCTCCACCAGGTG	546
hZC3H12A_gRNA_210	ACTGAAGTGGCCAGCACCCA	547
hZC3H12A_gRNA_211	GCCGGCCCAGTGGGTCATCA	548
hZC3H12A_gRNA_212	CCTGCAGAAGCTGGGCGTCC	549
hZC3H12A_gRNA_213	GCACCGTGTTGGTGTCTGCC	550
hZC3H12A_gRNA_214	GGCCCTGGAAGTGCAGATGA	551
hZC3H12A_gRNA_215	GTCTTGCTTGGGGCTCTGG	552
hZC3H12A_gRNA_216	CTCCCTGGAGAGCCAGATGT	553
hZC3H12A_gRNA_217	AAATTCCCACAGACTCATGG	554
hZC3H12A_gRNA_218	TCATCTGCCACAGAGCGCTG	555
hZC3H12A_gRNA_219	AGTCGGCAGGGACACTGAAG	556
hZC3H12A_gRNA_220	ACTCTCGAGGTGGAAAGGCA	557
hZC3H12A_gRNA_221	CCCAGTGAGTAAGCTGCCTG	558
hZC3H12A_gRNA_222	AGAGGGTGCAAAGAACTCTC	559
hZC3H12A_gRNA_223	CACGATCCCGTCAGACTCGT	560
hZC3H12A_gRNA_224	TCTGCACTGGGGGCTCCTGA	561
hZC3H12A_gRNA_225	CAGGGGGCATAAACCTGCAG	562
hZC3H12A_gRNA_226	TGAGGACAGCCACAGCCGTC	563
hZC3H12A_gRNA_227	GTTTCCCCCGCACCTGGTGG	564
hZC3H12A_gRNA_228	TTAGGGGTGCCACCACCCCG	565
hZC3H12A_gRNA_229	ACTGGGGTGCTGGGACTTGT	566
hZC3H12A_gRNA_230	CTCACTCCCGTACGTCTCCC	567
hZC3H12A_gRNA_231	AGGGGCTGGCAGGAGCCCGT	568
hZC3H12A_gRNA_232	TCCTTGTTCCCATGGCTGGG	569
hZC3H12A_gRNA_233	GCCAAAGGCAGAGAAGGCTG	570
hZC3H12A_gRNA_234	CACGGGCTCCTGCCAGCCCC	571
hZC3H12A_gRNA_235	CCACAGCGTCCTGCAGAAGC	572
hZC3H12A_gRNA_236	ACGGGCTCCTGCCAGCCCCT	573
hZC3H12A_gRNA_237	ATGGGAGCAACGTGGCCATG	574
hZC3H12A_gRNA_238	CCCAAGGCCGGGTCAAGAGC	575
hZC3H12A_gRNA_239	AATTGCTGAGAAGGGGCCGA	576
hZC3H12A_gRNA_240	GGGCAGGAGTGAGGAGGGCC	577
hZC3H12A_gRNA_241	GGCGGGACCCTGGGGATGCC	578
hZC3H12A_gRNA_242	GGGGCTGGCAGGAGCCCGTG	579
hZC3H12A_gRNA_243	TTCCGACATCTGGCTCTCCA	580
hZC3H12A_gRNA_244	GTGCTGCCCTTGCCAGCCAC	581

Target	Sequence	SEQ ID
hZC3H12A_gRNA_245	ACTCCTGCCGCTCGCCTTGG	582
hZC3H12A_gRNA_246	GTGGACTTCTTCCGGAAGCT	583
hZC3H12A_gRNA_247	CCAGTGCAGAGCCCAGGGGC	584
hZC3H12A_gRNA_248	GGGGCAGTGGCAGCAGCTTT	585
hZC3H12A_gRNA_249	GGGACTGTAGCCCGTGTAAG	586
hZC3H12A_gRNA_250	CCACAGACTCATGGTGGGGC	587
hZC3H12A_gRNA_251	AACACGGGACAGCCACCGAG	588
hZC3H12A_gRNA_252	GCAAAGAACTCTCTGGAGGT	589
hZC3H12A_gRNA_253	TGGGCCCCGTGCCGGCCCAGT	590
hZC3H12A_gRNA_254	CTCCTGCCGGGGCATCCTGC	591
hZC3H12A_gRNA_255	AGGCAGACAGGTGAGAGGAA	592
hZC3H12A_gRNA_256	AGGCAATCCTGGGAGACGTA	593
hZC3H12A_gRNA_257	TCAGACCAGTACTCTCGAGG	594
hZC3H12A_gRNA_258	AACATACTTGTCATTGACGA	595
hZC3H12A_gRNA_259	GGCAGCTTGGCCGCTCTGGG	596
hZC3H12A_gRNA_260	GAGTTCTTTGCACCCTCTGC	597
hZC3H12A_gRNA_261	GCCACAGGCAGCTTACTCAC	598
hZC3H12A_gRNA_262	AGGCTGCCTGCCCTGCCCCA	599
hZC3H12A_gRNA_263	CCGGCCCAGTGGGTCATCAG	600
hZC3H12A_gRNA_264	CTCTCGAGGTGGAAAGGCAG	601
hZC3H12A_gRNA_265	GATTGCCTGGACTCGGGCAT	602
hZC3H12A_gRNA_266	TCCTTGCTTGGGGCTCTGGG	603
hZC3H12A_gRNA_267	GCAGAGAAGGCTGCGGTGGC	604
hZC3H12A_gRNA_268	ACCGTGACCTCCAAGGCGAG	605
hZC3H12A_gRNA_269	CAGGACGCTGTGGATCTCCG	606
hZC3H12A_gRNA_270	AGGAAGCAGCCGTGTCCCTA	607
hZC3H12A_gRNA_271	ACGCAGGAAGTTGTCCAGGC	608
hZC3H12A_gRNA_272	GAGGTCCCCAAGAGGAAAAC	609
hZC3H12A_gRNA_273	CCCCCAGCTTCTTCCCATCC	610
hZC3H12A_gRNA_274	ATTCCCACAGACTCATGGTG	611
hZC3H12A_gRNA_275	TCCAAGGCGAGCGGCAGGAG	612
hZC3H12A_gRNA_276	GCTGGGAGCTCAGATCCATA	613
hZC3H12A_gRNA_277	TGGGGGCCCAGGCATCCCCA	614
hZC3H12A_gRNA_278	GGGTGCAAAGAACTCTCTGG	615
hZC3H12A_gRNA_279	GCGGGACTAGAGGGAGCTGA	616
hZC3H12A_gRNA_280	ACTGGAGAAGAAGAAGATCC	617
hZC3H12A_gRNA_281	CCAGCTCTTGACCCGGCCTT	618
hZC3H12A_gRNA_282	GAACCTTGGGGGGTTTCGAGG	619
hZC3H12A_gRNA_283	GAAACCAGTTCACTGCCAGC	620
hZC3H12A_gRNA_284	ACAGCCGTCAGGGCACCCCCA	621
hZC3H12A_gRNA_285	CCACCCCGAGCCCCTTACAC	622
hZC3H12A_gRNA_286	TCTCGGCAGCCAGCTGCTGG	623
hZC3H12A_gRNA_287	AGAGAGCTGGACTGGGATGA	624
hZC3H12A_gRNA_288	CCTTTCCACCTCGAGAGTAC	625
hZC3H12A_gRNA_289	AAGCTGGCCTACGAGTCTGA	626

Target	Sequence	SEQ ID
hZC3H12A_gRNA_290	GTCTGTGGGAGCCAGTCTGT	627
hZC3H12A_gRNA_291	AGACCTATGCCCCATCAGGC	628
hZC3H12A_gRNA_292	TGGGAAGAAGCTGGGGGCC	629
hZC3H12A_gRNA_293	CTGTGGAGAGAAGCCTGTCC	630
hZC3H12A_gRNA_294	GGGACTTCTAATTGCTGAGA	631
hZC3H12A_gRNA_295	GGA CTCGGGCATTGGCTCCC	632
hZC3H12A_gRNA_296	CATCTGCCACAGAGCGCTGG	633
hZC3H12A_gRNA_297	CTTCTGGGAGTGGAGGCTCC	634
hZC3H12A_gRNA_298	GCCCCCAGTGCAGAGCCCAG	635
hZC3H12A_gRNA_299	TTTGTCTTGCTTGGGGCTC	636
hZC3H12A_gRNA_300	GTGGGGCTGGCTTCCAGGAC	637
hZC3H12A_gRNA_301	TCAAGAGCTGGCCGCTGAGG	638
hZC3H12A_gRNA_302	CCTCTAGTCCCGCGGGGTGG	639
hZC3H12A_gRNA_303	GCTCATCTGCCACAGAGCGC	640
hZC3H12A_gRNA_304	CATGAGTCTGTGGGAATTTG	641
hZC3H12A_gRNA_305	TGCGAGGCTCCTGCCTGATG	642
hZC3H12A_gRNA_306	GGAGTGAGTCCAGCGTCTGT	643
hZC3H12A_gRNA_307	TGCAAAGAACTCTCTGGAGG	644
hZC3H12A_gRNA_308	CACAGCGTCCTGCAGAAGCT	645
hZC3H12A_gRNA_309	CAGCTTACTCACTGGGGTGC	646
hZC3H12A_gRNA_310	ACTGATGTGGGTGGGGGCAG	647
hZC3H12A_gRNA_311	GCAGGATGTGCTGGTCTGGG	648
hZC3H12A_gRNA_312	TCACAGTGTTTGTGCCATCC	649
hZC3H12A_gRNA_313	GTTTGTGCCATCCTGGAGGA	650
hZC3H12A_gRNA_314	TCCTGAAGGACTGATGTGGG	651
hZC3H12A_gRNA_315	TGTTAGCAGAGAGCTGGACT	652
hZC3H12A_gRNA_316	CAGTGTTTGTGCCATCCTGG	653
hZC3H12A_gRNA_317	AGTCTGTCAGGGCCTCTGGG	654
hZC3H12A_gRNA_318	TCTCGAGGTGGAAAGGCAGG	655
hZC3H12A_gRNA_319	AGACTGGCTCCCACAGACGC	656
hZC3H12A_gRNA_320	AGCCACTCACTTTGGAGCAC	657
hZC3H12A_gRNA_321	TCCCAGGATTGCCTGGACTC	658
hZC3H12A_gRNA_322	CCTGGAAGTGCAGATGAAGG	659
hZC3H12A_gRNA_323	GGGGCGCTTCCCACAGCTCC	660
hZC3H12A_gRNA_324	CAGCCCCTGGGCTCTGCACT	661
hZC3H12A_gRNA_325	GCGCGGGTGGGTAGTCGGCA	662
hZC3H12A_gRNA_326	GCCCCAAGCAAGGACAAAAA	663
hZC3H12A_gRNA_327	AGCCTGGATGGGAAGAAGCT	664
hZC3H12A_gRNA_328	CAGCTCTTGACCCGGCCTTG	665
hZC3H12A_gRNA_329	TAGGGGTGCCACCACCCCGC	666
hZC3H12A_gRNA_330	TCCACTCCCAGAAGAGGAAA	667
hZC3H12A_gRNA_331	GGAAGCGCTTCATCGAGGAG	668
hZC3H12A_gRNA_332	GCATCCTGCTGGCAGTGAAC	669
hZC3H12A_gRNA_333	TGGATGAATAGCCCAGCTTC	670
hZC3H12A_gRNA_334	ACACGGGACAGCCACCGAGC	671

Target	Sequence	SEQ ID
hZC3H12A_gRNA_335	GGGCTCCTGAAGGACTGATG	672
hZC3H12A_gRNA_336	CAGCCTGGATGGGAAGAAGC	673
hZC3H12A_gRNA_337	TTTTCCTCTTCTGGGAGTGG	674
hZC3H12A_gRNA_338	CTCCAGGTTGGGAGCCTTAG	675
hZC3H12A_gRNA_339	GGGAGCTGAGGGCAGGGGTC	676
hZC3H12A_gRNA_340	AGATGAAGGTGGACTTCTTC	677
hZC3H12A_gRNA_341	TTTGGCCGGGCCATGGGTGC	678
hZC3H12A_gRNA_342	CTCGCACCTAGCGGGGGCAG	679
hZC3H12A_gRNA_343	CCCGTGTAAGGGGCTCGGGG	680
hZC3H12A_gRNA_344	TGCCGGCCCAGTGGGTCATC	681
hZC3H12A_gRNA_345	AAAGGCAGAGAAGGCTGCGG	682
hZC3H12A_gRNA_346	AGGAGCCCGTGGGGCAGGGC	683
hZC3H12A_gRNA_347	TAAGGGGCTCGGGGTGGGCC	684
hZC3H12A_gRNA_348	ACACCATCACGACGCGTGGG	685
hZC3H12A_gRNA_349	CTGGCAGGAGCCCGTGGGGC	686
hZC3H12A_gRNA_350	CCGGCCTTGGGGTGCCCTGA	687
hZC3H12A_gRNA_351	CTGTGTTAGACCCTCTTGGC	688
hZC3H12A_gRNA_352	GTGATGGGCACGTGCGGGCCG	689
hZC3H12A_gRNA_353	GCCCCTGGGCTCTGCACTGG	690
hZC3H12A_gRNA_354	CTGGGTGAGCTGGTGAAACA	691
hZC3H12A_gRNA_355	GGCTGCTCCTTCTCCAGGA	692
hZC3H12A_gRNA_356	ACAGCCTCCACCAGGTGCGG	693
hZC3H12A_gRNA_357	TGCCCAGTCCAGGCAATCC	694
hZC3H12A_gRNA_358	AGGTGGAAAGGCAGGGGGCG	695
hZC3H12A_gRNA_359	CGACAGATTTCATTGTGAAGC	696
hZC3H12A_gRNA_360	GCGGGGTGGTGGCACCCCTA	697
hZC3H12A_gRNA_361	GGCAATCCTGGGAGACGTAC	698
hZC3H12A_gRNA_362	GCCGCTCGCCTTGGAGGTCA	699
hZC3H12A_gRNA_363	TCACTGCCAGCAGGATGCCC	700
hZC3H12A_gRNA_364	CCTGAAGGACTGATGTGGGT	701
hZC3H12A_gRNA_365	GTGCGAGGCTCCTGCCTGAT	702
hZC3H12A_gRNA_366	GCACCTGGTGGAGGCTGTGA	703
hZC3H12A_gRNA_367	TCACAGCCTCCACCAGGTGC	704
hZC3H12A_gRNA_368	GCCGCTCTGGGTGGAAGAAT	705
hZC3H12A_gRNA_369	GACTAGAGGGAGCTGAGGGC	706
hZC3H12A_gRNA_370	TCAGTCCCTCTAGTCCCGC	707
hZC3H12A_gRNA_371	GGAGCCTCCACTCCCAGAAG	708
hZC3H12A_gRNA_372	AGACCCTCTTGGCGGGACCC	709
hZC3H12A_gRNA_373	CCACCTTCATCTGCAGTTCC	710
hZC3H12A_gRNA_374	GGGAGTGGAGGCTCCAGGTT	711
hZC3H12A_gRNA_375	CAGTGAACCTGGTTTCTGGAG	712
hZC3H12A_gRNA_376	TCACCTGTGATGGGCACGTC	713
hZC3H12A_gRNA_377	TGCCAGCAGGATGCCCCGGC	714
hZC3H12A_gRNA_378	ACCCTCTTGGCGGGACCCCTG	715
hZC3H12A_gRNA_379	TGGGGGCAGCTTGGCCGCTC	716

Target	Sequence	SEQ ID
hZC3H12A_gRNA_380	AGGAGGAGGCCCTGGTGAGC	717
hZC3H12A_gRNA_381	CTGGAGGTGGGAGCCATGCA	718
hZC3H12A_gRNA_382	TCTGGAGGTGGGAGCCATGC	719
hZC3H12A_gRNA_383	CCTGGATGGGAAGAAGCTGG	720
hZC3H12A_gRNA_384	CCAGCCCCTGGGCTCTGCAC	721
hZC3H12A_gRNA_385	GGAGTGGAAGCGCTTCATCG	722
hZC3H12A_gRNA_386	TGTAGCCCGTGTAAGGGGCT	723
hZC3H12A_gRNA_387	GGAGTGAGGAGGGCCGGGGA	724
hZC3H12A_gRNA_388	GAGGTCACGGTATGTGTCGT	725
hZC3H12A_gRNA_389	CTAGAGGGAGCTGAGGGCAG	726
hZC3H12A_gRNA_390	TGGTGTGTTTCCCCCGCACC	727
hZC3H12A_gRNA_391	CTGATGTGGGTGGGGGCAGT	728
hZC3H12A_gRNA_392	AGGGCCGGGGAGGGCAGGCT	729
hZC3H12A_gRNA_393	TGAGCTATGAGTGGCCCCCTG	730
hZC3H12A_gRNA_394	TCTTACGCAGGAAGTTGTCC	731
hZC3H12A_gRNA_395	GTTCCGACATCTGGCTCTCC	732
hZC3H12A_gRNA_396	AGGGGGCGCGGGTGGGTAGT	733
hZC3H12A_gRNA_397	CGCTGGCCTGCTCCTTGGCC	734
hZC3H12A_gRNA_398	GAAAGGCAGGGGGCGCGGGT	735
hZC3H12A_gRNA_399	TAGCCCGTGTAAGGGGCTCG	736
hZC3H12A_gRNA_400	CTGAGGGCAGGGGTCCGGTG	737
hZC3H12A_gRNA_401	ACACAGCTTAGTATACACGC	738
hZC3H12A_gRNA_402	CCGTCAGGGCACCCCAAGGC	739
hZC3H12A_gRNA_403	GGCAGGGGTCCGGTGAGGTC	740
hZC3H12A_gRNA_404	GGACTTGTAGGAGAGGATCT	741
hZC3H12A_gRNA_405	TCCCAGCCATGGGAACAAGG	742
hZC3H12A_gRNA_406	GACTTCTAATTGCTGAGAAG	743
hZC3H12A_gRNA_407	GGCTCCTGAAGGACTGATGT	744
hZC3H12A_gRNA_408	TGGCAGGAGCCCGTGGGGCA	745
hZC3H12A_gRNA_409	AGACAGGTGAGAGGAAGGGC	746
hZC3H12A_gRNA_410	TCGGAAC TTTGGGGGGTTCG	747
hZC3H12A_gRNA_411	GCCTGGATGGGAAGAAGCTG	748
hZC3H12A_gRNA_412	TGAAGGACTGATGTGGGTGG	749
hZC3H12A_gRNA_413	CTGGGGGCCCAGGCATCCCC	750
hZC3H12A_gRNA_414	GAGCCCCCAGTGCAGAGCCC	751
hZC3H12A_gRNA_415	GGCGCGGGTGGGTAGTCGGC	752
hZC3H12A_gRNA_416	CCGTGTAAGGGGCTCGGGGT	753
hZC3H12A_gRNA_417	GTCGTGATGGTGTGAACACC	754
hZC3H12A_gRNA_418	ACGACGCGTGGGTGGCAAGC	755
hZC3H12A_gRNA_419	GGGGGCAGTGGCAGCAGCTT	756
hZC3H12A_gRNA_420	AGCGTGTATACTAAGCTGTG	757
hZC3H12A_gRNA_421	GCTCCTGCCTGATGGGGCAT	758
hZC3H12A_gRNA_422	GTCTGTCAAGGCCCTCTGGGA	759
hZC3H12A_gRNA_423	GTAGCCCGTGTAAGGGGCTC	760
hZC3H12A_gRNA_424	AGCCCCTGGGCTCTGCACTG	761

Target	Sequence	SEQ ID
hZC3H12A_gRNA_425	GTGAACTGGTTTCTGGAGCG	762
hZC3H12A_gRNA_426	CTACGAGTCTGACGGGATCG	763
hZC3H12A_gRNA_427	AGTGAACCTGGTTTCTGGAGC	764
hZC3H12A_gRNA_428	ACGCGTGGGTGGCAAGCGGG	765
hZC3H12A_gRNA_429	CGCGGGACTAGAGGGAGCTG	766
hZC3H12A_gRNA_430	GGCAGGAGTGAGGAGGGCCG	767
hZC3H12A_gRNA_431	AAGTGAGTGGCTTCTTACGC	768
hZC3H12A_gRNA_432	CTGAAGGACTGATGTGGGTG	769
hZC3H12A_gRNA_433	TTGCCACCCACGCGTCGTGA	770
hZC3H12A_gRNA_434	AGGGCAGGAGTGAGGAGGGC	771
hZC3H12A_gRNA_435	TCTTCTTCTCCAGTTCCCGC	772
hZC3H12A_gRNA_436	AGGAGTGAGGAGGGCCGGGG	773
hZC3H12A_gRNA_437	ACTCCCAGAAGAGGAAAAGG	774
hZC3H12A_gRNA_438	TGAGGAGGGCCGGGGAGGGC	775
hZC3H12A_gRNA_439	ACCTGGTGGAGGCTGTGATG	776
hZC3H12A_gRNA_440	CAGGGCCGAGGCCTCCTCAG	777
hZC3H12A_gRNA_441	TACTCTCGAGGTGGAAAGGC	778
hZC3H12A_gRNA_442	TTGGGGCTCTGGGGGGTGAG	779
hZC3H12A_gRNA_443	GCTCCTGGACCCCCAGCAGC	780
hZC3H12A_gRNA_444	GGGGGGTGAGAGGAGAGCAT	781
hZC3H12A_gRNA_445	CGGCCAGTGGGTCATCAGG	782
hZC3H12A_gRNA_446	AGGAAGGGCAGGAGTGAGGA	783
hZC3H12A_gRNA_447	GAGGGCCGGGAGGGCAGGC	784
hZC3H12A_gRNA_448	TGCTGGGGGTCCAGGAGCTG	785
hZC3H12A_gRNA_449	GCTGGGGGTCCAGGAGCTGT	786
hZC3H12A_gRNA_450	TGAGAGGAAGGGCAGGAGTG	787
hZC3H12A_gRNA_451	TGGGAGTGAGGCTCCAGGT	788
hZC3H12A_gRNA_452	GAGGAAGGGCAGGAGTGAGG	789

Table 31: Exemplary murine *Zc3h12a* gRNA sequences

Target	Sequence	SEQ ID
mZc3h12a_gRNA_1	GCTGGCTGTGAACTGGTTTC	790
mZc3h12a_gRNA_2	CTAGTTCCCGAAGGATGTGC	791
mZc3h12a_gRNA_3	ATTGGAGACCACCACTCCGT	792
mZc3h12a_gRNA_4	TTCCCTCCTCTGCCAGCCAT	793
mZc3h12a_gRNA_5	CGAAGGAAGTTGTCCAGGCT	794
mZc3h12a_gRNA_6	ATACCTGTGATAGGCACATC	795
mZc3h12a_gRNA_7	GACTTCCTTGTTCCCATGGC	796
mZc3h12a_gRNA_8	GGCCTTCGAATCCGACGGAG	797

[00601] In some embodiments, the gene-regulating system comprises at least one gRNA molecule that comprises a *CBLB*-targeting nucleic acid-binding segment (*i.e.*, a *CBLB*-targeting

gRNA). In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00602] In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808. In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808. Exemplary *CBLB/Cblb* target DNA sequences are shown in Tables 32 and 33.

[00603] In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808. In some embodiments, the nucleic acid-binding segment of the at least one *CBLB*-targeting gRNA molecules is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808. Exemplary DNA sequences encoding the nucleic acid-binding segment of the *CBLB/Cblb*-targeting gRNAs are shown in Tables 32 and 33.

Table 32: Exemplary human *CBLB* gRNA sequences

Target	Sequence	SEQ ID
hCBLB_gRNA_1	CCTTATGAAAAAGTCAAAAC	798
hCBLB_gRNA_2	AAAATATCAAGTATATATGG	799
hCBLB_gRNA_3	TCTAGCATCGGCATGCCAAA	800
hCBLB_gRNA_4	TTGGAAGCTCATGGACAAAG	801
hCBLB_gRNA_5	GATTCCTCCTCGACCACCA	802
hCBLB_gRNA_6	CTTCATCTCTTGGATCAAAG	803
hCBLB_gRNA_7	AATGTATGAAGAACAGTCAC	804
hCBLB_gRNA_8	TAAACTTACCTGAAACAGCC	805

hCBLB_gRNA_9	AAGAATATGATGTTCTCTCCC	806
hCBLB_gRNA_10	AGCAAGCTGCCGCAGATCGC	807
hCBLB_gRNA_11	AGTACTCATTCTCACTGAGT	808

Table 33: Exemplary murine *Cblb* gRNA sequences

Target	Sequence	SEQ ID
mCblb_gRNA_1	TCTTTGTTGCAGGAGTCTGA	809
mCblb_gRNA_2	CAGGGGCTTGTTATGAGGTA	810
mCblb_gRNA_3	CTGATTGATGGTAGCAGGGA	811
mCblb_gRNA_4	CCTTATCTTCAGTCACATGC	812
mCblb_gRNA_5	TCACATGCTGGCAGAAATCA	813
mCblb_gRNA_6	TTCTGTCGCTGTGAGATAAA	814
mCblb_gRNA_7	ACAAGGCAGTACCTGCCACG	815
mCblb_gRNA_8	TGTGACTCACCCGGGATACA	816
mCblb_gRNA_9	GAGGTCCATCAGATCAGCTC	817
mCblb_gRNA_10	ATCTCCCTGGAAGTGGCCAT	818
mCblb_gRNA_11	TGCAAAAATTGCAAACTCA	819
mCblb_gRNA_12	TGCACAGAACTATTGTACCA	820
mCblb_gRNA_13	CAGATTAGTGCTTACCTTCC	821
mCblb_gRNA_14	ATTCCGTAAAATAGAGCCCC	822
mCblb_gRNA_15	CTGCACTCGGCTGGGACAAT	823

[00604] In some embodiments, the gene-regulating system comprises at least one gRNA molecule that comprises a *RC3H1*-targeting nucleic acid-binding segment (*i.e.*, a *RC3H1*-targeting gRNA). In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00605] In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical

to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836. Exemplary *RC3H1/Rc3h1* target DNA sequences are shown in Tables 34 and 35.

[00606] In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the nucleic acid-binding segment of the at least one *RC3H1*-targeting gRNA molecules is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836. Exemplary DNA sequences encoding the nucleic acid-binding segment of the *RC3H1/Rc3h1*-targeting gRNAs are shown in Tables 34 and 35.

Table 34: Exemplary human *RC3H1* gRNA sequences

Target	Sequence	SEQ ID
h RC3H1_gRNA_1	AGTCCATATGGAACCCACGG	824
h RC3H1_gRNA_2	AGTCTGAGTGCAAATTGGGC	825
h RC3H1_gRNA_3	TACGAATTGCACCGGACCAG	826
h RC3H1_gRNA_4	TTAGAGGCTTGAGGAAACCG	827
h RC3H1_gRNA_5	TTAGAACCTATGAAGCTCTG	828
h RC3H1_gRNA_6	CCTGAATAAACTCCACCGCA	829
h RC3H1_gRNA_7	AATTCGAAAGCCCATCAGTT	830
h RC3H1_gRNA_8	TGGCCACAACCCAAACTGAT	831
h RC3H1_gRNA_9	CAGCATACTCTGAGGTACGA	832
h RC3H1_gRNA_10	TTACCTCTAGCACTGCTGAG	833
h RC3H1_gRNA_11	TATGCAGTCCATTATTGACA	834
h RC3H1_gRNA_12	GTAACACAGCTTATCCGCG	835
h RC3H1_gRNA_13	ACTTTCCTAGCAATGCAGG	836

Table 35: Exemplary murine *Rc3h1* gRNA sequences

Target	Sequence	SEQ ID
m Rc3h1_gRNA_1	CAAATGGGCAAGCCTTACGG	837
m Rc3h1_gRNA_2	CTCAATGTCCGTATTGATAG	838
m Rc3h1_gRNA_3	AGTCTGAGTGCAAATTGGGC	839
m Rc3h1_gRNA_4	CCAGATAGTGCAAATTGCTA	840
m Rc3h1_gRNA_5	TGATAGTGGTCTGGTCAAAT	841
m Rc3h1_gRNA_6	AATTCGAAAGCCCATCAGTT	842
m Rc3h1_gRNA_7	GCCCATTA CTTTGTGTAGTG	843
m Rc3h1_gRNA_8	TGGCCACAGCCCAAACCTGAT	844

[00607] In some embodiments, the gene-regulating system comprises at least one gRNA molecule that comprises a *NFKBIA*-targeting nucleic acid-binding segment (*i.e.*, a *NFKBIA*-targeting gRNA). In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12). In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12).

[00608] In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecules binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecules binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856. Exemplary *NFKBIA/Nfkb* target DNA sequences are shown in Tables 36 and 37.

[00609] In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the nucleic acid-binding segment of the at least one *NFKBIA*-targeting gRNA molecules is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856. Exemplary DNA sequences encoding the nucleic acid-binding segment of the *NFKBIA/Nfkb*-targeting gRNAs are shown in Tables 36 and 37.

Table 36: Exemplary human *NFKBIA* gRNA sequences

Target	Sequence	SEQ ID
hNFKBIA_gRNA_1	CGTCCGCGCCATGTTCCAGG	845
hNFKBIA_gRNA_2	TGGTTTCAGGAGCCCTGTAA	846
hNFKBIA_gRNA_3	ACCCGGATACAGCAGCAGCT	847
hNFKBIA_gRNA_4	TTCCAGGGCTCCGAGCCGCG	848

hNFKBIA _gRNA_5	CTGAAGGCTACCAACTACAA	849
hNFKBIA _gRNA_6	GGGTATTCCTCGAAAGTCT	850
hNFKBIA _gRNA_7	GAGCCGCAGGAGGTGCCGCG	851
hNFKBIA _gRNA_8	CTGAGTCAGGACTCCCACGC	852
hNFKBIA _gRNA_9	CACTTACGAGTCCCCGTCCT	853
hNFKBIA _gRNA_10	CTCAAATTCCTTTTGGTTTC	854
hNFKBIA _gRNA_11	GGTTGGTGATCACAGCCAAG	855
hNFKBIA _gRNA_12	GCAGGTTGTTCTGGAAGTTG	856

Table 37: Exemplary murine *Nfkb* gRNA sequences

Target	Sequence	SEQ ID
mNfkb _gRNA_1	CCTCGAAAGTCTCGGAGCTC	857
mNfkb _gRNA_2	CTGCGTCAAGACTGCTACAC	858
mNfkb _gRNA_3	TGCTCACAGGCAAGATGTAG	859
mNfkb _gRNA_4	CCGGACAGCCCTCCACCTTG	860
mNfkb _gRNA_5	AGACCTACCATTGTAGTTGG	861
mNfkb _gRNA_6	CCAAGTGCTCCACGATGGCC	862
mNfkb _gRNA_7	AGCCTCTATCCACGGCTACC	863
mNfkb _gRNA_8	GCCCCAGGTAAGCTGGTAGG	864
mNfkb _gRNA_9	GCAAGCAGCGCACCTGCTGC	865
mNfkb _gRNA_10	TCAAGACTGCTACACTGGCC	866
mNfkb _gRNA_11	GCAGGTTGTTCTGGAAGTTG	867
mNfkb _gRNA_12	GGGTGCTGATGTCAACGCTC	868
mNfkb _gRNA_13	CCACGATGGCCAGGTAGCCG	869
mNfkb _gRNA_14	TGGTCAGCGGCTTCTCTTCG	870
mNfkb _gRNA_15	AATGTGGGGCTGATGTCAAC	871
mNfkb _gRNA_16	ATTTCACAAGAGCGAAACC	872
mNfkb _gRNA_17	CACCTGACCAATGACTTCCA	873
mNfkb _gRNA_18	GCCCTGGAAGCAGCAGCTCA	874
mNfkb _gRNA_19	GCTCACAGGCAAGATGTAGA	875

[00610] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *SOCS1*-targeting gRNA molecule and at least one gRNA molecule is a *PTPN2*-targeting gRNA molecule. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA

sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00611] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00612] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00613] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00614] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *SOCS1*-targeting gRNA molecule and at least one gRNA molecule is a *ZC3H12A*-targeting gRNA molecule. In some embodiments, the at least

one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00615] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00616] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00617] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *SOCS1*-targeting gRNA

molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00618] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *PTPN2*-targeting gRNA molecule and at least one gRNA molecule is a *ZC3H12A*-targeting gRNA molecule. In some embodiments, the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00619] In some embodiments, the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00620] In some embodiments, the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs:

201-327 or 201-314 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00621] In some embodiments, the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00622] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *CBLB*-targeting gRNA molecule and at least one gRNA molecule is a *PTPN2*-targeting gRNA molecule. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *CBLB* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00623] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00624] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00625] In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00626] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *CBLB*-targeting gRNA molecule and at least one gRNA molecule is a *ZC3H12A*-targeting gRNA molecule. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00627] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown

in Table 11 or Table 12. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00628] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00629] In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00630] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *SOCS1*-targeting gRNA molecule and at least one gRNA molecule is a *CBLB*-targeting gRNA molecule. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8). In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8).

[00631] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18.

[00632] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808.

[00633] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808.

[00634] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *RC3H1*-targeting gRNA molecule and at least one gRNA molecule is a *PTPN2*-targeting gRNA molecule. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2*

gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00635] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00636] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00637] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00638] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *RC3H1*-targeting gRNA molecule and at least one gRNA molecule is a *ZC3H12A*-targeting gRNA molecule. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00639] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00640] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00641] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ

ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00642] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *SOCS1*-targeting gRNA molecule and at least one gRNA molecule is a *RC3H1*-targeting gRNA molecule. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00643] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00644] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the at least one *SOCS1*-targeting gRNA

molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836.

[00645] In some embodiments, the at least one *SOC31*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the at least one *SOC31*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836.

[00646] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *CBLB*-targeting gRNA molecule and at least one gRNA molecule is a *RC3H1*-targeting gRNA molecule. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10). In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10).

[00647] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20.

[00648] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836.

[00649] In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836. In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836.

[00650] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *NFKBIA*-targeting gRNA molecule and at least one gRNA molecule is a *PTPN2*-targeting gRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4). In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *PTPN2* gene (SEQ ID NO: 3) or the *Ptpn2* gene (SEQ ID NO: 4).

[00651] In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 9 or

Table 10. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 9 or Table 10.

[00652] In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00653] In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 201-327 or 201-314. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *PTPN2*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 201-327 or 201-314.

[00654] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *NFKBIA*-targeting gRNA molecule and at least one gRNA molecule is a *ZC3H12A*-targeting gRNA molecule. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6). In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb* gene (SEQ ID NO: 12) and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target

DNA sequence that is 100% identical to a DNA sequence in the *ZC3H12A* gene (SEQ ID NO: 5) or the *Zc3h12a* gene (SEQ ID NO: 6).

[00655] In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 11 or Table 12.

[00656] In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00657] In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789. In some embodiments, the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856 and the at least one *ZC3H12A*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 331-797, 338-797 or 338-789.

[00658] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *SOCS1*-targeting gRNA molecule and at least one gRNA molecule is a *NFKBIA*-targeting gRNA molecule. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%,

97%, 98%, or 99% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *SOCS1* gene (SEQ ID NO: 1) or the *Socs1* gene (SEQ ID NO: 2) and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00659] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 4 or Table 5 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00660] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00661] In some embodiments, the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-187 and the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *SOCS1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 23-200, 56-200 or 56-

187 and the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00662] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *CBLB*-targeting gRNA molecule and at least one gRNA molecule is a *NFKBIA*-targeting gRNA molecule. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *CBLB* gene (SEQ ID NO: 7) or the *Cblb* gene (SEQ ID NO: 8) and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00663] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 17 or Table 18 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00664] In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *CBLB*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00665] In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *CBLB*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 798-823 or 798-808 and the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00666] In some embodiments, the gene-regulating system comprises at least two gRNA molecules, wherein at least one gRNA molecule is a *RC3H1*-targeting gRNA molecule and at least one gRNA molecule is a *NFKBIA*-targeting gRNA molecule. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12). In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *RC3H1* gene (SEQ ID NO: 9) or the *Rc3h1* gene (SEQ ID NO: 10) and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence in the *NFKBIA* gene (SEQ ID NO: 11) or the *Nfkb1a* gene (SEQ ID NO: 12).

[00667] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 19 or Table 20 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to a DNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Table 21 or Table 22.

[00668] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID

NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting gRNA molecule binds to a target DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00669] In some embodiments, the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 845-875 or 845-856. In some embodiments, the at least one *RC3H1*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 824-844 or 824-836 and the at least one *NFKBIA*-targeting gRNA molecule is encoded by a DNA sequence that is 100% identical to one of SEQ ID NOs: 845-875 or 845-856.

[00670] In some embodiments, the nucleic acid-binding segments of the gRNA sequences described herein are designed to minimize off-target binding using algorithms known in the art (*e.g.*, Cas-OFF finder) to identify target sequences that are unique to a particular target locus or target gene.

[00671] In some embodiments, the gRNAs described herein can comprise one or more modified nucleosides or nucleotides which introduce stability toward nucleases. In such embodiments, these modified gRNAs may elicit a reduced innate immune as compared to a non-modified gRNA. The term “innate immune response” includes a cellular response to exogenous nucleic acids, including single stranded nucleic acids, generally of viral or bacterial origin, which involves the induction of cytokine expression and release, particularly the interferons, and cell death.

[00672] In some embodiments, the gRNAs described herein are modified at or near the 5' end (*e.g.*, within 1-10, 1-5, or 1-2 nucleotides of their 5' end). In some embodiments, the 5' end of a gRNA is modified by the inclusion of a eukaryotic mRNA cap structure or cap analog (*e.g.*, a G(5')ppp(5')G cap analog, a m7G(5')ppp(5')G cap analog, or a 3'-O-Me-m7G(5')ppp(5')G anti reverse cap analog (ARCA)). In some embodiments, an *in vitro* transcribed gRNA is modified by treatment with a phosphatase (*e.g.*, calf intestinal alkaline phosphatase) to remove the 5' triphosphate group. In some embodiments, a gRNA comprises a modification at or near its 3' end

(*e.g.*, within 1-10, 1-5, or 1-2 nucleotides of its 3' end). For example, in some embodiments, the 3' end of a gRNA is modified by the addition of one or more (*e.g.*, 25-200) adenine (A) residues.

[00673] In some embodiments, modified nucleosides and modified nucleotides can be present in a gRNA, but also may be present in other gene-regulating systems, *e.g.*, mRNA, RNAi, or siRNA- based systems. In some embodiments, modified nucleosides and nucleotides can include one or more of:

- (a) alteration, *e.g.*, replacement, of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage;
- (b) alteration, *e.g.*, replacement, of a constituent of the ribose sugar, *e.g.*, of the 2' hydroxyl on the ribose sugar;
- (c) wholesale replacement of the phosphate moiety with "dephospho" linkers;
- (d) modification or replacement of a naturally occurring nucleobase;
- (e) replacement or modification of the ribose-phosphate backbone;
- (f) modification of the 3' end or 5' end of the oligonucleotide, *e.g.*, removal, modification or replacement of a terminal phosphate group or conjugation of a moiety; and
- (g) modification of the sugar.

[00674] In some embodiments, the modifications listed above can be combined to provide modified nucleosides and nucleotides that can have two, three, four, or more modifications. For example, in some embodiments, a modified nucleoside or nucleotide can have a modified sugar and a modified nucleobase. In some embodiments, every base of a gRNA is modified. In some embodiments, each of the phosphate groups of a gRNA molecule are replaced with phosphorothioate groups.

[00675] In some embodiments, a software tool can be used to optimize the choice of gRNA within a user's target sequence, *e.g.*, to minimize total off-target activity across the genome. Off target activity may be other than cleavage. For example, for each possible gRNA choice using *S. pyogenes* Cas9, software tools can identify all potential off-target sequences (preceding either NAG or NGG PAMs) across the genome that contain up to a certain number (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of mismatched base-pairs. The cleavage efficiency at each off-target sequence can be predicted, *e.g.*, using an experimentally-derived weighting scheme. Each possible gRNA can then be ranked according to its total predicted off-target cleavage; the top-ranked gRNAs represent those that are likely to have the greatest on-target and the least off-target cleavage. Other functions,

e.g., automated reagent design for gRNA vector construction, primer design for the on-target Surveyor assay, and primer design for high-throughput detection and quantification of off-target cleavage via next-generation sequencing, can also be included in the tool.

Methods of producing modified TILs

[00676] In some embodiments, the present disclosure provides improved methods for producing modified TILs. In some embodiments, the methods comprise introducing a gene-regulating system into a population of TILs wherein the gene-regulating system is capable of reducing expression and/or function of one, two or more endogenous target genes selected from *ANKRD11*, *BCL2L1*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLII*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOC1*, *TANK*, *TGFB1*, *TGFB2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. (See International Publication Nos. WO 2019/178422, WO 2019/178420 and WO 2019/178421, incorporated by reference herein in their entireties.) In some embodiments, the one, two or more endogenous target genes selected from *SOC1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*.

[00677] The components of the gene-regulating systems described herein, *e.g.*, a nucleic acid-, protein-, or nucleic acid/protein-based system can be introduced into target cells in a variety of forms using a variety of delivery methods and formulations. In some embodiments, a polynucleotide encoding one or more components of the system is delivered by a recombinant vector (*e.g.*, a viral vector or plasmid). In some embodiments, where the system comprises more than a single component, a vector may comprise a plurality of polynucleotides, each encoding a component of the system. In some embodiments, where the system comprises more than a single component, a plurality of vectors may be used, wherein each vector comprises a polynucleotide encoding a particular component of the system. In some embodiments, a vector may also comprise a sequence encoding a signal peptide (*e.g.*, for nuclear localization, nucleolar localization, mitochondrial localization), fused to the polynucleotide encoding the one or more components of the system. For example, a vector may comprise a nuclear localization sequence (*e.g.*, from SV40) fused to the polynucleotide encoding the one or more components of the system. In some embodiments, the introduction of the gene-regulating system to the cell occurs *in vitro*. In some embodiments, the introduction of the gene-regulating system to the cell occurs *in vivo*. In some embodiments, the introduction of the gene-regulating system to the cell occurs *ex vivo*.

[00678] In some embodiments, the recombinant vector comprising a polynucleotide encoding one or more components of a gene-regulating system described herein is a viral vector. Suitable viral vectors include, but are not limited to, viral vectors based on vaccinia virus; poliovirus; adenovirus (see, *e.g.*, Li *et al.*, Invest Ophthalmol Vis Sci 35:2543-2549, 1994; Borrás *et al.*, Gene Ther 6:515-524, 1999; Li and Davidson, PNAS 92:7700-7704, 1995; Sakamoto *et al.*, Hum Gene Ther 5:1088-1097, 1999; WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655); adeno-associated virus (see, *e.g.*, U.S. Patent No. 7,078,387; Ali *et al.*, Hum Gene Ther 9:81-86, 1998; Flannery *et al.*, PNAS 94:6916-6921, 1997; Bennett *et al.*, Invest Ophthalmol Vis Sci 38:2857-2863, 1997; Jomary *et al.*, Gene Ther 4:683-690, 1997; Rolling *et al.*, Hum Gene Ther 10:641-648, 1999; Ali *et al.*, Hum Mol Genet 5:591-594, 1996; Srivastava in WO 93/09239, Samulski *et al.*, J. Vir. (1989) 63:3822-3828; Mendelson *et al.*, Virol. (1988) 166:154-165; and Flotte *et al.*, PNAS (1993) 90:10613-10617); SV40; herpes simplex virus; human immunodeficiency virus (see, *e.g.*, Miyoshi *et al.*, PNAS 94:10319-23, 1997; Takahashi *et al.*, J Virol 73:7812-7816, 1999); a retroviral vector (*e.g.*, Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus); and the like.

[00679] In some embodiments, the recombinant vector comprising a polynucleotide encoding one or more components of a gene-regulating system described herein is a plasmid. Numerous suitable plasmid expression vectors are known to those of skill in the art, and many are commercially available. The following vectors are provided by way of example; for eukaryotic host cells: pXT1, pSG5 (Stratagene), pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). However, any other plasmid vector may be used so long as it is compatible with the host cell. Depending on the cell type and gene-regulating system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see *e.g.*, Bitter *et al.* (1987) Methods in Enzymology, 153:516-544).

[00680] In some embodiments, a polynucleotide sequence encoding one or more components of a gene-regulating system described herein is operably linked to a control element, *e.g.*, a transcriptional control element, such as a promoter. The transcriptional control element may be functional in either a eukaryotic cell (*e.g.*, a mammalian cell) or a prokaryotic cell (*e.g.*, bacterial or archaeal cell). In some embodiments, a polynucleotide sequence encoding one or more components of a gene-regulating system described herein is operably linked to multiple control elements that allow expression of the polynucleotide in both prokaryotic and eukaryotic cells.

Depending on the cell type and gene-regulating system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see *e.g.*, Bitter *et al.* (1987) *Methods in Enzymology*, 153:516-544).

[00681] Non-limiting examples of suitable eukaryotic promoters (promoters functional in a eukaryotic cell) include those from cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector may also contain a ribosome binding site for translation initiation and a transcription terminator. The expression vector may also include appropriate sequences for amplifying expression. The expression vector may also include nucleotide sequences encoding protein tags (*e.g.*, 6xHis tag, hemagglutinin tag, green fluorescent protein, etc.) that are fused to the site-directed modifying polypeptide, thus resulting in a chimeric polypeptide.

[00682] In some embodiments, a polynucleotide sequence encoding one or more components of a gene-regulating system described herein is operably linked to an inducible promoter. In some embodiments, a polynucleotide sequence encoding one or more components of a gene-regulating system described herein is operably linked to a constitutive promoter.

[00683] Methods of introducing polynucleotides and recombinant vectors into a host cell are known in the art, and any known method can be used to introduce components of a gene-regulating system into a cell. Suitable methods include *e.g.*, viral or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct micro injection, nanoparticle-mediated nucleic acid delivery (see, *e.g.*, Panyam *et al.*, *Adv Drug Deliv Rev.* 2012 Sep 13. pii: S0169-409X(12)00283-9), microfluidics delivery methods (*See e.g.*, International PCT Publication No. WO 2013/059343), and the like. In some embodiments, delivery via electroporation comprises mixing the cells with the components of a gene-regulating system in a cartridge, chamber, or cuvette and applying one or more electrical impulses of defined duration and amplitude. In some embodiments, cells are mixed with components of a gene-regulating system in a vessel connected to a device (*e.g.*, a pump) which feeds the mixture into a cartridge, chamber, or cuvette wherein one or more electrical impulses of defined duration and amplitude are applied, after which the cells are delivered to a second vessel.

[00684] In some embodiments, electroporation is used to introduce components of a gene-regulating system into a cell. In some embodiments where a pre-REP and REP protocol is used, electroporation is used to introduce components of a gene-regulating system into a cell after the pre-REP stage but before the REP stage.

[00685] In some embodiments, one or more components of a gene-regulating system, or polynucleotide sequence encoding one or more components of a gene-regulating system described herein are introduced to a cell in a non-viral delivery vehicle, such as a transposon, a nanoparticle (*e.g.*, a lipid nanoparticle), a liposome, an exosome, an attenuated bacterium, or a virus-like particle. In some embodiments, the vehicle is an attenuated bacterium (*e.g.*, naturally or artificially engineered to be invasive but attenuated to prevent pathogenesis including *Listeria monocytogenes*, certain *Salmonella* strains, *Bifidobacterium longum*, and modified *Escherichia coli*), bacteria having nutritional and tissue-specific tropism to target specific cells, and bacteria having modified surface proteins to alter target cell specificity. In some embodiments, the vehicle is a genetically modified bacteriophage (*e.g.*, engineered phages having large packaging capacity, less immunogenicity, containing mammalian plasmid maintenance sequences and having incorporated targeting ligands). In some embodiments, the vehicle is a mammalian virus-like particle. For example, modified viral particles can be generated (*e.g.*, by purification of the “empty” particles followed by *ex vivo* assembly of the virus with the desired cargo). The vehicle can also be engineered to incorporate targeting ligands to alter target tissue specificity. In some embodiments, the vehicle is a biological liposome. For example, the biological liposome is a phospholipid-based particle derived from human cells (*e.g.*, erythrocyte ghosts, which are red blood cells broken down into spherical structures derived from the subject and wherein tissue targeting can be achieved by attachment of various tissue or cell-specific ligands), secretory exosomes, or subject derived membrane-bound nanovesicles (30 -100 nm) of endocytic origin (*e.g.*, can be produced from various cell types and can therefore be taken up by cells without the need for targeting ligands).

[00686] In some embodiments, the methods of modified TILs described herein comprise obtaining a population of TILs from a sample. In some embodiments, a sample comprises a tissue sample, a fluid sample, a cell sample, a protein sample, or a DNA or RNA sample. In some embodiments, a tissue sample may be derived from any tissue type including, but not limited to skin, hair (including roots), bone marrow, bone, muscle, salivary gland, esophagus, stomach, small intestine (*e.g.*, tissue from the duodenum, jejunum, or ileum), large intestine, liver, gallbladder, pancreas, lung, kidney, bladder, uterus, ovary, vagina, placenta, testes, thyroid, adrenal gland, cardiac tissue, thymus, spleen, lymph node, spinal cord, brain, eye, ear, tongue, cartilage, white

adipose tissue, or brown adipose tissue. In some embodiments, a tissue sample may be derived from a cancerous, pre-cancerous, or non-cancerous tumor. In some embodiments, a fluid sample comprises buccal swabs, blood, plasma, oral mucous, vaginal mucous, peripheral blood, cord blood, saliva, semen, urine, ascites fluid, pleural fluid, spinal fluid, pulmonary lavage, tears, sweat, semen, seminal fluid, seminal plasma, prostatic fluid, pre-ejaculatory fluid (Cowper's fluid), excreta, cerebrospinal fluid, lymph, cell culture media comprising one or more populations of cells, buffered solutions comprising one or more populations of cells, and the like.

[00687] In some embodiments, the sample is processed to enrich or isolate a particular cell type, such as an immune effector cell, from the remainder of the sample. In certain embodiments, the sample is a peripheral blood sample which is then subject to leukopheresis to separate the red blood cells and platelets and to isolate lymphocytes. In some embodiments, the sample is a leukopak from which immune effector cells can be isolated or enriched. In some embodiments, the sample is a tumor sample that is further processed to isolate lymphocytes present in the tumor (*i.e.*, to isolate tumor infiltrating lymphocytes).

[00688] In some embodiments, the isolated immune effector cells are expanded in culture to produce an expanded population of immune effector cells. One or more activating or growth factors may be added to the culture system during the expansion process. For example, in some embodiments, one or more cytokines (such as IL-2, IL-15, and/or IL-7) can be added to the culture system to enhance or promote cell proliferation and expansion. In some embodiments, one or more activating antibodies, such as an anti-CD3 antibody, may be added to the culture system to enhance or promote cell proliferation and expansion. In some embodiments, the immune effector cells may be co-cultured with feeder cells during the expansion process. In some embodiments, the methods provided herein comprise one or more expansion phases. For example, in some embodiments, the immune effector cells can be expanded after isolation from a sample, allowed to rest, and then expanded again. In some embodiments, the immune effector cells can be expanded in one set of expansion conditions followed by a second round of expansion in a second, different, set of expansion conditions. Previous methods for *ex vivo* expansion of immune cells are known in the art, for example, as described in US Patent Application Publication Nos. 20180282694 and 20170152478 and US Patent Nos. 8,383,099 and 8,034,334.

[00689] At any point during the culture and expansion process, the gene-regulating systems described herein can be introduced to the immune effector cells to produce a population of modified TILs. In some embodiments, the gene-regulating system is introduced to the population of immune effector cells immediately after enrichment from a sample. In some embodiments, the gene-regulating system is introduced to the population of immune effector cells before, during, or

after the one or more expansion process. In some embodiments, the gene-regulating system is introduced to the population of immune effector cells immediately after enrichment from a sample or harvest from a subject, and prior to any expansion rounds. In some embodiments, the gene-regulating system is introduced to the population of immune effector cells after a first round of expansion and prior to a second round of expansion. In some embodiments, the gene-regulating system is introduced to the population of immune effector cells after a first and a second round of expansion.

[00690] In some embodiments, the modified TILs produced by the methods described herein may be used immediately. Alternatively, the cells may be frozen at liquid nitrogen temperatures and stored for long periods of time, being thawed and capable of being reused. In such cases, the cells will usually be frozen in 10% dimethylsulfoxide (DMSO), 50% serum, 40% buffered medium, or some other such solution as is commonly used in the art to preserve cells at such freezing temperatures and thawed in a manner as commonly known in the art for thawing frozen cultured cells.

[00691] In some embodiments, the modified TILs may be cultured *in vitro* under various culture conditions. The cells may be expanded in culture, *i.e.*, grown under conditions that promote their proliferation. Culture medium may be liquid or semi-solid, *e.g.*, containing agar, methylcellulose, etc. The cell population may be suspended in an appropriate nutrient medium, such as Iscove's modified DMEM or RPMI 1640, normally supplemented with fetal calf serum (about 5-10%), L-glutamine, a thiol, particularly 2-mercaptoethanol, and antibiotics, *e.g.*, penicillin and streptomycin. The culture may contain growth factors to which the regulatory T cells are responsive. Growth factors, as defined herein, are molecules capable of promoting survival, growth and/or differentiation of cells, either in culture or in the intact tissue, through specific effects on a transmembrane receptor. Growth factors include polypeptides and non-polypeptide factors.

Producing modified TILs using CRISPR/Cas Systems

[00692] In some embodiments, a method of producing a modified TIL involves contacting a target DNA sequence with a complex comprising a gRNA and a Cas polypeptide. As discussed above, a gRNA and Cas polypeptide form a complex, wherein the DNA-binding domain of the gRNA targets the complex to a target DNA sequence and wherein the Cas protein (or heterologous protein fused to an enzymatically inactive Cas protein) modifies target DNA sequence. In some embodiments, this complex is formed intracellularly after introduction of the gRNA and Cas protein (or polynucleotides encoding the gRNA and Cas proteins) to a cell. In some embodiments,

the nucleic acid encoding the Cas protein is a DNA nucleic acid and is introduced to the cell by transduction. In some embodiments, the Cas and gRNA components of a CRISPR/Cas gene editing system are encoded by a single polynucleotide molecule. In some embodiments, the polynucleotide encoding the Cas protein and gRNA component are comprised in a viral vector and introduced to the cell by viral transduction. In some embodiments, the Cas9 and gRNA components of a CRISPR/Cas gene editing system are encoded by different polynucleotide molecules. In some embodiments, the polynucleotide encoding the Cas protein is comprised in a first viral vector and the polynucleotide encoding the gRNA is comprised in a second viral vector. In some aspects of this embodiment, the first viral vector is introduced to a cell prior to the second viral vector. In some aspects of this embodiment, the second viral vector is introduced to a cell prior to the first viral vector. In such embodiments, integration of the vectors results in sustained expression of the Cas9 and gRNA components. However, sustained expression of Cas9 may lead to increased off-target mutations and cutting in some cell types. Therefore, in some embodiments, an mRNA nucleic acid sequence encoding the Cas protein may be introduced to the population of cells by transfection. In such embodiments, the expression of Cas9 will decrease over time, and may reduce the number of off target mutations or cutting sites.

[00693] In some embodiments, this complex is formed in a cell-free system by mixing the gRNA molecules and Cas proteins together and incubating for a period of time sufficient to allow complex formation. This pre-formed complex, comprising the gRNA and Cas protein and referred to herein as a CRISPR-ribonucleoprotein (CRISPR-RNP) can then be introduced to a cell in order to modify a target DNA sequence. The complexing can also occur in the target cell, with the Cas protein and gRNA being introduced separately.

Producing modified TILs using shRNA systems

[00694] In some embodiments, a method of producing a modified TIL by introducing into the cell one or more DNA polynucleotides encoding one or more shRNA molecules with sequence complementary to the mRNA transcript of a target gene is disclosed. The TIL can be modified to produce the shRNA by introducing specific DNA sequences into the cell nucleus via a small gene cassette. Both retroviruses and lentiviruses can be used to introduce shRNA-encoding DNAs into TILs. The introduced DNA can either become part of the cell's own DNA or persist in the nucleus and instructs the cell machinery to produce shRNAs. shRNAs may be processed by Dicer or AGO2-mediated slicer activity inside the cell to induce RNAi mediated gene knockdown.

Producing modified TILs using siRNA systems

[00695] In some embodiments, a method of producing a modified TIL by introducing into the TIL one or more DNA polynucleotides encoding one or more siRNA molecules with sequence

complementary to the mRNA transcript of a target gene is disclosed. The TIL can be modified to produce the siRNA by introducing specific DNA sequences into the cell nucleus via a small gene cassette. Retrovirus, adeno-associated virus, adenovirus, and lentivirus can be used to introduce siRNA-encoding DNAs into TILs. The introduced DNA can either become part of the cell's own DNA or persist in the nucleus and instructs the cell machinery to produce siRNAs. The siRNA can interfere with gene expression.

Methods of reducing exhaustion, while maintaining cytotoxicity, in cultured TILs

[00696] In one aspect, the present disclosure provides methods of reducing exhaustion and maintaining cytotoxicity in a population of cultured TILs, or methods of inducing TIL persistence and expansion while maintaining cytotoxicity, the methods comprising culturing the population of TILs in a culture medium comprising the T cell-stimulating cytokine, IL-15, wherein the population of TILs are modified at the *SOCS1* gene. In another aspect, the present disclosure provides methods of reducing exhaustion and maintaining cytotoxicity in a population of cultured TILs, or methods of inducing TIL persistence and expansion while maintaining cytotoxicity, the methods comprising culturing the population of TILs in a culture medium comprising the T cell-stimulating cytokine, IL-15, wherein the population of TILs are modified at the *SOCS1* gene and the *ZC3H12A* gene. In some embodiments, the modification of the *SOCS1* gene and/or the *ZC3H12A* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene. In some embodiments, the population of TILs comprise a reduction in expression of one or more exhaustion related genes selected from *PTGER2*, *FASLG*, *TNFRSF9*, *IRF4*, *CTLA4*, *EOMES*, *PDPN*, *LAG3*, *TNFSF9*, *CD86*, *TIGIT*, *HAVCR2*, *CASP3*, *PROCR*, *MDFIC*, *CCL3*, *CD160*, *BATF*, *TOX*, *CD244*, *B3GAT1*, *KLRG1*, *LILRB4* and *PDCD1* relative to TILs modified at the *SOCS1* gene and cultured in culture medium without IL-15. In some embodiments, the expression levels of one or more cytotoxicity related genes selected from *ITGB2*, *CSF2*, *TNF*, *FASLG*, *TNFRSF10B*, *LCK*, *IFNG*, *IFNB1*, *BID*, *GZMB*, *PRF1*, *KLRK1*, *ZAP70*, *FYN*, *GZMA*, *VAV3*, *GZMH*, *GZMM*, *KIR3DL1*, *IFNGR2*, *VAV1*, *SOS2*, *PTPN6*, *PTK2B*, *SH3BP2*, *LAT*, *KLRC2*, *IFNA1*, *CASP3*, *ICAM1*, *SH2D1A*, *ARAF*, *NFATC1*, *IFNAR1*, *NCR1*, *NCR3*, *IFNGR1*, *NCR2*, *TYROBP*, *FCGR3B*, *KLRD1*, *FAS*, *CD244*, *RAC2* and *CD247* are increased relative to TILs un-modified at the *SOCS1* gene and cultured in culture medium with IL-15.

[00697] In some embodiments, the cytotoxicity and/or exhaustion measures are based on a scoring system. In some embodiments, cytotoxicity is measured by a cytotoxicity score. In some embodiments, exhaustion is measured by an exhaustion score. As used herein, the terms "cytotoxicity score" and "exhaustion score" refer to the scoring algorithms described in Tomfohr J, Lu J, Kepler TB, Pathway level analysis of gene expression using singular value

decomposition, *BMC Bioinformatics*. 2005;6:225, incorporated by reference in its entirety. NanoString “nSolver” software can be utilized to apply the algorithm to data. The term “exhaustion marker” refers to a gene or set of genes that can be utilized to determine the exhaustion score. The term “cytotoxicity marker” refers to a gene or set of genes that can be utilized to determine the cytotoxicity score. In some embodiments, the exhaustion or cytotoxicity markers are used according to the methods provided below. Exhaustion markers include, for example, *PTGER2*, *FASLG*, *TNFRSF9*, *IRF4*, *CTLA4*, *EOMES*, *PDPN*, *LAG3*, *TNFSF9*, *CD86*, *TIGIT*, *HAVCR2*, *CASP3*, *PROCR*, *MDFIC*, *CCL3*, *CD160*, *BATF*, *TOX*, *CD244*, *B3GAT1*, *KLRG1*, *LILRB4* and *PDCD1*. Cytotoxicity markers include, for example, *ITGB2*, *CSF2*, *TNF*, *FASLG*, *TNFRSF10B*, *LCK*, *IFNG*, *IFNB1*, *BID*, *GZMB*, *PRF1*, *KLRK1*, *ZAP70*, *FYN*, *GZMA*, *VAV3*, *GZMH*, *GZMM*, *KIR3DL1*, *IFNGR2*, *VAV1*, *SOS2*, *PTPN6*, *PTK2B*, *SH3BP2*, *LAT*, *KLRC2*, *IFNA1*, *CASP3*, *ICAM1*, *SH2D1A*, *ARAF*, *NFATC1*, *IFNAR1*, *NCR1*, *NCR3*, *IFNGR1*, *NCR2*, *TYROBP*, *FCGR3B*, *KLRD1*, *FAS*, *CD244*, *RAC2* and *CD247*.

[00698] To calculate the relevant exhaustion and cytotoxicity scores, the analysis starts by quantifying, in each sample, the level of activity of each pathway. The activity level of a pathway in a given sample can be defined as the level of expression of a certain metagene in that sample.

[00699] In some embodiments, calculation begins by standardizing the gene expression levels to have zero mean and unit variance over samples. For each pathway, a matrix Y (rows = genes, columns = samples) is formed containing the standardized expression levels from all samples but for the genes in that pathway only. The singular value decomposition of Y is expressed as

$$Y = WDC. \quad (1)$$

Here the columns of the matrix W are the orthonormal ($W^T W = I$, the identity matrix) eigenvectors or metagenes of Y , D is a diagonal matrix containing the associated eigenvalues, and each column of C is a vector of coefficients for one of the samples indicating the level of each metagene in the sample. The rows of C are also orthonormal ($CC^T = I$). Assume the eigenvalues are ordered from highest to lowest going down the diagonal of D . The first metagene $\mathbf{w}$ – that associated with the largest eigenvalue – is then the first column of W . The eigenvalue can be designated as λ and the associated coefficients (first row of C) as c_j . The activity level of a pathway in a given sample j is taken as the coefficient c_j for the first metagene. It follows also from the orthonormality of the columns of W and rows of C that

$$c_j = \lambda^{-1} \sum_i w_i y_{ij}. \quad (2)$$

That is, the activity level c_j can also be regarded (up to a non-essential scale factor) as a weighted sum of the standardized expression levels of the individual genes, the weights being given by the first metagene $\mathbf{w}$. One motivation for using the first metagene in SVD is that the resulting combination of activity levels and weights specifies an optimal approximation to the matrix Y (i.e., accounts for the main component of the variation in the data). Specifically, assume the following statistical model for the expression levels

$$y_{ij} = \alpha_i \chi_j + \varepsilon_{ij} \quad (3)$$

where the vector χ is constrained to have unit norm and the ε_{ij} are independent Gaussian random variables. The estimates for α and χ that minimize the sum of the squared errors are just the first metagene scaled by its eigenvalue, $\lambda \mathbf{w}$, and the associated vector of activity levels $\mathbf{c}$, respectively.

[00700] A useful fact about the first eigenvalue is that its square is a measure of the amount of variation accounted for by the first metagene. Specifically, with n_g = number of genes and n_s = number of samples, the total amount of variation in the data is $\sum_{ij} y_{ij}^2 = n_g(n_s - 1)$ (recall, the expression levels are standardized so that $\frac{1}{n_s - 1} \sum_j y_{ij}^2 = 1$) and the variation remaining after subtracting off the profile described by the first metagene is $\sum_{ij} (y_{ij} - \lambda w_i c_j)^2 = n_g(n_s - 1) - \lambda^2$.

Adoptive Cell Transfer

[00701] Adoptive cell transfer (ACT) is a very effective form of immunotherapy and involves the transfer of immune cells with antitumor activity into cancer patients. In some cases, ACT is a treatment approach that involves the identification, *in vitro*, of lymphocytes with antitumor activity, the *in vitro* expansion of these cells to large numbers and their infusion into the cancer-bearing host. Lymphocytes used for adoptive transfer can be derived from the stroma of resected tumors (tumor infiltrating lymphocytes or TILs). TILs for ACT can be prepared as described herein. ACT in which the lymphocytes originate from the cancer-bearing host to be infused is termed autologous ACT. ACT can also involve use of lymphocytes from donors other than the subject suffering from cancer. In some embodiments, the donor has the same type of cancer as the subject to be infused with allogeneic lymphocytes. U.S. Publication No. 2011/0052530, incorporated by reference herein in its entirety, relates to a method for performing adoptive cell therapy to promote cancer regression, primarily for treatment of patients suffering from metastatic melanoma, which is incorporated by reference in its entirety for these methods. In some embodiments, TILs can be administered as described herein. In some embodiments, TILs can be administered in a single dose. Such administration may be by injection, *e.g.*, intravenous

injection. In some embodiments, TILs and/or cytotoxic lymphocytes may be administered in multiple doses.

[0702] Prior to transfer immune cells with antitumor activity into cancer patients, a lymphodepletion step on the patient may be utilized. The lymphodepletion eliminate partially or completely regulatory T cells and competing elements of the immune system. In some embodiments, lymphodepletion is utilized. In other embodiments, lymphodepletion is not utilized.

Pharmaceutical Compositions, Dosages, and Dosing Regimens

[0703] In an embodiment, TILs expanded using the methods of the present disclosure are administered to a patient as a pharmaceutical composition. In an embodiment, the pharmaceutical composition is a suspension of TILs in a sterile buffer. In some embodiments, the TILs are administered as a single intra-arterial or intravenous infusion. Other suitable routes of administration include intraperitoneal, intrathecal, and intralymphatic administration. TILs expanded using PBMCs of the present disclosure may be administered by any suitable route as known in the art. In some embodiments, the T-cells are administered as a single intra-arterial or intravenous infusion, which preferably lasts approximately 30 to 60 minutes. Other suitable routes of administration include intraperitoneal, intrathecal, and intralymphatic administration.

[0704] Any suitable dose of TILs can be administered. In some embodiments, from about 1×10^9 to about 2×10^{11} of TILs are administered. In some embodiments, from about 2.3×10^{10} to about 13.7×10^{10} TILs are administered, with an average of around 7.8×10^{10} TILs, particularly if the cancer is melanoma. In an embodiment, about 1.2×10^{10} to about 4.3×10^{10} of TILs are administered. In some embodiments, about 3×10^{10} to about 12×10^{10} TILs are administered. In some embodiments, about 4×10^{10} to about 10×10^{10} TILs are administered. In some embodiments, about 5×10^{10} to about 8×10^{10} TILs are administered. In some embodiments, about 6×10^{10} to about 8×10^{10} TILs are administered. In some embodiments, about 7×10^{10} to about 8×10^{10} TILs are administered. In some embodiments, the therapeutically effective dosage is about 2.3×10^{10} to about 13.7×10^{10} . In some embodiments, the therapeutically effective dosage is about 7.8×10^{10} TILs, particularly of the cancer is melanoma. In some embodiments, the therapeutically effective dosage is about 1.2×10^{10} to about 4.3×10^{10} of TILs. In some embodiments, the therapeutically effective dosage is about 3×10^{10} to about 12×10^{10} TILs. In some embodiments, the therapeutically effective dosage is about 4×10^{10} to about 10×10^{10} TILs. In some embodiments, the therapeutically effective dosage is about 5×10^{10} to about 8×10^{10} TILs. In some embodiments, the therapeutically effective dosage is about 6×10^{10} to about 8×10^{10} TILs. In some embodiments, the therapeutically effective dosage is about 7×10^{10} to about 8×10^{10} TILs.

[0705] In some embodiments, the number of the TILs provided in the pharmaceutical compositions of the invention is an effective dosage of TILs. In some embodiments, an effective dosage of TILs is about 1×10^6 , 2×10^6 , 3×10^6 , 4×10^6 , 5×10^6 , 6×10^6 , 7×10^6 , 8×10^6 , 9×10^6 , 1×10^7 , 2×10^7 , 3×10^7 , 4×10^7 , 5×10^7 , 6×10^7 , 7×10^7 , 8×10^7 , 9×10^7 , 1×10^8 , 2×10^8 , 3×10^8 , 4×10^8 , 5×10^8 , 6×10^8 , 7×10^8 , 8×10^8 , 9×10^8 , 1×10^9 , 2×10^9 , 3×10^9 , 4×10^9 , 5×10^9 , 6×10^9 , 7×10^9 , 8×10^9 , 9×10^9 , 1×10^{10} , 2×10^{10} , 3×10^{10} , 4×10^{10} , 5×10^{10} , 6×10^{10} , 7×10^{10} , 8×10^{10} , 9×10^{10} , 1×10^{11} , 2×10^{11} , 3×10^{11} , and 4×10^{11} . In an embodiment, an effective dosage of TILs is in the range of 1×10^6 to 5×10^6 , 5×10^6 to 1×10^7 , 1×10^7 to 5×10^7 , 5×10^7 to 1×10^8 , 1×10^8 to 5×10^8 , 5×10^8 to 1×10^9 , 1×10^9 to 5×10^9 , 5×10^9 to 1×10^{10} , 1×10^{10} to 5×10^{10} , and 5×10^{10} to 4×10^{11} .

[0706] In some embodiments, the concentration of the TILs provided in the pharmaceutical compositions of the invention is less than, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w/w, w/v or v/v of the pharmaceutical composition.

[0707] In some embodiments, the concentration of the TILs provided in the pharmaceutical compositions of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25% 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25% 3%, 2.75%, 2.50%, 2.25% 2%, 1.75%, 1.50%, 1.25%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w/w, w/v, or v/v of the pharmaceutical composition.

[0708] In some embodiments, the concentration of the TILs provided in the pharmaceutical compositions of the invention is in the range from about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 30%, about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about

0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12% or about 1% to about 10% w/w, w/v or v/v of the pharmaceutical composition.

[0709] In some embodiments, the concentration of the TILs provided in the pharmaceutical compositions of the invention is in the range from about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to about 1%, about 0.1% to about 0.9% w/w, w/v or v/v of the pharmaceutical composition.

[0710] The TILs provided in the pharmaceutical compositions of the invention are effective over a wide dosage range. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the gender and age of the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician. The clinically-established dosages of the TILs may also be used if appropriate. The amounts of the pharmaceutical compositions administered using the methods herein, such as the dosages of TILs, will be dependent on the human or mammal being treated, the severity of the disorder or condition, the rate of administration, the disposition of the active pharmaceutical ingredients and the discretion of the prescribing physician.

[0711] In some embodiments, TILs may be administered in a single dose. Such administration may be by injection, *e.g.*, intravenous injection. In some embodiments, TILs may be administered in multiple doses. Administration of TILs may continue as long as necessary.

[0712] An effective amount of the TILs may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, topically, by transplantation, or by inhalation. In certain embodiments, TILs are administered intravenously.

Cell Counts, Cell Viability, Flow Cytometry

[0713] In some embodiments, cell counts and/or viability are measured. The expression of markers such as but not limited CD3, CD4, CD8, and CD56, as well as any other disclosed or described herein, can be measured by flow cytometry with antibodies, for example but not limited to those commercially available from BD Bio-sciences (BD Biosciences, San Jose, Calif.) using a FACSCanto™ flow cytometer (BD Biosciences). The cells can be counted manually using a

disposable c-chip hemocytometer (VWR, Batavia, Ill.) and viability can be assessed using any method known in the art, including but not limited to trypan blue staining.

[0714] In an embodiment, a method for expanding TILs may include using no more than 30,000 ml of cell medium. In some embodiments, a method for expanding TILs may include using from about 5,000 ml to about 25,000 ml of cell medium, about 5,000 ml to about 10,000 ml of cell medium, or about 5,800 ml to about 8,700 ml of cell medium. In an embodiment, expanding the number of TILs uses no more than one type of cell culture medium. Any suitable cell culture medium may be used, *e.g.*, AIM-V cell medium (L-glutamine, 50 μ M streptomycin sulfate, and 10 μ M gentamicin sulfate) cell culture medium (Invitrogen, Carlsbad Calif.). The REP stage, described above, can require the use of a maximum of 30,000 ml of cell media. The pre-REP stage, described above, can require the use of only up to 100 ml of cell media.

[0715] In an embodiment, TILs are expanded in gas-permeable containers. Gas-permeable containers have been used to expand TILs using PBMCs using methods, compositions, and devices known in the art, including those described in U.S. Patent Application Publication No. 2005/0106717 A1, the disclosure of which is incorporated herein by reference in its entirety. In an embodiment, TILs are expanded in gas-permeable bags. In an embodiment, TILs are expanded using a cell expansion system that expands TILs in gas permeable bags, such as the Xuri Cell Expansion System W25 (GE Healthcare). In an embodiment, TILs are expanded using a cell expansion system that expands TILs in gas permeable bags, such as the WAVE Bioreactor System, also known as the Xuri Cell Expansion System W5 (GE Healthcare). In an embodiment, the cell expansion system includes a gas permeable cell bag with a volume selected from the group consisting of about 100 ml, about 200 ml, about 300 ml, about 400 ml, about 500 ml, about 600 ml, about 700 ml, about 800 ml, about 900 ml, about 1 L, about 2 L, about 3 L, about 4 L, about 5 L, about 6 L, about 7 L, about 8 L, about 9 L, and about 10 L. In an embodiment, TILs can be expanded in G-Rex flasks (commercially available from Wilson Wolf Manufacturing). Such embodiments allow for cell populations to expand from about 5×10^5 cells/cm² to between 10×10^6 and 30×10^6 cells/cm². In an embodiment this expansion is conducted without adding fresh cell culture media to the cells (also referred to as feeding the cells). In an embodiment, this is without feeding so long as medium resides at a height of about 10 cm in the G-Rex flask. In an embodiment this is without feeding but with the addition of one or more cytokines. In an embodiment, the cytokine can be added as a bolus without any need to mix the cytokine with the medium. Such containers, devices, and methods are known in the art and have been used to expand TILs, and include those described in U.S. Patent Application Publication No. US 2014/0377739A1, International Publication No. WO 2014/210036 A1, U.S. Patent Application

Publication No. us 2013/0115617 A1, International Publication No. WO 2013/188427 A1, U.S. Patent Application Publication No. US 2011/0136228 A1, U.S. Pat. No. 8,809,050 B2, International publication No. WO 2011/072088 A2, U.S. Patent Application Publication No. US 2016/0208216 A1, U.S. Patent Application Publication No. US 2012/0244133 A1, International Publication No. WO 2012/129201 A1, U.S. Patent Application Publication No. US 2013/0102075 A1, U.S. Pat. No. 8,956,860 B2, International Publication No. WO 2013/173835 A1, U.S. Patent Application Publication No. US 2015/0175966 A1. Such processes are also described in Jin *et al.*, *J. Immunotherapy*, 2012, 35:283-292. All of these publications are incorporated by reference herein in their entireties.

[0716] All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entireties for all purposes. However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as, an acknowledgment or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.

Additional Embodiments

[0717] Additional embodiments of the present disclosure are encompassed by the following numbered paragraphs 1-388:

1. A method of expanding a population of tumor infiltrating lymphocytes (TILs), the method comprising the steps of:
 - culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to obtain a population of TILs; and
 - culturing the population of TILs in a second medium comprising: a T cell receptor (TCR) agonist, feeder cells and greater than 100 ng/ml IL-15, wherein the second medium does not comprise IL-2, thereby expanding the population of TILs.
2. The method of paragraph 1, wherein the final concentration of IL-15 in the second medium is less than or equal to 10,000 ng/ml, optionally less than or equal to 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml.
3. The method of paragraph 1 or 2, wherein the T cell-stimulating cytokine is selected from the group consisting of IL-2, IL-7, IL-15, IL-21, and combinations thereof.
4. The method of paragraph 1 or 2, wherein the first medium does not comprise IL-2, IL-21, or both IL-2 and IL-21.
5. The method of paragraph 1 or 2, wherein the first medium does not comprise IL-2.

6. The method of paragraph 1 or 2, wherein the first medium does not comprise IL-21.
7. The method of any one of the preceding paragraphs, wherein the second medium does not comprise IL-21.
8. The method of any one of the preceding paragraphs, wherein the second medium further comprises IL-7.
9. The method of any one of the preceding paragraphs, wherein the final concentration of the T cell-stimulating cytokine in the first medium is from 10 U/ml to 7,000 U/ml.
10. The method of paragraph 8, wherein the final concentration of IL-7 in the second medium is from 10 U/ml to 7,000 U/ml.
11. The method of any one of the preceding paragraphs, wherein the TCR agonist is a CD3 agonist.
12. The method of any one of the preceding paragraphs, wherein the TCR agonist is an antibody.
13. The method of paragraph 12, wherein the antibody is a humanized antibody.
14. The method of any one of the preceding paragraphs, wherein the TCR agonist is OKT3 or UCHT1.
15. The method of any one of paragraphs 1-11, wherein the feeder cells express the TCR agonist.
16. The method of any one of the preceding paragraphs, wherein the feeder cells express an agonist of a T cell costimulatory molecule.
17. The method of paragraph 16, wherein the agonist of a T cell costimulatory molecule is a CD28 agonist.
18. The method of paragraph 16, wherein the agonist of a T cell costimulatory molecule is a CD137 agonist.
19. The method of paragraph 16, wherein the agonist of a T cell costimulatory molecule is a CD2 agonist.
20. The method of any one of paragraphs 15-19, wherein the TCR agonist and/or agonist of a T cell costimulatory molecule are expressed on the surface of the feeder cells.
21. The method of any one of the preceding paragraphs, wherein a 4-1BB ligand is expressed on the surface of the feeder cells.
22. The method of any one of the preceding paragraphs, wherein the feeder cells are peripheral blood mononuclear cells or antigen presenting cells.
23. The method of any one of the preceding paragraphs, wherein the feeder cells are genetically modified to express IL-15, IL-7, or both IL-15 and IL-7.

24. The method of any one of the preceding paragraphs, wherein the disaggregated tumor sample comprises tumor fragments that are 0.5 to 4 mm³ in size.
25. The method of any one of the preceding paragraphs, wherein the disaggregated tumor sample comprises digested tumor fragments.
26. The method of any one of the preceding paragraphs, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that produced less than 100,000 TILs.
27. The method of any one of the preceding paragraphs, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that expanded TILs present in the disaggregated tumor sample by less than 5-fold.
28. The method of any one of the preceding paragraphs, wherein members of the population of TILs are modified by a gene-regulating system.
29. The method of paragraph 28, wherein the members of the population of TILs are modified using RNA interference.
30. The method of paragraph 28, wherein the members of the population of TILs are modified using a transcription activator-like effector nuclease (TALEN).
31. The method of paragraph 28, wherein the members of the population of TILs are modified using a zinc-finger nuclease.
32. The method of paragraph 28, wherein the members of the population of TILs are modified using an RNA-guided nuclease.
33. The method of paragraph 32, wherein members of the population of TILs are modified using a Cas enzyme and at least one guide RNA.
34. The method of paragraph 33, wherein the Cas enzyme is Cas9.
35. The method of any one of paragraphs 28-34, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.
36. The method of paragraph 35, wherein the modification at one or more genes is an insertion, deletion, or mutation of one or more nucleic acids.
37. The method of any one of paragraphs 35 and 36, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

38. The method of paragraph 28, wherein members of the population of TILs are epigenetically modified.
39. The method of paragraph 38, wherein the epigenetic modification is a histone modification.
40. The method of paragraph 38, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRPI*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBRI*, *TGFB2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.
41. The method of paragraph 40, wherein the modification at one or more genes is methylation of one or more nucleic acids.
42. The method of any one of paragraphs 40 and 41, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.
43. The method of any one of paragraphs 35 and 40, wherein members of the population of TILs are modified at the *SOCS1* gene.
44. The method of paragraph 43, wherein the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.
45. The method of any one of paragraphs 28-34, wherein members of the population of TILs are modified at more than one gene.
46. The method of paragraph 45, wherein members of the population of TILs are modified at the *SOCS1* gene and one or more additional genes.
47. The method of paragraph 45, wherein members of the population of TILs are modified at the *SOCS1* and *PTPN2* genes.
48. The method of paragraph 47, wherein the modification of the *SOCS1* and *PTPN2* genes results in the reduction or inhibition of expression of the genes and/or function of proteins encoded by the gene.
49. The method of any one of the preceding paragraphs, wherein the first medium is supplemented with the T cell-stimulating cytokine at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
50. The method of any one of the preceding paragraphs, wherein the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

51. The method of any one of the preceding paragraphs, wherein the second medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
52. The method of any one of the preceding paragraphs, wherein 30% to 99% of the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
53. The method of any one of the preceding paragraphs, wherein 30% to 99% of the second medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
54. The method of any one of the preceding paragraphs, wherein the TILs are expanded for up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.
55. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded for 9-25 days, 9-21 days, or 9-14 days.
56. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded from 500 to 500,000-fold.
57. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded from an initial population of from 100 to 100,000 TILs.
58. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded at least 1,500-fold by day 14 of the expansion.
59. The method of paragraph 58, wherein the population of TILs is expanded at most 100,000-fold by day 14 of expansion.
60. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded at least 15,000-fold by day 21 of the expansion.
61. The method of paragraph 60, wherein the population of TILs is expanded at most 500,000-fold by day 21 of expansion.
62. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype.
63. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype.
64. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion.

65. The method of any one of the preceding paragraphs, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
66. A composition comprising an expanded population of TILs produced by the method of any one of the preceding paragraphs.
67. A method of expanding a population of TILs, the method comprising the steps of:
culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to obtain a population of TILs;
modifying members of the population of TILs using a gene-regulating system to obtain a modified population of TILs; and
culturing the modified population of TILs in a second medium comprising a TCR agonist; feeder cells; and IL-15, thereby expanding the population of TILs.
68. The method of paragraph 67, wherein the T cell-stimulating cytokine is selected from the group consisting of IL-2, IL-7, IL-15, IL-21 and combinations thereof.
69. The method of paragraph 67, wherein the first medium does not comprise IL-2, IL-21, or both IL-2 and IL-21.
70. The method of any one of paragraphs 67-69, wherein the first medium does not comprise IL-2.
71. The method of any one of paragraphs 67-70, wherein the first medium does not comprise IL-21.
72. The method of any one of paragraphs 67-71, wherein the second medium does not comprise IL-21.
73. The method of any one of paragraphs 67-72, wherein the second medium does not comprise IL-2.
74. The method of any one of paragraphs 67-73, wherein the second medium further comprises IL-7.
75. The method of any one of paragraphs 67-74, wherein the final concentration of the T cell-stimulating cytokine in the first medium is from 1 U/ml to 7,000 U/ml.
76. The method of paragraph 74, wherein the final concentration of IL-7 in the second medium is from 1 U/ml to 7,000 U/ml.
77. The method of any one of paragraphs 67-76, wherein the final concentration of IL-15 in the second medium is from 10 ng/ml to 10,000 ng/ml.
78. The method of any one of paragraphs 67-77, wherein the final concentration of IL-15 is greater than 100 ng/ml.

79. The method of any one of paragraphs 67-78, wherein the TCR agonist is a CD3 agonist.
80. The method of any one of paragraphs 67-79, wherein the TCR agonist is an antibody.
81. The method of paragraph 80, wherein the antibody is a humanized antibody.
82. The method of any one of paragraphs 67-81, wherein the TCR agonist is OKT3 or UCHT1.
83. The method of any one of paragraphs 67-82, wherein the feeder cells express the TCR agonist.
84. The method of any one of paragraphs 67-83, wherein the feeder cells express an agonist of a T cell costimulatory molecule.
85. The method of paragraph 84, wherein the agonist of a T cell costimulatory molecule is a CD28 agonist.
86. The method of paragraph 84, wherein the agonist of a T cell costimulatory molecule is a CD137 agonist.
87. The method of paragraph 84, wherein the agonist of a T cell costimulatory molecule is a CD2 agonist.
88. The method of any one of paragraphs 83-87, wherein the TCR agonist and/or agonist of a T cell costimulatory molecule are expressed on the surface of the feeder cells.
89. The method of any one of paragraphs 67-88, wherein a 4-1BB ligand is expressed on the surface of the feeder cells.
90. The method of any one of paragraphs 67-89, wherein the feeder cells are peripheral blood mononuclear cells or antigen presenting cells.
91. The method of any one of paragraphs 67-90, wherein the feeder cells are genetically modified to express IL-15, IL-7, or both IL-15 and IL-7.
92. The method of any one of paragraphs 67-91, wherein the disaggregated tumor sample comprises tumor fragments that are 0.5 to 4 mm³ in size.
93. The method of any one of paragraphs 67-92, wherein the disaggregated tumor sample comprises digested tumor fragments.
94. The method of any one of paragraphs 67-93, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that produced less than 100,000 TILs.
95. The method of any one of paragraphs 67-94, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that expanded TILs present in the disaggregated tumor sample by less than 5-fold.
96. The method of any one of paragraphs 67-95, wherein the members of the population of TILs are modified using RNA interference.

97. The method of any one of paragraphs 67-95, wherein the members of the population of TILs are modified using a transcription activator-like effector nuclease (TALEN).
98. The method of any one of paragraphs 67-95, wherein the members of the population of TILs are modified using a zinc-finger nuclease.
99. The method of any one of paragraphs 67-95, wherein the members of the population of TILs are modified using an RNA-guided nuclease.
100. The method of paragraph 99, wherein members of the population of TILs are modified using a Cas enzyme and at least one guide RNA.
101. The method of paragraph 100, wherein the Cas enzyme is Cas9.
102. The method of any one of paragraphs 67-101, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.
103. The method of paragraph 102, wherein the modification at one or more genes is an insertion, deletion, or mutation of one or more nucleic acids.
104. The method of any one of paragraphs 102 and 103, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.
105. The method of any one of paragraphs 67-95, wherein members of the population of TILs are epigenetically modified.
106. The method of paragraph 105, wherein the epigenetic modification is a histone modification.
107. The method of paragraph 105, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.
108. The method of paragraph 107, wherein the modification at one or more genes is methylation of one or more nucleic acids.

109. The method of any one of paragraphs 107 and 108, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.
110. The method of any one of paragraphs 102 and 107, wherein members of the population of TILs are modified at the *SOCS1* gene.
111. The method of paragraph 110, wherein the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the genes and/or function of proteins encoded by the genes.
112. The method of any one of paragraphs 67-101 and 105-106, wherein members of the population of TILs are modified at more than one gene.
113. The method of paragraph 112, wherein members of the population of TILs are modified at the *SOCS1* gene and one or more additional genes.
114. The method of paragraph 112, wherein members of the population of TILs are modified at the *SOCS1* and *PTPN2* genes.
115. The method of paragraph 114, wherein the modification of the *SOCS1* and *PTPN2* genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the genes.
116. The method of any one of paragraphs 67-115, wherein the first medium is supplemented with the T cell-stimulating cytokine at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
117. The method of any one of paragraphs 67-116, wherein the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
118. The method of any one of paragraphs 67-117, wherein the second medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
119. The method of any one of paragraphs 67-118, wherein 30% to 99% of the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
120. The method of any one of paragraphs 67-119, wherein 30% to 99% of the second medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
121. The method of any one of paragraphs 67-120, wherein the TILs are expanded for up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.

122. The method of any one of paragraphs 67-121, wherein the population of TILs is expanded for 9-25 days, 9-21 days, or 9-14 days.
123. The method of any one of paragraphs 67-122, wherein the population of TILs is expanded from 500 to 500,000-fold.
124. The method of any one of paragraphs 67-123, wherein the population of TILs is expanded from an initial population of from 100 to 100,000 TILs.
125. The method of any one of paragraphs 67-124, wherein the population of TILs is expanded at least 1,500-fold by day 14 of the expansion.
126. The method of paragraph 125, wherein the population of TILs is expanded at most 100,000-fold by day 14 of expansion.
127. The method of any one of paragraphs 67-126, wherein the population of TILs is expanded at least 15,000-fold by day 21 of expansion.
128. The method of paragraph 127, wherein the population of TILs is expanded at most 500,000-fold by day 21 of expansion.
129. The method of any one of paragraphs 67-128, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype.
130. The method of any one of paragraphs 67-129, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype.
131. The method of any one of paragraphs 67-130, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
132. The method of any one of paragraphs 67-131, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
133. A composition comprising an expanded population of TILs produced by the method of any one of paragraphs 67-132.
134. A method of expanding a population of TILs in a disaggregated tumor sample, the method comprising culturing the disaggregated tumor sample in a culture medium comprising feeder cells; a TCR agonist; and IL-15, thereby expanding the population of TILs.
135. The method of paragraph 134, wherein the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21.
136. The method of paragraph 134, wherein the culture medium does not comprise IL-21.

137. The method of paragraph 134, wherein the culture medium does not comprise IL-2.
138. The method of any one of paragraphs 134-137, wherein the culture medium further comprises IL-7.
139. The method of paragraph 138, wherein the final concentration of IL-7 in the culture medium is from 10 U/ml to 7,000 U/ml.
140. The method of any one of paragraphs 134-139, wherein the final concentration of IL-15 in the culture medium is from 10 ng/ml to 10,000 ng/ml.
141. The method of any one of paragraphs 134-140, wherein the final concentration of IL-15 in the culture medium is greater than 100 ng/ml.
142. The method of any one of paragraphs 134-141, wherein the TCR agonist is a CD3 agonist.
143. The method of any one of paragraphs 134-142, wherein the TCR agonist is an antibody.
144. The method of paragraph 143, wherein the antibody is a humanized antibody.
145. The method of any one of paragraphs 143-144, wherein the TCR agonist is OKT3 or UCHT1.
146. The method of any one of paragraphs 134-142, wherein the feeder cells express the TCR agonist.
147. The method of any one of paragraphs 134-146, wherein the feeder cells express an agonist of a T cell costimulatory molecule.
148. The method of paragraph 147, wherein the agonist of a T cell costimulatory molecule is a CD28 agonist.
149. The method of paragraph 147, wherein the agonist of a T cell costimulatory molecule is a CD137 agonist.
150. The method of paragraph 147, wherein the agonist of a T cell costimulatory molecule is a CD2 agonist.
151. The method of any one of paragraphs 147-150, wherein the TCR agonist and/or agonist of a T cell costimulatory molecule are expressed on the surface of the feeder cells.
152. The method of any one of paragraphs 134-151, wherein a 4-1BB ligand is expressed on the surface of the feeder cells.
153. The method of any one of paragraphs 134-152, wherein the feeder cells are peripheral blood mononuclear cells or antigen presenting cells.
154. The method of any one of paragraphs 134-153, wherein the feeder cells are genetically modified to express IL-15, IL-7, or both IL-15 and IL-7.
155. The method of any one of paragraphs 134-154, wherein the disaggregated tumor sample comprises tumor fragments that are 0.5 to 4 mm³ in size.

156. The method of any one of paragraphs 134-155, wherein the disaggregated tumor sample comprises digested tumor fragments.
157. The method of any one of paragraphs 134-156, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that produced less than 100,000 TILs.
158. The method of any one of paragraphs 134-157, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that expanded TILs present in the disaggregated tumor sample by less than 5-fold.
159. The method of any one of paragraphs 134-158, wherein members of the population of TILs are modified by a gene-regulating system.
160. The method of paragraph 159, wherein the members of the population of TILs are modified using RNA interference.
161. The method of paragraph 159, wherein the members of the population of TILs are modified using a transcription activator-like effector nuclease (TALEN).
162. The method of paragraph 159, wherein the members of the population of TILs are modified using a zinc-finger nuclease.
163. The method of paragraph 159, wherein the members of the population of TILs are modified using an RNA-guided nuclease.
164. The method of paragraph 163, wherein members of the population of TILs are modified using a Cas enzyme and at least one guide RNA.
165. The method of paragraph 164, wherein the Cas enzyme is Cas9.
166. The method of any one of paragraphs 159-165, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.
167. The method of paragraph 166, wherein the modification at one or more genes is an insertion, deletion, or mutation of one or more nucleic acids.
168. The method of any one of paragraphs 166 and 167, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.
169. The method of any one of paragraphs 159, wherein members of the population of TILs are epigenetically modified.

170. The method of paragraph 169, wherein the epigenetic modification is a histone modification.

171. The method of paragraph 169, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRPI*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBRI*, *TGFBRI2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.

172. The method of paragraph 171, wherein the modification at one or more genes is methylation of one or more nucleic acids.

173. The method of any one of paragraphs 171 and 172, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

174. The method of any one of paragraphs 166 and 171, wherein members of the population of TILs are modified at the *SOCS1* gene.

175. The method of paragraph 174, wherein the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the genes and/or function of proteins encoded by the genes.

176. The method of any one of paragraphs 160-165 and 169-170, wherein members of the population of TILs are modified at more than one gene.

177. The method of paragraph 176, wherein members of the population of TILs are modified at the *SOCS1* gene and one or more additional genes.

178. The method of paragraph 176, wherein members of the population of TILs are modified at the *SOCS1* and *PTPN2* genes.

179. The method of paragraph 178, wherein the modification of the *SOCS1* and *PTPN2* genes results in the reduction or inhibition of expression of the genes and/or function of proteins encoded by the genes.

180. The method of any one of paragraphs 134-179, wherein the culture medium is supplemented with IL-15 at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

181. The method of any one of paragraphs 134-180, wherein the culture medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

182. The method of any one of paragraphs 134-181, wherein 30% to 99% of the culture medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
183. The method of any one of paragraphs 134-182, wherein the TILs are expanded for up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.
184. The method of any one of paragraphs 134-183, wherein the population of TILs is expanded for 9-25 days, 9-21 days, or 9-14 days.
185. The method of any one of paragraphs 134-184, wherein the population of TILs is expanded from 500 to 500,000-fold.
186. The method of any one of paragraphs 134-184, wherein the population of TILs is expanded from an initial population of from 100 to 100,000 TILs.
187. The method of any one of paragraphs 134-186, wherein the population of TILs is expanded at least 1,500-fold by day 14 of the expansion.
188. The method of paragraph 187, wherein the population of TILs is expanded at most 100,000-fold by day 14 of expansion.
189. The method of any one of paragraphs 134-188, wherein the population of TILs is expanded at least 15,000-fold by day 21 of the expansion.
190. The method of paragraph 189, wherein the population of TILs is expanded at most 500,000-fold by day 21 of expansion.
191. The method of any one of paragraphs 134-190, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype.
192. The method of any one of paragraphs 134-191, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype.
193. The method of any one of paragraphs 134-192, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
194. The method of any one of paragraphs 134-193, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
195. A composition comprising an expanded population of TILs produced by the method of any one of paragraphs 134-194.

196. A method of expanding a population of TILs in a disaggregated tumor sample, the method comprising culturing the disaggregated tumor sample in a culture medium comprising a TCR agonist; an agonist of a T cell costimulatory molecule; and IL-15, thereby expanding the population of TILs.
197. The method of paragraph 196, wherein the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21.
198. The method of paragraph 196, wherein the culture medium does not comprise IL-21.
199. The method of paragraph 196, wherein the culture medium does not comprise IL-2.
200. The method of any one of paragraphs 196-199, wherein the culture medium further comprises IL-7.
201. The method of paragraph 200, wherein the final concentration of IL-7 in the culture medium is from 10 U/ml to 7,000 U/ml.
202. The method of any one of paragraphs 196-201, wherein the final concentration of IL-15 in the culture medium is from 10 ng/ml to 10,000 ng/ml.
203. The method of any one of paragraphs 196-202, wherein the final concentration of IL-15 in the culture medium is greater than 100 ng/ml.
204. The method of any one of paragraphs 196-203, wherein the TCR agonist is a CD3 agonist.
205. The method of any one of paragraphs 196-204, wherein the TCR agonist is an antibody.
206. The method of paragraph 205, wherein the antibody is a humanized antibody.
207. The method of any one of paragraphs 205-206, wherein the TCR agonist is OKT3 or UCHT1.
208. The method of any one of paragraphs 205-206, wherein the TCR agonist comprises a soluble monospecific complex comprising two anti-CD3 antibodies linked together.
209. The method of any one of paragraphs 196-208, wherein the agonist of a T cell costimulatory molecule is selected from the group consisting of a CD28 agonist, a CD137 agonist, a CD2 agonist, and a combination thereof.
210. The method of any one of paragraphs 196-209, wherein the agonist of a T cell costimulatory molecule is a CD28 agonist.
211. The method of any one of paragraphs 209-210, wherein the CD28 agonist comprises a soluble monospecific complex comprising two anti-CD28 antibodies linked together.
212. The method of paragraph 209, wherein the CD2 agonist comprises a soluble monospecific complex comprising two anti-CD2 antibodies linked together.
213. The method of any one of paragraphs 196-212, wherein the TCR agonist and/or the agonist of a T cell costimulatory molecule are linked to a nanomatrix comprising a colloidal suspension

of matrices of polymer chains, wherein each matrix is 1 to 500 nm in length in its largest dimension.

214. The method of paragraph 213, wherein the TCR agonist and the agonist of a T cell costimulatory molecule are attached to the same polymer chains.

215. The method of paragraph 213, wherein the TCR agonist and the agonist of a T cell costimulatory molecule are attached to different polymer chains.

216. The method of any one of paragraphs 213-215, wherein the TCR agonist is attached to the nanomatrix at 25 µg per mg of nanomatrix.

217. The method of any one of paragraphs 196-216, wherein the disaggregated tumor sample comprises tumor fragments that are 0.5 to 4 mm³ in size.

218. The method of any one of paragraphs 196-217, wherein the disaggregated tumor sample comprises digested tumor fragments.

219. The method of any one of paragraphs 196-218, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that produced less than 100,000 TILs.

220. The method of any one of paragraphs 196-219, wherein the disaggregated tumor sample was previously exposed to a pre-REP step that expanded TILs present in the disaggregated tumor sample by less than 5-fold.

221. The method of any one of paragraphs 196-220, wherein members of the population of TILs are modified by a gene-regulating system.

222. The method of paragraph 221, wherein the members of the population of TILs are modified using RNA interference.

223. The method of paragraph 221, wherein the members of the population of TILs are modified using a transcription activator-like effector nuclease (TALEN).

224. The method of paragraph 221, wherein the members of the population of TILs are modified using a zinc-finger nuclease.

225. The method of paragraph 221, wherein the members of the population of TILs are modified using an RNA-guided nuclease.

226. The method of paragraph 225, wherein members of the population of TILs are modified using a Cas enzyme and at least one guide RNA.

227. The method of paragraph 226, wherein the Cas enzyme is Cas9.

228. The method of any one of paragraphs 221-227, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*,

PCBP1, PDCD1, PELI1, PIK3CD, PPP2R2D, PTPN1, PTPN2, PTPN22, PTPN6, RBM39, RC3H1, SEMA7A, SERPINA3, SETD5, SH2B3, SH2D1A, SMAD2, SOCS1, TANK, TGFB1, TGFB2, TIGIT, TNFAIP3, TNIP1, TRAF6, UMPS, WDR6 and ZC3H12A.

229. The method of paragraph 228, wherein the modification at one or more genes is an insertion, deletion, or mutation of one or more nucleic acids.

230. The method of any one of paragraphs 228 and 229, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

231. The method of paragraph 221, wherein members of the population of TILs are epigenetically modified.

232. The method of paragraph 231, wherein the epigenetic modification is a histone modification.

233. The method of paragraph 231, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11, BCL2L1, BCL3, BCOR, CALM2, CBLB, CHIC2, CTLA4, DHODH, E2F8, EGR2, FLI1, FOXP3, GATA3, GNAS, HAVCR2, IKZF1, IKZF2, IKZF3, LAG3, MAP4K, NFKBIA, NR4A3, NRPI, PBRM1, PCBP1, PDCD1, PELI1, PIK3CD, PPP2R2D, PTPN1, PTPN2, PTPN22, PTPN6, RBM39, RC3H1, SEMA7A, SERPINA3, SETD5, SH2B3, SH2D1A, SMAD2, SOCS1, TANK, TGFB1, TGFB2, TIGIT, TNFAIP3, TNIP1, TRAF6, UMPS, WDR6 and ZC3H12A.*

234. The method of paragraph 233, wherein the modification at one or more genes is methylation of one or more nucleic acids.

235. The method of any one of paragraphs 233 and 234, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

236. The method of any one of paragraphs 228 and 233, wherein members of the population of TILs are modified at the *SOCS1* gene.

237. The method of paragraph 236, wherein the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

238. The method of any one of paragraphs 222-227 and 231-232, wherein members of the population of TILs are modified at more than one gene.

239. The method of paragraph 238, wherein members of the population of TILs are modified at the *SOCS1* and *PTPN2* genes.

240. The method of paragraph 239, wherein the modification of the *SOCS1* and *PTPN2* genes results in the reduction or inhibition expression of the genes and/or function of proteins encoded by the genes.
241. The method of any one of paragraphs 196-240, wherein the culture medium is supplemented with IL-15 at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
242. The method of any one of paragraphs 196-241, wherein the culture medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
243. The method of any one of paragraphs 196-242, wherein 30% to 99% of the culture medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.
244. The method of any one of paragraphs 196-243, wherein the TILs are expanded for up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.
245. The method of any one of paragraphs 196-244, wherein the population of TILs is expanded for 9-25 days, 9-21 days, or 9-14 days.
246. The method of any one of paragraphs 196-245, wherein the population of TILs is expanded from 500 to 500,000-fold.
247. The method of any one of paragraphs 196-245, wherein the population of TILs is expanded from an initial population of from 100 to 100,000 TILs.
248. The method of any one of paragraphs 196-247, wherein the population of TILs is expanded at least 1,500-fold by day 14 of the expansion.
249. The method of paragraph 248, wherein the population of TILs is expanded at most 100,000-fold by day 14 of expansion.
250. The method of any one of paragraphs 196-249, wherein the population of TILs is expanded at least 15,000-fold by day 21 of the expansion.
251. The method of paragraph 250, wherein the population of TILs is expanded at most 500,000-fold by day 21 of expansion.
252. The method of any one of paragraphs 196-251, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype.
253. The method of any one of paragraphs 196-252, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype.

254. The method of any one of paragraphs 196-252, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
255. The method of any one of paragraphs 196-253, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
256. The method of any one of paragraphs 196-255, wherein the medium does not comprise feeder cells.
257. The method of any one of paragraphs 196-255, wherein the medium further comprises feeder cells.
258. The method of paragraph 257, wherein a 4-1BB ligand is expressed on the surface of the feeder cells.
259. The method of any one of paragraphs 257-258, wherein the feeder cells are peripheral blood mononuclear cells or antigen presenting cells.
260. The method of any one of paragraphs 257-259, wherein the feeder cells are genetically modified to express IL-15, IL-7, or both IL-15 and IL-7.
261. A composition comprising an expanded population of TILs produced by the method of any one of paragraphs 196-260.
262. A method for expanding a population of tumor infiltrating lymphocytes (TILs) comprising: culturing the population of TILs in a culture medium comprising IL-15, and a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein the matrices are attached to TCR agonists and agonists of a T cell costimulatory molecule, wherein each matrix is 1 to 500 nm in length in its largest dimension and wherein the method does not comprise the use of feeder cells during expansion of the population of TILs.
263. The method of paragraph 262, wherein the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21.
264. The method of paragraph 262, wherein the culture medium does not comprise IL-21.
265. The method of paragraph 262, wherein the culture medium does not comprise IL-2.
266. The method of any one of paragraphs 262-265, wherein the culture medium further comprises IL-7.
267. The method of paragraph 266, wherein the final concentration of IL-7 in the culture medium is from 10 U/ml to 7,000 U/ml.
268. The method of any one of paragraphs 262-267, wherein the final concentration of IL-15 in the culture medium is from 10 ng/ml to 10,000 ng/ml.

269. The method of any one of paragraphs 262-268, wherein the final concentration of IL-15 in the culture medium is greater than 100 ng/ml.
270. The method of any one of paragraphs 262-269, wherein the TCR agonist is a CD3 agonist.
271. The method of any one of paragraphs 262-270, wherein the agonist of a T cell costimulatory molecule is a CD28 agonist.
272. The method of any one of paragraphs 262-271, wherein the agonists are recombinant agonists.
273. The method of any one of paragraphs 262-272, wherein the agonists are antibodies.
274. The method of paragraph 273, wherein the antibodies are humanized antibodies.
275. The method of paragraph 270, wherein the CD3 agonist is OKT3 or UCHT1.
276. The method of any one of paragraphs 262-275, wherein the TCR agonists and agonists of a T cell costimulatory molecule are attached to the same polymer chains.
277. The method of any one of paragraphs 262-275, wherein the TCR agonists and agonists of a T cell costimulatory molecule are attached to different polymer chains.
278. The method of any one of paragraphs 262-277, wherein the TCR agonists are attached to the matrices at 25 µg per mg of matrix.
279. The method of any one of paragraphs 213 and 262-278, wherein the agonist of a T cell costimulatory molecule is attached to the matrices at 25 µg per mg of matrix.
280. The method of any one of paragraphs 213 and 262-279, wherein the nanomatrix further comprises magnetic, paramagnetic or superparamagnetic nanocrystals embedded among or within the matrices of polymer chains.
281. The method of any one of paragraphs 213 and 262-280 wherein the matrices of polymer chains comprise a polymer of dextran.
282. The method of any one of paragraphs 213 and 262-281, wherein the polymer chains are colloidal polymer chains.
283. The method of any one of paragraphs 213 and 262-282, wherein the population of TILs cultured with the nanomatrix further comprises tumor cells.
284. The method of any one of paragraphs 213 and 262-283, wherein the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:5.
285. The method of any one of paragraphs 213 and 262-284, wherein the ratio of number of matrices to TILs is greater than or equal to 1:500.
286. The method of any one of paragraphs 262-285, wherein the TILs to be expanded are from a subject who had previously submitted a sample of TILs for expansion, wherein the previous TIL

expansion comprises a pre-REP step and wherein the number of TILs isolated from the pre-REP step was less than 100,000 TILs.

287. The method of any one of paragraphs 262-286, wherein the TILs to be expanded are from a subject who had previously submitted a sample of TILs for expansion, wherein the previous TIL expansion comprises a pre-REP step and wherein the fold expansion of TILs isolated from the pre-REP step was less than 5-fold.

288. The method of any one of paragraphs 262-287, wherein members of the population of TILs are modified by a gene-regulating system.

289. The method of paragraph 288, wherein the members of the population of TILs are modified using RNA interference.

290. The method of paragraph 288, wherein the members of the population of TILs are modified using a transcription activator-like effector nuclease (TALEN).

291. The method of paragraph 288, wherein the members of the population of TILs are modified using a zinc-finger nuclease.

292. The method of paragraph 288, wherein the members of the population of TILs are modified using an RNA-guided nuclease.

293. The method of paragraph 292, wherein members of the population of TILs are modified using a Cas enzyme and at least one guide RNA.

294. The method of paragraph 293, wherein the Cas enzyme is Cas9.

295. The method of any one of paragraphs 288-294, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.

296. The method of paragraph 295, wherein the modification at one or more genes is an insertion, deletion, or mutation of one or more nucleic acids.

297. The method of any one of paragraphs 295 and 296, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

298. The method of paragraph 288, wherein members of the population of TILs are epigenetically modified.

299. The method of paragraph 298, wherein the epigenetic modification is a histone modification.

300. The method of paragraph 298, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRPI*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBRI*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.

301. The method of paragraph 300, wherein the modification at one or more genes is methylation of one or more nucleic acids.

302. The method of any one of paragraphs 300 and 301, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

303. The method of any one of paragraphs 295 and 300, wherein members of the population of TILs are modified at the *SOCS1* gene.

304. The method of paragraph 303, wherein the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

305. The method of any one of paragraphs 289-294 and 298-299, wherein members of the population of TILs are modified at more than one gene.

306. The method of paragraph 305, wherein members of the population of TILs are modified at the *SOCS1* and *PTPN2* genes.

307. The method of paragraph 306, wherein the modification of the *SOCS1* and *PTPN2* genes results in the reduction or inhibition of expression of the genes and/or function of proteins encoded by the genes.

308. The method of any one of paragraphs 262-307, wherein the TILs are contacted with IL-15 at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

309. The method of any one of paragraphs 262-308, wherein the TILs are expanded for up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.

310. The method of any one of paragraphs 262-309, wherein the population of TILs is expanded for 9-25 days, 9-21 days, or 9-14 days.

311. The method of any one of paragraphs 262-309, wherein the population of TILs is expanded from 500 to 500,000-fold.

312. The method of any one of paragraphs 262-309, wherein the population of TILs is expanded from an initial population of from 100 to 100,000 TILs.
313. The method of any one of paragraphs 262-312, wherein the population of TILs is expanded at least 1,500-fold by day 14 of the expansion.
314. The method of paragraph 313, wherein the population of TILs is expanded at most 100,000-fold by day 14 of expansion.
315. The method of any one of paragraphs 262-314, wherein the population of TILs is expanded at least 15,000-fold by day 21 of the expansion.
316. The method of paragraph 315, wherein the population of TILs is expanded at most 500,000-fold by day 21 of expansion.
317. The method of any one of paragraphs 262-316, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype.
318. The method of any one of paragraphs 262-317, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype.
319. The method of any one of paragraphs 262-317, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
320. The method of any one of paragraphs 262-319, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
321. The method of any one of paragraphs 262-320, wherein the population of TILs further comprises tumor cells.
322. A composition comprising an expanded population of TILs produced by the method of any one of paragraphs 262-321.
323. A method for expanding a population of TILs comprising culturing the population of TILs in a culture medium comprising IL-15; and a first soluble monospecific complex comprising an anti-CD3 antibody or fragment thereof, a second soluble monospecific complex comprising an anti-CD28 antibody or fragment thereof, and a third soluble monospecific complex comprising an anti-CD2 antibody or fragment thereof, wherein each soluble monospecific complex comprises two antibodies, or fragments thereof, linked together, and each antibody, or fragments thereof, of each soluble monospecific complex specifically binds to the same antigen on the population of TILs.

324. The method of paragraph 323, wherein the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21.
325. The method of paragraph 323, wherein the culture medium does not comprise IL-21.
326. The method of paragraph 323, wherein the culture medium does not comprise IL-2.
327. The method of any one of paragraphs 323-326, wherein the culture medium further comprises IL-7.
328. The method of paragraph 327, wherein the final concentration of IL-7 in the culture medium is from 10 U/ml to 7,000 U/ml.
329. The method of any one of paragraphs 323-328, wherein the final concentration of IL-15 in the culture medium is from 10 ng/ml to 10,000 ng/ml.
330. The method of any one of paragraphs 323-329, wherein the final concentration of IL-15 in the culture medium is greater than 100 ng/ml.
331. The method of any one of paragraphs 323-330, wherein the soluble monospecific complexes are tetrameric antibody complexes (TACs).
332. The method of paragraph 331, wherein each TAC comprises two antibodies from a first animal species bound by two antibody molecules from a second species that specifically bind to the Fc portion of the antibodies from the first animal species.
333. The method of any one of paragraphs 323-332, wherein the anti-CD3 antibody is OKT3 or UCHT1.
334. The method of any one of paragraphs 323-333, wherein the population of TILs contacted with the composition further comprises tumor cells.
335. The method of any one of paragraphs 323-334, wherein the method does not comprise the use of feeder cells during expansion of the population of TILs.
336. The method of any one of paragraphs 323-335, wherein the soluble monospecific complexes are at a concentration of 0.2-25 μ L/ml.
337. The method of any of one of paragraphs 323-336, wherein the population of TILs to be expanded are from a subject who had previously submitted a sample of TILs for expansion, wherein the previous TIL expansion comprises a pre-REP step and wherein the number of TILs isolated from the pre-REP step was less than 100,000 TILs.
338. The method of any of one of paragraphs 323-336, wherein the TILs to be expanded are from a subject who had previously submitted a sample of TILs for expansion, wherein the previous TIL expansion comprises a pre-REP step and wherein the fold expansion of TILs isolated from the pre-REP step was less than 5-fold.

339. The method of any one of paragraphs 323-338, wherein members of the population of TILs are modified by a gene-regulating system.
340. The method of paragraph 339, wherein the members of the population of TILs are modified using RNA interference.
341. The method of paragraph 339, wherein the members of the population of TILs are modified using a transcription activator-like effector nuclease (TALEN).
342. The method of paragraph 339, wherein the members of the population of TILs are modified using a zinc-finger nuclease.
343. The method of paragraph 340, wherein the members of the population of TILs are modified using an RNA-guided nuclease.
344. The method of paragraph 339, wherein members of the population of TILs are modified using a Cas enzyme and at least one guide RNA.
345. The method of paragraph 344, wherein the Cas enzyme is Cas9.
346. The method of any one of paragraphs 339-345, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOC31*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*.
347. The method of paragraph 346, wherein the modification at one or more genes is an insertion, deletion, or mutation of one or more nucleic acids.
348. The method of any one of paragraphs 346 and 347, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.
349. The method of paragraph 349, wherein members of the population of TILs are epigenetically modified.
350. The method of paragraph 349, wherein the epigenetic modification is a histone modification.
351. The method of paragraph 349, wherein members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*,

SEMA7A, SERPINA3, SETD5, SH2B3, SH2D1A, SMAD2, SOCS1, TANK, TGFBRI, TGFB2, TIGIT, TNFAIP3, TNIP1, TRAF6, UMPS, WDR6 and ZC3H12A.

352. The method of paragraph 351, wherein the modification at one or more genes is methylation of one or more nucleic acids.

353. The method of any one of paragraphs 351 and 352, wherein the modification at one or more genes results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

354. The method of any one of paragraphs 346 and 351, wherein members of the population of TILs are modified at the *SOCS1* gene.

355. The method of paragraph 354, wherein the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

356. The method of any one of paragraphs 340-345 and 349-350, wherein members of the population of TILs are modified at more than one gene.

357. The method of paragraph 356, wherein members of the population of TILs are modified at the *SOCS1* and *PTPN2* genes.

358. The method of paragraph 357, wherein the modification of the *SOCS1* and *PTPN2* genes results in the reduction or inhibition of expression of the genes and/or function of proteins encoded by the genes.

359. The method of any one of paragraphs 323-358, wherein the TILs are contacted with IL-15 at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

360. The method of any one of paragraphs 323-359, wherein the population of TILs are expanded for up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.

361. The method of any one of paragraphs 323-360, wherein the population of TILs are expanded for 9-25 days, 9-21 days, or 9-14 days.

362. The method of any one of paragraphs 323-361, wherein the TILs are expanded from 500 to 500,000-fold.

363. The method of any one of paragraphs 323-361, wherein the population of TILs is expanded from an initial population of from 100 to 100,000 TILs.

364. The method of any one of paragraphs 323-363, wherein the population of TILs is expanded at least 1,500-fold by day 14 of the expansion.

365. The method of paragraph 364, wherein the population of TILs is expanded at most 100,000-fold by day 14 of expansion.

366. The method of any one of paragraphs 323-365, wherein the population of TILs is expanded at least 15,000-fold by day 21 of the expansion.
367. The method of paragraph 366, wherein the population of TILs is expanded at most 500,000-fold by day 21 of expansion.
368. The method of any one of paragraphs 323-367, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype.
369. The method of any one of paragraphs 323-368, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype.
370. The method of any one of paragraphs 323-367, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
371. The method of any one of paragraphs 323-370, wherein the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion.
372. The method of any one of paragraphs 323-371, wherein the population of TILs is isolated from a subject and contacted with the culture medium without an additional expansion process of the population of TILs prior to contacting the population of TILs with the culture medium.
373. A composition comprising an expanded population of TILs produced by the method of any one of paragraphs 323-372.
374. A method of expanding, in a one or two step culture, a population of TILs in a disaggregated tumor sample, the method comprising culturing the disaggregated tumor sample in a culture medium comprising a T cell-stimulating cytokine; feeder cells; and a TCR agonist, wherein the T cell-stimulating cytokine consists of greater than 100 ng/ml IL-15, thereby expanding the population of TILs.
375. The method of paragraph 374, wherein members of the population of TILs are modified by a gene-regulating system.
376. The method of paragraph 375, wherein members of the population of TILs are modified at the *SOCS1* gene.
377. The method of any one of paragraphs 35, 40, 102, 107, 166, 171, 228, 233, 295, 300, 346 and 351, wherein the one or more genes are selected from the group consisting of *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*.

378. The method of paragraph 377, wherein the one or more genes are selected from the group consisting of *SOCS1* and *PTPN2*.

379. The method of paragraph 377, wherein the one or more genes are selected from the group consisting of *SOCS1* and *ZC3H12A*.

380. The method of any one of paragraphs 43, 46, 110, 113, 174, 177, 236, 303 and 354, wherein one or more genes additional genes are modified and wherein the one or more additional genes are selected from the group consisting of *ZC3H12A*, *PTPN2*, *CBLB*, *RC3H1* and *NFKBIA*.

381. The method of any of the preceding paragraphs wherein the exhaustion of the cultured population of TILs is reduced and/or the cytotoxicity of the cultured population of TILs is increased.

382. The method of paragraph 381, wherein the population of TILs is modified at the *SOCS1* gene.

383. The method of paragraph 382, wherein the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

384. The method of any one of paragraphs 381-383, wherein the population of TILs comprise a reduction in expression of one or more exhaustion related genes selected from *PTGER2*, *FASLG*, *TNFRSF9*, *IRF4*, *CTLA4*, *EOMES*, *PDPN*, *LAG3*, *TNFSF9*, *CD86*, *TIGIT*, *HAVCR2*, *CASP3*, *PROCR*, *MDFIC*, *CCL3*, *CD160*, *BATF*, *TOX*, *CD244*, *B3GAT1*, *KLRG1*, *LILRB4* and *PDCD1* relative to TILs modified at the *SOCS1* gene and cultured in culture medium without IL-15.

385. The method of any one of paragraphs 381-383 wherein the expression levels of one or more cytotoxicity related genes selected from *ITGB2*, *CSF2*, *TNF*, *FASLG*, *TNFRSF10B*, *LCK*, *IFNG*, *IFNB1*, *BID*, *GZMB*, *PRF1*, *KLRK1*, *ZAP70*, *FYN*, *GZMA*, *VAV3*, *GZMH*, *GZMM*, *KIR3DL1*, *IFNGR2*, *VAV1*, *SOS2*, *PTPN6*, *PTK2B*, *SH3BP2*, *LAT*, *KLRC2*, *IFNA1*, *CASP3*, *ICAM1*, *SH2D1A*, *ARAF*, *NFATC1*, *IFNAR1*, *NCR1*, *NCR3*, *IFNGR1*, *NCR2*, *TYROBP*, *FCGR3B*, *KLRD1*, *FAS*, *CD244*, *RAC2* and *CD247* are increased relative to TILs un-modified at the *SOCS1* gene and cultured in culture medium with IL-15.

386. The method of any one of paragraphs 381-385, wherein the exhaustion score is reduced.

387. The method of any one of paragraphs 381-386, wherein the cytotoxicity score is increased.

388. The method of any one of paragraphs 381-387, wherein the exhaustion score is reduced, and the cytotoxicity score is increased.

[0718] In one aspect, the present disclosure provides methods of expanding a population of TILs, comprising the steps of culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to obtain a population of TILs; and culturing the

population of TILs in a second medium comprising a T cell receptor (TCR) agonist; feeder cells; and greater than 100 ng/ml IL-15, wherein the second medium does not comprise IL-2, thereby expanding the population of TILs.

[0719] In another aspect, the present disclosure provides methods of expanding a population of TILs comprising the steps of culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to obtain a population of TILs; modifying members of the population of TILs using a gene-regulating system to obtain a modified population of TILs; and culturing the modified population of TILs in a second medium comprising a TCR agonist; feeder cells; and IL-15, thereby expanding the population of TILs.

[0720] In another aspect, the present disclosure provides methods of expanding a population of TILs in a disaggregated tumor sample comprising culturing the disaggregated tumor sample in a culture medium comprising feeder cells; a TCR agonist; and IL-15, thereby expanding the population of TILs.

[0721] In another aspect, the present disclosure provides methods of expanding, in a one or two step culture, a population of TILs in a disaggregated tumor sample comprising culturing the disaggregated tumor sample in a culture medium comprising a T cell-stimulating cytokine; feeder cells; and a TCR agonist, wherein the T cell-stimulating cytokine consists of greater than 100 ng/ml IL-15, thereby expanding the population of TILs.

[0722] In another aspect, the present disclosure provides methods of expanding a population of TILs in a disaggregated tumor sample comprising culturing the disaggregated tumor sample in a culture medium comprising a TCR agonist; an agonist of a T cell costimulatory molecule; and IL-15, thereby expanding the population of TILs.

[0723] In another aspect, the present disclosure provides methods for expanding a population of TILs comprising culturing the population of TILs in a culture medium comprising IL-15 and a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein the matrices are attached to TCR agonists and agonists of a T cell costimulatory molecule, wherein each matrix is about 1 to about 500 nm in length in its largest dimension and wherein the method does not comprise the use of feeder cells during expansion of the population of TILs.

[0724] In another aspect, the present disclosure provides methods for expanding a population of TILs comprising culturing the population of TILs in a culture medium comprising IL-15; and a first soluble monospecific complex comprising an anti-CD3 antibody or fragment thereof, a second soluble monospecific complex comprising an anti-CD28 antibody or fragment thereof, and a third soluble monospecific complex comprising an anti-CD2 antibody or fragment thereof, wherein each soluble monospecific complex comprises two antibodies, or fragments

thereof, linked together, and each antibody, or fragments thereof, of each soluble monospecific complex specifically binds to the same antigen on the population of TILs.

[0725] In some embodiments, the final concentration of IL-15 in the culture medium is from about 10 ng/ml to about 10,000 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is from about 10 ng/ml to about 50 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is from about 10 ng/ml to about 75 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is less than 10,000 ng/ml, optionally less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 150 ng/ml. In some embodiments, the final concentration of IL-15 in the culture medium is greater than 200 ng/ml. In some embodiments, the final concentration of IL-15 in the second medium is greater than 100 ng/ml. In some embodiments, the final concentration of IL-15 in the second medium is greater than 150 ng/ml. In some embodiments, the final concentration of IL-15 in the second medium is greater than 200 ng/ml. In further embodiments, the final concentration of IL-15 in the second medium is greater than 100 ng/ml and less than 1000 ng/ml, optionally less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/ml and optionally more than 150 or 200 ng/ml. In further embodiments, the final concentration of IL-15 in the second medium is less than or equal to 10,000 ng/ml, optionally less than or equal to 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 ng/ml. In some embodiments, the final concentration of IL-15 in the second medium is from 10 ng/ml to 10,000 ng/ml.

[0726] In some embodiments, the T cell-stimulating cytokine is selected from the group consisting of IL-2, IL-7, IL-15, IL-21, and combinations thereof. In some embodiments, the final concentration of the T cell-stimulating cytokine in the first medium is from about 10 U/ml to about 7,000 U/ml.

[0727] In some embodiments, the culture medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In some embodiments, the culture medium does not comprise IL-2. In some embodiments, the culture medium does not comprise IL-21. In some embodiments, the first medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In some embodiments, the second medium does not comprise IL-2, IL-21, or both IL-2 and IL-21. In some embodiments, the first medium does not comprise IL-2. In some embodiments, the second medium does not comprise IL-2. In some embodiments, the first medium does not comprise IL-21. In some embodiments, the second medium does not comprise IL-21.

[0728] In some embodiments, the culture medium further comprises IL-7. In one embodiment, the final concentration of IL-7 in the culture medium is from 10 U/ml to 7,000 U/ml. In some embodiments, the second medium further comprises IL-7. In certain embodiments, the final concentration of IL-7 in the second medium is from 10 U/ml to 7,000 U/ml.

[0729] In some embodiments, the first medium is supplemented with the T cell-stimulating cytokine at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In some embodiments, the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In some embodiments, 30% to 99% of the first medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

[0730] In some embodiments, the second medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days. In some embodiments, 30% to 99% of the second medium is changed at a time interval selected from the group consisting of 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days.

[0731] In some embodiments, the TCR agonists and agonists of a T cell costimulatory molecule are attached to the same polymer chains. In some embodiments, the TCR agonists and agonists of a T cell costimulatory molecule are attached to different polymer chains. In some embodiments, the TCR agonists are attached to the matrices at about 25 µg per mg of matrix. In some embodiments, the agonist of a T cell costimulatory molecule is attached to the matrices at about 25 µg per mg of matrix.

[0732] In some embodiments, the nanomatrix further comprises magnetic, paramagnetic or superparamagnetic nanocrystals embedded among or within the matrices of polymer chains. In some embodiments, the matrices of polymer chains comprise a polymer of dextran. In certain embodiments, the polymer chains are colloidal polymer chains.

[0733] In some embodiments, the population of TILs further comprises tumor cells. In some embodiments, the population of TILs cultured with the nanomatrix further comprises tumor cells. In some embodiments, the ratio of volume of nanomatrix to volume of TILs is greater than or equal to 1:5. In some embodiments, the ratio of number of matrices to TILs is greater than or equal to 1:500.

[0734] In some embodiments, the soluble monospecific complexes are tetrameric antibody complexes (TACs). In some embodiments, each TAC comprises two antibodies from a first animal species bound by two antibody molecules from a second species that specifically bind to the Fc portion of the antibodies from the first animal species.

[0735] In some embodiments, the agonists are recombinant agonists. In some embodiments, the TCR agonist is a CD3 agonist. In some embodiments, the TCR agonist is an antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the TCR agonist is an antibody such as, e.g., OKT3 or UCHT1.

[0736] In some embodiments, the feeder cells are peripheral blood mononuclear cells. In some embodiments, the feeder cells are antigen presenting cells.

[0737] In some embodiments, the feeder cells express the TCR agonist. In some embodiments, the feeder cells express an agonist of a T cell costimulatory molecule. In specific embodiments, the TCR agonist and/or agonist of a T cell costimulatory molecule are expressed on the surface of the feeder cells. In one embodiment, the agonist of a T cell costimulatory molecule is a CD28 agonist. In one embodiment, the agonist of a T cell costimulatory molecule is a CD137 agonist. In one embodiment, the agonist of a T cell costimulatory molecule is a CD2 agonist.

[0738] In some embodiments, a 4-1BB ligand is expressed on the surface of the feeder cells.

[0739] In some embodiments, the feeder cells are genetically modified to express IL-15, IL-7, or both IL-15 and IL-7.

[0740] In some embodiments, the methods described herein do not comprise the use of feeder cells during expansion of the population of TILs.

[0741] In some embodiments, the soluble monospecific complexes are at a concentration of about 0.2 to about 25 $\mu\text{L/ml}$.

[0742] In some embodiments, the disaggregated tumor sample comprises digested tumor fragments. In some embodiments, the disaggregated tumor sample comprises tumor fragments that are 0.5 to 4 mm^3 in size.

[0743] In some embodiments, the disaggregated tumor sample was previously exposed to a pre-REP step that produced less than 100,000 TILs. In some embodiments, the disaggregated tumor sample was previously exposed to a pre-REP step that expanded TILs present in the disaggregated tumor sample by less than 5-fold.

[0744] In some embodiments, members of the population of TILs are modified by a gene-regulating system. In some embodiments, the members of the population of TILs are modified using RNA interference. In some embodiments, the members of the population of TILs are modified using a transcription activator-like effector nuclease (TALEN). In some embodiments, the members of the population of TILs are modified using a zinc-finger nuclease. In one embodiment, the members of the population of TILs are modified using an RNA-guided nuclease.

In some embodiments, members of the population of TILs are modified using a Cas enzyme, such as e.g., Cas9, and at least one guide RNA.

[0745] In some embodiments, members of the population of TILs are modified at one or more genes selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. In some embodiments, members of the population of TILs are modified at one or more genes selected from the group consisting of *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, the modification at a one or more genes is an insertion, deletion, or mutation of one or more nucleic acids. In some embodiments, the modification at a single gene is an epigenetic modification, such as e.g., a histone modification. In some embodiments, the modification at a single gene is methylation of one or more nucleic acids. In one embodiment, the modification at a single gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

[0746] In some embodiments, members of the population of TILs are modified at the *SOCS1* gene. In some embodiments, the modification of the *SOCS1* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

[0747] In some embodiments, members of the population of TILs are modified at the *SOCS1* gene and the *ZC3H12A* gene. In some embodiments, the modification of the *SOCS1* gene and the *ZC3H12A* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene.

[0748] In some embodiments, members of the population of TILs are modified at more than one gene. In some embodiments the two or more genes are selected from the group consisting of *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*, *PTPN22*, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*. In some embodiments, members of the population of TILs are modified at two or more genes selected from the group consisting of *SOCS1*, *PTPN2*, *ZC3H12A*, *CBLB*, *RC3H1* and *NFKBIA*. In some embodiments, members of the population of TILs are modified at the *SOCS1* gene and one or more additional genes. In some embodiments, members of the population of TILs are modified at the

SOCS1 and *ZC3H12A*, *PTPN2*, *CBLB*, *RC3H1* or *NFKBIA*. In a specific embodiment, members of the population of TILs are modified at the *SOCS1* and *PTPN2* genes. In a specific embodiment, members of the population of TILs are modified at the *SOCS1* and *ZC3H12A* genes. In some embodiments, the modification of the *SOCS1* and *ZC3H12A*, *PTPN2*, *CBLB*, *RC3H1* or *NFKBIA* genes results in the reduction or inhibition of expression of the genes and/or function of proteins encoded by the genes.

[0749] In some embodiments, the TILs are expanded for up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days. In some embodiments, the population of TILs is expanded for 9-25 days, 9-21 days, or 9-14 days. In some embodiments, the population of TILs is expanded 500 to 500,000-fold. In some embodiments, the population of TILs is expanded from an initial population of TILs of 100 to 100,000 TILs. In some embodiments, the population of TILs is expanded at least 1,500-fold by day 14 of the expansion. In some embodiments, the population of TILs is expanded at most 100,000-fold by day 14 of expansion. In some embodiments, the population of TILs is expanded at least 15,000-fold by day 21 of the expansion. In some embodiments, the population of TILs is expanded at most 500,000-fold by day 21 of expansion.

[0750] In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 10% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein at least 15% of the expanded population have a central memory T cell phenotype. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 5 to 50% of the expanded population have a central memory T cell phenotype at day 14 of expansion. In some embodiments, the population of TILs is expanded to produce an expanded population of TILs, wherein 10 to 25% of the expanded population have a central memory T cell phenotype at day 14 of expansion.

[0751] In some embodiments, the population of TILs is isolated from a subject and contacted with the first medium without an additional expansion process of the population of TILs prior to contacting the population of TILs with the first medium. In some embodiments, the population of TILs is isolated from a subject and contacted with the culture medium without an additional expansion process of the population of TILs prior to contacting the population of TILs with the culture medium.

[0752] In some embodiments, the exhaustion of the cultured population of TILs is reduced and/or the cytotoxicity of the cultured population of TILs is increased. In some embodiments, the population of TILs is modified at the *SOCS1* gene. In some embodiments, the population of TILs is modified at the *SOCS1* gene and the *ZC3H12A* gene. In some embodiments,

the modification of the *SOCS1* and/or the *ZC3H12A* gene results in the reduction or inhibition of expression of the gene and/or function of a protein encoded by the gene. In some embodiments, the population of TILs comprise a reduction in expression of one or more exhaustion related genes selected from *PTGER2*, *FASLG*, *TNFRSF9*, *IRF4*, *CTLA4*, *EOMES*, *PDPN*, *LAG3*, *TNFSF9*, *CD86*, *TIGIT*, *HAVCR2*, *CASP3*, *PROCR*, *MDFIC*, *CCL3*, *CD160*, *BATF*, *TOX*, *CD244*, *B3GAT1*, *KLRG1*, *LILRB4* and *PDCD1* relative to TILs modified at the *SOCS1* gene and cultured in culture medium without IL-15. In some embodiments, the expression levels of one or more cytotoxicity related genes selected from *ITGB2*, *CSF2*, *TNF*, *FASLG*, *TNFRSF10B*, *LCK*, *IFNG*, *IFNB1*, *BID*, *GZMB*, *PRF1*, *KLRK1*, *ZAP70*, *FYN*, *GZMA*, *VAV3*, *GZMH*, *GZMM*, *KIR3DL1*, *IFNGR2*, *VAV1*, *SOS2*, *PTPN6*, *PTK2B*, *SH3BP2*, *LAT*, *KLRC2*, *IFNA1*, *CASP3*, *ICAM1*, *SH2D1A*, *ARAF*, *NFATC1*, *IFNAR1*, *NCR1*, *NCR3*, *IFNGR1*, *NCR2*, *TYROBP*, *FCGR3B*, *KLRD1*, *FAS*, *CD244*, *RAC2* and *CD247* are increased relative to TILs un-modified at the *SOCS1* gene and cultured in culture medium with IL-15. In some embodiments, the exhaustion score is reduced. In some embodiments, the cytotoxicity score is increased. In some embodiments, the exhaustion score is reduced, and the cytotoxicity score is increased.

[0753] In another aspect, the present disclosure provides compositions comprising an expanded population of TILs produced by any of the methods disclosed herein.

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions featured in the invention and are not intended to limit the scope of what the inventors regard as their invention.

Example 1: Two step methods for expanding TILs

[0754] TILs from at least 5 independent subjects were expanded using a two-step method. In the first step, the TILs were expanded from single cell suspensions of primary human melanoma metastases by incubating the cells in the presence of 6000 U/ml recombinant human IL-2 for up to 5 weeks. The expanded TILs are referred to as pre-REP TILs. In this example, pre-REP TILs were subsequently edited with CRISPR/Cas9 at the *OR1A1* locus, a gene not expressed in T cells.

[0755] In the second step, pre-REP TILs were expanded in a REP as follows. On Day 0 of the REP, 100,000 live pre-REP TILs were taken and seeded into the wells of a 24 well Grex plate (Wilson Wolf, Cat#80192M) in a 6 ml volume of TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum) containing 20M previously irradiated

(6,000 rads) pooled PBMC feeder cells (from five healthy donors in a 1:1:1:1:1 ratio) and further supplemented with 180 ng OKT3 (Biolegend Cat#317326). Subsequently, to the “conventional process” wells was added recombinant human IL-2 (CellGenix, Cat#1020-1000) to a final concentration of 6000 U/ml. To the “IL15 Process” wells was added recombinant human IL-15 (Peprotech Cat#200-15) to a final concentration of 1000 ng/ml. To the “IL7/15 process A” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 300 ng/ml, respectively. To the “IL7/15 process B” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 1000 ng/ml, respectively.

[0756] On Day 2 of the REP, to the “conventional process” wells was added recombinant human IL-2 (CellGenix, Cat#1020-1000) to a final concentration of 6000U/ml, assuming consumption of previously added cytokine. To the “IL15 Process” wells was added recombinant human IL-15 (Peprotech Cat#200-15) to a final concentration of 1000 ng/ml, assuming consumption of previously added cytokine. To the “IL7/15 process A” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 300 ng/ml, respectively, assuming consumption of the previously added cytokines. To the “IL7/15 process B” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 1000 ng/ml, respectively, assuming consumption of the previously added cytokines.

[0757] On Day 5 of the REP, a 50% media exchange was performed by removing 3ml of the media from the wells and replacing with 3ml of fresh REP media. Subsequently, to the “conventional process” wells was added recombinant human IL-2 (CellGenix, Cat#1020-1000) to a final concentration of 6000 U/ml, assuming consumption of previously added cytokine. To the “IL15 Process” wells was added recombinant human IL-15 (Peprotech Cat#200-15) to a final concentration of 1000 ng/ml, assuming consumption of previously added cytokine. To the “IL7/15 process A” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 300 ng/ml, respectively, assuming consumption of the previously added cytokines. To the “IL7/15 process B” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 1000 ng/ml, respectively, assuming consumption of the previously added cytokines.

[0758] On Day 7 of the REP, cells were transferred to a 6-well Grex plate (Wilson Wolf, Cat#80660M). To each well was added 90ml of REP media. Subsequently, to the “conventional process” wells was added recombinant human IL-2 (CellGenix, Cat#1020-1000) to a final concentration of 6000 U/ml, assuming consumption of previously added cytokine. To the “IL15 Process” wells was added recombinant human IL-15 (Peprotech Cat#200-15) to a final concentration of 1000 ng/ml, assuming consumption of previously added cytokine. To the “IL7/15 process A” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 300 ng/ml, respectively, assuming consumption of the previously added cytokines. To the “IL7/15 process B” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 1000 ng/ml, respectively, assuming consumption of the previously added cytokines.

[0759] On Day 9 of the REP, a 50% media exchange was performed by removing 50ml of media and replacing it with 50ml of fresh REP media. Subsequently, to the “conventional process” wells was added recombinant human IL-2 (CellGenix, Cat#1020-1000) to a final concentration of 6000U/ml, assuming consumption of previously added cytokine. To the “IL15 Process” wells was added recombinant human IL-15 (Peprotech Cat#200-15) to a final concentration of 1000 ng/ml, assuming consumption of previously added cytokine. To the “IL7/15 process A” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 300 ng/ml, respectively, assuming consumption of the previously added cytokines. To the “IL7/15 process B” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 1000 ng/ml, respectively, assuming consumption of the previously added cytokines.

[0760] On day 12 of the REP, 70ml of media was removed from the wells. Cells were resuspended in the remaining 30ml of media and split 1:3 such that 3 independent wells of a 6-well Grex plate could be seeded from a single well by transferring 10ml of cell suspension to the new wells. 90ml of fresh REP media was added to each well. Subsequently, to the “conventional process” wells was added recombinant human IL-2 (CellGenix, Cat#1020-1000) to a final concentration of 6000 U/ml, assuming consumption of previously added cytokine. To the “IL15 Process” wells was added recombinant human IL-15 (Peprotech Cat#200-15) to a final concentration of 1000 ng/ml, assuming consumption of previously added cytokine. To the “IL7/15 process A” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 300 ng/ml,

respectively, assuming consumption of the previously added cytokines. To the “IL7/15 process B” wells was added recombinant human IL-7 (Peprotech, Cat#200-07) and recombinant human IL-15 (Peprotech, Cat#200-15) to a final concentration of 10 ng/ml and 1000 ng/ml, respectively, assuming consumption of the previously added cytokines.

[0761] On day 14 of the REP, cells were harvested and counted. Cell fold expansions and viabilities are represented in **FIGS. 1A-1B**. REP of cells in media containing IL-7 and IL-15 supported cell expansion and increased viability, when compared to REPs in IL2 containing media.

Example 2: Phenotypic characterization of TILs generated in Example 1

[0762] The cellular composition of TILs after the TIL expansion process was assessed by flow cytometry (**FIGS. 2A-2B**). Cells were cultured as in Example 1, and an aliquot of cells was stained on day 14 post initiation of the REP with antibodies to detect cells that express CD45, CD3e, CD8, CCR7, and CD45RO. REP of cells in IL-15 or IL7/IL15 containing medias did not significantly impact the proportion of TILs that were CD8+ (**FIG. 2A**) compared to REP in IL2 containing media. However, a significant increase in the proportion of TILs that were designated as “T central memory cells” (defined as CD45+ CCR7+ CD45RO+) (**FIG. 2B**) was observed when REPs were carried out in IL15 or IL7/15 containing media, compared to REPs carried out using IL2 containing media.

Example 3: Polyfunctionality of TILs produced using IL7/IL15 process

[0763] Cytokine driven expansion of T cells can lead to terminal differentiation, which is associated with a loss in functionality of T cells such that they are no longer protective. In particular, it has been observed that the most effective, potent anti-tumor T cells maintain the ability to produce IFN γ , TNF α , IL-2, as well as degranulate in response to stimulation. To determine polyfunctionality of TILs generated in IL7/IL15 REP containing methods, TILs produced as in Example 1 were stimulated for 4 hours with a PMA/Ionomycin cell stimulation cocktail (Invitrogen Cat# LS00497003). During the stimulation, a fluorescent anti-CD107a antibody was incubated with the cells to identify cells that are actively degranulating in response to stimulation. Subsequently, cells were fixed and stained intracellularly for the production of IFN γ , IL-2, and TNF α . Of note, CD8+ TILs generated using the IL7/IL15 process demonstrated maintenance of ability to degranulate (**FIG. 3A**) with a high degree of polyfunctionality. Many CD107a+ cells were IFN γ + IL-2+ (**FIG. 3B**), CD107a+ TNF α + IL-2+ (**FIG. 3C**), and CD107a+ IFN γ + TNF α + (**FIG. 3D**). Cells generated with the highest doses of IL-15 trended toward increased polyfunctionality. Similarly, CD4 T cells within the TIL population generated using the

IL7/IL15 REP process also maintained a polyfunctional cytokine secretion profile comparable to those generated in the IL2 REP process.

Example 4: Methods to genetically engineer and subsequently expand TILs using CRISPR-Cas9

[0764] TILs expanded using the protocols described in Example 1 were genetically engineered using CRISPR-Cas9 to create functional genetic knockouts of a target gene. This genetic engineering was performed after the pre-REP expansion, but before the cells were seeded into the REP. Briefly, pre-REP TILs were centrifuged at 300xg for 5 minutes, and resuspended to 30M cells/ml in MaxCyte electroporation buffer (HyClone Cat#EPB1). Subsequently, a ribonucleoprotein (RNP) master mix was made containing 52 pmol Cas9 protein (Aldevron, Cat#9212) and 240 pmol of sgRNA targeting the *OR1A1*, *SOCS1*, or *PTPN2* loci, or a combination of 120 pmol *SOCS1* and 120 pmol *PTPN2* was made. The RNP mastermix was made as follows: A 100 μ M solution of sgRNA was made by resuspending lyophilized sgRNA in Nuclease Free Duplex Buffer (IDT Cat#1072570). Reagents were added as shown in Table 38 for OR1A1 or SOCS1:

Table 38. RNP mastermix for *OR1A1* or *SOCS1* targeting.

	Vol (μ L)
OR1A1 (Guide Sequence GCTGACCAGTAACTCCCAGG (SEQ ID NO:912) or SOCS1 (Guide Sequence ACGCCTGCGGATTCTACTGG (SEQ ID NO: 70) sgRNA (100 μ M)	9.6
Cas9 (61 μ M)	3.4
DPBS (1X)	7

[0765] Reagents were added as shown in Table 39 for the combination of *SOCS1* and *PTPN2*:

Table 39. RNP mastermix for *SOCS1* and *PTPN2* targeting.

	Vol (μ L)
SOCS1 (Guide Sequence ACGCCTGCGGATTCTACTGG (SEQ ID NO; 70)) sgRNA (100 μ M)	4.8

PTPN2 (Guide Sequence GGAAACTTGGCCACTCTATG (SEQ ID NO; 206) sgRNA (100 μM)	4.8
Cas9 (61 μM)	3.4
DPBS (1X)	7

[0766] The entire 20 μ L of the RNP master mix was added to 80 μ L of cell suspension (at 30M cells/ml). The complete 100 μ L reaction was then transferred to an OC100 X 2 processing assembly (MaxCyte, Cat#SOC-1X2). Cells were electroporated on a MaxCyte ExPERT electroporator using the “Optimization #9” program. Subsequently, 100 μ L REP media was added to the well and cells were transferred to a 96-well plate containing 100 μ L REP media, which was then incubated at 37 °C for 20 minutes. Subsequently, cells were counted, and 100K live cells were then seeded into a 24 well Grex plate containing 6 ml TIL media supplemented with either 6,000 U/ml IL-2 (Conventional Process), 1000ng/ml IL15 (IL15 Process), 10ng/ml IL7 and 300ng/ml IL15 (IL7/15 process A) or 10 ng/ml IL-7 and 1000 ng/ml IL15 (IL7/IL15 Process B). Cells were then cultured as in Example 1 through the REP.

[0767] The degree to which TILs were edited by the process was assessed post REP, using next generation amplicon sequencing. On average, across at least 5 subjects and multiple repeats, editing efficiencies at the *OR1A1* locus (when single editing) ranged from 53-87%, editing efficiencies at the *SOCS1* locus (when single editing) ranged from 75-93%, editing efficiencies at the *SOCS1* locus (when dual editing) were 91-93%, and editing efficiencies at the *PTPN2* locus (when dual editing) were 92-94%. Editing efficiency was not dramatically impacted by cytokine conditions in REP.

[0768] The cytokines present during the REP did impact the TIL yields for some of the cells. On average, REP of OR1A1-edited T cells in IL15 or IL7 and IL15 containing media produced at least as many TIL as REP of those same cells in IL2 (**FIG. 4A**). When TILs were edited for *SOCS1* and subsequently expanded, REP in IL15-containing or IL7 and IL15-containing media led to an approximately 1.5X increase in cell yields compared to the cells expanded in IL-2 (**FIG. 4B**). When cells were dual-edited for *SOCS1* and *PTPN2* and subsequently expanded, compared to the conventional process, the IL15 process led to a ~1.5-fold increase in cell yields, the IL7/15 Process A led to a ~2-fold increase in cell yields, and the IL7/15 process B led to a ~3-fold increase in cell yields (**FIG. 4C**)

Example 5: Two step methods for expanding tumor infiltrating lymphocytes (TILs) using artificial antigen presenting cells

[0769] TILs are expanded using a two-step method. In the first step, the TILs are expanded from single cell suspensions of primary human melanoma metastases by incubating the cells in the presence of 6000 U/ml recombinant human IL-2, or in the presence of 10 ng/ml IL-7 and 1000 ng/ml IL-15 for up to 5 weeks. These are referred to as pre-REP TILs.

[0770] In the second step, pre-REP TILs are expanded in a modified REP as follows. On Day 0 of the REP, 100,000 live pre-REP TIL are taken and seeded into the wells of a 24 well Grex plate (Wilson Wolf, Cat#80192M) in a 6 ml volume of TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum) containing 100,000 to 20M previously irradiated (15,000 rads) artificial antigen presenting cells. Artificial antigen presenting cells are tumor cells, such as K562 cells, that have been previously modified to additionally express OS8 (membrane bound OKT3), and additionally CD80, CD86, 41BBL, and/or IL-15 receptor alpha. Media is further supplemented with 1-50 ng/ml IL-7 and/or 500-2000 ng/ml IL-15. Media can be further supplemented with about 10 ng/ml IL-7 and/or about 1000 ng/ml IL-15.

[0771] On Day 2 of the modified REP, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0772] On Day 5 of the REP, a 50% media exchange is performed by removing 3ml of the media from the wells and replacing with 3ml of fresh REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0773] On Day 7 of the REP, cells are transferred to a 6-well Grex plate (Wilson Wolf, Cat#80660M). To each well is added 90ml of REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are being added, assuming consumption of previously added cytokines.

[0774] On Day 9 of the REP, a 50% media exchange is performed by removing 50ml of media and replacing it with 50ml of fresh REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0775] On day 12 of the REP, 70ml of media is removed from the wells. Cells are resuspended in the remaining 30ml of media and split 1:3 such that 3 independent wells of a 6-well Grex plate are seeded from a single well by transferring 10ml of cell suspension to the new wells. 90ml of fresh REP media is added to each well. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0776] On day 14 of the REP, cells are harvested and counted.

Example 6: Expansion of TILs using IL7/IL15 in a 1 step, PBMC feeder free method (K562)

[0777] TILs are expanded directly from single cell suspensions of primary human melanoma metastases. On Day 0 of the culture, single cell suspensions are taken and seeded into the wells of a 24 well Grex plate (Wilson Wolf, Cat#80192M) in a 6 ml volume of TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum) and supplemented with 1-50 ng/ml recombinant IL-7 and 500-2000 ng/ml IL-15. Media can be further supplemented with about 10 ng/ml IL-7 and/or about 1000 ng/ml IL-15. Further added to the wells are artificial antigen presenting cells (aAPC), such as K562 cells, which have been modified to express OS8 (membrane bound OKT3), CD80, CD86, and/or 41BBL. Cells are seeded such that there is a 1 T cells:1 aAPC to a 1 T cell: 200 aAPC ratio.

[0778] On Day 2 of the expansion, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0779] On Day 5 of the expansion, a 50% media exchange is performed by removing 3ml of the media from the wells and replacing with 3ml of fresh REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are being added, assuming consumption of previously added cytokines.

[0780] On Day 7 of the expansion, cells are transferred to a 6-well Grex plate (Wilson Wolf, Cat#80660M). To each well is added 90ml of REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0781] On Day 9 of the expansion, a 50% media exchange is performed by removing 50ml of media and replacing it with 50ml of fresh REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0782] On day 12 of the expansion, 70ml of media is removed from the wells. Cells are resuspended in the remaining 30ml of media and split 1:3 such that 3 independent wells of a 6-well Grex plate are seeded from a single well by transferring 10ml of cell suspension to the new wells. 90ml of fresh REP media is added to each well. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are being added, assuming consumption of previously added cytokines.

[0783] On day 14 of the expansion, cells may be harvested in some cases. In other cases, cells may be further expanded by continued culture in the presence of 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 for up to 2 more weeks.

Example 7: Expansion of TILs using IL2 in a 1 step, PBMC feeder free method (K562)

[0784] TILs are expanded directly from single cell suspensions of primary human melanoma metastases. On Day 0 of the culture, single cell suspensions are taken and seeded into the wells of a 24 well Grex plate (Wilson Wolf, Cat#80192M) in a 6 ml volume of TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum) and supplemented with 6000U/ml recombinant human IL-2. Further added to the wells are artificial antigen presenting cells (aAPC), such as K562 cells, which have been modified to express OS8 (membrane bound OKT3), CD80, CD86, and/or 41BBL. Cells are seeded such that there is a 1 T cells:1 aAPC to a 1 T cell: 25 aAPC ratio.

[0785] On Day 2 of the expansion, 6000 U/ml recombinant human IL-2 are added, assuming consumption of previously added cytokines.

[0786] On Day 5 of the expansion, a 50% media exchange is performed by removing 3ml of the media from the wells and replacing with 3ml of fresh REP media. Subsequently, 6000 U/ml recombinant human IL-2 are added, assuming consumption of previously added cytokines.

[0787] On Day 7 of the expansion, cells are transferred to a 6-well Grex plate (Wilson Wolf, Cat#80660M). To each well is added 90ml of REP media. Subsequently, 6000 U/ml recombinant human IL-2 are added, assuming consumption of previously added cytokines.

[0788] On Day 9 of the expansion, a 50% media exchange is performed by removing 50ml of media and replacing it with 50ml of fresh REP media. Subsequently, 6000 U/ml recombinant human IL-2 are added, assuming consumption of previously added cytokines.

[0789] On day 12 of the expansion, 70ml of media is removed from the wells. Cells are resuspended in the remaining 30ml of media and split 1:3 such that 3 independent wells of a 6-well Grex plate are seeded from a single well by transferring 10ml of cell suspension to the new wells. 90ml of fresh REP media is added to each well. Subsequently, 6000 U/ml recombinant human IL-2 are added, assuming consumption of previously added cytokines.

On day 14 of the expansion, cells may be harvested in some cases. In other cases, cells may be further expanded by continued culture in the presence of 6000 U/ml recombinant human IL-2 for up to 2 more weeks.

Example 8: Robust rapid expansion of peripheral blood derived memory T cells in an PBMC feeder cell-free method

[0790] Peripheral blood derived human memory T cells were expanded using artificial antigen presenting cells. Briefly, memory CD4 and CD8 T cells were isolated (from equal numbers of PBMCs) from 3 independent donors using magnetic selection kits (Stemcell technologies,

Cat#19157 and #19159), and combined (by donor) to form a pool of pan CD4 and CD8 memory T cells. 500,000 memory T cells per donor (with 2 replicates) were seeded together with either irradiated (15,000 rads) parental K562 cells, OS8- and CD86-expressing K562 artificial antigen presenting cells, or with OS8-, CD86-, and 41BBL-expressing artificial antigen presenting cells in ratios ranging from 1 T cell:10 K562 to 1 T cell: 50 K562 cells in X-VIVO15 (Lonza Cat#04-418Q) media containing 6000U/ml recombinant human IL-2. As a comparator, 500,000 memory T cells were seeded on irradiated PBMCs (pooled from 5 donors in a 1:1:1:1:1 ratio) at a 1 T cells:100 PBMC ratio, in media containing 6000U/ml recombinant human IL-2 and 30ng/ml soluble OKT3. Cells were all seeded into individual wells of a G-rex 6M well plate (Wilson Wolf Cat# 80660M) in a 100ml final volume.

[0791] On day 2 of the culture, IL2 was added to all conditions to 6000 U/ml, assuming consumption the previously added cytokine.

[0792] On day 4 of the culture, 50% of the media was removed, and replaced with fresh media. IL2 was added to a final concentration of 6000 U/ml, assuming consumption of the previously added cytokine.

[0793] On day 7 of the culture, 70% of the media was removed, and the cells were resuspended in the remaining 30 ml. Cells were split 1:3 by taking 10ml of this cell suspension and transferring to a new well of a G-rex 6M well plate. 90ml of X-VIVO 15 fresh media was added, and 6000 U/ml recombinant human IL2 was added, assuming consumption of the previously added cytokine.

[0794] On day 9 of the culture, 70% of the media was removed, and the cells were resuspended in the remaining 30 ml. Cells were split 1:6 by taking 5ml of this cell suspension and transferring to a new well of a G-rex 6M well plate. 95ml of X-VIVO 15 fresh media was added, and 6000 U/ml recombinant human IL2 was added, assuming consumption of the previously added cytokine.

[0795] On day 12 of the culture, 70% of the media was removed, and the cells were resuspended in the remaining 30 ml. Cells were split 1:3 by taking 10ml of this cell suspension and transferring to a new well of a G-rex 6M well plate. 90ml of X-VIVO 15 fresh media was added, and 6000 U/ml recombinant human IL2 was added, assuming consumption of the previously added cytokine.

[0796] On day 14 of the culture, cells were harvested and counted. Cells in PBMC and aAPC conditions demonstrated viabilities greater than 91%. During the 14-day expansion, cells cultured with artificial antigen presenting cells robustly expanded. Memory T cells cultured with K562 cells expressing CD86 and membrane bound anti-CD3, as well as those cultured with K562

cells expressing 41BBL, CD86, and membrane bound anti-CD3 expanded significantly better than those cells cultured with parental K562 cells (**FIGS. 5A-5C**). Expansion was robustly supported by culture at 1:10 (**FIG. 5A**), 1:25 (**FIG. 5B**), and 1:50 (**FIG. 5C**) responding T cell to K562 ratios. Furthermore, the fold expansion observed approached, and in some cases exceeded, that observed when cells were cultures with irradiated PBMCs + soluble OKT3, which was the REP positive control.

Example 9: Expansion of TILs using IL7/IL15 using feeder-free methods

[0797] TILs are expanded directly from single cell suspensions of primary human melanoma metastases. On Day 0 of the culture, single cell suspensions derived from primary tumor samples are taken and seeded into the wells of a 24 well Grex plate (Wilson Wolf, Cat#80192M) in a 6 ml volume of TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum), and further supplemented with 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15. To the wells are subsequently added the following:

- TIL Expansion Method A (“Stemcell”) – Anti-CD3/anti-CD2/anti-CD28 tetrameric antibody complex (TAC) from Stemcell Technologies (Cat # 10970) are added to the TILs, for a final concentration of 0.01-25 μ L/ml.
- TIL Expansion Method B (“Transact”) – A colloidal polymeric nanomatrix covalently attached to humanized recombinant agonists against human CD3 and CD28 from Miltenyi Biotec (MACS GMP T Cell Transact, Cat # 130-019-011) is added to the TILs, for a final concentration of 0.01-100 μ L/ml.

[0798] For both TIL expansion methods outlined above, a common protocol was followed at discrete time intervals with variations for each method indicated below:

[0799] On Day 2 of the expansion, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are being added, assuming consumption of previously added cytokines.

[0800] On Day 5 of the expansion, a 50% media exchange is performed by removing 3ml of the media from the wells and replacing with 3ml of fresh REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0801] On Day 7 of the expansion, cells are transferred to a 6-well Grex plate (Wilson Wolf, Cat#80660M). To each well is added 90ml of REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are being added, assuming consumption of previously added cytokines.

[0802] On Day 9 of the expansion, a 50% media exchange is performed by removing 50ml of media and replacing it with 50ml of fresh REP media. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are being added, assuming consumption of previously added cytokines.

[0803] On day 12 of the expansion, 70ml of media is removed from the wells. Cells are resuspended in the remaining 30ml of media and split 1:3 such that 3 independent wells of a 6-well Grex plate are seeded from a single well by transferring 10ml of cell suspension to the new wells. 90ml of fresh REP media is added to each well. Subsequently, 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 are added, assuming consumption of previously added cytokines.

[0804] On day 14 of the expansion, cells may be harvested in some cases. In other cases, cells may be further expanded by continued culture in the presence of 10-1000 ng/ml IL-7 and/or 10-1000 ng/ml IL-15 for up to 2 more weeks.

Example 10: Transcriptional analysis of TILs

[0805] The cellular composition of TILs after the TIL expansion processes shown above was assessed by the NanoString nCounter CAR-T Characterization Panel. An aliquot of cells from 5 donors expanded either by "conventional process" or "IL-15 Process", as described in Example 1, were pelleted and frozen prior to RNA isolation. One aliquot was made for *OR1A1*-edited TILs and one for *SOCS1*-edited TILs. For one donor, a technical replicate was made to assess concordance between the two samples for quality control. RNA isolation was performed using the Arcturus PicoPure RNA Isolation Kit with on-column DNase treatment. Normalized RNA was then used for mRNA:probe hybridization in an nCounter system. Raw counts were normalized, grouped, and analyzed for pathway enrichment using nSolver Analysis Software 4.0.

[0806] TILs that were *OR1A1*-edited and then cultured in IL-15 had significantly lower expression of T-cell exhaustion markers than their IL-2-cultured counterparts (8 + 1 % decrease in score, $p = 0.002$; FIG. 6). Exhaustion and cytotoxicity scores were calculated using NanoString nSolver software according to the teachings of Tomfohr J, Lu J, Kepler TB, Pathway level analysis of gene expression using singular value decomposition, BMC Bioinformatics. 2005;6:225. The exhaustion score is composed of pre-annotated genes whose expression are indicators of an exhausted state, for example *PTGER2*, *FASLG*, *TNFRSF9*, *IRF4*, *CTLA4*, *EOMES*, *PDPN*, *LAG3*, *TNFSF9*, *CD86*, *TIGIT*, *HAVCR2*, *CASP3*, *PROCR*, *MDFIC*, *CCL3*, *CD160*, *BATF*, *TOX*, *CD244*, *B3GAT1*, *KLRG1*, *LILRB4* and *PDCD1* among others. Consistent with a less-activated state, these IL-15-expanded TILs were depleted in pre-annotated genes that compose the cytotoxicity score (120 + 30% decrease, $p = 0.001$; FIG. 7), including *PTGER2*, *FASLG*, *TNFRSF9*, *IRF4*, *CTLA4*,

EOMES, *PDPN*, *LAG3*, *TNFSF9*, *CD86*, *TIGIT*, *HAVCR2*, *CASP3*, *PROCR*, *MDFIC*, *CCL3*, *CD160*, *BATF*, *TOX*, *CD244*, *B3GAT1*, *KLRG1*, *LILRB4* and *PDCD1*. When *SOCS1*-edited TILs cultured in IL-15 were compared to *OR1A1*-edited TILs in IL-2, a $4.6 \pm 0.8\%$ decrease in Exhaustion score was noted ($p = 0.003$), however no significant drop in cytotoxicity score was observed ($p > 0.05$). *SOCS1*-editing therefore reversed the negative impact of IL-15 on cytotoxicity score (**FIG. 7**) while still reducing T cell exhaustion score (**FIG. 6**), possibly through the activation of *IFNG* and Type II Interferon signaling (**FIG. 8**). Values represent mean $\pm$ SEM and statistical significance was assessed by one-way ANOVA with Dunnetts multiple comparisons tests (* $p < 0.05$).

Example 11: Methods for expanding pre-REP failure TILs with soluble activators or artificial antigen presenting cells (aAPCs)

[0807] Tumor infiltrating lymphocytes (TILs) were expanded directly from single cell suspensions of primary human melanoma metastases. TILs were obtained from three different donors: Donor 3239, Donor 6752, and Donor 6755. Donor 6752 and Donor 6755 were previously identified as pre-REP failures, unable to expand to 4×10^7 cells in 23 days in a pre-REP. On Day 0 of the culture, 400,000-800,000 live cells from single cell suspensions were taken and seeded into the wells of a 24 well Grex plate (Wilson Wolf, Cat#80192M) in a 6 ml volume of TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum) and supplemented with 6,000 U/ml of recombinant human IL-2 (Peprotech, Cat#200-02) or 1000ng/ml IL-15 (Peprotech, Cat#200-15). The viable cells seeded per condition contained 22K to 52K CD3+ T cells as determined by flow cytometry. Cells were activated and expanded using five different methods, as described below:

- TIL Expansion Method 1 (“REP-like”) – One-step Rapid Expansion Protocol without pre-REP. Feeder cells (PBMCs) from five healthy donors were irradiated (6,000 rads) and pooled in a 1:1:1:1:1 ratio. 1×10^7 irradiated PBMCs were added to each well, as well as 360 ng of OKT3 (Biolegend, Cat #317326) for a final concentration of 60 ng/ml.
- TIL Expansion Method 3 (“Stemcell”) – Tetrameric Antibody Complexes (TAC) from Stemcell. 37.5 μ l of anti-CD3/anti-CD2/anti-CD28 tetrameric antibody complex (TAC) from Stemcell Technologies (Cat # 10970) was added to the TILs, for a final concentration of 6.25 μ l/ml.
- TIL Expansion Method 4 (“Transact”) – Nanomatrix from Miltenyi Biotec. 85 μ l of a colloidal polymeric nanomatrix covalently attached to humanized recombinant

agonists against human CD3 and CD28 from Miltenyi Biotec (MACS GMP T Cell Transact, Cat # 170-076-156) was added to the TILs, for a final dilution of 70:1.

- TIL Expansion Method 5 (“aAPC-OKT3”) – K562 cells engineered to express OKT3 were irradiated (15,000 rads). 1×10^6 irradiated aAPC-OKT3 cells were added to each well for a final cell to area ratio of 5×10^5 cells/cm².
- TIL Expansion Method 6 (“aAPC-OKT3-CD86”) – K562 cells engineered to express OKT3 and CD86 were irradiated (15,000 rads). 1×10^6 irradiated aAPC-OKT3 cells were added to each well for a final cell to area ratio of 5×10^5 cells/cm².

[0808] For all five TIL expansion methods outlined above, a common protocol was followed at discrete time intervals with variations for each method indicated below:

- Day 2: 36,000U of recombinant human IL-2 was added to each well, for a final concentration of 6,000 U/ml, assuming consumption to the corresponding wells. IL-15 was added at a final concentration of 1000 ng/ml to the corresponding wells assuming consumption.
- Day 4 and Day 6: 50% media was replaced/exchanged. From each well, 3 ml of cell supernatant was removed and discarded, being careful not to disturb the cells at the bottom of the well. Subsequently, 3 ml of fresh TIL media and 36,000 U of IL-2 was then added, for a final concentration of 6,000 U/ml, assuming consumption. IL-15 was added at a final concentration of 1000 ng/ml to the corresponding wells assuming consumption.
- Day 7: For all conditions, cells were counted. The entire volume (6 ml) was transferred to a 6 well Grex (Wilson Wolf) containing 100 ml TIL media with either 6000 U/ml IL-2 or 1000 ng/ml IL-15.
- Day 10 or Day 11: On Day 10 and Day 11, all aAPC samples and soluble activator samples were engineered using CRISPR-Cas9 as described in Example 4 respectively. Following electroporation, 2×10^5 cells were transferred to a 24 well Grex (Wilson Wolf) in 6 ml TIL media containing 6000 U/ml of IL-2 or 1000 ng/ml of IL-15.
- Day 13: 36,000 U of recombinant human IL-2 was added to each well, for a final concentration of 6,000 U/ml, assuming consumption to the corresponding wells. IL-15 was added at a final concentration of 1000 ng/ml to the corresponding wells assuming consumption.
- Day 15: 50% media was replaced/exchanged. From each well, 50 ml of cell supernatant was removed and discarded, being careful not to disturb the cells at the bottom of the well. Subsequently, 50 ml of fresh TIL media and 36,000 U of IL-2 was then added,

for a final concentration of 6,000 U/ml, assuming consumption. IL-15 was added at a final concentration of 1000 ng/ml to the corresponding wells assuming consumption.

- Day 18: Donor 3339 samples were harvested. Donor 6755 samples were harvested, samples olfactory (O), *SOCS1* (S), and *SOCS1+PTPN2* (S+P2) activated with aAPC-OKT3 or aAPC-OKT3-CD86 in IL-2 and IL-15 underwent a 50% media exchange as described on day 15. Donor 6752 samples underwent a 50% media exchange as described on day 15.
- Day 21: Remaining Donor 6755 samples and Donor 6752 samples underwent a 50% media exchange as described on day 15.
- Day 23: Remaining Donor 6755 samples and Donor 6752 samples were harvested.

Example 12: Methods to genetically engineer pre-REP failure TILs with soluble activators or aAPCs using CRISPR-Cas9

[0809] TILs expanded using the protocols described in Example 11 were genetically engineered using CRISPR-Cas9 to create functional genetic knockouts of a target gene. This genetic engineering was performed on day 10 of each method described in Example 11, and also on other days, ranging from day 0-21. Briefly, on day 10, 1.2×10^6 expanded TILs were centrifuged at 300xg for 5 minutes and resuspended with 20 μ l of MaxCyte electroporation buffer (HyClone Cat#EPB1). Several ribonucleoprotein (RNP) master mixes were made containing 52 pmol Cas9 protein (Aldevron, Cat#9212) and 120 pmol of each individual sgRNA. Master mix 1 contained the sgRNA for the OR1A2 gene (O) (IDT, AGATGATGTCAACCAAGGAG SEQ ID NO: 913). Master mix 2 contained the sgRNA for the *SOCS1* gene (S) (IDT, GACGCCTGCGGATTCTACTG SEQ ID NO: 61). Master mix 3 contained sgRNAs for the *SOCS1* gene (SEQ ID NO: 61) and *PTPN2* gene (IDT, GGAAACTTGCCACTCTATG SEQ ID NO: 206) (S+P2). 100 μ M solution of OR1A2 sgRNA was made by resuspending 10 nmol lyophilized sgRNA with 100 μ l Nuclease Free Duplex Buffer (IDT Cat#1072570). Reagents were added as follows:

	Vol (μ L)
sgRNA (100 μ M)	1.2
Cas9 (61 μ M)	0.84
DPBS (1X)	1.76

[0810] The entire 5 μ l of the RNP master mix was added to the 20 μ l cell suspension. 25 μ l of cell suspension was then transferred to an OC25 X 3 processing assembly (MaxCyte, 319/337

Cat#OC-25x3). Cells were electroporated on a MaxCyte ExPERT electroporator using the “Optimization #9” program. Subsequently, 25 μ l TIL were transferred to a 96-well plate, each chamber was washed with 25 μ L TIL media twice and transferred to the 96-well recovery plate, which was then incubated at 37 °C for 20 minutes. Subsequently, cells were counted, and 2×10^5 live cells were then seeded into a 24 well Grex plate containing 6 ml TIL media supplemented with 6,000 U/ml IL-2 or 1000ng/ml IL-15. Further cell manipulations were conducted beginning on day 13 as described in Example 11. On days 18 and 23, cells were harvested and counted. Cell pellets were frozen, and editing was determined by amplicon sequencing (**FIG. 12**).

Example 13: Phenotypic characterization of pre-REP failure TILs with soluble activators or aAPCs

[0811] The phenotype of T cells produced on day 18 or 23 was assessed. In particular, the proportion of cells that were defined as central memory T cell phenotype (T_{cm} , with marker phenotype CD45RO+ CCR7+ CD45RA-) was determined by flow cytometry. Cells cultured as in Example 11 were taken, and on day 18 or 23 an aliquot of cells was stained with fluorescently labeled antibodies that detect CD45RO, CCR7, and CD45RA. Compared to pre-RNP (cells prior to electroporation) Method 3 (Stemcell) and Method 4 (Transact) generated similar percentages of T_{cm} cells on day 18 or 23 (**FIG. 11**). The percentage of CD8+ T cells showed a general enrichment as compared to pre-RNP cells for all methods at day 18 or 23 (data not shown).

[0812] The fold expansion (**FIG. 9**) of TILs at day 10 or 11 (relative to the number of cells on Day 0) prior to electroporation was assessed for TILs expanded by the addition of IL-2 or IL-15 for the five methods described in Example 11. All donors, including the two pre-REP failures showed expansions greater than 2600-fold in methods 1, 3, 4, 5, and 6. *SOCS1* edited TILs showed greater mean fold expansion than olfactory and *SOCS1+PTPN2* edited TILs across all methods on days 18 or 23 (**FIG. 10**). Method 6 showed greater mean fold expansion of *SOCS1* edited TIL as compared to Method 5 on day 18 or 23.

Example 14: Methods for expanding TILs from a tumor fragment using a soluble activator

[0813] Tumor infiltrating lymphocytes (TILs) were expanded directly from frozen melanoma tumor fragments from primary patients. Tumor fragments were obtained from 2 donors: Donor D4462 and Donor D7283. On Day 0, tumor fragments were thawed and placed in a 10 cm² dish containing TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum). Fragments were weighed and then evenly split (by number of fragments) into two aliquots and each aliquot was placed in a well of a 24 well Grex plate (Wilson Wolf,

Cat#80192M). 6 mL of TIL media was added to each well containing a 1:70 dilution of GMP TransAct reagent (MACS GMP T Cell Transact, Cat # 170-076-156) in either 6000 U/mL IL-2 (Peprotech, Cat#200-02) or 1000 ng/mL IL-15 (Peprotech, Cat#200-15). Cells were cultured at 37 °C.

[0814] On Day 2 of the expansion, 36,000 U of recombinant human IL-2 was added to each well, for a final concentration of 6,000 U/ml, assuming consumption to the corresponding wells. IL-15 was added at a final concentration of 1,000 ng/mL to the corresponding wells assuming consumption.

[0815] On Day 6 of the expansion, for D7283 a 50% media was replaced/exchanged. From each well, 3 mL of cell supernatant was removed and discarded, being careful not to disturb the cells at the bottom of the well. Subsequently, 3mL of fresh TIL media and 36,000 U of IL-2 was then added to a final concentration of 6,000 U/ml to the corresponding wells assuming consumption. IL-15 was added to a final concentration of 1,000 ng/mL to the corresponding wells assuming consumption. For D4462, samples were engineered using CRISPR-Cas9 as described in Example 15. Following electroporation, 4×10^5 cells were transferred to a 24 well Grex (Wilson Wolf) in 6 mL TIL media containing 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15.

[0816] On Day 9 of the expansion, a 50% media was replaced/exchanged. From each well, 3 mL of cell supernatant was removed and discarded, being careful not to disturb the cells at the bottom of the well. Subsequently, 3 mL of fresh TIL media and 36,000 U of IL-2 was then added, for a final concentration of 6,000 U/ml, assuming consumption. IL-15 was added at a final concentration of 1,000 ng/mL to the corresponding wells assuming consumption.

[0817] On Day 10 of the expansion, for D4462, 3 mL of media was aspirated from each well of a 24 well Grex. The remaining 3 mL was added to a 6 well Grex (Wilson Wolf) containing 100 mL TIL media with 6,000 U/mL IL-2 or 1,000 ng/mL IL-15. For D7283, samples were engineered using CRISPR-Cas9 as described in Example 15. Following electroporation, 4×10^5 cells were transferred to a 24 well Grex (Wilson Wolf) in 6 mL TIL media containing 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15.

[0818] On Day 14 of the expansion, D4462 wells were harvested. D7283, 3 mL of media was aspirated from each well of a 24 well Grex. The remaining 3 mL was added to a 6 well Grex (Wilson Wolf) containing 100 mL TIL media with 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15.

[0819] On Day 17 of the expansion, D7283, 50 mL TIL media was removed and replaced with 50 mL fresh TIL media. 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15 was added to consumption.

[0820] On Day 20 of the expansion, D7283 wells were harvested.

Example 15: Methods to genetically engineer fragment expanded TILs with soluble activators using CRISPR-Cas9

[0821] TILs expanded using the protocols described in Example 14 were genetically engineered using CRISPR-Cas9 to create functional genetic knockouts of a target gene. This genetic engineering was performed on day 6 or day 10. Briefly, on day 6 or 10, 1.2×10^6 expanded TILs were centrifuged at 300 xg for 5 minutes and resuspended with 20 μ L of MaxCyte electroporation buffer (HyClone Cat#EPB1). Two ribonucleoprotein (RNP) master mixes were made containing 52 pmol Cas9 protein (Aldevron, Cat#9212) and 120 pmol of each individual sgRNA. Master mix 1 contained the sgRNA for the OR1A2 gene (O) (IDT, AGATGATGTCAACCAAGGAG SEQ ID NO: 913). Master mix 2 contained the sgRNA for the SOCS1 gene (S) (IDT, GACGCCTGCGGATTCTACTG SEQ ID NO: 61). 100 μ M solution of OR1A2 sgRNA was made by resuspending 10 nmol lyophilized sgRNA with 100 μ L Nuclease Free Duplex Buffer (IDT Cat#1072570). Reagents were added as follows:

	Vol (μ L)
sgRNA (100 μ M)	1.2
Cas9 (61 μ M)	0.84
DPBS (1X)	1.76

[0822] The entire 5 μ L of the RNP master mix was added to the 20 μ L cell suspension. 25 μ L of cell suspension was then transferred to an OC25 X 3 processing assembly (MaxCyte, Cat#OC-25x3). Cells were electroporated on a MaxCyte ExPERT electroporator using the “Optimization #9” program. Subsequently, 25 μ L TIL were transferred to a 96-well plate, each chamber was washed with 25 μ L TIL media twice and transferred to the 96-well recovery plate, which was then incubated at 37 °C for 20 minutes. Subsequently, cells were counted, and 4×10^5 live cells were then seeded into a 24 well Grex plate containing 6 mL TIL media supplemented with 6,000 U/ml of IL-2 or 1000 ng/mL of IL-15. Further cell manipulations were conducted as described in Example 14. On days 14 and 20, cells were harvested and counted. Cell pellets were frozen, and editing was determined by NGS sequencing (**FIG. 15**).

Example 16: Phenotypic characterization of tumor fragment expanded TILs with soluble activators or aAPCs

[0823] The phenotype of T cells produced on day 14 or 20 was assessed. In particular, the proportion of cells that were defined as central memory T cell phenotype (T_{cm}, with marker

phenotype CD45RO+ CCR7+ CD45RA-) or effector memory T cell phenotype (Teff, with marker phenotype CD45RO+ CCR7- CD45RA-) was determined by flow cytometry. Cells cultured as in Example 14 were taken, and on day 14 or 20 an aliquot of cells was stained with fluorescently labeled antibodies that detect CD45RO, CCR7, and CD45RA. All conditions tested showed predominantly a Teff memory phenotype. SOCS1 editing modestly increased Tcm phenotype (FIG. 14).

[0824] The theoretical TIL cell numbers generated by the soluble activator tumor fragment expansion methods at day 14 or 20 was assessed for TILs expanded by the addition of IL-2 or IL-15. Theoretical cell counts were calculated assuming a one-gram tumor fragment sample. All conditions tested showed mean expansions greater than 1×10^{10} TIL after 20 days (FIG. 13).

Example 17: Frozen tumor digest TIL expansion and frozen tumor fragment TIL expansion

[0825] Frozen tumor digest TIL expansion was compared to frozen tumor fragment TIL expansion in the presence of IL-2 or IL-15 utilizing the TransACT activator. Following activation, editing for olfactory (O) and SOCS1 (S) was performed and compared to a no electroporation (no EP) control.

[0826] The materials used for this assessment were the following:

Human IL-2 (Lot 031912-1)	Peptotech	200-02
Human IL-15 (Lot 091924)	Peptotech	200-15
GMP T Cell TransAct (Lot 5200103426)	MACS	170-076-156
sNLS-SpCas9-sNLS Nuclease (Lot MPM030-04)	Aldevron	9212-5MG
sg_Nh.SOCS1_u728 (custom A. Hohmann)	Biospring	28May19
sgOR1A2_axfc	IDT	145243571.
Electroporation Buffer (Lot AD22541263, PD 10/2018)	Hyclone	EPB1
OC25x3 Processing Assembly (Lot LM236738)	MaxCyte	#OC-25x3
Greiner 24 well plate	Wilson Wolf	80192M
Greiner 6 well plate	Wilson Wolf	80660M
AccuCheck Counting Beads	Life Technologies	PCB100
Cryostor CS10	Stemcell Inc	07930
RPMI1640 1X L-Glutamine	Gibco	11875-093
AIM-V Medium 1X.	Gibco	12055-091
Human AB Serum- Sterile Filtered Heat Inactivated	Valley Biomedical	HP1022HI

*Complete media: 50/50 RPMI/AIM-V, 5% human serum

[0827] Melanoma digests were received from Conversant Bio and melanoma tumor fragments were received from iSpecimen. The donor information and references were the following:

- D3239 (Digest)

- D6138 (Digest)
- D6755 (Digest)
- D4462 (Fragment) Melanoma
- D7283 (Fragment) Melanoma

[0828] For both TIL expansions, a common protocol was followed at discrete time intervals as indicated below:

[0829] At Day 0 of the expansion, cells were thawed according to Discovery Life Sciences Protocol (Thawing Viable Cell Products-1.pdf) using three vials per donor. Each TIL donor tube were resuspended in 1mL complete media and combined for a total of 3 mL. The cells were counted using the Nexelcom Cellometer as per manufacturer's recommendations. 200 μ L was removed from each donor for FACS staining. WI-002 ACT FACS Differentiation Panel.docx work instruction was followed for the staining. At the final resuspension step, 100 μ L of an Accucheck beads solution was added (stock concentration 200,000 beads/mL) to obtain a total of 20,000 beads. The total number of T cells was calculated based upon acquired beads. Afterward, a TransAct reagent from a 2X working solution (1:35) was prepared to a final concentration of 1:70. 2×10^6 cells and 3mL of the 2X TransAct reagent were added to a well in a 24 well Grex, and the remaining TIL media was added to the cell to bring the total volume to 6 mL. IL-2 was added at a final concentration of 6,000 U/mL to the corresponding wells. IL-15 was added to a final concentration of 1,000 ng/mL to the corresponding wells. The cells were incubated at 37 °C.

[0830] Still at Day 0 of the expansion, the tumor fragment vials were thawed in a 37 °C water bath. The fragments were then poured into a 10 cm² dish containing 10 mL TIL media. The 10 cm² dish was placed on a measuring pad and the fragments were photographed. The fragments were split into two equal aliquots and each aliquot was placed into a 1.5 mL Eppendorf tube containing 1mL TIL media. The fragments were spun down at 200 g for 5 minutes. The media was aspirated, and the pooled fragments were weighted. 3mL of the 2X TransACT reagent and 3 mL of the TIL media were added to wells of a 24 well Grex. Fragments were added to the wells of a 24 well Grex. For D4462, 8 fragments were combined with IL-2 and 8 fragments were combined with IL-15. For D7283, 6 fragments were combined with IL-2 and 6 fragments were combined with IL-15. IL-2 was added at 6,000 U/mL or IL-15 was added at 1,000 ng/mL to the corresponding wells. The cells were incubated at 37 °C.

[0831] At Day 2 of the expansion, IL-2 or IL-15 was added to all donors. IL-2 was added to consumption to 6,000 U/mL or IL-15 was added to consumption to 1,000 ng/mL in the corresponding wells.

[0832] At Day 4 of the expansion, media for all donors were exchanged. 3 mL of media from each well was discarded and 3 mL of TIL media was added to each well. Afterward, IL-2

was added to a final concentration of 6,000 U/mL or IL-15 was added to a final concentration of 1,000 ng/mL in the corresponding wells.

[0833] At Day 6 of the expansion, the D3239, D6138, D6755, and D4462 were FACS stained and electroporated. The concentration of olfactory sgRNA was adjusted to 100 μ M by resuspending 10 nmol vial with 100 μ L duplex buffer. The SOCS1 guide was already at the necessary concentration. A RNP solution for a total of 15 tests was prepared with the volumes below:

	Vol/test (μ L)
sgRNA (100uM)	1.2
Cas9 (61uM)	0.84
DPBS (1X)	2.96
RNP solution	5
Maxcyte sol (cells)	20

The MaxCyt instrument was prepared and set to “optimization #9” OC25X3. 3 mL of media was aspirated from each well, the volume was recorded, and the cells were counted. 100 μ L of pre-electroporated cells was transferred to a 96 well v-bottom plate and stained according to WI-002 ACT FACS Differentiation Panel.docx protocol. 1.2×10^6 cells were added to a 1.5 mL Eppendorf tube for each condition. Tubes were spun down at 300 g for 5 minutes and the supernatant was removed. 20 μ L of MaxCyt electroporation buffer was added to 1.5 mL Eppendorf tube. 5 μ L of the Olfactory or SOCS1 RNP solution was added to the corresponding Eppendorf tube. Up to 25 μ L was transferred to the OC25X3 assembly and the cells were electroporated. 25 μ L of cells were transferred from a well from the OC25X3 to a 96 well recovery plate. The OC25X3 well was rinsed with 25 μ L of TIL media two times for a final volume of 75 μ L in the recovery plate well. The cells were incubated for 20 minutes at 37 °C. The cells were counted by: adding 5 μ L from the recovery plate to 45 μ L TIL media in a counting well (10-fold dilution); adding 50 μ L of AOPI and mixing; transferring to counting chamber; and counting the cells. 4×10^5 cells were then transferred to a well of a 24 well Grex. The well was incubated at 37 °C.

[0834] At Day 9 of the expansion, the media for all donors were exchanged. 3 mL of media was discarded from each well. 3 mL of TIL media was added to each well, and IL-2 was added to a final concentration of 6,000 U/mL or IL-15 was added to a final concentration of 1,000 ng/mL in the corresponding wells.

[0835] At Day 10 of the expansion, the D7283 was FACS stained and electroporated. Samples were prepared as stated for the samples at Day 6. Enough was prepared for 5 samples.

[0836] Still at Day 10 of the expansion, samples D3239, D6138, D6755, and D4462 were transferred to a 6 well Grex. 100 mL of TIL media was added to a 6 well Grex containing 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15. 3 mL of media from each donor well was discarded. Cells were counted and the volume recorded. 3 mL of donor cells was added to the corresponding well in a 6 well Grex containing 100 mL TIL media with cytokine.

[0837] At Day 14 of the expansion, takedown assays were performed for D3239, D6183, D6755, and D4462. 80 mL was aspirated from each well of the 6 well Grex, mixed, and their volume recorded. One vial was saved for NGS processing: 1 million of cells were transferred to a 1.5 mL Eppendorf tube, and the tube was spun down at 300 g for 5 minutes. Supernatant was aspirated and the cells stored at -80 °C. FACS analysis was preformed: 1 million cells per condition were transferred to a v-bottom or u-bottom 96 well plate for the differentiation and polyfunctional panel respectively. Cells were processed according to work instructions “WI-002 ACT FACS Differentiation Panel.docx” and “WI-008 ACT FACS Polyfunctional Panel CD25 APC.docx.” The remaining cells were frozen: 50 million cell pellets were prepared; the cells were spun at 300 g for 5 minutes; the supernatant was aspirated; cryostore was added; the cells were resuspended to 50 million cells/mL; 1 mL was added to cryovial and placed in a coozie at -80 °C overnight before transfer to LN2.

[0838] At Day 14 of the expansion, the D7283 was transferred to a 6 well Grex. 100 mL of TIL media was added to a 6 well Grex containing 6,000 U/mL of IL-2 or 1,000ng/mL of IL-15. 3 mL of media was discarded from each donor well. The cells were counted, and the volume was recorded. 3 mL of donor cells was added to the corresponding well in a 6 well Grex containing 100 mL TIL media with cytokine.

[0839] At Day 17 of the expansion, the cells from the sample D7283 were counted and a 50% media exchange was performed. 50 mL media was removed, and the cells were counted. 50 mL of TIL media was added for a total of 100 mL. IL-2 to 6,000 U/mL was added and IL-15 to 1,000 ng/mL was added assuming consumption.

[0840] At Day 20 of the expansion, takedown assays were performed for D7283 and the expansion was continued. 70 mL from each well of the 6 well Grex was aspirated, mixed and their volume recorded. 5 million cells were removed to support takedown assays below. One vial for NGS processing was saved: 1 million of cells were transferred to a 1.5 mL Eppendorf tube and spun down at 300 g for 5 minutes; the supernatant was aspirated; and the was stored at -80 °C. The editing efficiencies from Day 14 harvest are depicted in **FIG. 16** The FACS analysis was performed: 1 million of cells per condition were transferred to a v-bottom 96 well plate for the differentiation; and cells were processed according to work instruction “WI-002 ACT FACS

Differentiation Panel.docx.” The remaining cells were frozen: 50 million cell pellets were prepared; the cells were spun at 300 g for 5 minutes; the supernatant was aspirated; cryostore was added and the cells were resuspended to 50 million cells/mL; and 1 mL was added to cryovial and placed in a coozie at -80 °C overnight before being transferred to LN2. 70 mL TIL media was added to wells for a total of 100 mL. IL-2 to 6,000U/mL was added and IL-15 to 1,000 ng/mL was added assuming consumption.

[0841] At Day 23 of the expansion, takedown assays were performed for D7283 and the sample was frozen down. 70 mL was aspirated from each well of the 6 well Grex, mixed, and their volume recorded. 1 million cells were removed to support takedown assays below. The FACS analysis was performed: 1 million cells per condition were transferred to a u-bottom 96 well plate for the polyfunctional pane; and cells were processed according to work instruction “WI-008 ACT FACS Polyfunctional Panel CD25 APC.docx.” The remaining cells were frozen: 50 million cell pellets were prepared; the cells were spun at 300 g for 5 minutes; the supernatant was aspirated; Cryostore was added and cells were resuspended to 50 million cells/mL. 1mL was added to cryovial and placed in a coozie at -80 °C overnight before being transfer to LN2. TILs were determined to be highly viable (**FIG. 17**), with extrapolated TIL yields exceeding 1×10^9 cells for both fragment and digest samples (**FIG. 18**) by Day 14 of the process.

Example 18: Methods for expanding TILs from a tumor fragment using a soluble activator

[0842] Tumor infiltrating lymphocytes (TILs) were expanded directly from frozen melanoma tumor fragments from primary patients. Tumor fragments were obtained from 2 donors: Donor D4008 and Donor D4375. On Day 0, tumor fragments were thawed and placed in a 10 cm² dish containing TIL media (a 1:1 mixture of RPMI 1640 and AIM V, supplemented with 5% human AB serum). Fragments were weighed and then evenly split (by number of fragments) into two aliquots and each aliquot was placed in a well of a 24 well Grex plate (Wilson Wolf, Cat#80192M). 6 mL of TIL media was added to each well containing a 1:70 dilution of GMP TransAct reagent (MACS GMP T Cell Transact, Cat # 170-076-156) in either 6000 U/mL IL-2 (Peprotech, Cat#200-02) or 1000 ng/mL IL-15 (Peprotech, Cat#200-15). Cells were cultured at 37 °C.

[0843] On Day 2 of the expansion, 36,000 U of recombinant human IL-2 was added to each well for a final concentration of 6,000 U/ml, assuming consumption to the corresponding wells. IL-15 was added at a final concentration of 1,000 ng/mL to the corresponding wells assuming consumption.

[0844] On Day 4 of the expansion, a 50% media was replaced/exchanged. From each well, 3 mL of cell supernatant was removed and discarded, being careful not to disturb the cells at the bottom of the well. Subsequently, 3mL of fresh TIL media containing 6,000 U/ml IL-2 was then added to the corresponding wells. 3mL of fresh TIL media containing 1000ng/ml IL-15 was then added to the corresponding wells.

[0845] On Day 6 of the expansion, cells were resuspended using spent media in each well and counted. 36,000 U of recombinant human IL-2 was added to each well for a final concentration of 6,000 U/ml, assuming consumption to the corresponding wells. IL-15 was added at a final concentration of 1,000 ng/mL to the corresponding wells assuming consumption.

[0846] On Day 7 of the expansion, cells were resuspended using spent media in each well, counted and evenly split into two wells, ~3mL per well. Subsequently, 3mL of fresh TIL media containing 6,000 U/ml IL-2 was then added to the corresponding wells. 3mL of fresh TIL media containing 1000ng/ml IL-15 was then added to the corresponding wells.

[0847] On Day 9 of the expansion, cells were resuspended using spent media in each well and evenly split into two wells, ~3mL per well. Subsequently, 3mL of fresh TIL media containing 6,000 U/ml IL-2 was then added to the corresponding wells. 3mL of fresh TIL media containing 1000ng/ml IL-15 was then added to the corresponding wells.

[0848] On Day 10 of the expansion, same condition from each well was combined, filtered by cell strainer and counted; pre-electroporation cell number and viability is shown in **FIG. 20**. 3×10^6 cells from donor 4008 and 6×10^6 cells from donor 4375 were transferred to a 6 well Grex (Wilson Wolf Cat#80660M) in 50 mL TIL media without any cytokine (an oversight). The remaining samples were engineered using CRISPR-Cas9 as described in Example 19. Following electroporation, all cells from donor 4008 (3.9×10^6 ~ 5.5×10^6) were transferred to a 6 well Grex in 50 mL TIL media containing 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15. Following electroporation, 8.6×10^6 cells from donor 4375 were transferred to a 6 well Grex in 50 mL TIL media containing 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15.

[0849] On Day 13 of the expansion, all conditions (IL2 or IL15, No EP or edited TILs) from donor 4008 were discarded due to culture contamination. For donor 4375, 300,000 U of recombinant human IL-2 was added to each well for a final concentration of 6,000 U/ml, assuming consumption to the corresponding wells. IL-15 was added at a final concentration of 1,000 ng/mL to the corresponding wells assuming consumption.

[0850] On Day 15 of the expansion, 30 mL of supernatant was removed; cells were resuspended using spent media and counted. All no EP cells (16×10^6 ~ 35×10^6) and 30×10^6 of all

edited cells were re-plated to a 6 well Grex (Wilson Wolf). Fresh TIL media was added to each well to 100mL. 6,000 U/mL of IL-2 or 1,000 ng/mL of IL-15 was added to consumption.

[0851] On Day 17 of the expansion, all the wells were harvested. Post-electroporation cell number and viability is shown in **FIG. 21**. Together, these data demonstrate that IL-15 unexpectedly supports the viable manufacture of CRISPR/Cas9 engineered TIL, including the manufacture of viable dual CRISPR/Cas9 engineered TIL.

Example 19: Methods to genetically engineer fragment expanded TILs with soluble activators using CRISPR-Cas9

TILs expanded using the protocols described in Example 18 were genetically engineered using CRISPR-Cas9 to create functional genetic knockouts of a target gene, a streamlined protocol is depicted in **FIG. 19**. This genetic engineering was performed on day 10. Briefly, for donor 4008 on day 10, 18×10^6 expanded from either IL-2 or IL-15 cultured TILs were centrifuged at 300 xg for 7 minutes and resuspended with 320 μ L of MaxCyte electroporation buffer (HyClone Cat#EPB1); for donor 4375 on day 10, 36×10^6 expanded from either IL-2 or IL-15 cultured TILs were centrifuged at 300 xg for 7 minutes and resuspended with 480 μ L of MaxCyte electroporation buffer. Cell suspension from each donor was evenly split into two aliquots to account for two edit conditions. Eleven ribonucleoprotein (RNP) master mixes were made containing 2281 pmol Cas9 protein (Aldevron, Cat#9212) and 5280 pmol of each individual sgRNA. Master Mix 1 contained the sgRNA for the *SOCS1* gene (Biospring, GACGCCTGCGGATTCTACTG SEQ ID NO: 61) and *ZC3H12A* gene (IDT, AGGCACCACTCACCTGTGAT SEQ ID NO: 377 Master Mix 2 contained the sgRNA for the *SOCS1* gene (IDT, GACGCCTGCGGATTCTACTG SEQ ID NO: 61). 100 μ M solution of *ZC3H12A* sgRNA was made by resuspending 10 nmol lyophilized sgRNA with 100 μ L Nuclease Free Duplex Buffer (IDT Cat#1072570). Reagents were added as follows:

Master Mix 1	Vol (μ L)
<i>SOCS-1</i> sgRNA (100 μ M)	52.8
<i>ZC3H12A</i> sgRNA (100 μ M)	52.8
Cas9 (61 μ M)	37.4
DPBS (1X)	77.0

Master Mix 2	Vol (μ L)
<i>SOCS-1</i> sgRNA (100 μ M)	52.8
Cas9 (61 μ M)	37.4

DPBS (1X)	129.8
-----------	-------

[0852] For donor 4008, 40 μ L of the RNP master mix was added to the 160 μ L cell suspension. For donor 4375, 60 μ L of the RNP master mix was added to the 240 μ L cell suspension. 100 μ L/well of cell suspension was then transferred to an OC100 X 2 processing assembly (MaxCyte, Cat#OC-100x2). Cells were electroporated on a MaxCyte ExPERT electroporator using the “Optimization #9” program. Subsequently, 100 μ L TIL were transferred to a 96-well plate, each chamber was washed with 100 μ L TIL media twice and transferred to the 96-well recovery plate, which was then incubated at 37 °C for 20 minutes. Subsequently, cells were counted, and seeded as described in Example 18. Further cell manipulations were conducted as described in Example 18. On days 17, cells were harvested and counted. Cell pellets were frozen, and editing was determined by NGS sequencing (**FIG. 22**). These data demonstrate that CRISPR / Cas9-engineered TIL manufactured with either IL-2 or IL-15 demonstrate editing efficiencies of the target genes *SOCS1*, *ZC3H12A* or both to a degree of 90% or greater.

Example 20: Phenotypic characterization of tumor fragment expanded TILs with soluble activators

[0853] The phenotype of T cells produced from donor 4375 on day 17 was assessed. Gating strategy is shown in **FIG. 23**. Dot plots with CD4/CD8 population and dot plots with CD45RO/CCR7 populations are shown in **FIG. 24**. The proportion of cells that were defined as central memory T cell phenotype (Tcm, with marker phenotype CD45RO+ CCR7+, top right quadrant) or effector memory T cell phenotype (Teff, with marker phenotype CD45RO+ CCR7-, top left quadrant) was determined by flow cytometry. Cells cultured as in Example 18 were taken, and on day 17 an aliquot of cells was stained with fluorescently labeled antibodies that detect marker(s) of interest. All conditions tested showed predominantly a Teff memory phenotype. *SOCS1* and *ZC3H12A* editing increased Tcm phenotype compared with *SOCS1* editing cells (**FIG. 24**). IL-15 cultured TILs had increased Tcm phenotype compared with IL-2 cultured TILs (**FIG. 24**). A significantly reduced Tcm phenotype was observed in No EP cells which could have resulted from missing a cytokine boost on day 10. These data demonstrate that IL-15-supported manufacture of CRISPR/Cas9-engineered TIL leads to a preferential increase of TIL possessing a Tcm phenotype over IL-2-supported manufacture of TIL.

[0854] Half off-set histograms with CD28, CD27 and KLRG1 expression is shown in **FIG. 25**. All conditions (IL-2, IL-15, different edits) had comparable CD28 and CD27 expression. IL-2 cultured TILs had increased KLRG1 population compared with IL-15 cultured TILs. No EP

TILs had a noticeably higher KLRG1 population compared with edited TILs which could be resulted from No EP TILs missing a cytokine boost on day 10.

Example 21: ICOS expression on edited TILs

[0855] ICOS mRNA is one of the targets of REGNASE-1 (encoded by *ZC3H12A*) RNase activity (Uehata et al.). Half off-set histograms with ICOS expression is shown in **FIG. 26**. *SOCS1* and *ZC3H12A* editing had increased ICOS expression compared with *SOCS1* editing TILs. These data demonstrate that inactivation of *ZC3H12A*, encoding the REGNASE-1 protein, or both *ZC3H12A*, encoding the REGNASE-1 protein, and *SOCS1*, encoding the SOCS1 protein, in TIL leads to heightened expression of ICOS protein, whose mRNA is a direct substrate of REGNASE-1 RNase activity.

[0856] The data provided herein supports methods for activating and expanding TILs using unconventional cytokines. These methods include techniques for activating and expanding TILs using more streamlined approaches, including one-step approaches, approaches using agonists for stimulation, approaches more suitable for clinical manufacturing, and approaches without the requirement of feeder cells, are provided. Compositions of expanded populations of TILs are also provided, in addition to populations of expanded TILs enriched in central memory T cell phenotype.

[0857] The methods disclosed herein have a number of advantages over conventional IL-2-based REP methods for TIL expansion. For example, as shown in the examples, the methods disclosed herein can expand populations of TILs that have previously failed to expand using a conventional IL-2 based REP. Furthermore, IL-15 supports proliferation of effector T cells when included in the pre-REP or in the REP. Unexpectedly, single and double gene edited TILs have shown a 30-50% increase in fold expansion when grown in IL-15 compared to IL-2. Further, emerging from the REP, both unmodified and modified TILs generated using IL-15 have been found to express higher levels of CD25, a receptor for IL-2, in comparison to TILs generated using IL-2 in the REP. This suggests that TILs produced using IL-15 possess higher sensitivity to endogenous IL-2 survival signals upon infusion into patients in comparison to TIL produced using IL-2. The IL-15 based methods disclosed herein result in preferential expansion of effector T cells in the TIL population. In addition, applicants have discovered that, unexpectedly, expansion of TILs with IL-15 after the TILs have been edited using a CRISPR/Cas system results in improved TIL expansion relative to a conventional IL-2-based REP method. Specifically, applicants have discovered that when a TIL population is subject to simultaneous editing of multiple genes, the

recovery and expansion of the TIL population is improved relative to a conventional IL-2-based REP method. Moreover, the methods disclosed herein produce TILs that are phenotypically and functionally similar to or better than those produced using a conventional IL-2-based REP method.

CLAIMS

What is claimed:

1. A method of producing an expanded population of tumor infiltrating lymphocytes (TILs), the method comprising culturing the disaggregated tumor sample in a culture medium comprising (a) feeder cells or an agonist of a T cell costimulatory molecule, (b) a T cell receptor (TCR) agonist, and (c) interleukin (IL)-15, thereby producing an expanded population of TILs.
2. The method of claim 1, wherein the culture medium comprises the IL-15 at a concentration of greater than 100 ng/ml.
3. The method of claim 1 or 2, wherein the culture medium comprises the IL-15 at a concentration of less than 1000 ng/ml.
4. The method of any one of the preceding claims, wherein the culture medium does not comprise IL-2.
5. The method of any one of the preceding claims, wherein the culture medium does not comprise IL-21.
6. The method of any one of the preceding claims, wherein the culture medium further comprises IL-7, optionally at a concentration of 10 U/ml to 7,000 U/ml.
7. The method of any one of the preceding claims, wherein the TCR agonist is selected from a CD3 agonist, OKT3, and UCHT1.
8. The method of claim 7, wherein the CD3 agonist is an anti-CD3 antibody, optionally a humanized anti-CD3 antibody, or a soluble monospecific complex comprising two anti-CD3 antibodies linked together.
9. The method of any one of the preceding claims, wherein the agonist of the T cell costimulatory molecule is selected from: a CD28 agonist, a CD137 agonist, a CD2 agonist, and combinations thereof.

10. The method of claim 9, wherein:
the CD28 agonist comprises a soluble monospecific complex comprising two anti-CD28 antibodies linked together; or
the CD2 agonist comprises a soluble monospecific complex comprising two anti-CD2 antibodies linked together.
11. The method of any one of the preceding claims, wherein the TCR agonist and/or the agonist of a T cell costimulatory molecule are linked to a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein each matrix is 1 to 500 nm in length in its largest dimension.
12. The method of any one of the preceding claims, wherein:
(a) the disaggregated tumor sample comprises tumor fragments optionally generated by a dissection method, that are 0.5 to 4 mm³ in size; or
(b) the disaggregated tumor sample comprises tumor fragments optionally generated by a mechanical method, that are 25 to 30 mm³ in size,
optionally wherein the tumor fragments of (a) and (b) comprise digested tumor fragments.
13. The method of any one of the preceding claims, wherein cells of the expanded TIL population are genetically modified, optionally epigenetically modified.
14. The method of any one of the preceding claims, further comprising genetically modifying cells of the expanded TIL population using a gene-regulating system, optionally selected from a gene-regulating system comprising RNA interference molecules, transcription activator-like effector nucleases, zinc finger nucleases, and RNA-guided nucleases.
15. The method of claim 14, wherein gene-regulating system comprises a Cas enzyme, optionally a Cas9 enzyme, and a guide RNA.
16. The method of any one of claims 13-15, wherein cells of the TIL population comprise a modification, optionally an insertion, deletion, indel, or substitution, at one or more gene(s) selected from: *ANKRD11*, *BCL2L11*, *BCL3*, *BCOR*, *CALM2*, *CBLB*, *CHIC2*, *CTLA4*, *DHODH*, *E2F8*, *EGR2*, *FLI1*, *FOXP3*, *GATA3*, *GNAS*, *HAVCR2*, *IKZF1*, *IKZF2*, *IKZF3*, *LAG3*, *MAP4K*, *NFKBIA*, *NR4A3*, *NRP1*, *PBRM1*, *PCBP1*, *PDCD1*, *PELI1*, *PIK3CD*, *PPP2R2D*, *PTPN1*, *PTPN2*,

PTPN22, *PTPN6*, *RBM39*, *RC3H1*, *SEMA7A*, *SERPINA3*, *SETD5*, *SH2B3*, *SH2D1A*, *SMAD2*, *SOCS1*, *TANK*, *TGFBR1*, *TGFBR2*, *TIGIT*, *TNFAIP3*, *TNIP1*, *TRAF6*, *UMPS*, *WDR6* and *ZC3H12A*, optionally wherein the modification results in reduction or inhibition of expression of the one or more gene(s) and/or function of one or more protein(s) encoded by the one or more gene(s).

17. The method of claim 16, wherein cells of the TIL population comprise a modification, optionally an insertion, deletion, indel, or substitution, at the *SOCS1* gene and the *ZC3H12A* gene.

18. The method of any one of the preceding claims, wherein at least a portion of the culture medium is changed and/or supplemented with IL-15 during the culturing.

19. The method of any one of the preceding claims, wherein the culturing occurs over a period of 9-25 days, 9-21 days, or 9-14 days.

20. The method of any one of the preceding claims, wherein at least 10% or at least 15% of the expanded population of TILs have a central memory T cell phenotype.

21. A method of producing an expanded population of tumor infiltrating lymphocytes (TILs), the method comprising:

culturing a disaggregated tumor sample in a first medium comprising a T cell-stimulating cytokine to produce a population of TILs; and

culturing cells of the population of TILs in a second medium comprising feeder cells or an agonist of a T cell costimulatory molecule, a T cell receptor (TCR) agonist, and interleukin (IL)-15, thereby producing an expanded population of TILs.

22. The method of claim 21, further comprising modifying cells of the population of TILs from the first medium using a gene-regulating system to produce a subpopulation of modified TILs, wherein the population of TILs cultured in the second medium includes the subpopulation of modified TILs.

23. The method of claim 21 or 22, wherein the first and/or second medium does not comprise IL-2.

24. A method for expanding a population of tumor infiltrating lymphocytes (TILs) comprising: culturing the population of TILs in a culture medium comprising (a) IL-15 and (b) a nanomatrix comprising a colloidal suspension of matrices of polymer chains, wherein the matrices are attached to TCR agonists and agonists of a T cell costimulatory molecule, each matrix is 1 to 500 nm in length in its largest dimension, and optionally the method does not comprise the use of feeder cells during expansion of the population of TILs.
25. A method for expanding a population of tumor infiltrating lymphocytes (TILs) comprising: culturing the population of TILs in a culture medium comprising (a) IL-15, (b) a first soluble monospecific complex comprising an anti-CD3 antibody or fragment thereof, (c) a second soluble monospecific complex comprising an anti-CD28 antibody or fragment thereof, and (d) a third soluble monospecific complex comprising an anti-CD2 antibody or fragment thereof, wherein each of the soluble monospecific complexes comprises two antibodies, or fragments thereof, linked together, and each antibody, or fragments thereof, of each of the soluble monospecific complexes specifically binds to the same antigen on the population of TILs.
26. A composition comprising an expanded population of tumor infiltrating lymphocytes (TILs) produced by the method of any one of the preceding claims.
27. A composition comprising a disaggregated tumor sample and/or tumor infiltrating lymphocytes (TILs) in a culture medium comprising (a) feeder cells or an agonist of a T cell costimulatory molecule, (b) a T cell receptor (TCR) agonist, and (c) interleukin (IL)-15, optionally at a concentration of greater than 100 ng/ml and less than 1000 ng/ml.
28. The composition of claim 27, wherein the composition does not comprise IL-2.